
<html lang="en"     class="pb-page"  data-request-id="8482af78-944f-4591-9417-dbfdd7eb9108"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2018.61.issue-5;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.7b01837;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide–Drug Conjugate" /></meta><meta name="dc.Creator" content="Ahmed&#xA;F.  Salem" /></meta><meta name="dc.Creator" content="Si  Wang" /></meta><meta name="dc.Creator" content="Sandrine  Billet" /></meta><meta name="dc.Creator" content="Jie-Fu  Chen" /></meta><meta name="dc.Creator" content="Parima  Udompholkul" /></meta><meta name="dc.Creator" content="Luca  Gambini" /></meta><meta name="dc.Creator" content="Carlo  Baggio" /></meta><meta name="dc.Creator" content="Hsian-Rong  Tseng" /></meta><meta name="dc.Creator" content="Edwin M.  Posadas" /></meta><meta name="dc.Creator" content="Neil A.  Bhowmick" /></meta><meta name="dc.Creator" content="Maurizio  Pellecchia" /></meta><meta name="dc.Description" content="EphA2 overexpression has been associated with metastasis in multiple cancer types, including melanomas and ovarian, prostate, lung, and breast cancers. We have recently proposed the development of ..." /></meta><meta name="Description" content="EphA2 overexpression has been associated with metastasis in multiple cancer types, including melanomas and ovarian, prostate, lung, and breast cancers. We have recently proposed the development of ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 22, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01837" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01837" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01837" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01837" /></link>
        
    
    

<title>Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide–Drug Conjugate | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01837" /></meta><meta property="og:title" content="Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide–Drug Conjugate" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0006.jpeg" /></meta><meta property="og:description" content="EphA2 overexpression has been associated with metastasis in multiple cancer types, including melanomas and ovarian, prostate, lung, and breast cancers. We have recently proposed the development of peptide–drug conjugates (PDCs) using agonistic EphA2-targeting agents, such as the YSA peptide or its optimized version, 123B9. Although our studies indicated that YSA– and 123B9–drug conjugates can selectively deliver cytotoxic drugs to cancer cells in vivo, the relatively low cellular agonistic activities (i.e., the high micromolar concentrations required) of the agents toward the EphA2 receptor remained a limiting factor to the further development of these PDCs in the clinic. Here, we report that a dimeric version of 123B9 can induce receptor activation at nanomolar concentrations. Furthermore, we demonstrated that the conjugation of dimeric 123B9 with paclitaxel is very effective at targeting circulating tumor cells and inhibiting lung metastasis in breast-cancer models. These studies represent an important step toward the development of effective EphA2-targeting PDCs." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01837"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01837">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01837&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01837&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01837&amp;href=/doi/10.1021/acs.jmedchem.7b01837" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2052-2061</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b01806" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b01856" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide–Drug Conjugate</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Ahmed F. Salem</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ahmed F. Salem</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ahmed%0AF.++Salem">Ahmed F. Salem</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Si Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Si Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Sanford-Burnham-Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, California 92037, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Si++Wang">Si Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sandrine Billet</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sandrine Billet</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sandrine++Billet">Sandrine Billet</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jie-Fu Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jie-Fu Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jie-Fu++Chen">Jie-Fu Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Parima Udompholkul</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Parima Udompholkul</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Parima++Udompholkul">Parima Udompholkul</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Luca Gambini</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Luca Gambini</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Luca++Gambini">Luca Gambini</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carlo Baggio</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carlo Baggio</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carlo++Baggio">Carlo Baggio</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hsian-Rong Tseng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hsian-Rong Tseng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular & Medical Pharmacology, University of California, Los Angeles, 570 Westwood Plaza, Los Angeles, California 90095, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hsian-Rong++Tseng">Hsian-Rong Tseng</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9028-8527" title="Orcid link">http://orcid.org/0000-0001-9028-8527</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Edwin M. Posadas</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Edwin M. Posadas</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Edwin+M.++Posadas">Edwin M. Posadas</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Neil A. Bhowmick</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Neil A. Bhowmick</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, United States</div><div class="loa-info-affiliations-info">Department of Research, Greater Los Angeles Veterans Administration, Los Angeles, California 90073, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Neil+A.++Bhowmick">Neil A. Bhowmick</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Maurizio Pellecchia</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maurizio Pellecchia</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#3e535f4b4c57445751104e5b52525b5d5d56575f7e4b5d4c105b5a4b"><span class="__cf_email__" data-cfemail="731e1206011a091a1c5d03161f1f1610101b1a12330610015d161706">[email protected]</span></a>. Tel.: (951) 827-7829.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maurizio++Pellecchia">Maurizio Pellecchia</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5179-470X" title="Orcid link">http://orcid.org/0000-0001-5179-470X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01837&amp;href=/doi/10.1021%2Facs.jmedchem.7b01837" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2052–2061</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 22, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 December 2017</li><li><span class="item_label"><b>Published</b> online</span>22 February 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 March 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01837" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01837</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01837"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2881</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">28</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01837" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide–Drug Conjugate&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ahmed\nF.&quot;,&quot;last_name&quot;:&quot;Salem&quot;},{&quot;first_name&quot;:&quot;Si&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Sandrine&quot;,&quot;last_name&quot;:&quot;Billet&quot;},{&quot;first_name&quot;:&quot;Jie-Fu&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Parima&quot;,&quot;last_name&quot;:&quot;Udompholkul&quot;},{&quot;first_name&quot;:&quot;Luca&quot;,&quot;last_name&quot;:&quot;Gambini&quot;},{&quot;first_name&quot;:&quot;Carlo&quot;,&quot;last_name&quot;:&quot;Baggio&quot;},{&quot;first_name&quot;:&quot;Hsian-Rong&quot;,&quot;last_name&quot;:&quot;Tseng&quot;},{&quot;first_name&quot;:&quot;Edwin&quot;,&quot;last_name&quot;:&quot;M. Posadas&quot;},{&quot;first_name&quot;:&quot;Neil&quot;,&quot;last_name&quot;:&quot;A. Bhowmick&quot;},{&quot;first_name&quot;:&quot;Maurizio&quot;,&quot;last_name&quot;:&quot;Pellecchia&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;22&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;2052-2061&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01837&quot;},&quot;abstract&quot;:&quot;EphA2 overexpression has been associated with metastasis in multiple cancer types, including melanomas and ovarian, prostate, lung, and breast cancers. We have recently proposed the development of peptide–drug conjugates (PDCs) using agonistic EphA2-targeting agents, such as the YSA peptide or its optimized version, 123B9. Although our studies indicated that YSA– and 123B9–drug conjugates can selectively deliver cytotoxic drugs to cancer cells in vivo, the relatively low cellular agonistic activities (i.e., the high micromolar concentrations required) of the agents toward the EphA2 receptor remained a limiting factor to the further development of these PDCs in the clinic. Here, we report that a dimeric version of 123B9 can induce receptor activation at nanomolar concentrations. Furthermore, we demonstrated that the conjugation of dimeric 123B9 with paclitaxel is very effective at targeting circulating tumor cells and inhibiting lung metastasis in breast-cancer models. These studies represent an important step&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01837&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01837" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01837&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01837" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01837&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01837" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01837&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01837&amp;href=/doi/10.1021/acs.jmedchem.7b01837" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01837" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01837" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01837%26sid%3Dliteratum%253Aachs%26pmid%3D29470068%26genre%3Darticle%26aulast%3DSalem%26date%3D2018%26atitle%3DReduction%2Bof%2BCirculating%2BCancer%2BCells%2Band%2BMetastases%2Bin%2BBreast-Cancer%2BModels%2Bby%2Ba%2BPotent%2BEphA2-Agonistic%2BPeptide%25E2%2580%2593Drug%2BConjugate%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D5%26spage%3D2052%26epage%3D2061%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a>,</li><li><a href="/action/doSearch?ConceptID=291290" title="Conjugate acid-base pairs">Conjugate acid-base pairs</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/jmcmar.2018.61.issue-5/20180308/jmcmar.2018.61.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/medium/jm-2017-01837r_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01837&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">EphA2 overexpression has been associated with metastasis in multiple cancer types, including melanomas and ovarian, prostate, lung, and breast cancers. We have recently proposed the development of peptide–drug conjugates (PDCs) using agonistic EphA2-targeting agents, such as the YSA peptide or its optimized version, 123B9. Although our studies indicated that YSA– and 123B9–drug conjugates can selectively deliver cytotoxic drugs to cancer cells in vivo, the relatively low cellular agonistic activities (i.e., the high micromolar concentrations required) of the agents toward the EphA2 receptor remained a limiting factor to the further development of these PDCs in the clinic. Here, we report that a dimeric version of 123B9 can induce receptor activation at nanomolar concentrations. Furthermore, we demonstrated that the conjugation of dimeric 123B9 with paclitaxel is very effective at targeting circulating tumor cells and inhibiting lung metastasis in breast-cancer models. These studies represent an important step toward the development of effective EphA2-targeting PDCs.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47561" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47561" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Tumor-specific cell-surface receptors represent potentially very attractive targets for the development of targeted deliveries of chemotherapies.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> These receptors would allow in principle the design of agents that could selectively target malignant cells while sparing normal cells.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> One such tumor-specific target is the EphA2 receptor.<a onclick="showRef(event, 'ref5 ref6 ref7 ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7 ref8 ref9 ref10 ref11">(5−11)</a> Indeed, a high level of EphA2 has been detected in most solid tumors, including breast,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> prostate,<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> pancreatic,<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14−16)</a> urinary bladder,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> brain,<a onclick="showRef(event, 'ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20">(18−20)</a> ovarian,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> esophageal,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> lung,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and stomach<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> cancers and melanomas,<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> and potentially also in certain types of leukemia.<a onclick="showRef(event, 'ref27 ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29 ref30">(27−30)</a> During cancer progression, overexpression of the receptor EphA2 can lead to its ligand-independent pro-oncogenic activation, which is induced by reduced engagement with the ligand, ephrin-A. These pro-oncogenic effects of the unligated EphA2 receptor can be reversed by ligand stimulation, which triggers the intrinsic tumor-suppressive signaling pathways of EphA2, including the inhibition of the PI3K/Akt and ERK pathways,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Further interests in EphA2 signaling stem from the distinction between its physiological roles in tissue homeostasis, angiogenesis, and fetal development and its pathological role, which is associated with the metastasis of multiple cancer types, including breast cancer.<a onclick="showRef(event, 'ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34">(32−34)</a> These observations argue for the development of small-molecule EphA2 agonists as potential tumor-intervention agents. Because the receptor’s activation causes its internalization, antibody–drug conjugates (ADCs)<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> targeting the EphA2 ligand-binding domain (LBD) have been recently investigated. In particular, a recent Phase I study intended to evaluate increasing doses of MEDI-547, an ADC composed of a human anti-EphA2 monoclonal antibody (1C1) linked to a cytotoxic auristatin derivative (maleimido-caproylmonomethyl auristatin phenylalanine, mcMMAF) was carried out in a small cohort of patients with solid tumors that had relapsed or were refractory to standard therapies.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> However, the study was terminated because of the drug-related adverse effects noted at the starting dose. This could have been caused by cross-reactions between MEDI-547 and other proteins or insufficient subcellular internalization of the ADC.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Toxicity remains problematic because of EphA2’s nonspecific distribution; therefore, EphA2 remains a high-priority target in need of a therapeutic agent. To address this need, we pursued a peptide-based targeting of taxanes. In particular, we sought to derive peptide–drug conjugates (PDCs) that could be used to increase taxane delivery to metastatic tumors. We elected to focus on PDCs that target the ephrin-binding pocket in the extracellular N-terminal domain of EphA2 using previously reported agonistic peptides.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The amino acid sequence YSAYPDSVPMMS (YSA), identified using a phage-display technique, has been shown to bind to the extracellular domain of EphA2 and promote receptor activation and internalization in several cancer-cell types.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> We developed and further optimized an innovative antitriazole linker for the synthesis of EphA2-targeting peptide–drug conjugates to avoid the compatibility problems of disulfide and hydrazone linkers typical of ADCs.<a onclick="showRef(event, 'ref39 ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41 ref42">(39−42)</a> This strategy of deriving YSA-based drug conjugates has been used to target prostate cancer, renal cancer, melanoma, and pancreatic cancer.<a onclick="showRef(event, 'ref39 ref40 ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41 ref42 ref43">(39−43)</a> These previous studies identified agent 123B9 as a more plasma-stable compound, compared with YSA. Here, we report that a dimeric version of 123B9 can induce receptor activation at nanomolar concentrations, likely through the oligomerization of EphA2. Moreover, we showed that targeting EphA2 with a conjugation of the dimeric 123B9 with paclitaxel reduced circulating tumor cells and significantly inhibited lung metastasis in breast-cancer models.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23712" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23712" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Synthesis and Characterization of a 123B9-Based Dimeric PDC Targeting EphA2</h3><div class="NLM_p">The synthesis of dimeric 123B9 conjugated to paclitaxel, (123B9)<sub>2</sub>–L2–PTX, followed the general schemes illustrated in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A. Dimeric 123B9 was generated by a solid-phase synthetic scheme that introduced a Lys-Gly-Lys-Gly moiety and orthogonal protecting groups, which allowed the synthesis of two 123B9 agents on the backbone and side chain of the first Lys; the second Lys side chain was used for the subsequent coupling with 5-hexynoic acid. To elongate the linker between the two 123B9 moieties, an additional Gly residue was added at the C-terminus of 123B9 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B). The peptide–drug conjugate was subsequently generated by coupling the (123B9)<sub>2</sub>-motif to an azido-hexanoyl paclitaxel group. Briefly, 2′-(6-azidohexanoyl)-<i>O</i>-paclitaxel and the (123B9)<sub>2</sub>-motif in DMSO/water (4:1) were added to a solution of CuSO<sub>4</sub> (1.0 M) and sodium ascorbate (1.0 M) and continually stirred for 2 days. The product was purified on a reverse-phase C-18 column by HPLC with a gradient of 10–90% water/acetonitrile to give the desired agent (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C) as a white powder.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/medium/jm-2017-01837r_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures and general scheme for the synthesis of the reported agents. (A) Chemical structures of the YSA peptide, 123B9, and of the derivatized paclitaxel used for the conjugation. (B) General scheme for the synthesis of the (123B9)<sub>2</sub>-motif. Regents and conditions: (1) NH<sub>2</sub>NH<sub>2</sub>, DMF, room temperature (rt), 30 min; (2) 5-hexynoic acid, HTBU, HOBt, DIEPA, DMF, rt, 12 h; (3) TFA, phenol, TIPS, water, rt, 3 h. (C) Chemical structure of (123B9)<sub>2</sub>–L2–PTX. The L2 linker is highlighted by squared parentheses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01837&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further verify the binding affinity and selectivity of the resulting conjugates for the EphA2 ligand-binding domain (LBD), we expressed and purified the EphA2 and EphA4 ligand-binding domains (EphA2-LBD and EphA4-LBD). These proteins were dissolved to final concentrations of 100 μM in 50 mM phosphate buffer (pH = 6.5) containing 100 mM NaCl. The isothermal-titration-calorimetry (ITC) measurements under these experimental conditions revealed that 123B9 and the (123B9)<sub>2</sub>-motif bound to EphA2 with similar <i>K</i><sub>d</sub> values of 3.9 and 4.9 μM, respectively (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A,B). These similar values were expected for the agents when tested against the isolated ligand-binding domain, given that this domain did not present an appreciable dimerization propensity in solution. In contrast, much like 123B9, the (123B9)<sub>2</sub>-motif had no appreciable binding to EphA4-LBD (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C). To further quantify the relative ability of the dimeric agent to displace EphA2-LBD–123B9 binding, we developed a dissociation-enhanced-lanthanide-fluorescent-immunoassay (DELFIA) platform using 96-well streptavidin-coated plates (PerkinElmer) and biotinylated 123B9. Both 123B9 and the (123B9)<sub>2</sub>-motif were able to displace 123B9-biotin with comparable IC<sub>50</sub> values of 4.9 and 4.1 μM, respectively, in agreement with the binding of the agents to monomeric EphA2-LBD (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>D).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/medium/jm-2017-01837r_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Biophysical- and biochemical-activity comparisons of 123B9 and the (123B9)<sub>2</sub>-motif. (A) Isothermal-titration-calorimetry data relative to 123B9 (30 μM) titrated against EphA2-LBD (200 μM), resulting in a dissociation constant of 3.9 μM. (B) Isothermal-titration-calorimetry data relative to the (123B9)<sub>2</sub>-motif against EphA2-LBD, resulting in a dissociation constant of 4.9 μM. (C) Isothermal-titration-calorimetry data relative to the (123B9)<sub>2</sub>-motif against EphA4-LBD, showing no significant binding to this closely related ligand-binding domain. (D) Dose–response DELFIA curves for the displacement of biotinylated 123B9 from EphA2-LBD by compounds 123B9 and the (123B9)<sub>2</sub>-motif (IC<sub>50</sub> values of 4.9 and 4.1 μM, respectively).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01837&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> EphA2-Receptor Activation by Dimeric 123B9</h3><div class="NLM_p">Agonistic peptides have been previously shown to promote EphA2 phosphorylation (indicative of activation) in various cancer-cell lines at concentrations between 50 and 100 μM, which is 1 order of magnitude higher than the affinities of the peptides to the receptor in vitro (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). To assess (123B9)<sub>2</sub>-mediated receptor activation, HEK293T cells stably transfected with EphA2 were tested. For the controls, ephrin-A1 Fc was used as a positive control, and Fc alone was used as a negative control. After treatment with test agents, immunoprecipitated EphA2 was probed with antiphosphotyrosine antibodies (P-Tyr) and reprobed with anti-EphA2 antibodies (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). As previously reported, YSA and 123B9 induced receptor activation at relatively high micromolar concentrations (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A), whereas the (123B9)<sub>2</sub>-motif showed activation at all of the concentrations tested down to 1 μM. Subsequent testing of lower concentrations remarkably demonstrated that 10 nM concentrations of the (123B9)<sub>2</sub>-motif induced receptor activation similar to that of ephrin-A1 Fc (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/medium/jm-2017-01837r_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. EphA2 ligand dimers potently stimulate the EphA2 receptor in submicromolar concentrations. EphA2-overexpressing HEK293<i>T</i>/17 cells were starved and then treated with clustered Fc, clustered ephrin-A1 Fc, YSA, 123B9, or the 123B9 dimers for 30 min. The cells were lysed, and then the EphA2 receptor was immunoprecipitated. The samples were blotted with an antiphosphotyrosine antibodies, and then stripped and reblotted with anti-EphA2 antibodies to ensure equal loading. The 123B9 dimers phosphorylated the tyrosine residues in the EphA2 receptors with 2000-fold lower concentrations than YSA or the 123B9 monomer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01837&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Effect of (123B9)<sub>2</sub>–L2–PTX on Circulating Tumor Cells in an Orthotopic Breast-Cancer-Metastasis Model</h3><div class="NLM_p">The antimetastatic capacities of (123B9)<sub>2</sub>–L2–PTX were explored by examining its effects on circulating tumor cells (CTCs). The NanoVelcro system is a novel nanotechnology platform for rare-cell isolation used by our group. Its performance characteristics show a greater CTC-capture sensitivity for human prostate-cancer patients when compared with conventional CTC-capture methodologies, such as the CellSearch assay.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> To assess the ability of (123B9)<sub>2</sub>–L2–PTX to limit CTCs in vivo, we introduced triple-negative human MDA-MB-231 breast-cancer cells into the mammary fat pads of NOD SCID mice. The mice were monitored for the development of the primary tumors, which reached sizes of approximately 1 mm<sup>3</sup>. At that point, the mice were treated intravenously with Abraxane or (123B9)<sub>2</sub>–L2–PTX three times a week for a period of 2 weeks. The (123B9)<sub>2</sub>–L2–PTX doses were 24.5 mg/kg, the molecular equivalent to the PTX doses (5 mg/kg) in the Abraxane group. We were able to distinguish the cancer cells from the immune cells in the circulation using immunofluorescent staining for pan-cytokeratin and CD45, respectively. We revealed reduced lymph-node involvement and reductions in regrowth at the sites of the primary tumors, corresponding with significantly reduced CTC in the (123B9)<sub>2</sub>–L2–PTX-treatment group compared with in the Abraxane-treatment group (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). Differential staining of the CTC for pan-cytokeratin and CD45 further demonstrated that (123B9)<sub>2</sub>–L2–PTX reduced cancer-cell clusters (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B–E), especially strong indicators of metastasis.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46,47)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/medium/jm-2017-01837r_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. CTC evaluation using an orthotopic breast-cancer mouse metastatic model. CTC enumeration studies were done using NanoVelcro CTC Chips. (A) CTC counts in MDA-MB-231 breast-cancer cells orthotopically grafted into NOD-SCID mice treated with (123B9)<sub>2</sub>–L2–PTX or Abraxane (ABX). The CTC counts in the (123B9)<sub>2</sub>–L2–PTX group were significantly lower. (B) Captured cells directly stained for pan-cytokeratin (green) and CD45 (red) expression. (C) Pan-cytokeratin-expressing cells histologically evaluated as cancer. The cell clusters captured were elevated in the Abraxane-treated mice (D) compared with those from the (123B9)<sub>2</sub>–L2–PTX-treated mice (E). In panels B–E, the scale bars represent 10 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01837&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Effect of (123B9)<sub>2</sub>–L2–PTX in Vivo on a Syngeneic Breast-Cancer-Metastasis Model</h3><div class="NLM_p">To assess the antimetastatic properties in a direct and quantitative manner, we used a triple-negative breast-cancer cell line, 4T1, a model derived from a spontaneous mammary-gland carcinoma from a BALB/c mouse. These cells, introduced to the animals through intracardiac injections, are known to metastasize to the lungs, lymph nodes, adrenal glands, ovaries, and bones. Fifteen days after the injections, the animals were treated with (123B9)<sub>2</sub>–L2–PTX three times a week for a period of 2 weeks at a dose of 24.5 mg/kg, the equivalent to the PTX dose (5 mg/kg) in Abraxane group. The mice in the (123B9)<sub>2</sub>–L2–PTX-treated group seemed to tolerate the therapy well, with negligible weight loss. We observed the clear and significant (<i>p</i> < 0.0001) beneficial effects of the dimer drug on lung metastasis (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A,B), with a reduction of the gross lung-metastasis count by more than 75% compared with those in the control and Abraxane groups. H&E staining revealed additional reductions of microscopic lung nodules in the (123B9)<sub>2</sub>–L2–PTX group, compared with those in the Abraxane and control groups. Finally, examination of the metastatic tumors in each of the groups demonstrated a pronounced reduction in CD31-expressing vasculature by the (123B9)<sub>2</sub>–L2–PTX group compared with those in the Abraxane and vehicle groups (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C). Hence, the dimerization of the EphA2-targeting peptide improved the antimetastatic potential of the taxane over its albumin conjugation.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/medium/jm-2017-01837r_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Syngeneic breast-cancer metastasis model. 4T1 cells were introduced to BALB/c mice by intracardiac injections and treated with (123B9)<sub>2</sub>–L2–PTX or Abraxane. (A) Gross lung metastasis observed in the control, Abraxane, and (123B9)<sub>2</sub>–L2–PTX groups. (B) Metastasis to the left lung superior lobe quantitated under the microscope (*<i>P</i> < 0.05, ***<i>P</i> < 0.001). (C) Histochemistry on lung sections from the three groups demonstrating the tumors (H&E at 4× magnification) and the vascularization by CD31 immuno-localization (40× magnification).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01837&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Discussion and Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67113" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67113" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The design of potent and selective agonistic peptides or small molecules that target the Eph-receptor ligand-binding domain has remained challenging. A variety of approaches have been proposed over the past decade, including high-throughput screening<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> and computational-docking strategies,<a onclick="showRef(event, 'ref31 ref49 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref31 ref49 ref50 ref51">(31,49−51)</a> phage-display screening,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> and NMR-based screening.<a onclick="showRef(event, 'ref52 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref52 ref53 ref54">(52−54)</a> Each strategy accomplished the identification of potentially interesting compounds, but few have been fully validated in vivo. Although research is ongoing in the identification of potential small-molecule compounds,<a onclick="showRef(event, 'ref31 ref49'); return false;" href="javascript:void(0);" class="ref ref31 ref49">(31,49)</a> most of the success has revolved around the discovery and optimizations of EphA2/ephrin antagonists,<a onclick="showRef(event, 'ref48 ref50 ref51 ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref48 ref50 ref51 ref55 ref56">(48,50,51,55,56)</a> although agonistic peptides remain the most studied EphA2-targeting agents in vivo.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Small agonistic peptides, however, are still only moderately potent and suffer from rapid degradation in plasma and clearance in vivo. Our previous studies with the EphA2-targeting YSA peptide (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A) and YSA-drug conjugates revealed that the rapid degradation of the agents in plasma was likely due to aminopeptidases, which caused rapid cleavage of the essential first amino acids.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> On the basis of these observations, we designed an optimized YSA agent, namely, 123B9 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B), in which the first Tyr residue was replaced by a bioisostere lacking the amino-terminus, conferring a long half-life to the agent in plasma and in vivo.<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41,42)</a> Further in vivo pharmacology and efficacy studies with the 123B9-drug conjugates also resulted in the optimization of the linker between the targeting peptides and the cytotoxic agents.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> These data are consistent with our previous studies with unconjugated peptides and related paclitaxel conjugates.<a onclick="showRef(event, 'ref39 ref40 ref41 ref57'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41 ref57">(39−41,57)</a> Nonetheless, the abilities of these agents to cause receptor activation and internalization occur at relatively high concentrations of the agents (>50–100 μM),<a onclick="showRef(event, 'ref38 ref39 ref40 ref58'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40 ref58">(38−40,58)</a> likely limiting their potential translation to the clinic as effective targeted-delivery agents for tumor imaging or for capturing and killing circulating tumor cells. An interesting feature of EphA2 ligands is that their agonistic activities could be enhanced by properly clustering the targeting agent in nanoparticles or functionalized antibodies or by synthesizing dimers spaced by the appropriate linker.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> For example, the ephrin ligands in isolation are not very effective in activating the receptor; they require clustering on Fc antibodies.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Indeed, it is known that only membrane-bound or Fc-clustered ephrin ligands can activate the receptor in vitro, and although soluble monomeric ligands can bind to the receptor, they only induce limited receptor autophosphorylation and activation.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Similarly, it was recently reported that EphA2-targeting agonistic peptides, when synthesized as dimeric molecules, displayed increased receptor activation in cell assays.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Using the YSA-analogue agonistic peptide, SWL (sequence SWLAYPGAVSYR), a dimeric agent made of two agents linked at the C-terminus by a six-carbon linker resulted in about a 13-fold increase in receptor-activation potency as compared with that of SWL, with significant receptor activation at 5–10 μM.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> However, not surprisingly and similar to what we reported for YSA, the SWL dimer peptide presented a very short half-life in mouse serum, limiting its use in vivo.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Hence, we sought to first derive a dimeric version of our long-lived EphA2-agonistic agent 123B9 and assess its ability to retain the binding and selectivity for EphA2 in vitro and activate the receptor in cells. On the basis of the SWL-C6-dimer and the anticipated use of our dimeric agent for drug conjugation using our established antitriazole-linker click chemistry,<a onclick="showRef(event, 'ref39 ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41 ref42">(39−42)</a> we designed and synthesized the (123B9)<sub>2</sub>-motif as reported in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. This agent represents a dimeric version of 123B9, in which the linker between the molecules is equivalent in length to what was reported for the SWL-dimeric peptides but also presents the necessary alkyne for the subsequent drug conjugation (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). In vitro isothermal-titration-calorimetry (ITC) assays and displacement biochemical assays with purified EphA2-LBD confirmed that the dimeric agents bind to monomeric LBDs with a micromolar affinity that is surprisingly not similar to that of the monomeric agents, given that the isolated ligand-binding domains do not dimerize appreciably. In addition, no binding to the related EphA4 was observed under the same experimental conditions, again confirming the selectivity of these agents for EphA2 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). When tested in cells for receptor activation, the (123B9)<sub>2</sub>-motif was able to induce receptor phosphorylation at 1 μM, which was similar to what was produced by 100 μM YSA or 123B9 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). Moreover, when tested at lower concentrations, the (123B9)<sub>2</sub>-motif revealed remarkable receptor activation in the nanomolar range, similar to what was accomplished by the Fc–ephrin ligand (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). Hence, the dimeric (123B9)<sub>2</sub>-motif represented to our knowledge the most potent synthetic EphA2-agonistic agent reported to date.</div><div class="NLM_p">EphA2 expression is associated with increased metastatic behaviors in cancer cells. In our previous studies, we used a lung colonization and metastasis model of B16-F10-luc-G5 mouse melanoma cells with a 123B9–L2–PTX conjugate and compared the activity of the conjugate with that of albumin-bound paclitaxel (Abraxane).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> As expected in that experiment, there were extensive tumor infiltrations into the lungs and other sites after 14 days of treatment. Both of the agents were equally effective in inhibiting lung colonization. However, Abraxane was not effective in preventing metastases to other organs, similar to the untreated control, whereas the 123B9–L2–PTX-treated mice displayed significantly reduced metastases.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Hence, we hypothesized that a more potent EphA2-targeting agent linked to a chemotherapeutic might be even more effective in targeting CTC and preventing migration to distant metastatic sites. For this purpose, we further synthesized (123B9)<sub>2</sub>–L2–PTX, coupling the (123B9)<sub>2</sub>-motif and 2′-(6-azidohexanoyl)-<i>O</i>-paclitaxel (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A). To test the ability of (123B9)<sub>2</sub>–L2–PTX to selectively capture and kill circulating cancer cells in vivo, we employed a novel microfluidic-based capture approach, the NanoVelcro CTC chip. Circulating-tumor-cell capture has been used as a surrogate for determining the metastatic potentials of solid tumors. As such, CTC measurements can in principle provide new and important markers to monitor and predict the ability of a treatment to limit and prevent metastases.</div><div class="NLM_p">Hence, when PTX was tested side by side with Abraxane at equimolar equivalents in an orthotopic model of triple-negative human MDA-MB-231 breast cancer, the CTC count was significantly reduced in the (123B9)<sub>2</sub>–L2–PTX group compared with that in the group treated with Abraxane (<i>p</i> < 0.0001, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). As expected from these data, (123B9)<sub>2</sub>–L2–PTX performed remarkably better than Abraxane in preventing lung metastases, with a reduction of the gross lung-metastasis count by more than 75% compared with that of Abraxane in an intracardiac breast-cancer metastasis model (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). This observation is in agreement with our previous study of 123B9–L2–PTX and Abraxane in a melanoma mouse model,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> although the observed effect here is remarkably more impressive than what we had previously reported with 123B9–PTX.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Moreover, by virtue of the (123B9)<sub>2</sub>–L2 moiety more effectively carrying the taxane than albumin, (123B9)<sub>2</sub>–L2–PTX was capable of reducing the metastasis number and size by (1) targeting the primary tumor cells, (2) the diminishing CTCs, and (3) causing a marked reduction in tumor vasculature (CD31 staining, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), compared with Abraxane.</div><div class="NLM_p last">Paclitaxel remains to date one of the most effective broad-spectrum anticancer agents and is indeed approved for the treatment of a variety of cancers, including ovarian, breast, and lung cancers. However, given its low solubility in aqueous media, its requirement of long infusions and polyoxyethylated castor oil formulations, and the systemic distribution of the drug causing severe dose-limiting side effects, alternative PTX formulations have been proposed over the years.<a onclick="showRef(event, 'ref60 ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref60 ref61 ref62">(60−62)</a> Albumin-bound paclitaxel (Abraxane) presents several advantages over paclitaxel because of its aqueous solubility and the increased tumor uptake of the drug,<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> and it has received FDA approval thus far for metastatic breast cancer, advanced nonsmall-cell lung cancer, and more recently, metastatic pancreatic cancer. However, Abraxane shares the same side effects as paclitaxel, including dose-limiting bone-marrow suppression. We demonstrated recently that PDCs targeting EphA2-expressing cancer cells can deliver the cytotoxic drug to the tumor and the tumor vasculature, resulting in increased efficacy and reduced systemic toxicity.<a onclick="showRef(event, 'ref39 ref40 ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41 ref42 ref43">(39−43)</a> A limitation of our previous EphA2-targeting PDCs resided in the targeting agents (YSA or 123B9), which caused receptor activation only at relatively high concentrations. The data reported here with the (123B9)<sub>2</sub>-motif and (123B9)<sub>2</sub>–L2–PTX clearly indicated that we have made a major step toward resolving this limitation. Currently, we envision further and more detailed pharmacology and toxicology studies and iterative structure–activity-relationship optimizations of (123B9)<sub>2</sub>–L2–PTX to advance these discoveries into potentially a novel PDC for use in metastatic melanomas; breast, prostate, ovarian, and lung cancers; and potentially most solid tumors that depend on EphA2. Moreover, the (123B9)<sub>2</sub>-motif or its further improved derivatives could be used not only to deliver cytotoxic agents but also to selectively introduce siRNA into cancer cells and to deliver imaging or other diagnostic agents.<a onclick="showRef(event, 'ref64 ref65 ref66 ref67 ref42'); return false;" href="javascript:void(0);" class="ref ref64 ref65 ref66 ref67 ref42">(64−67,42)</a> For example, we have recently demonstrated that 123B9 conjugated with a near-infrared dye can be used to detect prostate cancer in mouse models.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Likewise, we anticipate that a conjugate of its dimeric version may have tremendous utility in devising more effective and sensitive cancer-imaging agents. Hence, we are confident that our present studies represent a novel and significant step that will open a wide range of opportunities for using more effective PDCs targeting EphA2 in the development of innovative diagnostics and cancer therapeutics targeting tumor metastases.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56460" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56460" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11"> General</h4><div class="NLM_p last">All of the reagents and anhydrous solvents were obtained from commercial sources, including the Fmoc-protected amino acids and the resins for the solid-phase synthesis. Biologically active agents were purified to >95% purities, as determined by an HPLC Breeze from Waters Company using an Atlantis T3 5.0 μM 4.6 × 150 mm reverse-phase column. 1D and 2D NMR spectra were recorded on a Bruker 600 MHz instrument equipped with a TCI cryoprobe. The chemical shifts were reported in parts per million (δ) relative to <sup>1</sup>H (Me<sub>4</sub>Si at 0.00 ppm), the coupling constants (<i>J</i>) were reported in Hz throughout, and the NMR-signal assignments were based on a variety of 1D and 2D experiments, including DEPT, 2D [<sup>13</sup>C, <sup>1</sup>H]-HSQC, 2D [<sup>1</sup>H, <sup>1</sup>H]-COSY, 2D [<sup>1</sup>H, <sup>1</sup>H]-TOCSY, and 2D [<sup>1</sup>H, <sup>1</sup>H]-HMBC experiments. Mass-spectrometry data were acquired on an Esquire LC00066 Mass Spectrometer, on an Agilent ESI-TOF Mass Spectrometer, or with a Bruker Daltonic Autoflex Maldi-Tof/Tof Mass Spectrometer.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> Preparation of the (123B9)<sub>2</sub>-Motif</h4><div class="NLM_p last">The preparation of the (123B9)2-motif followed a solid-phase synthetic scheme similar to what we had previously adopted for the syntheses of the YSA-motif<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and the 123B9-motif.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> In the current protocol, 10.0 g of the fully protected peptide on a Rink amide resin was treated with 5% NH<sub>2</sub>–NH<sub>2</sub> in DMF (3 × 40 mL, each 30 min) and was subsequently washed with DMF (3 × 50 mL) and THF (3 × 50 mL). This was followed by a treatment with 5-hexynoic acid (1.5 g, 13.38 mmol) in the presence of TBTU (6. 09 g, 16.05 mmol), HOBt (2.17 g, 16.05 mmol), and DIEPA (4.8 mL, 26.76 mmol) in DMF. For the lysine residue of the motif, we used an Fmoc-Lys(ivDde)-OH amino acid (<i>N</i>-α-Fmoc-<i>N</i>-ε-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl-<span class="smallcaps smallerCapital">l</span>-lysine). This protection contained a sterically hindered Dde variant, rendering the ivDde protecting group considerably more stable. The mixture was filtered to remove the excess coupling agents after being shaken overnight, and the resin was washed with DMF (3 × 50 mL) and THF (3 × 50 mL) and dried under high vacuum. The coupling completion was monitored by the Kaiser ninhydrin test. The dried resin was further treated with TFA/phenol/TIPS/water (88:5:2:5, 30 mL) for 3 h, filtered, and washed with TFA (2 × 10 mL). The filtrate was concentrated under reduced pressure and transferred into centrifuge tubes, and then cold ether (50 mL) was added to these centrifuge tubes to produce the white precipitate. After the tubes were centrifuged for 10 min, the supernatant was decanted, and the precipitate was collected and purified by a reverse-phase C-18 column eluted with water/acetonitrile (0–30%) to provide the title compound (807 mg, yield 8.07%). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.16 (m, 7H), 7.50–8.10 (m, 20H), 7.42 (m, 3H), 7.06 (m, 5H), 6.97 (m, 3H), 4.52–4.53 (m, 5H), 4.38 (m, 3H), 4.20–4.35 (m, 15H), 4.14 (m, 1H), 4.00 (brs, 1H), 3.58–3.90 (m, 20H), 3.54 (m, 8H), 3.43 (m, 4H), 2.98 (m, 6H), 2.89 (m, 1H), 2.78 (m, 1H), 2.76 (s, 1H), 2.72 (m, 1H), 2.63 (m, 1H), 2.53 (m, 1H), 2.13–2.15 (m, 4H), 1.98 (m, 4H), 1.75–1.90 (m, 19H), 1.55–1.70 (m, 8H), 1.49 (m, 4H), 1.35 (m, 2H), 1.20–1.30 (m, 8H), 1.13 (d, <i>J</i> = 7.2 Hz, 6H), 0.88 (d, <i>J</i> = 7.2 Hz, 6H), 0.84 (brs, 12H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 172.46, 172.31, 172.20, 172.09, 172.03, 171.96, 171.71, 171.35, 170.78, 170.71, 170.59, 170.08, 169.96, 169.67, 169.38, 169.24, 168.84, 167.59, 156.22, 154.75, 152.61 (<i>J</i><sub>CF</sub> = 245 Hz), 130.64, 128.11, 120.17, 120.04, 117.68, 117.54, 116.90, 115.65, 115.60, 115.36, 84.53, 71.88, 67.76, 62.17, 62.07, 60.13, 59.58, 57.96, 56.17, 55.58, 55.23, 54.83, 53.23, 52.99, 50.55, 50.45, 49.95, 49.02, 48.36, 47.51, 47.21, 42.57, 42.26, 38.89, 38.71, 36.19, 35.37, 35.30, 34.57, 32.24, 32.01, 31.77, 30.50, 29.37, 29.31, 29.23, 29.05, 27.62, 24.90, 24.83, 24.70, 23.08, 22.35, 21.47, 19.51, 18.69, 18.40, 18.26, 17.82, 14.27. MS (MALDI-TOF, <i>m</i>/<i>z</i>): [M + Na]<sup>+</sup> calcd for C<sub>142</sub>H<sub>204</sub>C<sub>l2</sub>F<sub>2</sub>N<sub>31</sub>O<sub>47</sub>: 3226.37, found: 3226.41.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> Preparation of (123B9)<sub>2</sub>–L2–PTX</h4><div class="NLM_p last">Solutions of CuSO<sub>4</sub> (1.0 M, 50 μL) and sodium ascorbate (1.0 M, 50 μL) were added to a stirred solution of 2′-(6-azidohexanoyl)-<i>O</i>-paclitaxel (103 mg, 0.103 mmol) and the 123B9-motif (422 mg, 0.103 mmol) in DMSO/water (4:1, 3.0 mL) and continually stirred for 2 days. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.50–8.16 (m, 46H), 6.68–7.50 (m, 19 H), 6.64 (d, <i>J</i> = 7.8 Hz, 4H), 6.29 (s, 1H), 5.81 (t, <i>J</i> = 9.0 Hz, 1H), 5.52 (t, <i>J</i> = 9.0 Hz, 1H), 5.41 (d, <i>J</i> = 9.0 Hz, 2H), 4.90 (d, <i>J</i> = 9.0 Hz, 1H), 4.54 (m, 4H), 4.41 (m, 2H), 4.20–4.38 (m, 19H), 4.17 (s, 2H), 4.11 (t, <i>J</i> = 7.2 Hz, 1H), 4.01 (m, 5H), 3.74 (m, 2H), 3.68 (m, 2H), 3.65 (s, 4H), 3.50–3.65 (m, 18H), 3.43 (m, 2H), 3.00 (m, 6H), 2.90 (m, 2H), 2.75 (m, 3H), 2.65 (m, 2H), 2.57 (t, <i>J</i> = 7.8 Hz, 2H), 2.31 (m, 1H), 2.22 (s, 3H), 2.09 (s, 3H), 2.08 (m, 3H), 1.98 (m, 4H), 1.80–1.90 (m, 16H), 1.78 (m, 3H), 1.76 (m, 2H), 1.65 (m, 6H), 1.49–1.55 (m, 6H), 1.49 (s, 3H), 1.37 (m, 1H), 1.19–1.30 (m, 13H), 1.15 (d, <i>J</i> = 7.2 Hz, 6H), 1.02 (s, 3H), 0.99 (s, 3H), 0.89 (d, <i>J</i> = 7.2 Hz, 6H), 0.83 (t, <i>J</i> = 7.2 Hz, 6H), 0.82 (s, 3H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>): δ 202.78, 172.73, 172.31, 172.20, 172.03, 171.97, 171.36, 170.78, 170.59, 170.08, 169.96, 169.67, 169.39, 169.20, 168.84, 167.58, 166.77, 165.63, 158.83, 158.58, 156.44, 156.22, 154.75, 152.61 (<i>J</i><sub>CF</sub> = 245 Hz), 146.85, 144.36, 143.39, 141.15, 139.76, 137.70, 134.59, 133.94, 133.81, 131.96, 130.64, 130.35, 129.99, 129.13, 128.77, 128.65, 128.28, 128.11, 128.05, 127.81, 127.66, 127.46, 125.56, 125.37, 122.09, 120.68, 128.11, 128.05, 127.81, 127.66, 127.46, 125.56, 125.37, 122.09, 120.68, 120.53, 120.17, 120.04, 117.68, 117.53, 116.91, 115.64, 115.60, 115.36, 84.02, 80.66, 77.12, 75.69, 75.13, 74.90, 71.25, 70.81, 70.59, 67.76, 65.57, 62.17, 62.07, 60.13, 59.57, 57.96, 57.80, 56.17, 55.59, 55.23, 54.71, 54.40, 53.25, 52.99, 52.24, 51.86, 50.55, 50.45, 49.95, 49.31, 49.02, 48.57, 48.36, 47.51, 47.19, 46.49, 43.21, 42.36, 42.26, 38.89, 38.74, 36.93, 36.19, 36.10, 35.30, 34.80, 33.32, 32.01, 31.88, 31.79, 31.16, 30.53, 29.72, 29.37, 29.06, 27.77, 27.02, 26.73, 25.67, 25.60, 25.10, 24.90, 24.83, 24.19, 23.12, 22.98, 22.75, 22.35, 21.79, 21.09, 19.51, 18.69, 18.40, 14.27, 10.20. MS (MALDI-TOF, <i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>195</sub>H<sub>264</sub>C<sub>l2</sub>F<sub>2</sub>N<sub>35</sub>O<sub>62</sub>: 4195.79, found: 4196.91. The product was purified on a reverse-phase C-18 column by HPLC with a gradient of 10–90% water/acetonitrile to give the title compound (299 mg, 69%) as a white powder (95% purity).</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Binding and Displacement Assays</h3><div class="NLM_p last">EphA2-LBD and EphA4-LBD were expressed and purified as we previously reported.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Isothermal-titration-calorimetry (ITC) measurements were obtained with a TA Instruments microcalorimeter. For the in vivo studies, all of the drugs were diluted in 10% Tween-80, 10% DMSO, and 80% PBS. For the dissociation-enhanced lanthanide-fluorescent immunoassays (DELFIAs), 100 μL of a 1 μM biotin-123B9 solution was added to each well of 96-well streptavidin-coated plates (PerkinElmer) and incubated for 2 h. The plates were subsequently washed three times to remove the unbound biotin-123B9. After the washing steps, 25 μL solutions of 0.712 μM EphA2-LBD were preincubated with 2.5 μL of serial dilutions of the test compounds for 15 min, and 11 μL of each mixture was added to an 89 μL solution of 4.17 nM Eu–N1-labeled anti-6×His antibody (PerkinElmer) and incubated for 1 h. At the end of the incubation period, a second washing step was performed to remove the unbound protein–Eu antibody complexes that were displaced by the test compounds. Subsequently, 200 μL of the DELFIA enhancement solution (PerkinElmer) was added to each well, which was followed by a 10 min incubation. Fluorescence readings were then measured using the VICTOR X5 microplate reader (PerkinElmer) with excitation and emission wavelengths of 340 and 615 nm, respectively. All of the protein, peptide, and antibody solutions were prepared in a DELFIA assay buffer (PerkinElmer), and the incubations were performed at room temperature. The fluorescence readings were normalized to that of the DMSO control and reported as percent inhibition. The IC<sub>50</sub> values were analyzed using GraphPad Prism Version 6.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Preparation of Viral Particles and Establishment of the EphA2-Expressing Cell Line</h3><div class="NLM_p last">Human embryonic kidney (HEK) 293T/17 cells were purchased from ATCC and grown in Dulbecco’s modified eagle medium (DMEM) with 10% fetal calf serum (FCS) at 37 °C and 5% CO<sub>2</sub>. The cells were transfected with the EphA2 lentiviral plasmid (EX-A0125-Lv105) using the Lenti-Pac HIV Expression Packing Kit (GeneCopoeia, Inc.) to produce lentivirus particles according to manufacturer’s protocol. After 2 days, viral particles were collected and filtered. Stable HEK 293T/17 cells overexpressing EphA2 were established by transducing fresh HEK 293T/17 cells with the viral particles and selecting the cells that overexpressed EphA2 with 1 μg/mL puromycin 2 days post-transduction. EphA2 overexpression was confirmed by a Western blot.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> EphA2 Stimulation and Immunoprecipitation</h3><div class="NLM_p last">The EphA2 stable cell line was plated in 6-well plates. The following day, the complete media was replaced with serum-free DMEM for 2 h, so that the cells were starved. The starved cells were stimulated with 0.5–1 μg/mL clustered mouse ephrin-A1 Fc or Fc (R&D systems) and with goat anti-human IgG Fc (Abcam, catalogue no. ab97221) for 30 min. During the stimulation, the indicated doses of YSA, 123B9, or the 123B9 dimers were added to each well. The control condition was treated with 1% DMSO. The stimulated cells were lysed with cell lysis buffer (20 mM Tris, pH 7.4, 120 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 1% IGEPAL, 5 mM EDTA) supplemented with EDTA-free Protease Inhibitor Cocktail and PhosStop (Sigma-Aldrich) for 30 min on ice. The cell lysates were then centrifuged for 10 min at 13 000 rpm and 4 °C to clear off the cell debris. Protein concentrations were quantified using a BCA Protein Assay kit (ThermoFisher), and the sample concentrations were adjusted to 1 μg/μL for all of the samples. The preclear steps for the cell lysates were performed using Pierce Protein A/G Agarose beads (ThermoFisher) for 1 h at 4 °C. The cell lysates and beads were centrifuged, and the supernatants were each incubated with 2 μg of mouse anti-EphA2-receptor antibodies (ThermoFisher, catalogue no. 1C11A12) at 4 °C overnight. The next day, the cell-lysate–antibody complexes were incubated with A/G agarose beads for 2 h at room temperature. After several washes, the target protein was eluted by being heated in 2× NuPAGE LDS sample buffer and NuPAGE antioxidant (ThermoFisher) for 5 min at 90 °C. The samples were loaded into 4–12% NuPAGE Bis-Tris precast gels and transferred to PVDF membranes. The membranes were blocked with 5% BSA in TBS and 0.1% Tween (TBST) for 1 h and then incubated with 1:3000 dilutions of mouse anti-phosphotyrosine antibodies (BD Biosciences, catalogue no. 610000, clone PY20) for 1 h. The antigen–antibody complexes were visualized using a Clarity Western ECL kit (BIO-RAD). The membranes were washed and stripped using the Restore Western Blot Stripping Buffer for 1 h and subsequently blocked with 5% nonfat milk in TBST. This was followed by a 1 h incubation with primary mouse anti-EphA2-receptor antibodies at 1:2000 dilutions. The membranes were then washed with TBST and incubated with goat anti-mouse HRP. The bands were visualized as mentioned previously.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> In Vivo Allogeneic Breast-Cancer-Metastasis Model</h3><div class="NLM_p last">Animal studies were carried out in accordance with the approved Cedars-Sinai Institutional Animal Care and Use Committee (IACUC) protocol. In order to evaluate (123B9)<sub>2</sub>–L2–PTX on metastasis and more specifically on CTC, we used a basal MDA-MB-231 human breast carcinoma (1 × 10<sup>6</sup> cells) orthotopically injected into the mammary fat pads of NOD SCID mice. Once the primary tumors reached sizes of approximately 1 mm<sup>3</sup>, the mice were intravenously treated with (123B9)<sub>2</sub>–L2–PTX three times a week for a period of 2 weeks at a dose of 24.5 mg/kg, the molecular equivalent of the PTX dose (5 mg/kg) in the Abraxane group. When each animal was sacrificed, whole blood was collected, and CTC was estimated. (123B9)<sub>2</sub>–PTX was dissolved in an aqueous formulation containing 84% PBS, 8% DMSO, and 8% Tween-20 and injected in a 100 μL final volume.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> In Vivo Syngeneic Breast-Cancer-Metastasis Model</h3><div class="NLM_p last">Mouse triple-negative 4T1 breast-cancer cells (1 × 10<sup>5</sup> cells) were injected into the left ventricles of hearts, which served as the syngeneic metastasis model. Fifteen days after injection, the animals were treated with (123B9)<sub>2</sub>–L2–PTX or Abraxane three times a week for a period of 2 weeks at the previously indicated doses.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Immunohistochemical Analyses</h3><div class="NLM_p last">CD31 staining was done by immunochemistry. Briefly, paraffin-embedded sections were deparaffinized in xylene, rehydrated through graded ethanol, and then submerged into citric acid buffer for the heat-induced antigenic retrieval. They were then blocked with 10% bovine serum albumin, incubated with the CD31 primary antibodies at 4 °C overnight, and developed using the DAKO ChemMate Envision Kit/HRP (Dako-Cytomation). They were then counterstained with hematoxylin, dehydrated, cleared, and mounted.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> NanoVelcro Chip for Single CTC Isolation</h3><div class="NLM_p last">NanoVelcro CTC assays represented a unique rare-cell sorting method that enabled the detection, isolation, and characterization of CTCs in peripheral blood. The NanoVelcro Chip was composed of (1) a cell-affinity substrate coated with poly(lactic-<i>co</i>-glycolic acid) (PLGA) nanofibers and (2) an overlaid PDMS chaotic mixer. This chip was used in conjunction with an LCM microscope to isolate the captured CTCs.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> In brief, the PLGA-nanofibers covalently functionalized with streptavidin enabled the selective capture of CTCs labeled with biotinylated anti-EpCAM antibodies. This surface facilitated CTC capture through its unique topography. After the CTCs were immobilized on the substrate, the CTCs were stained with FITC-labeled anticytokeratin (for the epithelia) and TRITC-labeled anti-CD45 (for the immune cells). The CTCs were defined as cytokeratin-expressing cells that were absent of CD45 expression and whose morphology could be confirmed by a board-certified pathologist using bright-field microscopy.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01837" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45643" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45643" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01837" class="ext-link">10.1021/acs.jmedchem.7b01837</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Biological data cited in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01837/suppl_file/jm7b01837_si_001.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01837/suppl_file/jm7b01837_si_001.csv">jm7b01837_si_001.csv (0.9 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b01837" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64401" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64401" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maurizio Pellecchia</span> - <span class="hlFld-Affiliation affiliation">Division
of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5179-470X" title="Orcid link">http://orcid.org/0000-0001-5179-470X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#74191501061d0e1d1b5a041118181117171c1d15340117065a111001"><span class="__cf_email__" data-cfemail="c1aca0b4b3a8bba8aeefb1a4adada4a2a2a9a8a081b4a2b3efa4a5b4">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ahmed
F. Salem</span> - <span class="hlFld-Affiliation affiliation">Division
of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Si Wang</span> - <span class="hlFld-Affiliation affiliation">Sanford-Burnham-Prebys
Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, California 92037, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandrine Billet</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jie-Fu Chen</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Parima Udompholkul</span> - <span class="hlFld-Affiliation affiliation">Division
of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luca Gambini</span> - <span class="hlFld-Affiliation affiliation">Division
of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carlo Baggio</span> - <span class="hlFld-Affiliation affiliation">Division
of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hsian-Rong Tseng</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular & Medical Pharmacology, University of California, Los Angeles, 570 Westwood Plaza, Los
Angeles, California 90095, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9028-8527" title="Orcid link">http://orcid.org/0000-0001-9028-8527</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Edwin M. Posadas</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neil A. Bhowmick</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Research, Greater Los Angeles Veterans
Administration, Los Angeles, California 90073, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>A.F.S., S.W., and S.B. contributed equally to this work</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28875" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28875" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Financial support was obtained in part by the NIH with NCI grants CA149668 and CA168517. M.P. holds the Daniel Hays Chair in Cancer Research at the School of Medicine at the University of California, Riverside (UCR). P.U. is a recipient of the 2017–2018 Pease Cancer Fellowship through the Division of Biomedical Sciences, School of Medicine, UCR.</p></div><table summary="" class="NLM_def-list" id="DEF-LIST-d7e1243-autogenerated"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">EphA2-LBD</td><td class="NLM_def"><p class="first last">ephrin type-A receptor 2 ligand-binding domain</p></td></tr><tr><td class="NLM_term">PTX</td><td class="NLM_def"><p class="first last">paclitaxel</p></td></tr><tr><td class="NLM_term">ABX</td><td class="NLM_def"><p class="first last">Abraxane</p></td></tr><tr><td class="NLM_term">CTC</td><td class="NLM_def"><p class="first last">circulating tumor cells</p></td></tr><tr><td class="NLM_term">PLGA</td><td class="NLM_def"><p class="first last">poly(lactic-<i>co</i>-glycolic acid)</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30313" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30313" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 68 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugahara, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teesalu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karmali, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotamraju, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agemy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwald, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoslahti, E.</span></span> <span> </span><span class="NLM_article-title">Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>328</i></span>,  <span class="NLM_fpage">1031</span>– <span class="NLM_lpage">1035</span>, <span class="refDoi"> DOI: 10.1126/science.1183057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1126%2Fscience.1183057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=20378772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtFCnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=328&publication_year=2010&pages=1031-1035&author=K.+N.+Sugaharaauthor=T.+Teesaluauthor=P.+P.+Karmaliauthor=V.+R.+Kotamrajuauthor=L.+Agemyauthor=D.+R.+Greenwaldauthor=E.+Ruoslahti&title=Coadministration+of+a+tumor-penetrating+peptide+enhances+the+efficacy+of+cancer+drugs&doi=10.1126%2Fscience.1183057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs</span></div><div class="casAuthors">Sugahara, Kazuki N.; Teesalu, Tambet; Karmali, Priya Prakash; Kotamraju, Venkata Ramana; Agemy, Lilach; Greenwald, Daniel R.; Ruoslahti, Erkki</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">328</span>
        (<span class="NLM_cas:issue">5981</span>),
    <span class="NLM_cas:pages">1031-1035</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Poor penetration of anticancer drugs into tumors can be an important factor limiting their efficacy.  We studied mouse tumor models to show that a previously characterized tumor-penetrating peptide, iRGD, increased vascular and tissue permeability in a tumor-specific and neuropilin-1-dependent manner, allowing coadministered drugs to penetrate into extravascular tumor tissue.  Importantly, this effect did not require the drugs to be chem. conjugated to the peptide.  Systemic injection with iRGD improved the therapeutic index of drugs of various compns., including a small mol. (doxorubicin), nanoparticles (nab-paclitaxel and doxorubicin liposomes), and a monoclonal antibody (trastuzumab).  Thus, coadministration of iRGD may be a valuable way to enhance the efficacy of anticancer drugs while reducing their side effects, a primary goal of cancer therapy research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnpbZBSXSmfrVg90H21EOLACvtfcHk0ljeSxY1ahPGbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtFCnsb4%253D&md5=c8103ff227adc4061b92a62157b7a36f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.1183057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1183057%26sid%3Dliteratum%253Aachs%26aulast%3DSugahara%26aufirst%3DK.%2BN.%26aulast%3DTeesalu%26aufirst%3DT.%26aulast%3DKarmali%26aufirst%3DP.%2BP.%26aulast%3DKotamraju%26aufirst%3DV.%2BR.%26aulast%3DAgemy%26aufirst%3DL.%26aulast%3DGreenwald%26aufirst%3DD.%2BR.%26aulast%3DRuoslahti%26aufirst%3DE.%26atitle%3DCoadministration%2520of%2520a%2520tumor-penetrating%2520peptide%2520enhances%2520the%2520efficacy%2520of%2520cancer%2520drugs%26jtitle%3DScience%26date%3D2010%26volume%3D328%26spage%3D1031%26epage%3D1035%26doi%3D10.1126%2Fscience.1183057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teesalu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugahara, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoslahti, E.</span></span> <span> </span><span class="NLM_article-title">Tumor-penetrating peptides</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">216</span>, <span class="refDoi"> DOI: 10.3389/fonc.2013.00216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.3389%2Ffonc.2013.00216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=23986882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A280%3ADC%252BC3sbjtlGrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=216&author=T.+Teesaluauthor=K.+N.+Sugaharaauthor=E.+Ruoslahti&title=Tumor-penetrating+peptides&doi=10.3389%2Ffonc.2013.00216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-penetrating peptides</span></div><div class="casAuthors">Teesalu Tambet; Sugahara Kazuki N; Ruoslahti Erkki</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">216</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Tumor-homing peptides can be used to deliver drugs into tumors.  Phage library screening in live mice has recently identified homing peptides that specifically recognize the endothelium of tumor vessels, extravasate, and penetrate deep into the extravascular tumor tissue.  The prototypic peptide of this class, iRGD (CRGDKGPDC), contains the integrin-binding RGD motif.  RGD mediates tumor-homing through binding to αv integrins, which are selectively expressed on various cells in tumors, including tumor endothelial cells.  The tumor-penetrating properties of iRGD are mediated by a second sequence motif, R/KXXR/K.  This C-end Rule (or CendR) motif is active only when the second basic residue is exposed at the C-terminus of the peptide.  Proteolytic processing of iRGD in tumors activates the cryptic CendR motif, which then binds to neuropilin-1 activating an endocytic bulk transport pathway through tumor tissue.  Phage screening has also yielded tumor-penetrating peptides that function like iRGD in activating the CendR pathway, but bind to a different primary receptor.  Moreover, novel tumor-homing peptides can be constructed from tumor-homing motifs, CendR elements and protease cleavage sites.  Pathologies other than tumors can be targeted with tissue-penetrating peptides, and the primary receptor can also be a vascular "zip code" of a normal tissue.  The CendR technology provides a solution to a major problem in tumor therapy, poor penetration of drugs into tumors.  The tumor-penetrating peptides are capable of taking a payload deep into tumor tissue in mice, and they also penetrate into human tumors ex vivo.  Targeting with these peptides specifically increases the accumulation in tumors of a variety of drugs and contrast agents, such as doxorubicin, antibodies, and nanoparticle-based compounds.  Remarkably the drug to be targeted does not have to be coupled to the peptide; the bulk transport system activated by the peptide sweeps along any compound that is present in the blood.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQW6rUhtQrVfgHqQV89nF-2fW6udTcc2eY-ii0DLI7a_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbjtlGrtg%253D%253D&md5=5bd13d57c5bc6026c30e04de0ab2d087</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2013.00216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2013.00216%26sid%3Dliteratum%253Aachs%26aulast%3DTeesalu%26aufirst%3DT.%26aulast%3DSugahara%26aufirst%3DK.%2BN.%26aulast%3DRuoslahti%26aufirst%3DE.%26atitle%3DTumor-penetrating%2520peptides%26jtitle%3DFront.%2520Oncol.%26date%3D2013%26volume%3D3%26spage%3D216%26doi%3D10.3389%2Ffonc.2013.00216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coffman, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carles-Kinch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donacki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munyon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kifle, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langermann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiener, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span> <span> </span><span class="NLM_article-title">Differential EphA2 epitope display on normal versus malignant cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">7907</span>– <span class="NLM_lpage">7912</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=7907-7912&author=K.+T.+Coffmanauthor=M.+Huauthor=K.+Carles-Kinchauthor=D.+Ticeauthor=N.+Donackiauthor=K.+Munyonauthor=G.+Kifleauthor=R.+Woodsauthor=S.+Langermannauthor=P.+A.+Kienerauthor=M.+S.+Kinch&title=Differential+EphA2+epitope+display+on+normal+versus+malignant+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCoffman%26aufirst%3DK.%2BT.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DCarles-Kinch%26aufirst%3DK.%26aulast%3DTice%26aufirst%3DD.%26aulast%3DDonacki%26aufirst%3DN.%26aulast%3DMunyon%26aufirst%3DK.%26aulast%3DKifle%26aufirst%3DG.%26aulast%3DWoods%26aufirst%3DR.%26aulast%3DLangermann%26aufirst%3DS.%26aulast%3DKiener%26aufirst%3DP.%2BA.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26atitle%3DDifferential%2520EphA2%2520epitope%2520display%2520on%2520normal%2520versus%2520malignant%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D7907%26epage%3D7912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zelinski, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zantek, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irizarry, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span> <span> </span><span class="NLM_article-title">EphA2 overexpression causes tumorigenesis of mammary epithelial cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2301</span>– <span class="NLM_lpage">2306</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=11280802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD3MXit1Ogt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=2301-2306&author=D.+P.+Zelinskiauthor=N.+D.+Zantekauthor=J.+C.+Stewartauthor=A.+R.+Irizarryauthor=M.+S.+Kinch&title=EphA2+overexpression+causes+tumorigenesis+of+mammary+epithelial+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2 overexpression causes tumorigenesis of mammary epithelial cells</span></div><div class="casAuthors">Zelinski, Daniel P.; Zantek, Nicole Dodge; Stewart, Jane C.; Irizarry, Armando R.; Kinch, Michael S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2301-2306</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Elevated levels of protein tyrosine phosphorylation contribute to a malignant phenotype, although the tyrosine kinases that are responsible for this signaling remain largely unknown.  Here we report increased levels of the EphA2 (ECK) protein tyrosine kinase in clin. specimens and cell models of breast cancer.  We also show that EphA2 overexpression is sufficient to confer malignant transformation and tumorigenic potential on nontransformed (MCF-10A) mammary epithelial cells.  The transforming capacity of EphA2 is related to the failure of EphA2 to interact with its cell-attached ligands.  Interestingly, stimulation of EphA2 reverses the malignant growth and invasiveness of EphA2-transformed cells.  Taken together, these results identify EphA2 as a powerful oncoprotein in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo58hxWRfVuHbVg90H21EOLACvtfcHk0liFJ46_kME4Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXit1Ogt7k%253D&md5=85938000464a9c614e24d0889fbe2dff</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZelinski%26aufirst%3DD.%2BP.%26aulast%3DZantek%26aufirst%3DN.%2BD.%26aulast%3DStewart%26aufirst%3DJ.%2BC.%26aulast%3DIrizarry%26aufirst%3DA.%2BR.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26atitle%3DEphA2%2520overexpression%2520causes%2520tumorigenesis%2520of%2520mammary%2520epithelial%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D2301%26epage%3D2306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ireton, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.2174/1568009053765780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.2174%2F1568009053765780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=15892616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksFKksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=149-157&author=R.+C.+Iretonauthor=J.+Chen&title=EphA2+receptor+tyrosine+kinase+as+a+promising+target+for+cancer+therapeutics&doi=10.2174%2F1568009053765780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics</span></div><div class="casAuthors">Ireton, Renee C.; Chen, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">149-157</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Eph receptors are a unique family of receptor tyrosine kinases (RTK) that play crit. roles in embryonic patterning, neuronal targeting, and vascular development during normal embryogenesis.  Eph RTKs and their ligands, the ephrins, are also frequently overexpressed in a variety of cancers and tumor cell lines.  In particular, one family member, EphA2, is overexpressed in breast, prostate, lung, and colon cancers.  Unlike traditional oncogenes that often function only in tumor cells, recent data show that Eph receptors mediate cell-cell interactions both in tumor cells and in the tumor microenvironment, namely the tumor stroma and tumor vasculature.  Thus, EphA2 receptors are attractive targets for drug design, as targeting these mols. could simultaneously inhibit several aspects of tumor progression.  This review focuses on the multiple roles of EphA2 in cancer progression, the mechanisms by which EphA2 inhibition may halt this progression, and the pre-clin. results of EphA2 inhibition in various cancer model systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXkP68V5-EhLVg90H21EOLACvtfcHk0liFJ46_kME4Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksFKksbc%253D&md5=4ec492801946594928f5b87a4727134a</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2174%2F1568009053765780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009053765780%26sid%3Dliteratum%253Aachs%26aulast%3DIreton%26aufirst%3DR.%2BC.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DEphA2%2520receptor%2520tyrosine%2520kinase%2520as%2520a%2520promising%2520target%2520for%2520cancer%2520therapeutics%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2005%26volume%3D5%26spage%3D149%26epage%3D157%26doi%3D10.2174%2F1568009053765780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tandon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemula, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, S. K.</span></span> <span> </span><span class="NLM_article-title">Emerging strategies for EphA2 receptor targeting for cancer therapeutics</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1517/14728222.2011.538682</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1517%2F14728222.2011.538682" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=21142802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGlurbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=31-51&author=M.+Tandonauthor=S.+V.+Vemulaauthor=S.+K.+Mittal&title=Emerging+strategies+for+EphA2+receptor+targeting+for+cancer+therapeutics&doi=10.1517%2F14728222.2011.538682"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging strategies for EphA2 receptor targeting for cancer therapeutics</span></div><div class="casAuthors">Tandon, Manish; Vemula, Sai Vikram; Mittal, Suresh K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-51</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: High mortality rates with cancers warrant further development of earlier diagnostics and better treatment strategies.  Membrane-bound erythropoietin-producing hepatocellular receptor tyrosine kinase class A2 (EphA2) is overexpressed in breast, prostate, urinary bladder, skin, lung, ovary and brain cancers.  Areas covered in this review: EphA2 overexpression in cancers, its signaling mechanisms and strategies to target its deregulation.  What the reader will gain: High EphA2 expression in cancer cells is correlated with a poor prognosis assocd. with recurrence due to enhanced metastasis.  Interaction of the EphA2 receptor with its ligand (e.g., ephrinA1) triggers events that are deregulated and implicated in carcinogenesis.  EphrinA1-independent oncogenic activity and ephrinA1-dependent tumor suppressor roles for EphA2 are described.  Mol. interactions of EphA2 with signaling proteins are assocd. with the modulation of cytoskeleton dynamics, cell adhesion, proliferation, differentiation and metastasis.  The deregulated signaling by EphA2 and its involvement in oncogenesis provide multiple avenues for the rational design of intervention approaches.  Take home message: EphA2 has been tested as a drug target using multiple approaches such as agonist antibodies, RNA interference, immunotherapy, virus vector-mediated gene transfer, small-mol. inhibitors and nanoparticles.  With over a decade of research, encouraging results with targeting of EphA2 expression in various pre-clin. cancer models necessitate further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkUoM-7uf_sLVg90H21EOLACvtfcHk0liFJ46_kME4Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGlurbP&md5=2b082cbbe88132ae4e6b21c56e7defc1</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1517%2F14728222.2011.538682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2011.538682%26sid%3Dliteratum%253Aachs%26aulast%3DTandon%26aufirst%3DM.%26aulast%3DVemula%26aufirst%3DS.%2BV.%26aulast%3DMittal%26aufirst%3DS.%2BK.%26atitle%3DEmerging%2520strategies%2520for%2520EphA2%2520receptor%2520targeting%2520for%2520cancer%2520therapeutics%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2011%26volume%3D15%26spage%3D31%26epage%3D51%26doi%3D10.1517%2F14728222.2011.538682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wykosky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debinski, W.</span></span> <span> </span><span class="NLM_article-title">The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1795</span>– <span class="NLM_lpage">1806</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-08-0244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1158%2F1541-7786.MCR-08-0244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=19074825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsV2iu7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=1795-1806&author=J.+Wykoskyauthor=W.+Debinski&title=The+EphA2+receptor+and+ephrinA1+ligand+in+solid+tumors%3A+function+and+therapeutic+targeting&doi=10.1158%2F1541-7786.MCR-08-0244"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting</span></div><div class="casAuthors">Wykosky, Jill; Debinski, Waldemar</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1795-1806</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The Eph receptor tyrosine kinases and ephrin ligands have been studied extensively for their roles in developmental processes.  In recent years, Eph receptors and ephrins have been found to be integral players in cancer formation and progression.  Among these are EphA2 and ephrinA1, which are involved in the development and maintenance of many different types of solid tumors.  The function of EphA2 and ephrinA1 in tumorigenesis and tumor progression is complex and seems to be dependent on cell type and microenvironment.  These variables affect the expression of the EphA2 and ephrinA1 proteins, the pathways through which they induce signaling, and the functional consequences of that signaling on the behavior of tumor cells and tumor-assocd. cells.  This review will specifically focus on the roles that EphA2 and ephrinA1 play in the different cell types that contribute to the malignancy of solid tumors, with emphasis on the opportunities for therapeutic targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbwIAXRgx44LVg90H21EOLACvtfcHk0lh1RCcKhh-0Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsV2iu7nI&md5=b507c55f0e81cb70cede51f69b3d5870</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-08-0244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-08-0244%26sid%3Dliteratum%253Aachs%26aulast%3DWykosky%26aufirst%3DJ.%26aulast%3DDebinski%26aufirst%3DW.%26atitle%3DThe%2520EphA2%2520receptor%2520and%2520ephrinA1%2520ligand%2520in%2520solid%2520tumors%253A%2520function%2520and%2520therapeutic%2520targeting%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2008%26volume%3D6%26spage%3D1795%26epage%3D1806%26doi%3D10.1158%2F1541-7786.MCR-08-0244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span> <span> </span><span class="NLM_article-title">Eph receptors and ephrins in cancer: bidirectional signalling and beyond</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">180</span>, <span class="refDoi"> DOI: 10.1038/nrc2806</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1038%2Fnrc2806" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=20179713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitlaitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=165-180&author=E.+B.+Pasquale&title=Eph+receptors+and+ephrins+in+cancer%3A+bidirectional+signalling+and+beyond&doi=10.1038%2Fnrc2806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Eph receptors and ephrins in cancer: bidirectional signaling and beyond</span></div><div class="casAuthors">Pasquale, Elena B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">165-180</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The Eph receptor tyrosine kinases and their ephrin ligands have intriguing expression patterns in cancer cells and tumor blood vessels, which suggest important roles for their bidirectional signals in many aspects of cancer development and progression.  Eph gene mutations probably also contribute to cancer pathogenesis.  Eph receptors and ephrins have been shown to affect the growth, migration and invasion of cancer cells in culture as well as tumor growth, invasiveness, angiogenesis and metastasis in vivo.  However, Eph signaling activities in cancer seem to be complex, and are characterized by puzzling dichotomies.  Nevertheless, the Eph receptors are promising new therapeutic targets in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryHNhAMFltdbVg90H21EOLACvtfcHk0lh1RCcKhh-0Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitlaitrw%253D&md5=bbbb8188202649354faa3c50d204d0c5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrc2806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2806%26sid%3Dliteratum%253Aachs%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26atitle%3DEph%2520receptors%2520and%2520ephrins%2520in%2520cancer%253A%2520bidirectional%2520signalling%2520and%2520beyond%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D165%26epage%3D180%26doi%3D10.1038%2Fnrc2806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biao-Xue, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi-Guang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuan-Ying, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zong-Juan, M.</span></span> <span> </span><span class="NLM_article-title">EphA2-dependent molecular targeting therapy for malignant tumors</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1082</span>– <span class="NLM_lpage">1097</span>, <span class="refDoi"> DOI: 10.2174/156800911798073050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.2174%2F156800911798073050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=21933105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A280%3ADC%252BC383gs1ehtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1082-1097&author=R.+Biao-Xueauthor=C.+Xi-Guangauthor=Y.+Shuan-Yingauthor=L.+Weiauthor=M.+Zong-Juan&title=EphA2-dependent+molecular+targeting+therapy+for+malignant+tumors&doi=10.2174%2F156800911798073050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2-dependent molecular targeting therapy for malignant tumors</span></div><div class="casAuthors">Biao-xue Rong; Xi-guang Cai; Shuan-ying Yang; Wei Li; Zong-juan Ming</div><div class="citationInfo"><span class="NLM_cas:title">Current cancer drug targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1082-97</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Clarification of the molecular mechanisms of oncogenesis and drug resistance is a prerequisite for the development of new treatment strategies like molecularly targeted therapies.  Recent studies demonstrate that EphA2 is overexpressed in human cancers and that EphA2 increases tumor invasion and survival.  Thus, an EphA2 receptor antagonist, such as a specific tyrosine kinase inhibitor (in the form of an antibody, small molecule, peptide, or siRNA) or an antibody-drug conjugate that targets the EphA2 receptor could be the basis for a novel targeted antineoplastic therapy.  This review summarizes the role of EphA2 in tumorigenesis and the development of EphA2 receptor antagonists as candidate anti-cancer agents.  We suggests that continued research into the function of EphA2 signaling in the pathobiology of neoplasia could lead to more rationally designed therapeutics targeting EphA2 in solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTMsB4DmqQ9_pp6t8nS6Nc3fW6udTcc2eZKKma43014xLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383gs1ehtA%253D%253D&md5=04ec16254a29e8ee8e910def8cafef70</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F156800911798073050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156800911798073050%26sid%3Dliteratum%253Aachs%26aulast%3DBiao-Xue%26aufirst%3DR.%26aulast%3DXi-Guang%26aufirst%3DC.%26aulast%3DShuan-Ying%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DZong-Juan%26aufirst%3DM.%26atitle%3DEphA2-dependent%2520molecular%2520targeting%2520therapy%2520for%2520malignant%2520tumors%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2011%26volume%3D11%26spage%3D1082%26epage%3D1097%26doi%3D10.2174%2F156800911798073050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beauchamp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debinski, W.</span></span> <span> </span><span class="NLM_article-title">Ephs and ephrins in cancer: ephrin-A1 signalling</span>. <i>Semin. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1016/j.semcdb.2011.10.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.semcdb.2011.10.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=109-115&author=A.+Beauchampauthor=W.+Debinski&title=Ephs+and+ephrins+in+cancer%3A+ephrin-A1+signalling&doi=10.1016%2Fj.semcdb.2011.10.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.semcdb.2011.10.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcdb.2011.10.019%26sid%3Dliteratum%253Aachs%26aulast%3DBeauchamp%26aufirst%3DA.%26aulast%3DDebinski%26aufirst%3DW.%26atitle%3DEphs%2520and%2520ephrins%2520in%2520cancer%253A%2520ephrin-A1%2520signalling%26jtitle%3DSemin.%2520Cell%2520Dev.%2520Biol.%26date%3D2012%26volume%3D23%26spage%3D109%26epage%3D115%26doi%3D10.1016%2Fj.semcdb.2011.10.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasqualini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindberg, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span> <span> </span><span class="NLM_article-title">The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6043</span>– <span class="NLM_lpage">6052</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1204004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1038%2Fsj.onc.1204004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=11146556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsFCrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=6043-6052&author=K.+Ogawaauthor=R.+Pasqualiniauthor=R.+A.+Lindbergauthor=R.+Kainauthor=A.+L.+Freemanauthor=E.+B.+Pasquale&title=The+ephrin-A1+ligand+and+its+receptor%2C+EphA2%2C+are+expressed+during+tumor+neovascularization&doi=10.1038%2Fsj.onc.1204004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization</span></div><div class="casAuthors">Ogawa, Kazushige; Pasqualini, Renata; Lindberg, Richard A.; Kain, Renate; Freeman, Andrew L.; Pasquale, Elena B.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">6043-6052</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Eph receptor tyrosine kinases and their ephrin ligands have been implicated in embryonic vascular development and in in vivo models of angiogenesis.  Eph proteins may also regulate tumor neovascularization, but this role has not been previously investigated.  To screen for Eph proteins expressed in tumor blood vessels, we used tumor xenografts grown in nude mice from MDA-MB-435 human breast cancer cells or KS1767 human Kaposi's sarcoma cells.  By immunohistochem., the ephrin-A1 ligand and one of its receptors, EphA2, were detected throughout tumor vasculature.  Double-labeling with anti-CD34 antibodies demonstrated that both ephrin-A1 and EphA2 were expressed in xenograft endothelial cells and also tumor cells.  Furthermore, EphA2 was tyrosine-phosphorylated in the xenograft tumors, indicating that it was activated, presumably by interacting with ephrin-A1.  Ephrin-A1 and EphA2 were also detected in both the vasculature and tumor cells of surgically removed human cancers.  In an in vitro angiogenesis model, a dominant neg. form of EphA2 inhibited capillary tube-like formation by human umbilical vein endothelial cells (HUVECs), demonstrating a requirement for EphA receptor signaling.  These data suggest that ephrin-A1 and EphA2 play a role in human cancers, at least in part by influencing tumor neovascularization.  Eph proteins may represent promising new targets for antiangiogenic cancer treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCCtY-hNNoh7Vg90H21EOLACvtfcHk0lh0UN0zjAUB2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsFCrsw%253D%253D&md5=26f020aa24c07f8adc321af3d6ac5924</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1204004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1204004%26sid%3Dliteratum%253Aachs%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DPasqualini%26aufirst%3DR.%26aulast%3DLindberg%26aufirst%3DR.%2BA.%26aulast%3DKain%26aufirst%3DR.%26aulast%3DFreeman%26aufirst%3DA.%2BL.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26atitle%3DThe%2520ephrin-A1%2520ligand%2520and%2520its%2520receptor%252C%2520EphA2%252C%2520are%2520expressed%2520during%2520tumor%2520neovascularization%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D6043%26epage%3D6052%26doi%3D10.1038%2Fsj.onc.1204004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker-Daniels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhim, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bostwick, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span> <span> </span><span class="NLM_article-title">Overexpression of the EphA2 tyrosine kinase in prostate cancer</span>. <i>Prostate</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1002%2F%28SICI%291097-0045%2819991201%2941%3A4%3C275%3A%3AAID-PROS8%3E3.0.CO%3B2-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10544301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADyaK1MXotFWktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1999&pages=275-280&author=J.+Walker-Danielsauthor=K.+Coffmanauthor=M.+Azimiauthor=J.+S.+Rhimauthor=D.+G.+Bostwickauthor=P.+Snyderauthor=B.+J.+Kernsauthor=D.+J.+Watersauthor=M.+S.+Kinch&title=Overexpression+of+the+EphA2+tyrosine+kinase+in+prostate+cancer&doi=10.1002%2F%28SICI%291097-0045%2819991201%2941%3A4%3C275%3A%3AAID-PROS8%3E3.0.CO%3B2-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of the EphA2 tyrosine kinase in prostate cancer</span></div><div class="casAuthors">Walker-Daniels, J.; Coffman, K.; Azimi, M.; Rhim, J. S.; Bostwick, D. G.; Snyder, P.; Kerns, B. J.; Waters, D. J.; Kinch, M. S.</div><div class="citationInfo"><span class="NLM_cas:title">Prostate (New York)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">275-280</span>CODEN:
                <span class="NLM_cas:coden">PRSTDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-4137</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">BACKGROUND. Mols. that are highly expressed by human prostate cancers may serve as therapeutically relevant targets or tumor markers.  Tyrosine kinases are frequently over-expressed in metastatic tumor cells and this prompted us to screen for tyrosine kinases that are overexpressed in prostate cancer cells.  METHODS. Expression levels of the EphA2 receptor tyrosine kinase were detd. by Western blot anal. in canine and human prostate cancer cell lines and in immortalized and transformed variants of 267B1 prostatic epithelial cells.  EphA2 levels in benign human prostate and prostate cancers were also detd. in formalin-fixed, paraffin-embedded tissues using immunohistochem. staining.  RESULTS. Metastatic prostate cancer cells overexpressed EphA2 by 10-100 fold as compared with non-invasive prostatic epithelial cells.  EphA2 immunoreactivity in vivo was also significantly greater in human prostate cancers as compared with benign prostate epithelium.  CONCLUSIONS. The EphA2 receptor tyrosine kinase is differentially expressed in human and canine prostate cancer cell lines and overexpressed in human prostate cancers as compared with benign prostate tissues.  Metastasis-derived canine prostate carcinoma cell lines overexpress EphA2 and may provide pre-clin. models to further evaluate the role of EphA2 in prostate carcinogenesis.  Further investigations are needed to det. the utility of EphA2 as a tumor marker and a novel target in human prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbX-v8g0g3xbVg90H21EOLACvtfcHk0lh0UN0zjAUB2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXotFWktrw%253D&md5=79382dfa07eb5866eb6dc91970fdc49a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-0045%2819991201%2941%3A4%3C275%3A%3AAID-PROS8%3E3.0.CO%3B2-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-0045%252819991201%252941%253A4%253C275%253A%253AAID-PROS8%253E3.0.CO%253B2-T%26sid%3Dliteratum%253Aachs%26aulast%3DWalker-Daniels%26aufirst%3DJ.%26aulast%3DCoffman%26aufirst%3DK.%26aulast%3DAzimi%26aufirst%3DM.%26aulast%3DRhim%26aufirst%3DJ.%2BS.%26aulast%3DBostwick%26aufirst%3DD.%2BG.%26aulast%3DSnyder%26aufirst%3DP.%26aulast%3DKerns%26aufirst%3DB.%2BJ.%26aulast%3DWaters%26aufirst%3DD.%2BJ.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26atitle%3DOverexpression%2520of%2520the%2520EphA2%2520tyrosine%2520kinase%2520in%2520prostate%2520cancer%26jtitle%3DProstate%26date%3D1999%26volume%3D41%26spage%3D275%26epage%3D280%26doi%3D10.1002%2F%28SICI%291097-0045%2819991201%2941%3A4%3C275%3A%3AAID-PROS8%3E3.0.CO%3B2-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flockhart, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldridge, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulbright, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eble, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span> <span> </span><span class="NLM_article-title">High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">2271</span>– <span class="NLM_lpage">2276</span>, <span class="refDoi"> DOI: 10.1016/S0002-9440(10)63584-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2FS0002-9440%2810%2963584-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=14633601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkslGm" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2003&pages=2271-2276&author=G.+Zengauthor=Z.+Huauthor=M.+S.+Kinchauthor=C.+X.+Panauthor=D.+A.+Flockhartauthor=C.+Kaoauthor=T.+A.+Gardnerauthor=S.+Zhangauthor=L.+Liauthor=L.+A.+Baldridgeauthor=M.+O.+Kochauthor=T.+M.+Ulbrightauthor=J.+N.+Ebleauthor=L.+Cheng&title=High-level+expression+of+EphA2+receptor+tyrosine+kinase+in+prostatic+intraepithelial+neoplasia&doi=10.1016%2FS0002-9440%2810%2963584-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia</span></div><div class="casAuthors">Zeng, Guangyuan; Hu, Zhiqiang; Kinch, Michael S.; Pan, Chong-Xian; Flockhart, David A.; Kao, Chinghai; Gardner, Thomas A.; Zhang, Shaobo; Li, Lang; Baldridge, Lee Ann; Koch, Michael O.; Ulbright, Thomas M.; Eble, John N.; Cheng, Liang</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2271-2276</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">EphA2 is a transmembrane receptor tyrosine kinase that is overexpressed in many carcinomas.  Specific targeting of EphA2 with monoclonal antibodies is sufficient to inhibit the growth, migration and invasiveness of aggressive cancers in animal models.  Using immunohistochem. analyses, the authors measured the expression of EphA2 in prostatic adenocarcinoma, high-grade prostatic intraepithelial neoplasia, and adjacent benign prostate tissue from 93 radical prostatectomy specimens.  These results were related to multiple clin. and pathol. characteristics.  The fraction of cells staining pos. with EphA2 in benign prostatic epithelium (mean, 12%) was significantly lower than that in high-grade prostatic intraepithelial neoplasia (mean, 67%, P < 0.001) and prostatic adenocarcinoma (mean, 85%, P < 0.001).  Moreover, the intensity of EphA2 immunoreactivity in prostatic adenocarcinoma was significantly higher than in benign prostatic tissue (P < 0.001) or high-grade prostatic intraepithelial neoplasia (P < 0.001).  Benign prostatic epithelium showed weak or no immunoreactivity for EphA2 in all cases examd.  Whereas EphA2 immunoreactivity related to neoplastic transformation, it did not correlate with other clin. and pathol. parameters examd.  These data suggest that EphA2 levels increase as prostatic epithelial cells progress toward a more aggressive phenotype.  Progressively higher levels of EphA2 in high-grade prostatic intraepithelial neoplasia and prostatic carcinoma are consistent with recent evidence that EphA2 functions as a powerful oncogene.  Moreover, the presence of high levels of EphA2 in these cells suggests opportunities for prostate cancer prevention and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJTyngvcUd8bVg90H21EOLACvtfcHk0lh0UN0zjAUB2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkslGm&md5=d8a1ab5f0342f77db41c822c2641bfd5</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2963584-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252963584-5%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DG.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DPan%26aufirst%3DC.%2BX.%26aulast%3DFlockhart%26aufirst%3DD.%2BA.%26aulast%3DKao%26aufirst%3DC.%26aulast%3DGardner%26aufirst%3DT.%2BA.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DBaldridge%26aufirst%3DL.%2BA.%26aulast%3DKoch%26aufirst%3DM.%2BO.%26aulast%3DUlbright%26aufirst%3DT.%2BM.%26aulast%3DEble%26aufirst%3DJ.%2BN.%26aulast%3DCheng%26aufirst%3DL.%26atitle%3DHigh-level%2520expression%2520of%2520EphA2%2520receptor%2520tyrosine%2520kinase%2520in%2520prostatic%2520intraepithelial%2520neoplasia%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2003%26volume%3D163%26spage%3D2271%26epage%3D2276%26doi%3D10.1016%2FS0002-9440%2810%2963584-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duxbury, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinner, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashley, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whang, E. E.</span></span> <span> </span><span class="NLM_article-title">Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>320</i></span>,  <span class="NLM_fpage">1096</span>– <span class="NLM_lpage">1102</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2004.06.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.bbrc.2004.06.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=15249202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1eisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2004&pages=1096-1102&author=M.+S.+Duxburyauthor=H.+Itoauthor=M.+J.+Zinnerauthor=S.+W.+Ashleyauthor=E.+E.+Whang&title=Ligation+of+EphA2+by+Ephrin+A1-Fc+inhibits+pancreatic+adenocarcinoma+cellular+invasiveness&doi=10.1016%2Fj.bbrc.2004.06.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness</span></div><div class="casAuthors">Duxbury, Mark S.; Ito, Hiromichi; Zinner, Michael J.; Ashley, Stanley W.; Whang, Edward E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1096-1102</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">The Eph tyrosine kinases interact with ligands of the Ephrin family and have diverse cellular functions.  EphA2 has been recognized to be an oncoprotein of importance in a range of cancers.  Here, we examine the effect of EphA2 overexpression and ligation by chimeric Ephrin A1-Fc on the invasive phenotype of pancreatic adenocarcinoma cells.  We show that EphA2 overexpression induces a FAK-dependent increase in MMP-2 expression and invasiveness.  EphA2 ligation induces proteosomal degrdn. of EphA2, attenuates the invasive phenotype, and decreases both FAK phosphorylation and MMP-2 expression.  EphA2 appears to represent a rational therapeutic target and ligation by Ephrin A1-Fc is one strategy to modulate levels of this oncoprotein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwoGIkE2FMFLVg90H21EOLACvtfcHk0lgpg41igafyaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1eisr0%253D&md5=98cbb73a035773464adfd8b60d979d5b</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2004.06.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2004.06.054%26sid%3Dliteratum%253Aachs%26aulast%3DDuxbury%26aufirst%3DM.%2BS.%26aulast%3DIto%26aufirst%3DH.%26aulast%3DZinner%26aufirst%3DM.%2BJ.%26aulast%3DAshley%26aufirst%3DS.%2BW.%26aulast%3DWhang%26aufirst%3DE.%2BE.%26atitle%3DLigation%2520of%2520EphA2%2520by%2520Ephrin%2520A1-Fc%2520inhibits%2520pancreatic%2520adenocarcinoma%2520cellular%2520invasiveness%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2004%26volume%3D320%26spage%3D1096%26epage%3D1102%26doi%3D10.1016%2Fj.bbrc.2004.06.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duxbury, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinner, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashley, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whang, E. E.</span></span> <span> </span><span class="NLM_article-title">EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1448</span>– <span class="NLM_lpage">1456</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1207247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1038%2Fsj.onc.1207247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=14973554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtlKhtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=1448-1456&author=M.+S.+Duxburyauthor=H.+Itoauthor=M.+J.+Zinnerauthor=S.+W.+Ashleyauthor=E.+E.+Whang&title=EphA2%3A+a+determinant+of+malignant+cellular+behavior+and+a+potential+therapeutic+target+in+pancreatic+adenocarcinoma&doi=10.1038%2Fsj.onc.1207247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma</span></div><div class="casAuthors">Duxbury, Mark S.; Ito, Hiromichi; Zinner, Michael J.; Ashley, Stanley W.; Whang, Edward E.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1448-1456</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The EphA2 receptor tyrosine kinase is overexpressed in a variety of human cancers.  We sought to characterize the role of EphA2 in pancreatic adenocarcinoma and, using RNA interference (RNAi) mediated by small interfering RNA (siRNA), we detd. the effects of suppressing EphA2 expression in vitro and in vivo.  EphA2 expression in PANC1, MIAPaCa2, BxPC3 and Capan2 cells was assessed by Northern and Western blot.  We artificially overexpressed EphA2 by transient transfection and suppressed EphA2 expression using RNAi.  Cellular invasiveness was quantified by modified Boyden chamber assay.  Anoikis was induced by anchorage-independent polyHEMA culture and caspase 3 activity was quantified fluorometrically.  Focal adhesion kinase (FAK) phosphorylation was assessed by immunopptn.  EphA2 siRNA treatment was assessed in a nude mouse xenograft model.  Pancreatic adenocarcinoma cells differentially express EphA2.  Inherent and induced EphA2 overexpression is assocd. with increased cellular invasiveness and anoikis resistance.  EphA2 siRNA suppresses EphA2 expression, cellular invasiveness, anoikis resistance and FAK phosphorylation in vitro and retards tumor growth and inhibits metastasis in vivo.  EphA2 is both a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVvai6Ri2Z4LVg90H21EOLACvtfcHk0lgpg41igafyaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtlKhtbo%253D&md5=0336c1b3bcb340b2a74b21e7464f7a00</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1207247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1207247%26sid%3Dliteratum%253Aachs%26aulast%3DDuxbury%26aufirst%3DM.%2BS.%26aulast%3DIto%26aufirst%3DH.%26aulast%3DZinner%26aufirst%3DM.%2BJ.%26aulast%3DAshley%26aufirst%3DS.%2BW.%26aulast%3DWhang%26aufirst%3DE.%2BE.%26atitle%3DEphA2%253A%2520a%2520determinant%2520of%2520malignant%2520cellular%2520behavior%2520and%2520a%2520potential%2520therapeutic%2520target%2520in%2520pancreatic%2520adenocarcinoma%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D1448%26epage%3D1456%26doi%3D10.1038%2Fsj.onc.1207247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mudali, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakkur, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Embuscado, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobuzio-Donahue, C.
A.</span></span> <span> </span><span class="NLM_article-title">Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status</span>. <i>Clin. Exp. Metastasis</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1007/s10585-006-9045-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1007%2Fs10585-006-9045-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjvFGhtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2007&pages=357-365&author=S.+V.+Mudaliauthor=B.+Fuauthor=S.+S.+Lakkurauthor=M.+Luoauthor=E.+E.+Embuscadoauthor=C.%0AA.+Iacobuzio-Donahue&title=Patterns+of+EphA2+protein+expression+in+primary+and+metastatic+pancreatic+carcinoma+and+correlation+with+genetic+status&doi=10.1007%2Fs10585-006-9045-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status</span></div><div class="casAuthors">Mudali, Shiyama V.; Fu, Baojin; Lakkur, Sindhu S.; Luo, Mingde; Embuscado, Erlinda E.; Iacobuzio-Donahue, Christine A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & Experimental Metastasis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">357-365</span>CODEN:
                <span class="NLM_cas:coden">CEXMD2</span>;
        ISSN:<span class="NLM_cas:issn">0262-0898</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">EphA2 is a transmembrane receptor tyrosine kinase that functions in the regulation of cell growth, survival, angiogenesis, and migration and EphA2 targeting has been proposed as a novel therapeutic strategy for neoplasms that overexpress this protein.  EphA2 overexpression has been correlated with increased invasive and metastatic ability in pancreatic cancer cell lines.  However, the patterns of EphA2 expression in human pancreatic cancers and assocd. metastases is unknown, as are the genetics of EphA2 in this tumor type.  We collected clinico-pathol. data and paraffin-embedded materials from 98 patients with primary and/or metastatic pancreatic cancer and performed immunohistochem. labeling for EphA2 protein.  EphA2 protein immunolabeling was found in 207 of 219 samples (95%).  The expression was predominantly cytoplasmic, although predominant membranous staining was obsd. in a minority of cases.  When evaluated specifically for labeling intensity, primary and metastatic carcinomas were more strongly pos. compared to benign ducts and PanIN lesions (P < 0.00001 and P < 0.01, resp.) and poorly differentiated carcinomas were more strongly pos. for EphA2 than well and moderately differentiated tumors (P < 0.005).  When primary carcinomas without metastatic disease were specifically compared to carcinomas with assocd. metastatic disease, the advanced carcinomas showed relatively less strong pos. labeling for EphA2 (P < 0.008).  Moreover, decreased EphA2 labeling was more commonly found in liver (P < 0.002), lung (P < 0.004) or peritoneal metastases (P < 0.01) as compared to distant lymph node metastases (P < 0.01).  Genetic sequencing of the tyrosine kinase domain of EPHA2 in 22 samples of xenograft enriched pancreatic cancer did not reveal any inactivating mutations.  However, EPHA2 amplification was found in 1 of 33 pancreatic cancers corresponding to a lymph node metastasis, indicating EPHA2 genomic amplification may underlie EphA2 overexpression in a minority of patients.  Our data confirms that EphA2 is overexpressed in pancreatic cancer, but suggests a relative loss of EphA2 in co-existent pancreatic cancer metastases as well as a role for EPHA2 in organ specific metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsvOa3W9AmhLVg90H21EOLACvtfcHk0lgpg41igafyaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjvFGhtr4%253D&md5=586f96358a780e92711c1124d64670e0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs10585-006-9045-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10585-006-9045-7%26sid%3Dliteratum%253Aachs%26aulast%3DMudali%26aufirst%3DS.%2BV.%26aulast%3DFu%26aufirst%3DB.%26aulast%3DLakkur%26aufirst%3DS.%2BS.%26aulast%3DLuo%26aufirst%3DM.%26aulast%3DEmbuscado%26aufirst%3DE.%2BE.%26aulast%3DIacobuzio-Donahue%26aufirst%3DC.%2BA.%26atitle%3DPatterns%2520of%2520EphA2%2520protein%2520expression%2520in%2520primary%2520and%2520metastatic%2520pancreatic%2520carcinoma%2520and%2520correlation%2520with%2520genetic%2520status%26jtitle%3DClin.%2520Exp.%2520Metastasis%26date%3D2007%26volume%3D23%26spage%3D357%26epage%3D365%26doi%3D10.1007%2Fs10585-006-9045-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bangari, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhariwal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, S. I.</span></span> <span> </span><span class="NLM_article-title">Expression of EphA2 and ephrin A-1 in carcinoma of the urinary bladder</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-1505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1158%2F1078-0432.CCR-05-1505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=16428472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtlGqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=353-360&author=S.+Abrahamauthor=D.+W.+Knappauthor=L.+Chengauthor=P.+W.+Snyderauthor=S.+K.+Mittalauthor=D.+S.+Bangariauthor=M.+Kinchauthor=L.+Wuauthor=J.+Dhariwalauthor=S.+I.+Mohammed&title=Expression+of+EphA2+and+ephrin+A-1+in+carcinoma+of+the+urinary+bladder&doi=10.1158%2F1078-0432.CCR-05-1505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of EphA2 and Ephrin A-1 in Carcinoma of the Urinary Bladder</span></div><div class="casAuthors">Abraham, Shaji; Knapp, Deborah W.; Cheng, Liang; Snyder, Paul W.; Mittal, Suresh K.; Bangari, Dinesh S.; Kinch, Michael; Wu, Lan; Dhariwal, Jay; Mohammed, Sulma I.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">353-360</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The EphA2 receptor tyrosine kinase is believed to play a role in tumor growth and metastasis.  The clin. significance of the expression of EphA2 was obsd. in breast, prostate, colon, skin, cervical, ovarian, and lung cancers.  The purpose of this work was to det. the expression of EphA2 and its ligand, Ephrin A-1, and E-cadherin in carcinoma of the urinary bladder, and det. EphA2 as a new target for therapy in bladder cancer.  Exptl. Design: EphA2 mRNA and protein expression was investigated by reverse transcription-PCR and Western blot, resp., in bladder cancer cell lines.  In addn., the expression of EphA2, Ephrin A-1, and E-cadherin in tissues from patients with different stages of urinary bladder cancer was detd. by immunohistochem.  Furthermore, the ability of Ephrin A-1 to inhibit growth of bladder cancer cells was also investigated using an adenoviral delivery system.  Results: Western blot anal. showed high EphA2 expression in TCCSUP, T24, and UMUC-3 cell lines.  In tissues, the staining intensity of EphA2 was less in normal urothelium but increased greatly in advancing stages of urothelial carcinoma (P < 0.05).  Similarly, the staining intensity of Ephrin A-1 was low in normal tissues and high in cancerous tissues, but it was similar across the various stages of urothelial carcinoma (Ta-T4).  E-cadherin immunoreactivity decreased in urothelial cancer.  Assocn. of EphA2 and Ephrin A-1 expression was found to be significant between Ta stage and T1-T2 (P < 0.04) and Ta and T3-T4 stages (P < 0.0001).  Adenovirus delivery of Ephrin A-1 inhibited proliferation of TCCSUP cells.  Conclusion: EphA2 may serve as a novel target for bladder cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi0Lw0XE9I4rVg90H21EOLACvtfcHk0lhZxh0otuc34Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtlGqug%253D%253D&md5=ab840113d0c83a676cfb9123c4273138</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1505%26sid%3Dliteratum%253Aachs%26aulast%3DAbraham%26aufirst%3DS.%26aulast%3DKnapp%26aufirst%3DD.%2BW.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DSnyder%26aufirst%3DP.%2BW.%26aulast%3DMittal%26aufirst%3DS.%2BK.%26aulast%3DBangari%26aufirst%3DD.%2BS.%26aulast%3DKinch%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DDhariwal%26aufirst%3DJ.%26aulast%3DMohammed%26aufirst%3DS.%2BI.%26atitle%3DExpression%2520of%2520EphA2%2520and%2520ephrin%2520A-1%2520in%2520carcinoma%2520of%2520the%2520urinary%2520bladder%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D353%26epage%3D360%26doi%3D10.1158%2F1078-0432.CCR-05-1505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fokas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rexin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagenstecher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engenhart-Cabillic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, H. X.</span></span> <span> </span><span class="NLM_article-title">Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.3892/or.19.1.151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.3892%2For.19.1.151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=18097589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A280%3ADC%252BD2sjlvVOnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=151-156&author=L.+F.+Wangauthor=E.+Fokasauthor=M.+Biekerauthor=F.+Roseauthor=P.+Rexinauthor=Y.+Zhuauthor=A.+Pagenstecherauthor=R.+Engenhart-Cabillicauthor=H.+X.+An&title=Increased+expression+of+EphA2+correlates+with+adverse+outcome+in+primary+and+recurrent+glioblastoma+multiforme+patients&doi=10.3892%2For.19.1.151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients</span></div><div class="casAuthors">Wang Lin-Fang; Fokas Emmanouil; Bieker Michael; Rose Frank; Rexin Peter; Zhu Yuan; Pagenstecher Axel; Engenhart-Cabillic Rita; An Han-Xiang</div><div class="citationInfo"><span class="NLM_cas:title">Oncology reports</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">151-6</span>
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    </div><div class="casAbstract">Glioblastoma multiforme (GBM) is the most aggressive form of brain tumor characterized by excessive angiogenesis.  The dismal prognosis of patients with GBM warrants the development of new targeting therapies based on novel molecular markers.  The EphA2 receptor tyrosine kinase plays a pivotal role in tumor angiogenesis and an increased expression in glioma patients has recently been reported.  In this study, we investigated the expression of EphA2 in human normal brain, primary and recurrent GBM and correlated it with clinical pathological parameters and patient's outcome.  In addition, intratumor microvascular density was quantified by immunostaining for the endothelial cell marker, von Willebrand factor.  A different intensity of the membranous and cytoplastic expression of EphA2 was observed in the 40 primary and recurrent samples of GBM analyzed but not in the normal brain.  A high level expression of EphA2 was demonstrated in 24 (60%) of the primary and recurrent GBM analyzed.  The increased expression of the EphA2 protein was significantly associated with the adverse outcome of GBM patients (p<0.01 for overall survival).  The data presented in this study define the expression pattern of EphA2 in both primary and recurrent glioblastoma and suggest an important role of EphA2 in the pathogenesis of GBM.  The EphA2 may be used as a surrogate marker to screen patients for tyrosine kinase inhibitor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrQlWD-_F7-OkdrW1FkXG-fW6udTcc2eYsnmwD92Fi4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjlvVOnug%253D%253D&md5=ffc322f4165474411371be77339ae5c7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.3892%2For.19.1.151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.19.1.151%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%2BF.%26aulast%3DFokas%26aufirst%3DE.%26aulast%3DBieker%26aufirst%3DM.%26aulast%3DRose%26aufirst%3DF.%26aulast%3DRexin%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DPagenstecher%26aufirst%3DA.%26aulast%3DEngenhart-Cabillic%26aufirst%3DR.%26aulast%3DAn%26aufirst%3DH.%2BX.%26atitle%3DIncreased%2520expression%2520of%2520EphA2%2520correlates%2520with%2520adverse%2520outcome%2520in%2520primary%2520and%2520recurrent%2520glioblastoma%2520multiforme%2520patients%26jtitle%3DOncol.%2520Rep.%26date%3D2008%26volume%3D19%26spage%3D151%26epage%3D156%26doi%3D10.3892%2For.19.1.151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wykosky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibo, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debinski, W.</span></span> <span> </span><span class="NLM_article-title">EphA2 as a novel molecular marker and target in glioblastoma multiforme</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-05-0056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1158%2F1541-7786.MCR-05-0056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=16254188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFGmsr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2005&pages=541-551&author=J.+Wykoskyauthor=D.+M.+Giboauthor=C.+Stantonauthor=W.+Debinski&title=EphA2+as+a+novel+molecular+marker+and+target+in+glioblastoma+multiforme&doi=10.1158%2F1541-7786.MCR-05-0056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2 as a Novel Molecular Marker and Target in Glioblastoma Multiforme</span></div><div class="casAuthors">Wykosky, Jill; Gibo, Denise M.; Stanton, Constance; Debinski, Waldemar</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">541-551</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We investigated the presence of EphA2, and its ligand, ephrinA1, in glioblastoma multiforme (GBM), a malignant neoplasm of glial cells, and normal brain.  We also initially examd. the functional importance of the interaction between EphA2 and ephrinA1 in glioma cells.  Expression and localization of EphA2 and ephrinA1 in human GBM and normal brain were examd. using Western blotting, immunofluorescence, and immunohistochem.  A functional role for EphA2 was investigated by assessing the activation status of the receptor and the effect of ephrinA1 on the anchorage-independent growth and invasiveness of GBM cells.  We found EphA2 to be elevated in ∼90% of GBM specimens and cell lines but not in normal brain, whereas ephrinA1 was present at consistently low levels in both GBM and normal brain.  EphA2 was activated and phosphorylated by ephrinA1 in GBM cells.  Furthermore, ephrinA1 induced a prominent, dose-dependent inhibitory effect on the anchorage-independent growth and invasiveness of GBM cells highly overexpressing EphA2, which was not seen in cells expressing low levels of the receptor.  Thus, EphA2 is both specifically overexpressed in GBM and expressed differentially with respect to its ligand, ephrinA1, which may reflect on the oncogenic processes of malignant glioma cells.  EphA2 seems to be functionally important in GBM cells and thus may play an important role in GBM pathogenesis.  Hence, EphA2 represents a new marker and novel target for the development of mol. therapeutics against GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkjpJH4NTKwrVg90H21EOLACvtfcHk0lhZxh0otuc34Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFGmsr%252FJ&md5=163c288c48ebacc0da6d08f0e09aebb0</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-05-0056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-05-0056%26sid%3Dliteratum%253Aachs%26aulast%3DWykosky%26aufirst%3DJ.%26aulast%3DGibo%26aufirst%3DD.%2BM.%26aulast%3DStanton%26aufirst%3DC.%26aulast%3DDebinski%26aufirst%3DW.%26atitle%3DEphA2%2520as%2520a%2520novel%2520molecular%2520marker%2520and%2520target%2520in%2520glioblastoma%2520multiforme%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2005%26volume%3D3%26spage%3D541%26epage%3D551%26doi%3D10.1158%2F1541-7786.MCR-05-0056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Binda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visioli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamorte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitter, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huse, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cajola, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanetti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMeco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Filippis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangiola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anile, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bonis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vescovi, A. L.</span></span> <span> </span><span class="NLM_article-title">The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">765</span>– <span class="NLM_lpage">780</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2012.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.ccr.2012.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=23238013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVWgu7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=765-780&author=E.+Bindaauthor=A.+Visioliauthor=F.+Gianiauthor=G.+Lamorteauthor=M.+Copettiauthor=K.+L.+Pitterauthor=J.+T.+Huseauthor=L.+Cajolaauthor=N.+Zanettiauthor=F.+DiMecoauthor=L.+De+Filippisauthor=A.+Mangiolaauthor=G.+Mairaauthor=C.+Anileauthor=P.+De+Bonisauthor=B.+A.+Reynoldsauthor=E.+B.+Pasqualeauthor=A.+L.+Vescovi&title=The+EphA2+receptor+drives+self-renewal+and+tumorigenicity+in+stem-like+tumor-propagating+cells+from+human+glioblastomas&doi=10.1016%2Fj.ccr.2012.11.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The EphA2 Receptor Drives Self-Renewal and Tumorigenicity in Stem-like Tumor-Propagating Cells from Human Glioblastomas</span></div><div class="casAuthors">Binda, Elena; Visioli, Alberto; Giani, Fabrizio; Lamorte, Giuseppe; Copetti, Massimiliano; Pitter, Ken L.; Huse, Jason T.; Cajola, Laura; Zanetti, Nadia; DiMeco, Francesco; De Filippis, Lidia; Mangiola, Annunziato; Maira, Giulio; Anile, Carmelo; De Bonis, Pasquale; Reynolds, Brent A.; Pasquale, Elena B.; Vescovi, Angelo L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">765-780</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">In human glioblastomas (hGBMs), tumor-propagating cells with stem-like characteristics (TPCs) represent a key therapeutic target.  We found that the EphA2 receptor tyrosine kinase is overexpressed in hGBM TPCs.  Cytofluorimetric sorting into EphA2High and EphA2Low populations demonstrated that EphA2 expression correlates with the size and tumor-propagating ability of the TPC pool in hGBMs.  Both ephrinA1-Fc, which caused EphA2 downregulation in TPCs, and siRNA-mediated knockdown of EPHA2 expression suppressed TPCs self-renewal ex vivo and intracranial tumorigenicity, pointing to EphA2 downregulation as a causal event in the loss of TPCs tumorigenicity.  Infusion of ephrinA1-Fc into intracranial xenografts elicited strong tumor-suppressing effects, suggestive of therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo99dmT2JcdHrVg90H21EOLACvtfcHk0liiSjfgE4c0pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVWgu7fE&md5=913794b634f7b4094861c11e4bd482c7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DBinda%26aufirst%3DE.%26aulast%3DVisioli%26aufirst%3DA.%26aulast%3DGiani%26aufirst%3DF.%26aulast%3DLamorte%26aufirst%3DG.%26aulast%3DCopetti%26aufirst%3DM.%26aulast%3DPitter%26aufirst%3DK.%2BL.%26aulast%3DHuse%26aufirst%3DJ.%2BT.%26aulast%3DCajola%26aufirst%3DL.%26aulast%3DZanetti%26aufirst%3DN.%26aulast%3DDiMeco%26aufirst%3DF.%26aulast%3DDe%2BFilippis%26aufirst%3DL.%26aulast%3DMangiola%26aufirst%3DA.%26aulast%3DMaira%26aufirst%3DG.%26aulast%3DAnile%26aufirst%3DC.%26aulast%3DDe%2BBonis%26aufirst%3DP.%26aulast%3DReynolds%26aufirst%3DB.%2BA.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DVescovi%26aufirst%3DA.%2BL.%26atitle%3DThe%2520EphA2%2520receptor%2520drives%2520self-renewal%2520and%2520tumorigenicity%2520in%2520stem-like%2520tumor-propagating%2520cells%2520from%2520human%2520glioblastomas%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D22%26spage%3D765%26epage%3D780%26doi%3D10.1016%2Fj.ccr.2012.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thaker, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landen, C. N.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deavers, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamat, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershenson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A. K.</span></span> <span> </span><span class="NLM_article-title">Analysis of EphA2 expression and mutant p53 in ovarian carcinoma</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1357</span>– <span class="NLM_lpage">1360</span>, <span class="refDoi"> DOI: 10.4161/cbt.5.10.3225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.4161%2Fcbt.5.10.3225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=16969087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsF2lsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1357-1360&author=W.+M.+Merrittauthor=P.+H.+Thakerauthor=C.+N.+Landenauthor=M.+T.+Deaversauthor=M.+S.+Fletcherauthor=Y.+G.+Linauthor=L.+Y.+Hanauthor=A.+A.+Kamatauthor=D.+M.+Gershensonauthor=M.+S.+Kinchauthor=A.+K.+Sood&title=Analysis+of+EphA2+expression+and+mutant+p53+in+ovarian+carcinoma&doi=10.4161%2Fcbt.5.10.3225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of EphA2 expression and mutant p53 in ovarian carcinoma</span></div><div class="casAuthors">Merritt, William M.; Thaker, Premal H.; Landen, Charles N., Jr.; Deavers, Michael T.; Fletcher, Mavis S.; Lin, Yvonne G.; Han, Liz Y.; Kamat, Aparna A.; Schmandt, Rosemarie; Gershenson, David M.; Kinch, Michael S.; Sood, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1357-1360</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">The EphA2 tyrosine kinase receptor is frequently overexpressed in ovarian cancer and this feature is predictive of poor clin. outcome.  Preclin. investigation has also linked EphA2 with p53.  In our present study, we examd. EphA2 and p53 status (both expression and full-length mutation status) in 6 ovarian cell lines and 79 human ovarian cancers to det. potential assocns.  EphA2 was overexpressed in 80% of ovarian cancer cell lines and in 75% of clin. specimens.  In particular, high levels of EphA2 occurred in 91% of tumors with p53 null mutations compared to 68% in tumors with wild-type or missense mutations (p = 0.027).  EphA2 expression did not relate to crit. vs. non-crit. site missense p53 mutations or the location of mutations on specific p53 exons.  We also demonstrated that while EphA2 and p53 can provide independent information regarding clin. status, the combination of EphA2 and p53 status can predict poor clin. outcome.  In particular, the combination of EphA2 overexpression and p53 null status was assocd. with decreased overall patient survival and related to increased incidence of ascites and distant metastasis.  Taken together, these data indicate a complex relationship between EphA2 and p53 that appears to regulate EphA2 expression and clin. outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRjeQ86wSzv7Vg90H21EOLACvtfcHk0liiSjfgE4c0pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsF2lsb0%253D&md5=107a4b727dab8a76a4d6cb39256fc749</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.4161%2Fcbt.5.10.3225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.5.10.3225%26sid%3Dliteratum%253Aachs%26aulast%3DMerritt%26aufirst%3DW.%2BM.%26aulast%3DThaker%26aufirst%3DP.%2BH.%26aulast%3DLanden%26aufirst%3DC.%2BN.%26aulast%3DDeavers%26aufirst%3DM.%2BT.%26aulast%3DFletcher%26aufirst%3DM.%2BS.%26aulast%3DLin%26aufirst%3DY.%2BG.%26aulast%3DHan%26aufirst%3DL.%2BY.%26aulast%3DKamat%26aufirst%3DA.%2BA.%26aulast%3DGershenson%26aufirst%3DD.%2BM.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DSood%26aufirst%3DA.%2BK.%26atitle%3DAnalysis%2520of%2520EphA2%2520expression%2520and%2520mutant%2520p53%2520in%2520ovarian%2520carcinoma%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D1357%26epage%3D1360%26doi%3D10.4161%2Fcbt.5.10.3225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwano, H.</span></span> <span> </span><span class="NLM_article-title">EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">657</span>– <span class="NLM_lpage">663</span>, <span class="refDoi"> DOI: 10.1002/ijc.10860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1002%2Fijc.10860" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=12494475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmtFKntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2003&pages=657-663&author=T.+Miyazakiauthor=H.+Katoauthor=M.+Fukuchiauthor=M.+Nakajimaauthor=H.+Kuwano&title=EphA2+overexpression+correlates+with+poor+prognosis+in+esophageal+squamous+cell+carcinoma&doi=10.1002%2Fijc.10860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma</span></div><div class="casAuthors">Miyazaki, Tatsuya; Kato, Hiroyuki; Fukuchi, Minoru; Nakajima, Masanobu; Kuwano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">657-663</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">EphA2 is a member of the Eph family of receptor tyrosine kinases, which interact with cell-bound ligands known as ephrins.  EphA2 expression was investigated by immunohistochem. with an anti-EphA2 monoclonal antibody in 80 patients with esophageal squamous cell carcinoma (ESCC) who had undergone surgery.  EphA2 overexpression was pos. in 40 of the 80 patients (50%).  A significant correlation was obsd. between EphA2 expression and regional lymph node metastasis (p=0.023), no. of lymph node metastases (p=0.011) and poor degree of tumor differentiation (p=0.004).  The survival rates of EphA2-pos. patients were poorer than those of EphA2-neg. patients (p=0.014).  The 5-yr survival rate of patients without EphA2 overexpression was 68%, whereas that of patients with EphA2 overexpression was 29%.  EphA2 expression was also investigated in 7 ESCC cell lines (TE-1, -2, -8, -13, -15, TT and TTn) and 1 immortalized human esophageal keratinocyte cell line (CHEK-1).  Western blotting revealed different levels of EphA2 expression in the 8 cell lines.  EphA2 was expressed at a high level in the ESCC cell lines compared to CHEK-1.  EphA2 phosphorylation was demonstrated in all cell lines.  Northern blot anal. showed that EphA2 mRNA expression in TE-1 was greater than that in the other ESCC cell lines.  The observation of small gaps on Western blot anal. of the ESCC cell lines suggests that there may be a mechanism for EphA2 regulation at the point of translation.  In conclusion, EphA2 overexpression appears to be related to poor degree of tumor differentiation and lymph node metastasis in ESCC.  Consequently, patients with EphA2 overexpression have a poorer prognosis than those without.  EphA2 is a potential target to prevent ESCC cells spreading into the lymphatic drainage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyZLBkO7X3GrVg90H21EOLACvtfcHk0liiSjfgE4c0pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmtFKntg%253D%253D&md5=a3e41d56e291ff333007e36c95f36c5c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fijc.10860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10860%26sid%3Dliteratum%253Aachs%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DH.%26aulast%3DFukuchi%26aufirst%3DM.%26aulast%3DNakajima%26aufirst%3DM.%26aulast%3DKuwano%26aufirst%3DH.%26atitle%3DEphA2%2520overexpression%2520correlates%2520with%2520poor%2520prognosis%2520in%2520esophageal%2520squamous%2520cell%2520carcinoma%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2003%26volume%3D103%26spage%3D657%26epage%3D663%26doi%3D10.1002%2Fijc.10860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faoro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennon, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choong, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanteti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husain, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tretiakova, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramnath, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vokes, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgia, R.</span></span> <span> </span><span class="NLM_article-title">EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">18575</span>– <span class="NLM_lpage">18585</span>, <span class="refDoi"> DOI: 10.1074/jbc.M109.075085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1074%2Fjbc.M109.075085" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=18575-18585&author=L.+Faoroauthor=P.+A.+Singletonauthor=G.+M.+Cervantesauthor=F.+E.+Lennonauthor=N.+W.+Choongauthor=R.+Kantetiauthor=B.+D.+Fergusonauthor=A.+N.+Husainauthor=M.+S.+Tretiakovaauthor=N.+Ramnathauthor=E.+E.+Vokesauthor=R.+Salgia&title=EphA2+mutation+in+lung+squamous+cell+carcinoma+promotes+increased+cell+survival%2C+cell+invasion%2C+focal+adhesions%2C+and+mammalian+target+of+rapamycin+activation&doi=10.1074%2Fjbc.M109.075085"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.075085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.075085%26sid%3Dliteratum%253Aachs%26aulast%3DFaoro%26aufirst%3DL.%26aulast%3DSingleton%26aufirst%3DP.%2BA.%26aulast%3DCervantes%26aufirst%3DG.%2BM.%26aulast%3DLennon%26aufirst%3DF.%2BE.%26aulast%3DChoong%26aufirst%3DN.%2BW.%26aulast%3DKanteti%26aufirst%3DR.%26aulast%3DFerguson%26aufirst%3DB.%2BD.%26aulast%3DHusain%26aufirst%3DA.%2BN.%26aulast%3DTretiakova%26aufirst%3DM.%2BS.%26aulast%3DRamnath%26aufirst%3DN.%26aulast%3DVokes%26aufirst%3DE.%2BE.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DEphA2%2520mutation%2520in%2520lung%2520squamous%2520cell%2520carcinoma%2520promotes%2520increased%2520cell%2520survival%252C%2520cell%2520invasion%252C%2520focal%2520adhesions%252C%2520and%2520mammalian%2520target%2520of%2520rapamycin%2520activation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D18575%26epage%3D18585%26doi%3D10.1074%2Fjbc.M109.075085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. H.</span></span> <span> </span><span class="NLM_article-title">Over-expression of EphA2 and ephrinA-1 in human gastric adenocarcinoma and its prognostic value for postoperative patients</span>. <i>Dig. Dis. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2410</span>– <span class="NLM_lpage">2417</span>, <span class="refDoi"> DOI: 10.1007/s10620-008-0649-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1007%2Fs10620-008-0649-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=19101799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KntrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2009&pages=2410-2417&author=W.+J.+Yuanauthor=J.+Geauthor=Z.+K.+Chenauthor=S.+B.+Wuauthor=H.+Shenauthor=P.+Yangauthor=B.+Huauthor=G.+W.+Zhangauthor=Z.+H.+Chen&title=Over-expression+of+EphA2+and+ephrinA-1+in+human+gastric+adenocarcinoma+and+its+prognostic+value+for+postoperative+patients&doi=10.1007%2Fs10620-008-0649-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Over-Expression of EphA2 and EphrinA-1 in Human Gastric Adenocarcinoma and Its Prognostic Value for Postoperative Patients</span></div><div class="casAuthors">Yuan, Wei-Jie; Ge, Jie; Chen, Zhi-Kang; Wu, Shao-Bin; Shen, Hong; Yang, Pu; Hu, Bin; Zhang, Ge-Wen; Chen, Zi-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Digestive Diseases and Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2410-2417</span>CODEN:
                <span class="NLM_cas:coden">DDSCDJ</span>;
        ISSN:<span class="NLM_cas:issn">0163-2116</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">This study aims to investigate the expression and significance of EphA2 and EphrinA-1 in human gastric adenocarcinoma progression and prognosis.  The expression of EphA2 and EphrinA-1 was detected in the cell lines and tissues of gastric adenocarcinoma.  Different expression levels of EphA2 and EphrinA-1 were found in two cell lines.  The expression of EphA2 and EphrinA-1 was significantly higher in gastric adenocarcinoma tissues than in normal tissues.  Statistical anal. showed a significant correlation of EphA2 expression with the depth of tumor invasion, tumor-node-metastasis (TNM) stages, and lymph node metastasis.  EphrinA-1 over-expression was significantly correlated with TNM stages and lymph node metastasis, while EphA2 expression was found to be an independent prognostic factor of postoperative gastric adenocarcinoma.  In conclusion, the increased expression of EphA2 and EphrinA-1 plays an important role in the progression of human gastric adenocarcinoma, in which elevated EphA2 expression is an independent factor that indicates poor prognosis in postoperative gastric adenocarcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT0PcLBKA1b7Vg90H21EOLACvtfcHk0lhej71PxdrK-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KntrnI&md5=968038e62b5253ab0aa49b170d56de26</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2Fs10620-008-0649-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10620-008-0649-4%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DW.%2BJ.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%2BK.%26aulast%3DWu%26aufirst%3DS.%2BB.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DG.%2BW.%26aulast%3DChen%26aufirst%3DZ.%2BH.%26atitle%3DOver-expression%2520of%2520EphA2%2520and%2520ephrinA-1%2520in%2520human%2520gastric%2520adenocarcinoma%2520and%2520its%2520prognostic%2520value%2520for%2520postoperative%2520patients%26jtitle%3DDig.%2520Dis.%2520Sci.%26date%3D2009%26volume%3D54%26spage%3D2410%26epage%3D2417%26doi%3D10.1007%2Fs10620-008-0649-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hess, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seftor, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carles-Kinch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seftor, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, M. J.</span></span> <span> </span><span class="NLM_article-title">Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2)</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3250</span>– <span class="NLM_lpage">3255</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=3250-3255&author=A.+R.+Hessauthor=E.+A.+Seftorauthor=L.+M.+Gardnerauthor=K.+Carles-Kinchauthor=G.+B.+Schneiderauthor=R.+E.+Seftorauthor=M.+S.+Kinchauthor=M.+J.+Hendrix&title=Molecular+regulation+of+tumor+cell+vasculogenic+mimicry+by+tyrosine+phosphorylation%3A+role+of+epithelial+cell+kinase+%28Eck%2FEphA2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHess%26aufirst%3DA.%2BR.%26aulast%3DSeftor%26aufirst%3DE.%2BA.%26aulast%3DGardner%26aufirst%3DL.%2BM.%26aulast%3DCarles-Kinch%26aufirst%3DK.%26aulast%3DSchneider%26aufirst%3DG.%2BB.%26aulast%3DSeftor%26aufirst%3DR.%2BE.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DHendrix%26aufirst%3DM.%2BJ.%26atitle%3DMolecular%2520regulation%2520of%2520tumor%2520cell%2520vasculogenic%2520mimicry%2520by%2520tyrosine%2520phosphorylation%253A%2520role%2520of%2520epithelial%2520cell%2520kinase%2520%2528Eck%252FEphA2%2529%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D3250%26epage%3D3255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Margaryan, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strizzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbott, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seftor, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, A. R.</span></span> <span> </span><span class="NLM_article-title">EphA2 as a promoter of melanoma tumorigenicity</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">288</span>, <span class="refDoi"> DOI: 10.4161/cbt.8.3.7485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.4161%2Fcbt.8.3.7485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=19223760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotV2qt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=279-288&author=N.+V.+Margaryanauthor=L.+Strizziauthor=D.+E.+Abbottauthor=E.+A.+Seftorauthor=M.+S.+Raoauthor=M.+J.+Hendrixauthor=A.+R.+Hess&title=EphA2+as+a+promoter+of+melanoma+tumorigenicity&doi=10.4161%2Fcbt.8.3.7485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2 as a promoter of melanoma tumorigenicity</span></div><div class="casAuthors">Margaryan, Naira V.; Strizzi, Luigi; Abbott, Daniel E.; Seftor, Elizabeth A.; Rao, M. Sambasiva; Hendrix, Mary J. C.; Hess, Angela R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">279-288</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">The greatest health threat from malignant melanoma is death due to metastatic disease.  Consequently, the identification of markers predictive of metastatic disease is essential for identifying new therapeutic targets.  EphA2, a protein tyrosine kinase receptor commonly expressed in epithelial cells, has been found to be overexpressed and constitutively active in melanoma tumor cells having a metastatic phenotype as characterized by increased invasion, proliferation and vasculogenic mimicry (VM).  Based on this observation, we hypothesized that increased expression of EphA2 by melanoma tumor cells could promote these characteristics of a metastatic phenotype in addn. to promoting tumorigenicity as a whole.  We analyzed a panel of human melanoma tumor cell lines derived from patient tissues classified as primary (either radial growth phase or vertical growth phase) and/or metastatic for the expression of EphA2 and found a correlation between increased EphA2 expression and metastatic potential.  Expts. using the most metastatic of the human melanoma cell lines demonstrated that downregulation of EphA2 results in a significant decrease in invasion, proliferation, clonogenicity and VM in vitro, in addn. to suppressed tumorigenicity in an orthotopic mouse model.  Lastly, utilization of a human phospho-kinase array revealed increased phosphorylation of several different protein kinases involved in mediating various aspects of cellular proliferation.  To the best of our knowledge these results provide the first direct in vivo evidence demonstrating a role for EphA2 in promoting melanoma tumorigenicity and suggest EphA2 as a significant mol. target for the therapeutic intervention of malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp19CzDddCbh7Vg90H21EOLACvtfcHk0lhej71PxdrK-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotV2qt70%253D&md5=e186491217adab34563402e43938d2da</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.4161%2Fcbt.8.3.7485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.8.3.7485%26sid%3Dliteratum%253Aachs%26aulast%3DMargaryan%26aufirst%3DN.%2BV.%26aulast%3DStrizzi%26aufirst%3DL.%26aulast%3DAbbott%26aufirst%3DD.%2BE.%26aulast%3DSeftor%26aufirst%3DE.%2BA.%26aulast%3DRao%26aufirst%3DM.%2BS.%26aulast%3DHendrix%26aufirst%3DM.%2BJ.%26aulast%3DHess%26aufirst%3DA.%2BR.%26atitle%3DEphA2%2520as%2520a%2520promoter%2520of%2520melanoma%2520tumorigenicity%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D279%26epage%3D288%26doi%3D10.4161%2Fcbt.8.3.7485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tohda, S.</span></span> <span> </span><span class="NLM_article-title">Effect of Eph-ephrin signaling on the growth of human leukemia cells</span>. <i>Anticancer research</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2913</span>– <span class="NLM_lpage">2918</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=2913-2918&author=Y.+Takahashiauthor=M.+Itohauthor=N.+Naraauthor=S.+Tohda&title=Effect+of+Eph-ephrin+signaling+on+the+growth+of+human+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DY.%26aulast%3DItoh%26aufirst%3DM.%26aulast%3DNara%26aufirst%3DN.%26aulast%3DTohda%26aufirst%3DS.%26atitle%3DEffect%2520of%2520Eph-ephrin%2520signaling%2520on%2520the%2520growth%2520of%2520human%2520leukemia%2520cells%26jtitle%3DAnticancer%2520research%26date%3D2014%26volume%3D34%26spage%3D2913%26epage%3D2918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trinidad, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapata, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Colmenar, L. M.</span></span> <span> </span><span class="NLM_article-title">Eph-ephrin bidirectional signaling comes into the context of lymphocyte transendothelial migration</span>. <i>Cell adhesion & migration</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">363</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.4161/cam.4.3.11586</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.4161%2Fcam.4.3.11586" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=363-367&author=E.+M.+Trinidadauthor=A.+G.+Zapataauthor=L.+M.+Alonso-Colmenar&title=Eph-ephrin+bidirectional+signaling+comes+into+the+context+of+lymphocyte+transendothelial+migration&doi=10.4161%2Fcam.4.3.11586"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.4161%2Fcam.4.3.11586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcam.4.3.11586%26sid%3Dliteratum%253Aachs%26aulast%3DTrinidad%26aufirst%3DE.%2BM.%26aulast%3DZapata%26aufirst%3DA.%2BG.%26aulast%3DAlonso-Colmenar%26aufirst%3DL.%2BM.%26atitle%3DEph-ephrin%2520bidirectional%2520signaling%2520comes%2520into%2520the%2520context%2520of%2520lymphocyte%2520transendothelial%2520migration%26jtitle%3DCell%2520adhesion%2520%2526%2520migration%26date%3D2010%26volume%3D4%26spage%3D363%26epage%3D367%26doi%3D10.4161%2Fcam.4.3.11586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-C, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trinidad, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Garcillan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballesteros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellanos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotillo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapata, A. G.</span></span> <span> </span><span class="NLM_article-title">Expression profile of Eph receptors and ephrin ligands in healthy human B lymphocytes and chronic lymphocytic leukemia B-cells</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2008.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.leukres.2008.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=18819711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVCru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2009&pages=395-406&author=L.+M.+Alonso-Cauthor=E.+M.+Trinidadauthor=B.+de+Garcillanauthor=M.+Ballesterosauthor=M.+Castellanosauthor=I.+Cotilloauthor=J.+J.+Munozauthor=A.+G.+Zapata&title=Expression+profile+of+Eph+receptors+and+ephrin+ligands+in+healthy+human+B+lymphocytes+and+chronic+lymphocytic+leukemia+B-cells&doi=10.1016%2Fj.leukres.2008.08.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Expression profile of Eph receptors and ephrin ligands in healthy human B lymphocytes and chronic lymphocytic leukemia B-cells</span></div><div class="casAuthors">Alonso-C, Luis M.; Trinidad, Eva M.; de Garcillan, Beatriz; Ballesteros, Monica; Castellanos, Milagros; Cotillo, Ignacio; Munoz, Juan J.; Zapata, Agustin G.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">395-406</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Increasing information relates some Eph receptors and their ligands, ephrins (EFN), with the immune system.  Herein, the authors found that normal B-cells from peripheral blood (PB) and lymph nodes (LN) showed a differential expression of certain Eph/EFN members, some of them being modulated upon in vitro stimulation including EFNA1, EFNA4, EphB6 and EphA10.  In contrast, PB CLL B-cells showed a more heterogeneous Eph/EFN profile than their normal PB B-cell counterparts, expressing Eph/EFN members frequently found within the LN and activated B-cells, specially EFNA4, EphB6 and EphA10.  Two of them, EphB6 and EFNA4 were further related with the clin. course of CLL patients.  EphB6 expression correlated with a high content of ZAP-70 mRNA and a poor prognosis.  High serum levels of a sol. EFNA4 isoform pos. correlated with increasing peripheral blood lymphocyte counts and lymphadenopathy.  These findings suggest that Eph/EFN might be relevant in normal B-cell biol. and could represent new potential prognostic markers and therapeutic targets for CLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6iDfF_JHxlrVg90H21EOLACvtfcHk0lj_LxT-AuSr8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVCru7Y%253D&md5=20a4a9faa8ceffeb5fdfd71f052a5e7b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2008.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2008.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DAlonso-C%26aufirst%3DL.%2BM.%26aulast%3DTrinidad%26aufirst%3DE.%2BM.%26aulast%3Dde%2BGarcillan%26aufirst%3DB.%26aulast%3DBallesteros%26aufirst%3DM.%26aulast%3DCastellanos%26aufirst%3DM.%26aulast%3DCotillo%26aufirst%3DI.%26aulast%3DMunoz%26aufirst%3DJ.%2BJ.%26aulast%3DZapata%26aufirst%3DA.%2BG.%26atitle%3DExpression%2520profile%2520of%2520Eph%2520receptors%2520and%2520ephrin%2520ligands%2520in%2520healthy%2520human%2520B%2520lymphocytes%2520and%2520chronic%2520lymphocytic%2520leukemia%2520B-cells%26jtitle%3DLeuk.%2520Res.%26date%3D2009%26volume%3D33%26spage%3D395%26epage%3D406%26doi%3D10.1016%2Fj.leukres.2008.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span> <span> </span><span class="NLM_article-title">Copy number variations of EphA3 are associated with multiple types of hematologic malignancies</span>. <i>Clinical lymphoma, myeloma & leukemia</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.3816/CLML.2011.n.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.3816%2FCLML.2011.n.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=50-53&author=M.+Guanauthor=L.+Liuauthor=X.+Zhaoauthor=Q.+Wuauthor=B.+Yuauthor=Y.+Shaoauthor=H.+Yangauthor=X.+Fuauthor=J.+Wanauthor=W.+Zhang&title=Copy+number+variations+of+EphA3+are+associated+with+multiple+types+of+hematologic+malignancies&doi=10.3816%2FCLML.2011.n.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.3816%2FCLML.2011.n.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3816%252FCLML.2011.n.006%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DFu%26aufirst%3DX.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26atitle%3DCopy%2520number%2520variations%2520of%2520EphA3%2520are%2520associated%2520with%2520multiple%2520types%2520of%2520hematologic%2520malignancies%26jtitle%3DClinical%2520lymphoma%252C%2520myeloma%2520%2526%2520leukemia%26date%3D2011%26volume%3D11%26spage%3D50%26epage%3D53%26doi%3D10.3816%2FCLML.2011.n.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myshkin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tochtrop, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharya, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKerell, A. D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficker, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span> <span> </span><span class="NLM_article-title">A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e42120</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0042120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1371%2Fjournal.pone.0042120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=22916121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ejtbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e42120&author=A.+Pettyauthor=E.+Myshkinauthor=H.+Qinauthor=H.+Guoauthor=H.+Miaoauthor=G.+P.+Tochtropauthor=J.+T.+Hsiehauthor=P.+Pageauthor=L.+Liuauthor=D.+J.+Lindnerauthor=C.+Acharyaauthor=A.+D.+MacKerellauthor=E.+Fickerauthor=J.+Songauthor=B.+Wang&title=A+small+molecule+agonist+of+EphA2+receptor+tyrosine+kinase+inhibits+tumor+cell+migration+in+vitro+and+prostate+cancer+metastasis+in+vivo&doi=10.1371%2Fjournal.pone.0042120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo</span></div><div class="casAuthors">Petty, Aaron; Myshkin, Eugene; Qin, Haina; Guo, Hong; Miao, Hui; Tochtrop, Gregory P.; Hsieh, Jer-Tsong; Page, Phillip; Liu, Lili; Lindner, Daniel J.; Acharya, Chayan; MacKerell, Alexander D., Jr.; Ficker, Eckhard; Song, Jianxing; Wang, Bingcheng</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e42120</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">During tumor progression, EphA2 receptor can gain ligand-independent pro-oncogenic functions due to Akt activation and reduced ephrin-A ligand engagement.  The effects can be reversed by ligand stimulation, which triggers the intrinsic tumor suppressive signaling pathways of EphA2 including inhibition of PI3/Akt and Ras/ERK pathways.  These observations argue for development of small mol. agonists for EphA2 as potential tumor intervention agents.  Through virtual screening and cell-based assays, we report here the identification and characterization of doxazosin as a novel small mol. agonist for EphA2 and EphA4, but not for other Eph receptors tested.  NMR studies revealed extensive contacts of doxazosin with EphA2/A4, recapitulating both hydrophobic and electrostatic interactions recently found in the EphA2/ephrin-A1 complex.  Clin. used as an α1-adrenoreceptor antagonist (Cardura) for treating hypertension and benign prostate hyperplasia, doxazosin activated EphA2 independent of α1-adrenoreceptor.  Similar to ephrin-A1, doxazosin inhibited Akt and ERK kinase activities in an EphA2-dependent manner.  Treatment with doxazosin triggered EphA2 receptor internalization and suppressed haptotactic and chemotactic migration of prostate cancer, breast cancer and glioma cells.  Moreover, in an orthotopic xenograft model, doxazosin reduced distal metastasis of human prostate cancer cells and prolonged survival in recipient mice.  To our knowledge, doxazosin is the first small mol. agonist of a receptor tyrosine kinase that is capable of inhibiting malignant behaviors in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlr0BOi0YQT7Vg90H21EOLACvtfcHk0lj_LxT-AuSr8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ejtbrI&md5=10df3aa4d684e10d4b6135370973466e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0042120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0042120%26sid%3Dliteratum%253Aachs%26aulast%3DPetty%26aufirst%3DA.%26aulast%3DMyshkin%26aufirst%3DE.%26aulast%3DQin%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DMiao%26aufirst%3DH.%26aulast%3DTochtrop%26aufirst%3DG.%2BP.%26aulast%3DHsieh%26aufirst%3DJ.%2BT.%26aulast%3DPage%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLindner%26aufirst%3DD.%2BJ.%26aulast%3DAcharya%26aufirst%3DC.%26aulast%3DMacKerell%26aufirst%3DA.%2BD.%26aulast%3DFicker%26aufirst%3DE.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DB.%26atitle%3DA%2520small%2520molecule%2520agonist%2520of%2520EphA2%2520receptor%2520tyrosine%2520kinase%2520inhibits%2520tumor%2520cell%2520migration%2520in%2520vitro%2520and%2520prostate%2520cancer%2520metastasis%2520in%2520vivo%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De42120%26doi%3D10.1371%2Fjournal.pone.0042120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwano, H.</span></span> <span> </span><span class="NLM_article-title">Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">605</span>– <span class="NLM_lpage">611</span>, <span class="refDoi"> DOI: 10.3892/or.11.3.605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.3892%2For.11.3.605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=14767510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitVartLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=605-611&author=T.+Saitoauthor=N.+Masudaauthor=T.+Miyazakiauthor=K.+Kanohauthor=H.+Suzukiauthor=T.+Shimuraauthor=T.+Asaoauthor=H.+Kuwano&title=Expression+of+EphA2+and+E-cadherin+in+colorectal+cancer%3A+correlation+with+cancer+metastasis&doi=10.3892%2For.11.3.605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis</span></div><div class="casAuthors">Saito, Tetsuya; Masuda, Norihiro; Miyazaki, Tatsuya; Kanoh, Kenichi; Suzuki, Hideki; Shimura, Tatsuo; Asao, Takayuki; Kuwano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">605-611</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">Recently, overexpression of EphA2, a member of the Eph family of receptor tyrosine kinases, was reported in several cancers.  Reduced expression of E-cadherin, an intercellular adhesion mol. of epithelial cells, was reported to be assocd. with aggressive clinicopathol. phenotypes in various cancers.  In epithelial cells, EphA2 and E-cadherin co-localize to sites of cell-cell contact, and it was shown that E-cadherin regulates EphA2.  This study aimed to clarify the relationship between the expression of the EphA2 and E-cadherin proteins and clinicopathol. characteristics, with ref. to the expression levels of both EphA2 and E-cadherin, in patients with colorectal cancer.  The authors performed immunohistochem. staining of EphA2 and E-cadherin with EphA2 and E-cadherin monoclonal antibodies in samples from 194 primary lesions of colorectal cancer.  The expression level of EphA2 had a statistically significant relationship with liver metastasis, lymphatic vessel invasion and clin. stage (p = 0.0477, 0.0316 and 0.0467, resp.).  In addn., the positivity rate of EphA2 was significantly higher in primary lesions with lymph node metastasis than in those without metastasis (p = 0.0014).  However, the expression level of E-cadherin had an inverse relationship with both differentiation level of the tumor and lymphatic vessel invasion (p = 0.0430 and 0.0320, resp.).  Furthermore, a significant relationship between the expression of EphA2 and E-cadherin was obsd.  In conclusion, the authors' study revealed that the overexpression of EphA2 protein in colorectal carcinoma tissue correlates closely with cancer progression and hematogenous and lymphogenous metastasis, suggesting that both EphA2 and E-cadherin may play an important role in tumor metastasis in colorectal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGJ5UMgSywObVg90H21EOLACvtfcHk0lhDsTl2pPUMaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitVartLk%253D&md5=9befcd19834fabcb412ce3e38206ad0d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3892%2For.11.3.605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.11.3.605%26sid%3Dliteratum%253Aachs%26aulast%3DSaito%26aufirst%3DT.%26aulast%3DMasuda%26aufirst%3DN.%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DKanoh%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DShimura%26aufirst%3DT.%26aulast%3DAsao%26aufirst%3DT.%26aulast%3DKuwano%26aufirst%3DH.%26atitle%3DExpression%2520of%2520EphA2%2520and%2520E-cadherin%2520in%2520colorectal%2520cancer%253A%2520correlation%2520with%2520cancer%2520metastasis%26jtitle%3DOncol.%2520Rep.%26date%3D2004%26volume%3D11%26spage%3D605%26epage%3D611%26doi%3D10.3892%2For.11.3.605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taddei, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelucci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onnis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannoni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raugei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calorini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rucci, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bologna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarugi, P.</span></span> <span> </span><span class="NLM_article-title">Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">1492</span>– <span class="NLM_lpage">1503</span>, <span class="refDoi"> DOI: 10.2353/ajpath.2009.080473</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.2353%2Fajpath.2009.080473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=19264906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVOku7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2009&pages=1492-1503&author=M.+L.+Taddeiauthor=M.+Parriauthor=A.+Angelucciauthor=B.+Onnisauthor=F.+Bianchiniauthor=E.+Giannoniauthor=G.+Raugeiauthor=L.+Caloriniauthor=N.+Rucciauthor=A.+Tetiauthor=M.+Bolognaauthor=P.+Chiarugi&title=Kinase-dependent+and+-independent+roles+of+EphA2+in+the+regulation+of+prostate+cancer+invasion+and+metastasis&doi=10.2353%2Fajpath.2009.080473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis</span></div><div class="casAuthors">Taddei, Maria Letizia; Parri, Matteo; Angelucci, Adriano; Onnis, Barbara; Bianchini, Francesca; Giannoni, Elisa; Raugei, Giovanni; Calorini, Lido; Rucci, Nadia; Teti, Anna; Bologna, Maura; Chiarugi, Paola</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1492-1503</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Ligand-activated Eph tyrosine kinases regulate cellular repulsion, morphol., adhesion, and motility.  EphA2 kinase is frequently up-regulated in several different types of cancers, including prostate, breast, colon, and lung carcinomas, as well as in melanoma.  The existing data do not clarify whether EphA2 receptor phosphorylation or its simple overexpression, which likely leads to Eph kinase-independent responses, plays a role in the progression of malignant prostate cancer.  In this study, we address the role of EphA2 tyrosine phosphorylation in prostate carcinoma cell adhesion, motility, invasion, and formation of metastases.  Tumor cells expressing kinase-deficient EphA2 mutants, as well as an EphA2 variant lacking the cytoplasmic domain, are defective in ephrinA1-mediated cell rounding, retraction fiber formation, de-adhesion from the extracellular matrix, RhoA and Rac1 GTPase regulation, three-dimensional matrix invasion, and in vivo metastasis, suggesting a key role for EphA2 kinase activity.  Nevertheless, EphA2 regulation of cell motility and invasion, as well as the formation of bone and visceral tumor colonies, reveals a component of both EphA2 kinase-dependent and -independent features.  These results uncover a differential requirement for EphA2 kinase activity in the regulation of prostate carcinoma metastasis outcome, suggesting that although the kinase activity of EphA2 is required for the regulation of cell adhesion and cytoskeletal rearrangement, some distinct kinase-dependent and -independent pathways likely cooperate to drive cancer cell migration, invasion, and metastasis outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSqcUiLk3JZrVg90H21EOLACvtfcHk0lhDsTl2pPUMaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVOku7o%253D&md5=6ea11c43509901cde0a8df2621ec444b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2009.080473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2009.080473%26sid%3Dliteratum%253Aachs%26aulast%3DTaddei%26aufirst%3DM.%2BL.%26aulast%3DParri%26aufirst%3DM.%26aulast%3DAngelucci%26aufirst%3DA.%26aulast%3DOnnis%26aufirst%3DB.%26aulast%3DBianchini%26aufirst%3DF.%26aulast%3DGiannoni%26aufirst%3DE.%26aulast%3DRaugei%26aufirst%3DG.%26aulast%3DCalorini%26aufirst%3DL.%26aulast%3DRucci%26aufirst%3DN.%26aulast%3DTeti%26aufirst%3DA.%26aulast%3DBologna%26aufirst%3DM.%26aulast%3DChiarugi%26aufirst%3DP.%26atitle%3DKinase-dependent%2520and%2520-independent%2520roles%2520of%2520EphA2%2520in%2520the%2520regulation%2520of%2520prostate%2520cancer%2520invasion%2520and%2520metastasis%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2009%26volume%3D174%26spage%3D1492%26epage%3D1503%26doi%3D10.2353%2Fajpath.2009.080473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brantley-Sieders, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">7859</span>– <span class="NLM_lpage">7868</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1208937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1038%2Fsj.onc.1208937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=16103880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1GisLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=7859-7868&author=W.+B.+Fangauthor=D.+M.+Brantley-Siedersauthor=M.+A.+Parkerauthor=A.+D.+Reithauthor=J.+Chen&title=A+kinase-dependent+role+for+EphA2+receptor+in+promoting+tumor+growth+and+metastasis&doi=10.1038%2Fsj.onc.1208937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis</span></div><div class="casAuthors">Fang, Wei Bin; Brantley-Sieders, Dana M.; Parker, Monica A.; Reith, Alastair D.; Chen, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">53</span>),
    <span class="NLM_cas:pages">7859-7868</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Receptor tyrosine kinases of the Eph family are upregulated in several different types of cancer.  One family member in particular, the EphA2 receptor, has been linked to breast, prostate, lung and colon cancer, as well as melanoma.  However, mechanisms by which EphA2 contributes to tumor progression are far from clear.  In certain tumor cell lines, EphA2 receptor is underphosphorylated, raising the question of whether ligand-induced receptor phosphorylation and its kinase activity play a role in oncogenesis.  To test directly the role of EphA2 receptor phosphorylation/kinase activity in tumor progression, we generated EphA2 receptor variants that were either lacking the cytoplasmic domain or carrying a point mutation that inhibits its kinase activity.  Expression of these EphA2 mutants in breast cancer cells resulted in decreased tumor vol. and increased tumor apoptosis in primary tumors.  In addn., the nos. of lung metastases were significantly reduced in both exptl. and spontaneous metastasis models.  Reduced tumor vol. and metastasis are not due to defects in tumor angiogenesis, as there is no significant difference in tumor vessel d. between wild-type tumors and tumors expressing EphA2-signaling-defective mutants.  In contrast, tumor cells expressing the EphA2 mutants are defective in RhoA GTPase activation and cell migration.  Taken together, these results suggest that receptor phosphorylation and kinase activity of the EphA2 receptor, at least in part, contribute to tumor malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqT7wm3lqIt7Vg90H21EOLACvtfcHk0lhDsTl2pPUMaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1GisLrL&md5=ca391f6cd90a39642ab2112f6eaa6bd2</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1208937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1208937%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DW.%2BB.%26aulast%3DBrantley-Sieders%26aufirst%3DD.%2BM.%26aulast%3DParker%26aufirst%3DM.%2BA.%26aulast%3DReith%26aufirst%3DA.%2BD.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DA%2520kinase-dependent%2520role%2520for%2520EphA2%2520receptor%2520in%2520promoting%2520tumor%2520growth%2520and%2520metastasis%26jtitle%3DOncogene%26date%3D2005%26volume%3D24%26spage%3D7859%26epage%3D7868%26doi%3D10.1038%2Fsj.onc.1208937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gooya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinneer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazenbaker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swamynathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coats, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiener, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, D. A.</span></span> <span> </span><span class="NLM_article-title">A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">9367</span>– <span class="NLM_lpage">9374</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-1933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1158%2F0008-5472.CAN-08-1933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=19010911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9367-9374&author=D.+Jacksonauthor=J.+Gooyaauthor=S.+Maoauthor=K.+Kinneerauthor=L.+Xuauthor=M.+Camaraauthor=C.+Fazenbakerauthor=R.+Flemingauthor=S.+Swamynathanauthor=D.+Meyerauthor=P.+D.+Senterauthor=C.+Gaoauthor=H.+Wuauthor=M.+Kinchauthor=S.+Coatsauthor=P.+A.+Kienerauthor=D.+A.+Tice&title=A+human+antibody-drug+conjugate+targeting+EphA2+inhibits+tumor+growth+in+vivo&doi=10.1158%2F0008-5472.CAN-08-1933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A Human Antibody-Drug Conjugate Targeting EphA2 Inhibits Tumor Growth In vivo</span></div><div class="casAuthors">Jackson, Dowdy; Gooya, John; Mao, Shenlan; Kinneer, Krista; Xu, Linda; Camara, Margarita; Fazenbaker, Christine; Fleming, Ryan; Swamynathan, Sudha; Meyer, Damon; Senter, Peter D.; Gao, Changshou; Wu, Herren; Kinch, Michael; Coats, Steven; Kiener, Peter A.; Tice, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9367-9374</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The EphA2 receptor tyrosine kinase is selectively expressed on the surface of many different human tumors.  We have previously shown that tumor cells can be targeted by EphA2 monoclonal antibodies and that these antibodies function, in part, by inducing EphA2 internalization and degrdn.  In this report, we describe the isolation and characterization of a fully human monoclonal antibody (1C1) that selectively binds both the human and rodent EphA2 receptor.  After cell binding, the antibody induces rapid tyrosine phosphorylation, internalization, and degrdn. of the EphA2 receptor.  Because monoclonal antibodies that selectively bind tumor cells and internalize provide a vehicle for targeted delivery of cytotoxics, 1C1 was conjugated to the microtubule inhibitor monomethylauristatin phenylalanine using a stable maleimidocaproyl linker.  The anti-EphA2 antibody-drug conjugate [1C1-maleimidocaproyl-MMAF (mcMMAF)] stimulated the activation of caspase-3/caspase-7 and the death of EphA2-expressing cells with IC50 values as low as 3 ng/mL.  Similarly, the conjugate induced degrdn. of the EphA2 receptor and inhibited tumor growth in vivo.  Administration of 1C1-mcMMAF at doses as low as 1 mg/kg once weekly resulted in significant growth inhibition of EphA2-expressing tumors without any observable adverse effects in mouse xenograft and rat syngeneic tumor models.  Our data support the use of an antibody-drug conjugate approach to selectively target and inhibit the growth of EphA2-expressing tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC1fbfPqDzS7Vg90H21EOLACvtfcHk0lgZUieKU4b7zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7vK&md5=1e17e48422e5fc318773fd1de578ac16</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1933%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DD.%26aulast%3DGooya%26aufirst%3DJ.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DKinneer%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DCamara%26aufirst%3DM.%26aulast%3DFazenbaker%26aufirst%3DC.%26aulast%3DFleming%26aufirst%3DR.%26aulast%3DSwamynathan%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DD.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DKinch%26aufirst%3DM.%26aulast%3DCoats%26aufirst%3DS.%26aulast%3DKiener%26aufirst%3DP.%2BA.%26aulast%3DTice%26aufirst%3DD.%2BA.%26atitle%3DA%2520human%2520antibody-drug%2520conjugate%2520targeting%2520EphA2%2520inhibits%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D9367%26epage%3D9374%26doi%3D10.1158%2F0008-5472.CAN-08-1933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Annunziata, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohn, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buzoianu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbie, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechleider, R.</span></span> <span> </span><span class="NLM_article-title">Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1007/s10637-012-9801-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1007%2Fs10637-012-9801-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=22370972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Ogs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=77-84&author=C.+M.+Annunziataauthor=E.+C.+Kohnauthor=P.+LoRussoauthor=N.+D.+Houstonauthor=R.+L.+Colemanauthor=M.+Buzoianuauthor=G.+Robbieauthor=R.+Lechleider&title=Phase+1%2C+open-label+study+of+MEDI-547+in+patients+with+relapsed+or+refractory+solid+tumors&doi=10.1007%2Fs10637-012-9801-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors</span></div><div class="casAuthors">Annunziata, Christina M.; Kohn, Elise C.; LoRusso, Patricia; Houston, Nicole D.; Coleman, Robert L.; Buzoianu, Manuela; Robbie, Gabriel; Lechleider, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-84</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background: Targeting the cell-surface receptor EphA2, which is highly expressed in some solid tumors, is a novel approach for cancer therapy.  We aimed to evaluate the safety profile, max. tolerated dose (MTD), pharmacokinetics, and antitumor activity of MEDI-547, an antibody drug conjugate composed of the cytotoxic drug auristatin (toxin) linked to a human anti-EphA2 monoclonal antibody (1C1), in patients with solid tumors relapsed/refractory to std. therapy.  Methods: In this phase 1, open-label study with planned dose-escalation and dose-expansion cohorts, patients received a 1-h i.v. infusion of MEDI-547 (0.08 mg/kg) every 3 wk.  Results: Six patients received 0.08 mg/kg; all discontinued treatment.  Dose escalation was not pursued.  The study was stopped before cohort 2 enrollment due to treatment-related bleeding and coagulation events (hemorrhage-related, n = 3; epistaxis, n = 2).  Therefore, lower doses were not explored and an MTD could not be selected.  The most frequently reported treatment-related adverse events (AEs) were increased liver enzymes, decreased Hb, decreased appetite, and epistaxis.  Three patients (50%) experienced treatment-related serious AEs, including conjunctival hemorrhage, pain (led to study drug discontinuation), liver disorder, and hemorrhage.  Best response included progressive disease (n = 5; 83.3%) and stable disease (n = 1; 16.7%).  Minimal or no dissocn. of toxin from 1C1 conjugate occurred in the blood.  Serum MEDI-547 concns. decreased rapidly, ∼70% by 3 days post-dose.  No accumulation of MEDI-547 was obsd. at 0.08 mg/kg upon administration of a second dose 3 wk following dose 1.  Conclusions: The safety profile of MEDI-547 does not support further clin. investigation in patients with advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRCw89EUGfabVg90H21EOLACvtfcHk0lgZUieKU4b7zA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Ogs78%253D&md5=9af486f7c7287d8c150dade6baaf45b6</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs10637-012-9801-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-012-9801-2%26sid%3Dliteratum%253Aachs%26aulast%3DAnnunziata%26aufirst%3DC.%2BM.%26aulast%3DKohn%26aufirst%3DE.%2BC.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DHouston%26aufirst%3DN.%2BD.%26aulast%3DColeman%26aufirst%3DR.%2BL.%26aulast%3DBuzoianu%26aufirst%3DM.%26aulast%3DRobbie%26aufirst%3DG.%26aulast%3DLechleider%26aufirst%3DR.%26atitle%3DPhase%25201%252C%2520open-label%2520study%2520of%2520MEDI-547%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D77%26epage%3D84%26doi%3D10.1007%2Fs10637-012-9801-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koolpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dail, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span> <span> </span><span class="NLM_article-title">An ephrin mimetic peptide that selectively targets the EphA2 receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">46974</span>– <span class="NLM_lpage">46979</span>, <span class="refDoi"> DOI: 10.1074/jbc.M208495200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1074%2Fjbc.M208495200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=46974-46979&author=M.+Koolpeauthor=M.+Dailauthor=E.+B.+Pasquale&title=An+ephrin+mimetic+peptide+that+selectively+targets+the+EphA2+receptor&doi=10.1074%2Fjbc.M208495200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M208495200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M208495200%26sid%3Dliteratum%253Aachs%26aulast%3DKoolpe%26aufirst%3DM.%26aulast%3DDail%26aufirst%3DM.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26atitle%3DAn%2520ephrin%2520mimetic%2520peptide%2520that%2520selectively%2520targets%2520the%2520EphA2%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D46974%26epage%3D46979%26doi%3D10.1074%2Fjbc.M208495200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggineni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship analysis of peptides targeting the EphA2 receptor</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6687</span>– <span class="NLM_lpage">6695</span>, <span class="refDoi"> DOI: 10.1021/bi1006223</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi1006223" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVSmt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=6687-6695&author=S.+Mitraauthor=S.+Duggineniauthor=M.+Koolpeauthor=X.+Zhuauthor=Z.+Huangauthor=E.+B.+Pasquale&title=Structure-activity+relationship+analysis+of+peptides+targeting+the+EphA2+receptor&doi=10.1021%2Fbi1006223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship Analysis of Peptides Targeting the EphA2 Receptor</span></div><div class="casAuthors">Mitra, Sayantan; Duggineni, Srinivas; Koolpe, Mitchell; Zhu, Xuejun; Huang, Ziwei; Pasquale, Elena B.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">6687-6695</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The EphA2 receptor tyrosine kinase has emerged as a promising new therapeutic target in cancer because of its high level of expression in tumors.  EphA2-specific antibodies have been used to deliver drugs and toxins to tumor cells, leading to inhibition of tumor growth and metastatic dissemination.  The authors previously identified two related peptides, YSA and SWL, that selectively bind to the ligand-binding domain of EphA2 but not other Eph receptors and could therefore be useful as selective targeting agents.  Here the authors characterize the two peptides and a series of derivs.  On the basis of systematic amino acid replacements, only five YSA residues appear to be crit. for high-affinity receptor binding.  Furthermore, a peptide comprising only the first five residues of YSA retains selectivity for EphA2.  Similar to ephrin-A1, the physiol. ligand for EphA2, both YSA and SWL activate EphA2 and inhibit downstream oncogenic signaling pathways in PC3 cancer cells.  The two peptides and derivs. are quite stable in conditioned cell culture medium and show promise for delivering drugs and as imaging agents to EphA2-expressing tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHmJrdhjP9w7Vg90H21EOLACvtfcHk0liiFVtKMvzPiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVSmt7o%253D&md5=a542f4e46d5f65a6abb6268dc53fd7d4</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fbi1006223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi1006223%26sid%3Dliteratum%253Aachs%26aulast%3DMitra%26aufirst%3DS.%26aulast%3DDuggineni%26aufirst%3DS.%26aulast%3DKoolpe%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26atitle%3DStructure-activity%2520relationship%2520analysis%2520of%2520peptides%2520targeting%2520the%2520EphA2%2520receptor%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D6687%26epage%3D6695%26doi%3D10.1021%2Fbi1006223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Placzek, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noberini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2427</span>– <span class="NLM_lpage">2436</span>, <span class="refDoi"> DOI: 10.1021/jm201743s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201743s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFequ7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2427-2436&author=S.+Wangauthor=W.+J.+Placzekauthor=J.+L.+Stebbinsauthor=S.+Mitraauthor=R.+Noberiniauthor=M.+Koolpeauthor=Z.+Zhangauthor=R.+Dahlauthor=E.+B.+Pasqualeauthor=M.+Pellecchia&title=Novel+targeted+system+to+deliver+chemotherapeutic+drugs+to+EphA2-expressing+cancer+cells&doi=10.1021%2Fjm201743s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells</span></div><div class="casAuthors">Wang, Si; Placzek, William J.; Stebbins, John L.; Mitra, Sayantan; Noberini, Roberta; Koolpe, Mitchell; Zhang, Ziming; Dahl, Russell; Pasquale, Elena B.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2427-2436</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The efficacy of anticancer drugs is often limited by their systemic toxicities and adverse side effects.  We report that the EphA2 receptor is overexpressed preferentially in several human cancer cell lines compared to normal tissues and that an EphA2 targeting peptide (YSAYPDSVPMMS) can be effective in delivering anticancer agents to such tumors.  Hence, we report on the synthesis and characterizations of a novel EphA2-targeting agent conjugated with the chemotherapeutic drug paclitaxel.  We found that the peptide-drug conjugate is dramatically more effective than paclitaxel alone at inhibiting tumor growth in a prostate cancer xenograft model, delivering significantly higher levels of drug to the tumor site.  We believe these studies open the way to the development of a new class of therapeutic compds. that exploit the EphA2 receptor for drug delivery to cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1Pu5ES26uUrVg90H21EOLACvtfcHk0liiFVtKMvzPiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFequ7k%253D&md5=3835d4051c60b26e126da69b9b7510ca</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm201743s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201743s%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DPlaczek%26aufirst%3DW.%2BJ.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DMitra%26aufirst%3DS.%26aulast%3DNoberini%26aufirst%3DR.%26aulast%3DKoolpe%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DNovel%2520targeted%2520system%2520to%2520deliver%2520chemotherapeutic%2520drugs%2520to%2520EphA2-expressing%2520cancer%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2427%26epage%3D2436%26doi%3D10.1021%2Fjm201743s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noberini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhowmick, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Targeted delivery of paclitaxel to EphA2-expressing cancer cells</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-2654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1158%2F1078-0432.CCR-12-2654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=23155185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFGitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=128-137&author=S.+Wangauthor=R.+Noberiniauthor=J.+L.+Stebbinsauthor=S.+Dasauthor=Z.+Zhangauthor=B.+Wuauthor=S.+Mitraauthor=S.+Billetauthor=A.+Fernandezauthor=N.+A.+Bhowmickauthor=S.+Kitadaauthor=E.+B.+Pasqualeauthor=P.+B.+Fisherauthor=M.+Pellecchia&title=Targeted+delivery+of+paclitaxel+to+EphA2-expressing+cancer+cells&doi=10.1158%2F1078-0432.CCR-12-2654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Delivery of Paclitaxel to EphA2-Expressing Cancer Cells</span></div><div class="casAuthors">Wang, Si; Noberini, Roberta; Stebbins, John L.; Das, Swadesh; Zhang, Ziming; Wu, Bainan; Mitra, Sayantan; Billet, Sandrine; Fernandez, Ana; Bhowmick, Neil A.; Kitada, Shinichi; Pasquale, Elena B.; Fisher, Paul B.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-137</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: YSA is an EphA2-targeting peptide that effectively delivers anticancer agents to prostate cancer tumors.  Here, we report on how we increased the drug-like properties of this delivery system.  Exptl. Design: By introducing non-natural amino acids, we have designed two new EphA2 targeting peptides: YNH, where norleucine and homoserine replace the two methionine residues of YSA, and dYNH, where a D-tyrosine replaces the L-tyrosine at the first position of the YNH peptide.  We describe the details of the synthesis of YNH and dYNH paclitaxel conjugates (YNH-PTX and dYNH-PTX) and their characterization in cells and in vivo.  Results: dYNH-PTX showed improved stability in mouse serum and significantly reduced tumor size in a prostate cancer xenograft model and also reduced tumor vasculature in a syngeneic orthotopic allograft mouse model of renal cancer compared with vehicle or paclitaxel treatments.  Conclusion: This study reveals that targeting EphA2 with dYNH drug conjugates could represent an effective way to deliver anticancer agents to a variety of tumor types.  Clin Cancer Res; 19(1); 128-37. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM9wK1ey90VLVg90H21EOLACvtfcHk0lith1beHOwgRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFGitQ%253D%253D&md5=9d11d8f57028d5245b0d344652ef311e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2654%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DNoberini%26aufirst%3DR.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DMitra%26aufirst%3DS.%26aulast%3DBillet%26aufirst%3DS.%26aulast%3DFernandez%26aufirst%3DA.%26aulast%3DBhowmick%26aufirst%3DN.%2BA.%26aulast%3DKitada%26aufirst%3DS.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DTargeted%2520delivery%2520of%2520paclitaxel%2520to%2520EphA2-expressing%2520cancer%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D128%26epage%3D137%26doi%3D10.1158%2F1078-0432.CCR-12-2654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barile, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noberini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1403</span>– <span class="NLM_lpage">1412</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201400067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1002%2Fcmdc.201400067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=24677792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVKitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1403-1412&author=E.+Barileauthor=S.+Wangauthor=S.+K.+Dasauthor=R.+Noberiniauthor=R.+Dahlauthor=J.+L.+Stebbinsauthor=E.+B.+Pasqualeauthor=P.+B.+Fisherauthor=M.+Pellecchia&title=Design%2C+synthesis+and+bioevaluation+of+an+EphA2+receptor-based+targeted+delivery+system&doi=10.1002%2Fcmdc.201400067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis and Bioevaluation of an EphA2 Receptor-Based Targeted Delivery System</span></div><div class="casAuthors">Barile, Elisa; Wang, Si; Das, Swadesh K.; Noberini, Roberta; Dahl, Russell; Stebbins, John L.; Pasquale, Elena B.; Fisher, Paul B.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1403-1412</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Because of its overexpression in a range of solid tumors, the EphA2 receptor is a validated target for cancer therapeutics.  The authors recently described a new targeted delivery system based on specific EphA2-targeting peptides conjugated with the chemotherapeutic agent paclitaxel.  Here, the chem. determinants responsible for the stability and degrdn. of these agents in plasma were investigated.  Introducing modifications in both the peptide and the linker between the peptide and paclitaxel resulted in drug conjugates that are both long-lived in rat plasma and that markedly decrease tumor size in a prostate cancer xenograft model compared with paclitaxel alone treatment.  These studies identify crit. rate-limiting degrdn. sites on the peptide-drug conjugates, enabling the design of agents with increased stability and efficacy.  These results provide support for the central hypothesis that peptide-drug conjugates targeting EphA2 represent an innovative and potentially effective strategy to selectively deliver cytotoxic drugs to cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0PtVZMIpXmrVg90H21EOLACvtfcHk0lith1beHOwgRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVKitrk%253D&md5=4b83eea1d0ea2ee884f003e7565eb65f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201400067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201400067%26sid%3Dliteratum%253Aachs%26aulast%3DBarile%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DDas%26aufirst%3DS.%2BK.%26aulast%3DNoberini%26aufirst%3DR.%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%2520and%2520bioevaluation%2520of%2520an%2520EphA2%2520receptor-based%2520targeted%2520delivery%2520system%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D1403%26epage%3D1412%26doi%3D10.1002%2Fcmdc.201400067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barile, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zharkikh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purves, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshima, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Design and characterization of novel EphA2 agonists for targeted delivery of chemotherapy to cancer Cells</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">887</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2015.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.chembiol.2015.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=26165155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCqtbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=876-887&author=B.+Wuauthor=S.+Wangauthor=S.+K.+Deauthor=E.+Barileauthor=B.+A.+Quinnauthor=I.+Zharkikhauthor=A.+Purvesauthor=J.+L.+Stebbinsauthor=R.+G.+Oshimaauthor=P.+B.+Fisherauthor=M.+Pellecchia&title=Design+and+characterization+of+novel+EphA2+agonists+for+targeted+delivery+of+chemotherapy+to+cancer+Cells&doi=10.1016%2Fj.chembiol.2015.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells</span></div><div class="casAuthors">Wu, Bainan; Wang, Si; De, Surya K.; Barile, Elisa; Quinn, Bridget A.; Zharkikh, Irina; Purves, Angela; Stebbins, John L.; Oshima, Robert G.; Fisher, Paul B.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">876-887</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The development of novel, targeted delivery agents for anti-cancer therapies requires the design and optimization of potent and selective tumor-targeting agents that are stable and amenable to conjugation with chemotherapeutic drugs.  While short peptides represent potentially an excellent platform for these purposes, they often get degraded and are eliminated too rapidly in vivo.  In this study, we used a combination of NMR-guided structure-activity relationships along with biochem. and cellular studies to derive a novel tumor-homing agent, named 123B9, targeting the EphA2 tyrosine kinase receptor ligand-binding domain.  Conjugating 123B9 to the chemotherapeutic drug paclitaxel (PTX) via a stable linker results in an agent that is significantly more effective than the unconjugated drug in both a pancreatic cancer xenograft model and a melanoma lung colonization and metastases model.  Hence, 123B9 could represent a promising strategy for the development of novel targeted therapies for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5FFEE4-jdhLVg90H21EOLACvtfcHk0lith1beHOwgRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCqtbbM&md5=5bd8b17e5b9bac6ce74e54cd1049d4b9</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2015.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2015.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DDe%26aufirst%3DS.%2BK.%26aulast%3DBarile%26aufirst%3DE.%26aulast%3DQuinn%26aufirst%3DB.%2BA.%26aulast%3DZharkikh%26aufirst%3DI.%26aulast%3DPurves%26aufirst%3DA.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DOshima%26aufirst%3DR.%2BG.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DDesign%2520and%2520characterization%2520of%2520novel%2520EphA2%2520agonists%2520for%2520targeted%2520delivery%2520of%2520chemotherapy%2520to%2520cancer%2520Cells%26jtitle%3DChem.%2520Biol.%26date%3D2015%26volume%3D22%26spage%3D876%26epage%3D887%26doi%3D10.1016%2Fj.chembiol.2015.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barile, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emdad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morvaridi, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandol, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">17103</span>– <span class="NLM_lpage">17110</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.7931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.18632%2Foncotarget.7931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=26959746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A280%3ADC%252BC28jotlGitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=17103-17110&author=B.+A.+Quinnauthor=S.+Wangauthor=E.+Barileauthor=S.+K.+Dasauthor=L.+Emdadauthor=D.+Sarkarauthor=S.+K.+Deauthor=S.+K.+Morvaridiauthor=J.+L.+Stebbinsauthor=S.+J.+Pandolauthor=P.+B.+Fisherauthor=M.+Pellecchia&title=Therapy+of+pancreatic+cancer+via+an+EphA2+receptor-targeted+delivery+of+gemcitabine&doi=10.18632%2Foncotarget.7931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine</span></div><div class="casAuthors">Quinn Bridget A; Das Swadesh K; Emdad Luni; Sarkar Devanand; Fisher Paul B; Wang Si; Barile Elisa; De Surya K; Stebbins John L; Fisher Paul B; Pellecchia Maurizio; Barile Elisa; De Surya K; Pellecchia Maurizio; Morvaridi Susan Kharagh; Pandol Stephen J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">17103-10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">First line treatment for pancreatic cancer consists of surgical resection, if possible, and a subsequent course of chemotherapy using the nucleoside analogue gemcitabine.  In some patients, an active transport mechanism allows gemcitabine to enter efficiently into the tumor cells, resulting in a significant clinical benefit.  However, in most patients, low expression of gemcitabine transporters limits the efficacy of the drug to marginal levels, and patients need frequent administration of the drug at high doses, significantly increasing systemic drug toxicity.  In this article we focus on a novel targeted delivery approach for gemcitabine consisting of conjugating the drug with an EphA2 targeting agent.  We show that the EphA2 receptor is highly expressed in pancreatic cancers, and accordingly, the drug-conjugate is more effective than gemcitabine alone in targeting pancreatic tumors.  Our preliminary observations suggest that this approach may provide a general benefit to pancreatic cancer patients and offers a comprehensive strategy for enhancing delivery of diverse therapeutic agents to a wide range of cancers overexpressing EphA2, thereby potentially reducing toxicity while enhancing therapeutic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkle74R4yp-ekdrW1FkXG-fW6udTcc2eb3hZ1XrC5bELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jotlGitA%253D%253D&md5=0b5e311729fc3517d90882844ab3d3f2</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.7931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.7931%26sid%3Dliteratum%253Aachs%26aulast%3DQuinn%26aufirst%3DB.%2BA.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DBarile%26aufirst%3DE.%26aulast%3DDas%26aufirst%3DS.%2BK.%26aulast%3DEmdad%26aufirst%3DL.%26aulast%3DSarkar%26aufirst%3DD.%26aulast%3DDe%26aufirst%3DS.%2BK.%26aulast%3DMorvaridi%26aufirst%3DS.%2BK.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DPandol%26aufirst%3DS.%2BJ.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DTherapy%2520of%2520pancreatic%2520cancer%2520via%2520an%2520EphA2%2520receptor-targeted%2520delivery%2520of%2520gemcitabine%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D17103%26epage%3D17110%26doi%3D10.18632%2Foncotarget.7931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jan, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ro, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisarska, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, H. R.</span></span> <span> </span><span class="NLM_article-title">Imprinted nanovelcro microchips for isolation and characterization of circulating fetal trophoblasts: toward non-invasive prenatal diagnostics</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">8167</span>– <span class="NLM_lpage">8177</span>, <span class="refDoi"> DOI: 10.1021/acsnano.7b03073</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.7b03073" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=8167-8177&author=S.+Houauthor=J.+F.+Chenauthor=M.+Songauthor=Y.+Zhuauthor=Y.+J.+Janauthor=S.+H.+Chenauthor=T.+H.+Wengauthor=D.+A.+Lingauthor=S.+F.+Chenauthor=T.+Roauthor=A.+J.+Liangauthor=T.+Leeauthor=H.+Jinauthor=M.+Liauthor=L.+Liuauthor=Y.+S.+Hsiaoauthor=P.+Chenauthor=H.+H.+Yuauthor=M.+S.+Tsaiauthor=M.+D.+Pisarskaauthor=A.+Chenauthor=L.+C.+Chenauthor=H.+R.+Tseng&title=Imprinted+nanovelcro+microchips+for+isolation+and+characterization+of+circulating+fetal+trophoblasts%3A+toward+non-invasive+prenatal+diagnostics&doi=10.1021%2Facsnano.7b03073"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facsnano.7b03073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.7b03073%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%2BF.%26aulast%3DSong%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DJan%26aufirst%3DY.%2BJ.%26aulast%3DChen%26aufirst%3DS.%2BH.%26aulast%3DWeng%26aufirst%3DT.%2BH.%26aulast%3DLing%26aufirst%3DD.%2BA.%26aulast%3DChen%26aufirst%3DS.%2BF.%26aulast%3DRo%26aufirst%3DT.%26aulast%3DLiang%26aufirst%3DA.%2BJ.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DHsiao%26aufirst%3DY.%2BS.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DYu%26aufirst%3DH.%2BH.%26aulast%3DTsai%26aufirst%3DM.%2BS.%26aulast%3DPisarska%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DL.%2BC.%26aulast%3DTseng%26aufirst%3DH.%2BR.%26atitle%3DImprinted%2520nanovelcro%2520microchips%2520for%2520isolation%2520and%2520characterization%2520of%2520circulating%2520fetal%2520trophoblasts%253A%2520toward%2520non-invasive%2520prenatal%2520diagnostics%26jtitle%3DACS%2520Nano%26date%3D2017%26volume%3D11%26spage%3D8167%26epage%3D8177%26doi%3D10.1021%2Facsnano.7b03073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agopian, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posadas, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, H. R.</span></span> <span> </span><span class="NLM_article-title">Clinical applications of nanovelcro rare-cell assays for detection and characterization of circulating tumor cells</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1425</span>– <span class="NLM_lpage">1439</span>, <span class="refDoi"> DOI: 10.7150/thno.15359</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.7150%2Fthno.15359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=27375790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC2sXns1Cisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=1425-1439&author=J.+F.+Chenauthor=Y.+Zhuauthor=Y.+T.+Luauthor=E.+Hodaraauthor=S.+Houauthor=V.+G.+Agopianauthor=J.+S.+Tomlinsonauthor=E.+M.+Posadasauthor=H.+R.+Tseng&title=Clinical+applications+of+nanovelcro+rare-cell+assays+for+detection+and+characterization+of+circulating+tumor+cells&doi=10.7150%2Fthno.15359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical applications of nanovelcro rare cell assays for detection and characterization of circulating tumor cells</span></div><div class="casAuthors">Chen, Jie-Fu; Zhu, Yazhen; Lu, Yi-Tsung; Hodara, Elisabeth; Hou, Shuang; Agopian, Vatche G.; Tomlinson, James S.; Posadas, Edwin M.; Tseng, Hsian-Rong</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1425-1439</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Liq. biopsy of tumor through isolation of circulating tumor cells (CTCs) allows non-invasive, repetitive, and systemic sampling of disease.  Although detecting and enumerating CTCs is of prognostic significance in metastatic cancer, it is conceivable that performing mol. and functional characterization on CTCs will reveal unprecedented insight into the pathogenic mechanisms driving lethal disease.  Nanomaterial-embedded cancer diagnostic platforms, i.e., NanoVelcro CTC Assays represent a unique rare-cell sorting method that enables detection isolation, and characterization of CTCs in peripheral blood, providing an opportunity to noninvasively monitor disease progression in individual cancer patients.  Over the past decade, a series of NanoVelcro CTC Assays has been demonstrated for exploring the full potential of CTCs as a clin. biomarker, including CTC enumeration, phenotyping, genotyping and expression profiling.  In this review article, the authors will briefly introduce the development of three generations of NanoVelcro CTC Assays, and highlight the clin. applications of each generation for various types of solid cancers, including prostate cancer, pancreatic cancer, lung cancer, and melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq14bqqVWPzDLVg90H21EOLACvtfcHk0liJ2PvP2K9VDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXns1Cisr4%253D&md5=2476c77edf0dda57465fb899039a4b28</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.7150%2Fthno.15359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.15359%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%2BF.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%2BT.%26aulast%3DHodara%26aufirst%3DE.%26aulast%3DHou%26aufirst%3DS.%26aulast%3DAgopian%26aufirst%3DV.%2BG.%26aulast%3DTomlinson%26aufirst%3DJ.%2BS.%26aulast%3DPosadas%26aufirst%3DE.%2BM.%26aulast%3DTseng%26aufirst%3DH.%2BR.%26atitle%3DClinical%2520applications%2520of%2520nanovelcro%2520rare-cell%2520assays%2520for%2520detection%2520and%2520characterization%2520of%2520circulating%2520tumor%2520cells%26jtitle%3DTheranostics%26date%3D2016%26volume%3D6%26spage%3D1425%26epage%3D1439%26doi%3D10.7150%2Fthno.15359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarioglu, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aceto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donaldson, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeinali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamza, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaresan, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittner, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaswamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shioda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ting, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maheswaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toner, M.</span></span> <span> </span><span class="NLM_article-title">A microfluidic device for label-free, physical capture of circulating tumor cell clusters</span>. <i>Nat. Methods</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">685</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1038/nmeth.3404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1038%2Fnmeth.3404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=25984697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFWqtbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=685-691&author=A.+F.+Sariogluauthor=N.+Acetoauthor=N.+Kojicauthor=M.+C.+Donaldsonauthor=M.+Zeinaliauthor=B.+Hamzaauthor=A.+Engstromauthor=H.+Zhuauthor=T.+K.+Sundaresanauthor=D.+T.+Miyamotoauthor=X.+Luoauthor=A.+Bardiaauthor=B.+S.+Wittnerauthor=S.+Ramaswamyauthor=T.+Shiodaauthor=D.+T.+Tingauthor=S.+L.+Stottauthor=R.+Kapurauthor=S.+Maheswaranauthor=D.+A.+Haberauthor=M.+Toner&title=A+microfluidic+device+for+label-free%2C+physical+capture+of+circulating+tumor+cell+clusters&doi=10.1038%2Fnmeth.3404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A microfluidic device for label-free, physical capture of circulating tumor cell clusters</span></div><div class="casAuthors">Sarioglu, A. Fatih; Aceto, Nicola; Kojic, Nikola; Donaldson, Maria C.; Zeinali, Mahnaz; Hamza, Bashar; Engstrom, Amanda; Zhu, Huili; Sundaresan, Tilak K.; Miyamoto, David T.; Luo, Xi; Bardia, Aditya; Wittner, Ben S.; Ramaswamy, Sridhar; Shioda, Toshi; Ting, David T.; Stott, Shannon L.; Kapur, Ravi; Maheswaran, Shyamala; Haber, Daniel A.; Toner, Mehmet</div><div class="citationInfo"><span class="NLM_cas:title">Nature Methods</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">685-691</span>CODEN:
                <span class="NLM_cas:coden">NMAEA3</span>;
        ISSN:<span class="NLM_cas:issn">1548-7091</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer cells metastasize through the bloodstream either as single migratory circulating tumor cells (CTCs) or as multicellular groupings (CTC clusters).  Existing technologies for CTC enrichment are designed to isolate single CTCs, and although CTC clusters are detectable in some cases, their true prevalence and significance remain to be detd.  Here we developed a microchip technol. (the Cluster-Chip) to capture CTC clusters independently of tumor-specific markers from unprocessed blood.  CTC clusters are isolated through specialized bifurcating traps under low-shear stress conditions that preserve their integrity, and even two-cell clusters are captured efficiently.  Using the Cluster-Chip, we identified CTC clusters in 30-40% of patients with metastatic breast or prostate cancer or with melanoma.  RNA sequencing of CTC clusters confirmed their tumor origin and identified tissue-derived macrophages within the clusters.  Efficient capture of CTC clusters will enable the detailed characterization of their biol. properties and role in metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZETw8HzHH_bVg90H21EOLACvtfcHk0liuydgTAvXDzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFWqtbbE&md5=6ce523882376f88875f506e33cb04b22</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnmeth.3404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmeth.3404%26sid%3Dliteratum%253Aachs%26aulast%3DSarioglu%26aufirst%3DA.%2BF.%26aulast%3DAceto%26aufirst%3DN.%26aulast%3DKojic%26aufirst%3DN.%26aulast%3DDonaldson%26aufirst%3DM.%2BC.%26aulast%3DZeinali%26aufirst%3DM.%26aulast%3DHamza%26aufirst%3DB.%26aulast%3DEngstrom%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DSundaresan%26aufirst%3DT.%2BK.%26aulast%3DMiyamoto%26aufirst%3DD.%2BT.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DBardia%26aufirst%3DA.%26aulast%3DWittner%26aufirst%3DB.%2BS.%26aulast%3DRamaswamy%26aufirst%3DS.%26aulast%3DShioda%26aufirst%3DT.%26aulast%3DTing%26aufirst%3DD.%2BT.%26aulast%3DStott%26aufirst%3DS.%2BL.%26aulast%3DKapur%26aufirst%3DR.%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DToner%26aufirst%3DM.%26atitle%3DA%2520microfluidic%2520device%2520for%2520label-free%252C%2520physical%2520capture%2520of%2520circulating%2520tumor%2520cell%2520clusters%26jtitle%3DNat.%2520Methods%26date%3D2015%26volume%3D12%26spage%3D685%26epage%3D691%26doi%3D10.1038%2Fnmeth.3404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Au, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storey, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javaid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarioglu, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madden, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Keefe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maheswaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langenau, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toner, M.</span></span> <span> </span><span class="NLM_article-title">Clusters of circulating tumor cells traverse capillary-sized vessels</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">4947</span>– <span class="NLM_lpage">4952</span>, <span class="refDoi"> DOI: 10.1073/pnas.1524448113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1073%2Fpnas.1524448113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=27091969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmt1Shurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=4947-4952&author=S.+H.+Auauthor=B.+D.+Storeyauthor=J.+C.+Mooreauthor=Q.+Tangauthor=Y.+L.+Chenauthor=S.+Javaidauthor=A.+F.+Sariogluauthor=R.+Sullivanauthor=M.+W.+Maddenauthor=R.+O%E2%80%99Keefeauthor=D.+A.+Haberauthor=S.+Maheswaranauthor=D.+M.+Langenauauthor=S.+L.+Stottauthor=M.+Toner&title=Clusters+of+circulating+tumor+cells+traverse+capillary-sized+vessels&doi=10.1073%2Fpnas.1524448113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Clusters of circulating tumor cells traverse capillary-sized vessels</span></div><div class="casAuthors">Au, Sam H.; Storey, Brian D.; Moore, John C.; Tang, Qin; Chen, Yeng-Long; Javaid, Sarah; Sarioglu, A. Fatih; Sullivan, Ryan; Madden, Marissa W.; O'Keefe, Ryan; Haber, Daniel A.; Maheswaran, Shyamala; Langenau, David M.; Stott, Shannon L.; Toner, Mehmet</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4947-4952</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Multicellular aggregates of circulating tumor cells (CTC clusters) are potent initiators of distant organ metastasis.  However, it is currently assumed that CTC clusters are too large to pass through narrow vessels to reach these organs.  Here, we present evidence that challenges this assumption through the use of microfluidic devices designed to mimic human capillary constrictions and CTC clusters obtained from patient and cancer cell origins.  Over 90% of clusters contg. up to 20 cells successfully traversed 5- to 10-μm constrictions even in whole blood.  Clusters rapidly and reversibly reorganized into single-file chain-like geometries that substantially reduced their hydrodynamic resistances.  Xenotransplantation of human CTC clusters into zebrafish showed similar reorganization and transit through capillary-sized vessels in vivo.  Preliminary expts. demonstrated that clusters could be disrupted during transit using drugs that affected cellular interaction energies.  These findings suggest that CTC clusters may contribute a greater role to tumor dissemination than previously believed and may point to strategies for combating CTC cluster-initiated metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXe_FYTSq_U7Vg90H21EOLACvtfcHk0liuydgTAvXDzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmt1Shurs%253D&md5=574c93c923954fcd660b8e6474864a68</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1524448113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1524448113%26sid%3Dliteratum%253Aachs%26aulast%3DAu%26aufirst%3DS.%2BH.%26aulast%3DStorey%26aufirst%3DB.%2BD.%26aulast%3DMoore%26aufirst%3DJ.%2BC.%26aulast%3DTang%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DY.%2BL.%26aulast%3DJavaid%26aufirst%3DS.%26aulast%3DSarioglu%26aufirst%3DA.%2BF.%26aulast%3DSullivan%26aufirst%3DR.%26aulast%3DMadden%26aufirst%3DM.%2BW.%26aulast%3DO%25E2%2580%2599Keefe%26aufirst%3DR.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DLangenau%26aufirst%3DD.%2BM.%26aulast%3DStott%26aufirst%3DS.%2BL.%26aulast%3DToner%26aufirst%3DM.%26atitle%3DClusters%2520of%2520circulating%2520tumor%2520cells%2520traverse%2520capillary-sized%2520vessels%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3D4947%26epage%3D4952%26doi%3D10.1073%2Fpnas.1524448113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giorgio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Incerti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corrado, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiodelli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callegari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferlenghi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballabeni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barocelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognolini, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2017.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.bcp.2017.11.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2018&pages=21-29&author=C.+Giorgioauthor=M.+Incertiauthor=M.+Corradoauthor=M.+Rusnatiauthor=P.+Chiodelliauthor=S.+Russoauthor=D.+Callegariauthor=F.+Ferlenghiauthor=V.+Ballabeniauthor=E.+Barocelliauthor=A.+Lodolaauthor=M.+Tognolini&title=Pharmacological+evaluation+of+new+bioavailable+small+molecules+targeting+Eph%2Fephrin+interaction&doi=10.1016%2Fj.bcp.2017.11.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2017.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2017.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DGiorgio%26aufirst%3DC.%26aulast%3DIncerti%26aufirst%3DM.%26aulast%3DCorrado%26aufirst%3DM.%26aulast%3DRusnati%26aufirst%3DM.%26aulast%3DChiodelli%26aufirst%3DP.%26aulast%3DRusso%26aufirst%3DS.%26aulast%3DCallegari%26aufirst%3DD.%26aulast%3DFerlenghi%26aufirst%3DF.%26aulast%3DBallabeni%26aufirst%3DV.%26aulast%3DBarocelli%26aufirst%3DE.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DTognolini%26aufirst%3DM.%26atitle%3DPharmacological%2520evaluation%2520of%2520new%2520bioavailable%2520small%2520molecules%2520targeting%2520Eph%252Fephrin%2520interaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2018%26volume%3D147%26spage%3D21%26epage%3D29%26doi%3D10.1016%2Fj.bcp.2017.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idippily, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobba, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geldenhuys, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of small molecule agonists of EphA2 receptor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">1261</span>– <span class="NLM_lpage">1276</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.10.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.ejmech.2017.10.026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=1261-1276&author=A.+Pettyauthor=N.+Idippilyauthor=V.+Bobbaauthor=W.+J.+Geldenhuysauthor=B.+Zhongauthor=B.+Suauthor=B.+Wang&title=Design+and+synthesis+of+small+molecule+agonists+of+EphA2+receptor&doi=10.1016%2Fj.ejmech.2017.10.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DPetty%26aufirst%3DA.%26aulast%3DIdippily%26aufirst%3DN.%26aulast%3DBobba%26aufirst%3DV.%26aulast%3DGeldenhuys%26aufirst%3DW.%2BJ.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DSu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DB.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520small%2520molecule%2520agonists%2520of%2520EphA2%2520receptor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D1261%26epage%3D1276%26doi%3D10.1016%2Fj.ejmech.2017.10.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hassan-Mohamed, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Incerti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanotti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barocelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognolini, M.</span></span> <span> </span><span class="NLM_article-title">UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">5195</span>– <span class="NLM_lpage">5208</span>, <span class="refDoi"> DOI: 10.1111/bph.12669</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1111%2Fbph.12669" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=24597515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVamt7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2014&pages=5195-5208&author=I.+Hassan-Mohamedauthor=C.+Giorgioauthor=M.+Incertiauthor=S.+Russoauthor=D.+Palaauthor=E.+B.+Pasqualeauthor=I.+Zanottiauthor=P.+Viciniauthor=E.+Barocelliauthor=S.+Rivaraauthor=M.+Morauthor=A.+Lodolaauthor=M.+Tognolini&title=UniPR129+is+a+competitive+small+molecule+Eph-ephrin+antagonist+blocking+in+vitro+angiogenesis+at+low+micromolar+concentrations&doi=10.1111%2Fbph.12669"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations</span></div><div class="casAuthors">Hassan-Mohamed, I.; Giorgio, C.; Incerti, M.; Russo, S.; Pala, D.; Pasquale, E. B.; Zanotti, I.; Vicini, P.; Barocelli, E.; Rivara, S.; Mor, M.; Lodola, A.; Tognolini, M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5195-5208</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : The Eph receptor tyrosine kinases and their ephrin ligands are key players in tumorigenesis and many reports have correlated changes in their expression with a poor clin. prognosis in many solid tumors.  Agents targeting the Eph-ephrin system might emerge as new tools useful for the inhibition of different components of cancer progression.  Even if different classes of small mols. targeting Eph-ephrin interactions have been reported, their use is hampered by poor chem. stability and low potency.  Stable and potent ligands are crucial to achieve robust pharmacol. performance.  Exptl. Approach : UniPR129 (the L-homo-Trp conjugate of lithocholic acid) was designed by means of computational methods, synthesized and tested for its ability to inhibit the interaction between the EphA2 receptor and the ephrin-A1 ligand in an elisa binding study.  The ability of UniPR129 to disrupt EphA2-ephrin-A1 interaction was functionally evaluated in a prostate adenocarcinoma cell line and its anti-angiogenic effect was tested in vitro using cultures of HUVECs.  Key Results : UniPR129 disrupted EphA2-ephrin-A1 interaction with Ki = 370 nM in an elisa binding assay and with low micromolar potency in cellular functional assays, including inhibition of EphA2 activation, inhibition of PC3 cell rounding and disruption of in vitro angiogenesis, without cytotoxic effects.  Conclusions and Implications : The discovery of UniPR129 represents not only a major advance in potency compared with the existing Eph-ephrin antagonists but also an improvement in terms of cytotoxicity, making this mol. a useful pharmacol. tool and a promising lead compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjj_0wPmI-9rVg90H21EOLACvtfcHk0lhcDb50Nq6Xcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVamt7bF&md5=941a213e381fa47f61573fc654661956</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Fbph.12669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12669%26sid%3Dliteratum%253Aachs%26aulast%3DHassan-Mohamed%26aufirst%3DI.%26aulast%3DGiorgio%26aufirst%3DC.%26aulast%3DIncerti%26aufirst%3DM.%26aulast%3DRusso%26aufirst%3DS.%26aulast%3DPala%26aufirst%3DD.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DZanotti%26aufirst%3DI.%26aulast%3DVicini%26aufirst%3DP.%26aulast%3DBarocelli%26aufirst%3DE.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DTognolini%26aufirst%3DM.%26atitle%3DUniPR129%2520is%2520a%2520competitive%2520small%2520molecule%2520Eph-ephrin%2520antagonist%2520blocking%2520in%2520vitro%2520angiogenesis%2520at%2520low%2520micromolar%2520concentrations%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D171%26spage%3D5195%26epage%3D5208%26doi%3D10.1111%2Fbph.12669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tognolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Incerti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan-Mohamed, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodola, A.</span></span> <span> </span><span class="NLM_article-title">Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201300305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1002%2Fcmdc.201300305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=24115725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2nsL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=67-72&author=M.+Tognoliniauthor=M.+Incertiauthor=D.+Palaauthor=S.+Russoauthor=R.+Castelliauthor=I.+Hassan-Mohamedauthor=C.+Giorgioauthor=A.+Lodola&title=Target+hopping+as+a+useful+tool+for+the+identification+of+novel+EphA2+protein-protein+antagonists&doi=10.1002%2Fcmdc.201300305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein-Protein Antagonists</span></div><div class="casAuthors">Tognolini, Massimiliano; Incerti, Matteo; Pala, Daniele; Russo, Simonetta; Castelli, Riccardo; Hassan-Mohamed, Iftiin; Giorgio, Carmine; Lodola, Alessio</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-72</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The target hopping approach was used to identify novel EphA2 protein-protein interaction inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTnb61cln51bVg90H21EOLACvtfcHk0lhcDb50Nq6Xcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2nsL7L&md5=ff9f51ec9a4c0a04dfb860a64c5949fe</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300305%26sid%3Dliteratum%253Aachs%26aulast%3DTognolini%26aufirst%3DM.%26aulast%3DIncerti%26aufirst%3DM.%26aulast%3DPala%26aufirst%3DD.%26aulast%3DRusso%26aufirst%3DS.%26aulast%3DCastelli%26aufirst%3DR.%26aulast%3DHassan-Mohamed%26aufirst%3DI.%26aulast%3DGiorgio%26aufirst%3DC.%26aulast%3DLodola%26aufirst%3DA.%26atitle%3DTarget%2520hopping%2520as%2520a%2520useful%2520tool%2520for%2520the%2520identification%2520of%2520novel%2520EphA2%2520protein-protein%2520antagonists%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D67%26epage%3D72%26doi%3D10.1002%2Fcmdc.201300305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulinich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salem, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barile, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethell, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Potent and selective EphA4 agonists for the treatment of ALS</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.chembiol.2017.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=28196613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisF2isLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=293-305&author=B.+Wuauthor=S.+K.+Deauthor=A.+Kulinichauthor=A.+F.+Salemauthor=J.+Koeppenauthor=R.+Wangauthor=E.+Barileauthor=S.+Wangauthor=D.+Zhangauthor=I.+Ethellauthor=M.+Pellecchia&title=Potent+and+selective+EphA4+agonists+for+the+treatment+of+ALS&doi=10.1016%2Fj.chembiol.2017.01.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and Selective EphA4 Agonists for the Treatment of ALS</span></div><div class="casAuthors">Wu, Bainan; De, Surya K.; Kulinich, Anna; Salem, Ahmed F.; Koeppen, Jordan; Wang, Rengang; Barile, Elisa; Wang, Si; Zhang, Dongxiang; Ethell, Iryna; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">293-305</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Amyotrophic lateral sclerosis (ALS) is a progressive degenerative disease that affects motor neurons.  Recent studies identified the receptor tyrosine kinase EphA4 as a disease-modifying gene that is crit. for the progression of motor neuron degeneration.  We report on the design and characterization of a family of EphA4 targeting agents that bind to its ligand binding domain with nanomolar affinity.  The mols. exhibit excellent selectivity and display efficacy in a SOD1 mutant mouse model of ALS.  Interestingly, the mols. appear to act as agonists for the receptor in certain surrogate cellular assays.  While the exact mechanisms responsible for the therapeutic effect of the new agonists remain to be elucidated, we believe that the described agent represents both an invaluable pharmacol. tool to further decipher the role of the EphA4 in ALS and potentially other human diseases, and a significant stepping stone for the development of novel treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpuO9wvkH8jLVg90H21EOLACvtfcHk0ljHaycWYKbL9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisF2isLw%253D&md5=4701fc563841cf233e9e8c8ac7c256f7</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DB.%26aulast%3DDe%26aufirst%3DS.%2BK.%26aulast%3DKulinich%26aufirst%3DA.%26aulast%3DSalem%26aufirst%3DA.%2BF.%26aulast%3DKoeppen%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DBarile%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DEthell%26aufirst%3DI.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DPotent%2520and%2520selective%2520EphA4%2520agonists%2520for%2520the%2520treatment%2520of%2520ALS%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2017%26volume%3D24%26spage%3D293%26epage%3D305%26doi%3D10.1016%2Fj.chembiol.2017.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barile, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purves, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">High-Throughput Screening by nuclear magnetic resonance (HTS by NMR) for the identification of PPIs antagonists</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2032</span>– <span class="NLM_lpage">2042</span>, <span class="refDoi"> DOI: 10.2174/1568026615666150519102459</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.2174%2F1568026615666150519102459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=25986689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFKrsbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=2032-2042&author=B.+Wuauthor=E.+Barileauthor=S.+K.+Deauthor=J.+Weiauthor=A.+Purvesauthor=M.+Pellecchia&title=High-Throughput+Screening+by+nuclear+magnetic+resonance+%28HTS+by+NMR%29+for+the+identification+of+PPIs+antagonists&doi=10.2174%2F1568026615666150519102459"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">High-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs Antagonists</span></div><div class="casAuthors">Wu, Bainan; Barile, Elisa; De, Surya K.; Wei, Jun; Purves, Angela; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2032-2042</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In recent years the ever so complex field of drug discovery has embraced novel design strategies based on biophys. fragment screening (fragment-based drug design; FBDD) using NMR spectroscopy (NMR) and/or structure-guided approaches, most often using X-ray crystallog. and computer modeling.  Experience from recent years unveiled that these methods are more effective and less prone to artifacts compared to biochem. high-throughput screening (HTS) of large collection of compds. in designing protein inhibitors.  Hence these strategies are increasingly becoming the most utilized in the modern pharmaceutical industry.  Nonetheless, there is still an impending need to develop innovative and effective strategies to tackle other more challenging targets such as those involving protein-protein interactions (PPIs).  While HTS strategies notoriously fail to identify viable hits against such targets, few successful examples of PPIs antagonists derived by FBDD strategies exist.  Recently, we reported on a new strategy that combines some of the basic principles of fragment-based screening with combinatorial chem. and NMR-based screening.  The approach, termed HTS by NMR, combines the advantages of combinatorial chem. and NMR-based screening to rapidly and unambiguously identify bona fide inhibitors of PPIs.  This review will reiterate the crit. aspects of the approach with examples of possible applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkGSp-cBTsYbVg90H21EOLACvtfcHk0ljHaycWYKbL9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFKrsbnN&md5=85549ba32660d4907ffc8b30e36956ee</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.2174%2F1568026615666150519102459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026615666150519102459%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DB.%26aulast%3DBarile%26aufirst%3DE.%26aulast%3DDe%26aufirst%3DS.%2BK.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DPurves%26aufirst%3DA.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DHigh-Throughput%2520Screening%2520by%2520nuclear%2520magnetic%2520resonance%2520%2528HTS%2520by%2520NMR%2529%2520for%2520the%2520identification%2520of%2520PPIs%2520antagonists%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2015%26volume%3D15%26spage%3D2032%26epage%3D2042%26doi%3D10.2174%2F1568026615666150519102459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noberini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barile, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giulianotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinilla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghten, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">HTS by NMR of combinatorial libraries: a fragment-based approach to ligand discovery</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2012.10.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.chembiol.2012.10.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=23352136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1ems7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=19-33&author=B.+Wuauthor=Z.+Zhangauthor=R.+Noberiniauthor=E.+Barileauthor=M.+Giulianottiauthor=C.+Pinillaauthor=R.+A.+Houghtenauthor=E.+B.+Pasqualeauthor=M.+Pellecchia&title=HTS+by+NMR+of+combinatorial+libraries%3A+a+fragment-based+approach+to+ligand+discovery&doi=10.1016%2Fj.chembiol.2012.10.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">HTS by NMR of Combinatorial Libraries: A Fragment-Based Approach to Ligand Discovery</span></div><div class="casAuthors">Wu, Bainan; Zhang, Ziming; Noberini, Roberta; Barile, Elisa; Giulianotti, Marc; Pinilla, Clemencia; Houghten, Richard A.; Pasquale, Elena B.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-33</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Fragment-based ligand design (FBLD) approaches have become more widely used in drug discovery projects from both academia and industry, and are even often preferred to traditional high-throughput screening (HTS) of large collection of compds. (>105).  A key advantage of FBLD approaches is that these often rely on robust biophys. methods such as NMR spectroscopy for detection of ligand binding, hence are less prone to artifacts that too often plague the results from HTS campaigns.  In this article, we introduce a screening strategy that takes advantage of both the robustness of protein NMR spectroscopy as the detection method, and the basic principles of combinatorial chem. to enable the screening of large libraries of fragments (>105 compds.) preassembled on a common backbone.  We used the method to identify compds. that target protein-protein interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqurl4asdOJGrVg90H21EOLACvtfcHk0ljHaycWYKbL9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1ems7s%253D&md5=0e6be57be59243913c34178cf10a2329</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.10.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.10.015%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DNoberini%26aufirst%3DR.%26aulast%3DBarile%26aufirst%3DE.%26aulast%3DGiulianotti%26aufirst%3DM.%26aulast%3DPinilla%26aufirst%3DC.%26aulast%3DHoughten%26aufirst%3DR.%2BA.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DHTS%2520by%2520NMR%2520of%2520combinatorial%2520libraries%253A%2520a%2520fragment-based%2520approach%2520to%2520ligand%2520discovery%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D19%26epage%3D33%26doi%3D10.1016%2Fj.chembiol.2012.10.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Incerti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan-Mohamed, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noberini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piersanti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barocelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodola, A.</span></span> <span> </span><span class="NLM_article-title">Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2936</span>– <span class="NLM_lpage">2947</span>, <span class="refDoi"> DOI: 10.1021/jm301890k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301890k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2936-2947&author=M.+Incertiauthor=M.+Tognoliniauthor=S.+Russoauthor=D.+Palaauthor=C.+Giorgioauthor=I.+Hassan-Mohamedauthor=R.+Noberiniauthor=E.+B.+Pasqualeauthor=P.+Viciniauthor=S.+Piersantiauthor=S.+Rivaraauthor=E.+Barocelliauthor=M.+Morauthor=A.+Lodola&title=Amino+acid+conjugates+of+lithocholic+acid+as+antagonists+of+the+EphA2+receptor&doi=10.1021%2Fjm301890k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm301890k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301890k%26sid%3Dliteratum%253Aachs%26aulast%3DIncerti%26aufirst%3DM.%26aulast%3DTognolini%26aufirst%3DM.%26aulast%3DRusso%26aufirst%3DS.%26aulast%3DPala%26aufirst%3DD.%26aulast%3DGiorgio%26aufirst%3DC.%26aulast%3DHassan-Mohamed%26aufirst%3DI.%26aulast%3DNoberini%26aufirst%3DR.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DVicini%26aufirst%3DP.%26aulast%3DPiersanti%26aufirst%3DS.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DBarocelli%26aufirst%3DE.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DLodola%26aufirst%3DA.%26atitle%3DAmino%2520acid%2520conjugates%2520of%2520lithocholic%2520acid%2520as%2520antagonists%2520of%2520the%2520EphA2%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2936%26epage%3D2947%26doi%3D10.1021%2Fjm301890k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacondio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Incerti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callegari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan-Mohamed, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanotti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugatti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Festuccia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barocelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodola, A.</span></span> <span> </span><span class="NLM_article-title">Delta(5)-cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.08.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.ejmech.2015.08.048" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2015&pages=312-324&author=R.+Castelliauthor=M.+Tognoliniauthor=F.+Vacondioauthor=M.+Incertiauthor=D.+Palaauthor=D.+Callegariauthor=S.+Bertoniauthor=C.+Giorgioauthor=I.+Hassan-Mohamedauthor=I.+Zanottiauthor=A.+Bugattiauthor=M.+Rusnatiauthor=C.+Festucciaauthor=S.+Rivaraauthor=E.+Barocelliauthor=M.+Morauthor=A.+Lodola&title=Delta%285%29-cholenoyl-amino+acids+as+selective+and+orally+available+antagonists+of+the+Eph-ephrin+system&doi=10.1016%2Fj.ejmech.2015.08.048"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.08.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.08.048%26sid%3Dliteratum%253Aachs%26aulast%3DCastelli%26aufirst%3DR.%26aulast%3DTognolini%26aufirst%3DM.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DIncerti%26aufirst%3DM.%26aulast%3DPala%26aufirst%3DD.%26aulast%3DCallegari%26aufirst%3DD.%26aulast%3DBertoni%26aufirst%3DS.%26aulast%3DGiorgio%26aufirst%3DC.%26aulast%3DHassan-Mohamed%26aufirst%3DI.%26aulast%3DZanotti%26aufirst%3DI.%26aulast%3DBugatti%26aufirst%3DA.%26aulast%3DRusnati%26aufirst%3DM.%26aulast%3DFestuccia%26aufirst%3DC.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DBarocelli%26aufirst%3DE.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DLodola%26aufirst%3DA.%26atitle%3DDelta%25285%2529-cholenoyl-amino%2520acids%2520as%2520selective%2520and%2520orally%2520available%2520antagonists%2520of%2520the%2520Eph-ephrin%2520system%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D103%26spage%3D312%26epage%3D324%26doi%3D10.1016%2Fj.ejmech.2015.08.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barile, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zharkikh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purves, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshima, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Design and characterization of novel EphA2 agonists for targeted delivery of chemotherapy to cancer cells</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">887</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2015.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.chembiol.2015.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=26165155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCqtbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=876-887&author=B.+Wuauthor=S.+Wangauthor=S.+K.+Deauthor=E.+Barileauthor=B.+A.+Quinnauthor=I.+Zharkikhauthor=A.+Purvesauthor=J.+L.+Stebbinsauthor=R.+G.+Oshimaauthor=P.+B.+Fisherauthor=M.+Pellecchia&title=Design+and+characterization+of+novel+EphA2+agonists+for+targeted+delivery+of+chemotherapy+to+cancer+cells&doi=10.1016%2Fj.chembiol.2015.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells</span></div><div class="casAuthors">Wu, Bainan; Wang, Si; De, Surya K.; Barile, Elisa; Quinn, Bridget A.; Zharkikh, Irina; Purves, Angela; Stebbins, John L.; Oshima, Robert G.; Fisher, Paul B.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">876-887</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The development of novel, targeted delivery agents for anti-cancer therapies requires the design and optimization of potent and selective tumor-targeting agents that are stable and amenable to conjugation with chemotherapeutic drugs.  While short peptides represent potentially an excellent platform for these purposes, they often get degraded and are eliminated too rapidly in vivo.  In this study, we used a combination of NMR-guided structure-activity relationships along with biochem. and cellular studies to derive a novel tumor-homing agent, named 123B9, targeting the EphA2 tyrosine kinase receptor ligand-binding domain.  Conjugating 123B9 to the chemotherapeutic drug paclitaxel (PTX) via a stable linker results in an agent that is significantly more effective than the unconjugated drug in both a pancreatic cancer xenograft model and a melanoma lung colonization and metastases model.  Hence, 123B9 could represent a promising strategy for the development of novel targeted therapies for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5FFEE4-jdhLVg90H21EOLACvtfcHk0lj8jhv6pv827A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCqtbbM&md5=5bd8b17e5b9bac6ce74e54cd1049d4b9</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2015.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2015.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DDe%26aufirst%3DS.%2BK.%26aulast%3DBarile%26aufirst%3DE.%26aulast%3DQuinn%26aufirst%3DB.%2BA.%26aulast%3DZharkikh%26aufirst%3DI.%26aulast%3DPurves%26aufirst%3DA.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DOshima%26aufirst%3DR.%2BG.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DDesign%2520and%2520characterization%2520of%2520novel%2520EphA2%2520agonists%2520for%2520targeted%2520delivery%2520of%2520chemotherapy%2520to%2520cancer%2520cells%26jtitle%3DChem.%2520Biol.%26date%3D2015%26volume%3D22%26spage%3D876%26epage%3D887%26doi%3D10.1016%2Fj.chembiol.2015.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duggineni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamberto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of potent bivalent peptide agonists targeting the EphA2 receptor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">344</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1021/ml3004523</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml3004523" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitFajur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=344-348&author=S.+Duggineniauthor=S.+Mitraauthor=I.+Lambertoauthor=X.+Hanauthor=Y.+Xuauthor=J.+Anauthor=E.+B.+Pasqualeauthor=Z.+Huang&title=Design+and+synthesis+of+potent+bivalent+peptide+agonists+targeting+the+EphA2+receptor&doi=10.1021%2Fml3004523"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Potent Bivalent Peptide Agonists Targeting the EphA2 Receptor</span></div><div class="casAuthors">Duggineni, Srinivas; Mitra, Sayantan; Lamberto, Ilaria; Han, Xiaofeng; Xu, Yan; An, Jing; Pasquale, Elena B.; Huang, Ziwei</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">344-348</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing potent and selective peptides and small mols. that target Eph receptor tyrosine kinases remains a challenge, and new strategies are needed for developing novel and potent ligands for these receptors.  In this study, we performed a structure-activity relationship study of a previously identified 12 amino acid-long peptide, SWL, by alanine scanning to identify residues important for receptor binding.  To further enhance and optimize the receptor binding affinity of the SWL peptide, we applied the concept of bivalent ligand design to synthesize several SWL-derived dimeric peptides as novel ligands capable of binding simultaneously to two EphA2 receptor mols.  The dimeric peptides possess higher receptor binding affinity than the original monomeric SWL peptide, consistent with bivalent binding.  The most potent dimeric peptide, a SWL dimer with a six-carbon linker, has about 13-fold increased potency as compared to SWL.  Furthermore, similar to SWL, the dimeric peptide is an agonist and can promote EphA2 tyrosine phosphorylation (activation) in cultured cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5CfG69V9xzLVg90H21EOLACvtfcHk0lj8jhv6pv827A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitFajur4%253D&md5=cfde81669466bc1ce0733c0816baf7c9</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fml3004523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml3004523%26sid%3Dliteratum%253Aachs%26aulast%3DDuggineni%26aufirst%3DS.%26aulast%3DMitra%26aufirst%3DS.%26aulast%3DLamberto%26aufirst%3DI.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DAn%26aufirst%3DJ.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DHuang%26aufirst%3DZ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520potent%2520bivalent%2520peptide%2520agonists%2520targeting%2520the%2520EphA2%2520receptor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D344%26epage%3D348%26doi%3D10.1021%2Fml3004523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maisonpierre, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lhotak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldfarb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yancopoulos, G. D.</span></span> <span> </span><span class="NLM_article-title">Ligands for eph-related receptor tyrosine kinases that require membrane attachment or clustering for activity</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>266</i></span>,  <span class="NLM_fpage">816</span>– <span class="NLM_lpage">819</span>, <span class="refDoi"> DOI: 10.1126/science.7973638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1126%2Fscience.7973638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=7973638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADyaK2MXitVGgt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=266&publication_year=1994&pages=816-819&author=S.+Davisauthor=N.+W.+Galeauthor=T.+H.+Aldrichauthor=P.+C.+Maisonpierreauthor=V.+Lhotakauthor=T.+Pawsonauthor=M.+Goldfarbauthor=G.+D.+Yancopoulos&title=Ligands+for+eph-related+receptor+tyrosine+kinases+that+require+membrane+attachment+or+clustering+for+activity&doi=10.1126%2Fscience.7973638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity</span></div><div class="casAuthors">Davis, Samuel; Gale, Nicholas W.; Aldrich, Thomas H.; Maisonpierre, Peter C.; Lhotak, Vladimir; Pawson, Tony; Goldfarb, Mitchell; Yancopoulos, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">266</span>
        (<span class="NLM_cas:issue">5186</span>),
    <span class="NLM_cas:pages">816-19</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The EPH-related transmembrane tyrosine kinases constitute the largest known family of receptor-like tyrosine kinases, with many members displaying specific patterns of expression in the developing and adult nervous system.  A three cell surface-bound ligands (B61, EHK1-L, and ELK-L) exhibiting distinct, but overlapping, specificities for these EPH-related kinases as well as tissue distribution were identified, cloned and sequenced.  These ligands were unable to act as conventional sol. factors.  However, they did function when presented in membrane-bound form, suggesting that they require direct cell-to-cell contact to activate their receptors.  Membrane attachment may serve to facilitate ligand dimerization or aggregation, because antibody-mediated clustering activated previously inactive sol. forms of these ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXYS_jRbSuUrVg90H21EOLACvtfcHk0lhwyvrd8x2BMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXitVGgt7s%253D&md5=702b337e26b15fd7b411d54b78d014b3</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1126%2Fscience.7973638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.7973638%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DS.%26aulast%3DGale%26aufirst%3DN.%2BW.%26aulast%3DAldrich%26aufirst%3DT.%2BH.%26aulast%3DMaisonpierre%26aufirst%3DP.%2BC.%26aulast%3DLhotak%26aufirst%3DV.%26aulast%3DPawson%26aufirst%3DT.%26aulast%3DGoldfarb%26aufirst%3DM.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26atitle%3DLigands%2520for%2520eph-related%2520receptor%2520tyrosine%2520kinases%2520that%2520require%2520membrane%2520attachment%2520or%2520clustering%2520for%2520activity%26jtitle%3DScience%26date%3D1994%26volume%3D266%26spage%3D816%26epage%3D819%26doi%3D10.1126%2Fscience.7973638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bakrania, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Variya, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. S.</span></span> <span> </span><span class="NLM_article-title">Novel targets for paclitaxel nano formulations: hopes and hypes in triple negative breast cancer</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">591</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.07.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.phrs.2016.07.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=27461138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ygsrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=577-591&author=A.+K.+Bakraniaauthor=B.+C.+Variyaauthor=S.+S.+Patel&title=Novel+targets+for+paclitaxel+nano+formulations%3A+hopes+and+hypes+in+triple+negative+breast+cancer&doi=10.1016%2Fj.phrs.2016.07.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer</span></div><div class="casAuthors">Bakrania, Anita K.; Variya, Bhavesh C.; Patel, Snehal S.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">577-591</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Triple neg. breast cancer is defined as one of the utmost prevailing breast cancers worldwide, possessing an inadequate prognosis and treatment option limited to chemotherapy and radiotherapy, creating a challenge for researchers as far as developing a specific targeted therapy is concerned.  The past research era has shown several promising outcomes for TNBC such as nano-formulations of the chemotherapeutic agents already used for the management of the malignant tumor.  Taking a glance at paclitaxel nano formulations, it has been proven beneficial in several researches in the past decade; nevertheless its soly. is often a challenge to scientists in achieving success.  We have henceforth discussed the basic heterogeneity of triple neg. breast cancer along with the current management options as well as a brief outlook on pros and cons of paclitaxel, known as the most widely used chemotherapeutic agent for the treatment of the disease.  We further analyzed the need of nanotechnol. pertaining to the problems encountered with the current paclitaxel formulations available discussing the strategic progress in various nano-formulations till date taking into account the basic research strategies required in terms of soly., permeability, physicochem. properties, active and passive targeting.  A thorough review in recent advances in active targeting for TNBC was carried out whereby the various ligands which are at present finding its way into TNBC research such as hyaluronic acid, folic acid, transferrin, etc. were discussed.  These ligands have specific receptor affinity to TNBC tumor cells hence can be beneficial for novel drug targeting approaches.  Conversely, there are currently several novel strategies in the research pipeline whose targeting ligands have not yet been studied.  Therefore, we reviewed upon the numerous novel receptor targets along with the resp. nano-formulation aspects which have not yet been fully researched upon and could be exemplified as outstanding target strategies for TNBC which is currently an urgent requirement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSvLub0Fq-LbVg90H21EOLACvtfcHk0lhwyvrd8x2BMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ygsrjL&md5=e24e7ce07227134ef35403d034d13988</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.07.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.07.023%26sid%3Dliteratum%253Aachs%26aulast%3DBakrania%26aufirst%3DA.%2BK.%26aulast%3DVariya%26aufirst%3DB.%2BC.%26aulast%3DPatel%26aufirst%3DS.%2BS.%26atitle%3DNovel%2520targets%2520for%2520paclitaxel%2520nano%2520formulations%253A%2520hopes%2520and%2520hypes%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D577%26epage%3D591%26doi%3D10.1016%2Fj.phrs.2016.07.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nehate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saneja, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khare, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubey, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P. N.</span></span> <span> </span><span class="NLM_article-title">Paclitaxel formulations: challenges and novel delivery options</span>. <i>Curr. Drug Delivery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">666</span>– <span class="NLM_lpage">686</span>, <span class="refDoi"> DOI: 10.2174/1567201811666140609154949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.2174%2F1567201811666140609154949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=24909147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFygu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=666-686&author=C.+Nehateauthor=S.+Jainauthor=A.+Sanejaauthor=V.+Khareauthor=N.+Alamauthor=R.+D.+Dubeyauthor=P.+N.+Gupta&title=Paclitaxel+formulations%3A+challenges+and+novel+delivery+options&doi=10.2174%2F1567201811666140609154949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel Formulations: Challenges and Novel Delivery Options</span></div><div class="casAuthors">Nehate, Chetan; Jain, Sharad; Saneja, Ankit; Khare, Vaibhav; Alam, Noor; Dubey, Ravindra Dhar; Gupta, Prem N.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Delivery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">666-686</span>CODEN:
                <span class="NLM_cas:coden">CDDUBJ</span>;
        ISSN:<span class="NLM_cas:issn">1567-2018</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Paclitaxel (PTX), a taxane plant product, is one of the most effective broad-spectrum anti-cancer agents and approved for the treatment of a variety of cancers including ovarian, breast, lung, head and neck as well as Kaposi's sarcoma.  Poor aq. soly. and serious side effects assocd. with com. prepn. of PTX (Taxol) triggered the development of alternative PTX formulations.  Over past three decades, plethora of research work has been published towards the development of cremophor free and efficient formulations.  Various nanocarrier systems including nanoparticles, liposomes, micelles, bioconjugates and dendrimers have been employed in order to improve PTX soly. and eliminate undesired side effects.  These nanocarriers offer the advantage of high degree of encapsulation and cellular uptake, escape from elimination by P-glycoprotein (P-gp) mediated efflux, and can be explored for targeted drug delivery.  The potential of these nanocarriers is reflected by the fact that various nanocarriers of PTX are in different stages of clin. trials and a few have already been commercialized including Abraxane, Lipusu and Genexol PM.  This review focuses on the various challenges assocd. with PTX formulation development, limitations of existing formulations and novel approaches for the development of alternative formulations for PTX and also highlights the development of novel formulations in clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotvOzqjm_TbrVg90H21EOLACvtfcHk0lhwyvrd8x2BMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFygu7fP&md5=ee429ec0dd5626ac8789a8bc80c0b856</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.2174%2F1567201811666140609154949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1567201811666140609154949%26sid%3Dliteratum%253Aachs%26aulast%3DNehate%26aufirst%3DC.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DSaneja%26aufirst%3DA.%26aulast%3DKhare%26aufirst%3DV.%26aulast%3DAlam%26aufirst%3DN.%26aulast%3DDubey%26aufirst%3DR.%2BD.%26aulast%3DGupta%26aufirst%3DP.%2BN.%26atitle%3DPaclitaxel%2520formulations%253A%2520challenges%2520and%2520novel%2520delivery%2520options%26jtitle%3DCurr.%2520Drug%2520Delivery%26date%3D2014%26volume%3D11%26spage%3D666%26epage%3D686%26doi%3D10.2174%2F1567201811666140609154949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singla, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, D.</span></span> <span> </span><span class="NLM_article-title">Paclitaxel and its formulations</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>235</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1016/S0378-5173(01)00986-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2FS0378-5173%2801%2900986-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=11879753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsV2qsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=235&publication_year=2002&pages=179-192&author=A.+K.+Singlaauthor=A.+Gargauthor=D.+Aggarwal&title=Paclitaxel+and+its+formulations&doi=10.1016%2FS0378-5173%2801%2900986-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel and its formulations</span></div><div class="casAuthors">Singla, Anil K.; Garg, Alka; Aggarwal, Deepika</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">235</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">179-192</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review with refs.  Paclitaxel (Taxol) is a promising antitumor agent with poor water soly.  It is effective for various cancers esp. ovarian and breast cancer.  I.v. administration of a current formulation in a non-aq. vehicle contg. Cremophor EL may cause allergic reactions and pptn. on aq. diln.  Moreover, the extensive clin. use of this drug is somewhat delayed due to the lack of appropriate delivery vehicles.  Due to this there is a need for the development of alternate formulation of paclitaxel having good aq. soly. and at the same time free of any side effects.  Various approaches employed so far include cosolvents, emulsions, micelles, liposomes, microspheres nanoparticles, cyclodextrins, pastes, and implants etc. which are discussed in this study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRkpWcoDTMmbVg90H21EOLACvtfcHk0lhwyvrd8x2BMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsV2qsro%253D&md5=bfa6d3f8055b197735c2be13bbe19eca</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2FS0378-5173%2801%2900986-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-5173%252801%252900986-3%26sid%3Dliteratum%253Aachs%26aulast%3DSingla%26aufirst%3DA.%2BK.%26aulast%3DGarg%26aufirst%3DA.%26aulast%3DAggarwal%26aufirst%3DD.%26atitle%3DPaclitaxel%2520and%2520its%2520formulations%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2002%26volume%3D235%26spage%3D179%26epage%3D192%26doi%3D10.1016%2FS0378-5173%2801%2900986-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brachmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerwin, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carleton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinghoffer, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmisano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span> <span> </span><span class="NLM_article-title">Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">699</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1007/s00280-015-2833-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1007%2Fs00280-015-2833-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=26231955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFagur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2015&pages=699-712&author=N.+Chenauthor=C.+Brachmannauthor=X.+Liuauthor=D.+W.+Pierceauthor=J.+Deyauthor=W.+S.+Kerwinauthor=Y.+Liauthor=S.+Zhouauthor=S.+Houauthor=M.+Carletonauthor=R.+A.+Klinghofferauthor=M.+Palmisanoauthor=R.+Chopra&title=Albumin-bound+nanoparticle+%28nab%29+paclitaxel+exhibits+enhanced+paclitaxel+tissue+distribution+and+tumor+penetration&doi=10.1007%2Fs00280-015-2833-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration</span></div><div class="casAuthors">Chen, Nianhang; Brachmann, Carrie; Liu, Xiping; Pierce, Daniel W.; Dey, Joyoti; Kerwin, William S.; Li, Yan; Zhou, Simon; Hou, Shihe; Carleton, Michael; Klinghoffer, Richard A.; Palmisano, Maria; Chopra, Rajesh</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">699-712</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: nab-paclitaxel demonstrates improved clin. efficacy compared with conventional Cremophor EL (CrEL)-paclitaxel in multiple tumor types.  This study explored the distinctions in drug distribution between nab-paclitaxel and CrEL-paclitaxel and the underlying mechanisms.  Methods: Uptake and transcytosis of paclitaxel were analyzed by vascular permeability assay across human endothelial cell monolayers.  The tissue penetration of paclitaxel within tumors was evaluated by local injections into tumor xenografts and quant. image anal.  The distribution profile of paclitaxel in solid-tumor patients was assessed using pharmacokinetic modeling and simulation.  Results: Live imaging demonstrated that albumin and paclitaxel were present in punctae in endothelial cells and could be obsd. in very close proximity, suggesting cotransport.  Uptake and transport of albumin, nab-paclitaxel and paclitaxel were inhibited by clin. relevant CrEL concns.  Further, nab-paclitaxel causes greater mitotic arrest in wider area within xenografted tumors than CrEL- or DMSO-paclitaxel following local microinjection, demonstrating enhanced paclitaxel penetration and uptake by albumin within tumors.  Modeling of paclitaxel distribution in patients with solid tumors indicated that nab-paclitaxel is more dependent upon transporter-mediated pathways for drug distribution into tissues than CrEL-paclitaxel.  The percent dose delivered to tissue via transporter-mediated pathways is predicted to be const. with nab-paclitaxel but decrease with increasing CrEL-paclitaxel dose.  Conclusions: Compared with CrEL-paclitaxel, nab-paclitaxel demonstrated more efficient transport across endothelial cells, greater penetration and cytotoxic induction in xenograft tumors, and enhanced extravascular distribution in patients that are attributed to carrier-mediated transport.  These observations are consistent with the distinct clin. efficacy and toxicity profile of nab-paclitaxel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquUPORPsNHN7Vg90H21EOLACvtfcHk0lgjpkeFI4uEyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFagur%252FJ&md5=f4cd73246f00961f3c931528d0f85fdf</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1007%2Fs00280-015-2833-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-015-2833-5%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DN.%26aulast%3DBrachmann%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DPierce%26aufirst%3DD.%2BW.%26aulast%3DDey%26aufirst%3DJ.%26aulast%3DKerwin%26aufirst%3DW.%2BS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DHou%26aufirst%3DS.%26aulast%3DCarleton%26aufirst%3DM.%26aulast%3DKlinghoffer%26aufirst%3DR.%2BA.%26aulast%3DPalmisano%26aufirst%3DM.%26aulast%3DChopra%26aufirst%3DR.%26atitle%3DAlbumin-bound%2520nanoparticle%2520%2528nab%2529%2520paclitaxel%2520exhibits%2520enhanced%2520paclitaxel%2520tissue%2520distribution%2520and%2520tumor%2520penetration%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2015%26volume%3D76%26spage%3D699%26epage%3D712%26doi%3D10.1007%2Fs00280-015-2833-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chougule, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span> <span> </span><span class="NLM_article-title">EphA2 targeting pegylated nanocarrier drug delivery system for treatment of lung cancer</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">2796</span>– <span class="NLM_lpage">2809</span>, <span class="refDoi"> DOI: 10.1007/s11095-014-1377-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1007%2Fs11095-014-1377-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2014&pages=2796-2809&author=A.+R.+Patelauthor=M.+Chouguleauthor=M.+Singh&title=EphA2+targeting+pegylated+nanocarrier+drug+delivery+system+for+treatment+of+lung+cancer&doi=10.1007%2Fs11095-014-1377-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1007%2Fs11095-014-1377-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-014-1377-4%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DA.%2BR.%26aulast%3DChougule%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DM.%26atitle%3DEphA2%2520targeting%2520pegylated%2520nanocarrier%2520drug%2520delivery%2520system%2520for%2520treatment%2520of%2520lung%2520cancer%26jtitle%3DPharm.%2520Res.%26date%3D2014%26volume%3D31%26spage%3D2796%26epage%3D2809%26doi%3D10.1007%2Fs11095-014-1377-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, J.</span></span> <span> </span><span class="NLM_article-title">Cell-penetrating peptide-siRNA conjugate loaded YSA-modified nanobubbles for ultrasound triggered siRNA delivery</span>. <i>Colloids Surf., B</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">650</span>, <span class="refDoi"> DOI: 10.1016/j.colsurfb.2015.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.colsurfb.2015.10.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2015&pages=641-650&author=X.+Xieauthor=Y.+Yangauthor=W.+Linauthor=H.+Liuauthor=H.+Liuauthor=Y.+Yangauthor=Y.+Chenauthor=X.+Fuauthor=J.+Deng&title=Cell-penetrating+peptide-siRNA+conjugate+loaded+YSA-modified+nanobubbles+for+ultrasound+triggered+siRNA+delivery&doi=10.1016%2Fj.colsurfb.2015.10.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.colsurfb.2015.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.colsurfb.2015.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DX.%26aulast%3DDeng%26aufirst%3DJ.%26atitle%3DCell-penetrating%2520peptide-siRNA%2520conjugate%2520loaded%2520YSA-modified%2520nanobubbles%2520for%2520ultrasound%2520triggered%2520siRNA%2520delivery%26jtitle%3DColloids%2520Surf.%252C%2520B%26date%3D2015%26volume%3D136%26spage%3D641%26epage%3D650%26doi%3D10.1016%2Fj.colsurfb.2015.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebrahimnejad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Quantitative radioimmuno PET imaging of EphA2 in tumor-bearing mice</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2024</span>– <span class="NLM_lpage">2036</span>, <span class="refDoi"> DOI: 10.1007/s00259-007-0503-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1007%2Fs00259-007-0503-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=17673999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlyiurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2007&pages=2024-2036&author=W.+Caiauthor=A.+Ebrahimnejadauthor=K.+Chenauthor=Q.+Caoauthor=Z.+B.+Liauthor=D.+A.+Ticeauthor=X.+Chen&title=Quantitative+radioimmuno+PET+imaging+of+EphA2+in+tumor-bearing+mice&doi=10.1007%2Fs00259-007-0503-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice</span></div><div class="casAuthors">Cai, Weibo; Ebrahimnejad, Alireza; Chen, Kai; Cao, Qizhen; Li, Zi-Bo; Tice, David A.; Chen, Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2024-2036</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: EphA2 receptor tyrosine kinase is significantly overexpressed in a wide variety of cancer types.  High EphA2 expression has been correlated with increased metastatic potential and poor patient survival.  Although many recent reports have focused on blocking the EphA2 signaling pathway in cancer, the in vivo imaging of EphA2 has not yet been investigated.  Methods: We labeled 1C1, a humanized monoclonal antibody against both human and murine EphA2, with 64Cu through the chelating agent 1,4,7,10-tetraazacyclododecane N,N',N'',N'''-tetraacetic acid (DOTA) and carried out positron emission tomog. (PET) imaging of eight tumor models with different EphA2 expression levels.  Western blotting of tumor tissue lysate was performed to correlate the EphA2 expression level with 64Cu-DOTA-1C1 uptake in the tumors.  Immunofluorescence staining and biodistribution studies were also carried out to validate the in vivo results.  Results: The radiolabeling yield was 88.9 ± 9.5% (n = 7) and the specific activity of 64Cu-DOTA-1C1 was 1.32 ± 0.14 GBq/mg of 1C1 mAb.  The antibody retained antigen-binding affinity/specificity after DOTA conjugation as measured by FACS anal.  The uptake of 64Cu-DOTA-1C1 in CT-26 tumors was as high as 25.1 ± 2.5 %ID/g (n = 3) at 18 h post injection.  64Cu-DOTA-IgG, an isotype-matched control, exhibited minimal non-specific uptake in all eight tumor models.  In vivo EphA2 specificity of 64Cu-DOTA-1C1 was confirmed by successful blocking of CT-26 tumor uptake by unlabeled 1C1.  Most importantly, the tumor uptake value obtained from PET imaging had excellent linear correlation with the relative tumor tissue EphA2 expression level measured by Western blot, where r 2 equals 0.90 and 0.92 at 18 h and 42 h post injection, resp.  Conclusion: The tumor uptake of 64Cu-DOTA-1C1 measured by microPET imaging reflects tumor EphA2 expression level in vivo.  This is, to our knowledge, the first report of quant. radioimmunoPET imaging of EphA2 in living subjects.  Future clin. investigation of 64Cu-DOTA-1C1 is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzMZbuvqQ4m7Vg90H21EOLACvtfcHk0lgjpkeFI4uEyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlyiurzO&md5=6353b6d0f2d30a2fb7e5126f34862c39</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1007%2Fs00259-007-0503-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-007-0503-5%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DW.%26aulast%3DEbrahimnejad%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DZ.%2BB.%26aulast%3DTice%26aufirst%3DD.%2BA.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DQuantitative%2520radioimmuno%2520PET%2520imaging%2520of%2520EphA2%2520in%2520tumor-bearing%2520mice%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2007%26volume%3D34%26spage%3D2024%26epage%3D2036%26doi%3D10.1007%2Fs00259-007-0503-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, R.</span></span> <span> </span><span class="NLM_article-title">(99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">450</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.1016/j.nucmedbio.2014.03.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.nucmedbio.2014.03.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=24768147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFCqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=450-456&author=Y.+Liuauthor=X.+Lanauthor=T.+Wuauthor=J.+Langauthor=X.+Jinauthor=X.+Sunauthor=Q.+Wenauthor=R.+An&title=%2899m%29Tc-labeled+SWL+specific+peptide+for+targeting+EphA2+receptor&doi=10.1016%2Fj.nucmedbio.2014.03.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">99mTc-labeled SWL specific peptide for targeting EphA2 receptor</span></div><div class="casAuthors">Liu, Yu; Lan, Xiaoli; Wu, Tao; Lang, Juntao; Jin, Xueyan; Sun, Xun; Wen, Qiong; An, Rui</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">450-456</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">EphA2, one member of the Eph receptor family, is widely expressed in multiple aggressive cancers.  SWL, a small peptide identified by phage display, has high binding affinity to EphA2, suggesting that it could be exploited for targeted mol. imaging.  Therefore, a novel peptide-based probe, 99mTc-HYNIC-SWL, was developed and its potential to specifically target EphA2-pos. tumors was investigated.The SWL peptide was labeled with hydrazinonicotinic acid (HYNIC), followed by 99mTc labeling.  Immunofluorescence staining was carried out to detect the expression of EphA2 in A549 lung cancer cells and OCM-1 melanoma cells.  Satn. binding expts. were performed by incubating A549 cells with increasing concns. of radiolabeled peptide in vitro.  To test the probe in vivo, nude mice bearing either A549 or OCM-1 derived tumors were established, injected with 99mTc-HYNIC-SWL, and subjected to SPECT imaging.  Mice injected with excess unlabeled SWL were used as a specific control.  Ex vivo γ-counting of dissected tissues from the mice was also performed to evaluate biodistribution.  Immunofluorescence staining showed that A549 cells intensively expressed EphA2, while OCM-1 cells had little expression.  99mTc-HYNIC-SWL displayed high binding affinity with A549 cells (KD = 2.6 ± 0.7 nM).  From the SPECT images and the results of the biodistribution study, significantly higher uptake of the tracer was seen in A549 tumors (1.44 ± 0.12 %ID/g) than in OCM-1 tumors (0.43 ± 0.20 %ID/g) at 1 h after injection.  Pre-injection with excess unlabeled peptide in A549-bearing nude mice, significantly reduced tumor uptake of the radiolabeled probe (0.58 ± 0.20 %ID/g) was seen.  These data suggest that 99mTc-HYNIC-SWL specifically targets EphA2 in tumors.The expression of EphA2 can be noninvasively investigated using 99mTc-HYNIC-SWL by SPECT imaging.  The in vitro and in vivo characteristics of 99mTc-HYNIC-SWL make it a promising probe for EphA2-pos. tumor imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5VuLqYK3h2rVg90H21EOLACvtfcHk0ljlSW-SGnAYEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFCqtr8%253D&md5=40192836654e1ac71adf6556c040b3fd</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2014.03.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2014.03.020%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLan%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DLang%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DWen%26aufirst%3DQ.%26aulast%3DAn%26aufirst%3DR.%26atitle%3D%252899m%2529Tc-labeled%2520SWL%2520specific%2520peptide%2520for%2520targeting%2520EphA2%2520receptor%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2014%26volume%3D41%26spage%3D450%26epage%3D456%26doi%3D10.1016%2Fj.nucmedbio.2014.03.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichterman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OuYang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posadas, E. M.</span></span> <span> </span><span class="NLM_article-title">A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">44781</span>– <span class="NLM_lpage">44793</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.6330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.18632%2Foncotarget.6330" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=44781-44793&author=R.+Jiangauthor=Y.+T.+Luauthor=H.+Hoauthor=B.+Liauthor=J.+F.+Chenauthor=M.+Linauthor=F.+Liauthor=K.+Wuauthor=H.+Wuauthor=J.+Lichtermanauthor=H.+Wanauthor=C.+L.+Luauthor=W.+OuYangauthor=M.+Niauthor=L.+Wangauthor=G.+Liauthor=T.+Leeauthor=X.+Zhangauthor=J.+Yangauthor=M.+Rettigauthor=L.+W.+Chungauthor=H.+Yangauthor=K.+C.+Liauthor=Y.+Houauthor=H.+R.+Tsengauthor=S.+Houauthor=X.+Xuauthor=J.+Wangauthor=E.+M.+Posadas&title=A+comparison+of+isolated+circulating+tumor+cells+and+tissue+biopsies+using+whole-genome+sequencing+in+prostate+cancer&doi=10.18632%2Foncotarget.6330"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.6330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.6330%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DR.%26aulast%3DLu%26aufirst%3DY.%2BT.%26aulast%3DHo%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DJ.%2BF.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DLichterman%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DC.%2BL.%26aulast%3DOuYang%26aufirst%3DW.%26aulast%3DNi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DRettig%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DL.%2BW.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DK.%2BC.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DTseng%26aufirst%3DH.%2BR.%26aulast%3DHou%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPosadas%26aufirst%3DE.%2BM.%26atitle%3DA%2520comparison%2520of%2520isolated%2520circulating%2520tumor%2520cells%2520and%2520tissue%2520biopsies%2520using%2520whole-genome%2520sequencing%2520in%2520prostate%2520cancer%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D44781%26epage%3D44793%26doi%3D10.18632%2Foncotarget.6330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 28 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Mona Alas, Azam Saghaeidehkordi, <span class="NLM_string-name hlFld-ContribAuthor">Kamaljit Kaur</span>. </span><span class="cited-content_cbyCitation_article-title">Peptide–Drug Conjugates with Different Linkers for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 216-232. <a href="https://doi.org/10.1021/acs.jmedchem.0c01530" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01530</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01530%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPeptide%2525E2%252580%252593Drug%252BConjugates%252Bwith%252BDifferent%252BLinkers%252Bfor%252BCancer%252BTherapy%26aulast%3DAlas%26aufirst%3DMona%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D01092020%26date%3D31122020%26volume%3D64%26issue%3D1%26spage%3D216%26epage%3D232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Gemma E. Mudd, Amy Brown, Liuhong Chen, Katerine van Rietschoten, Sophie Watcham, Daniel P. Teufel, Silvia Pavan, Rachid Lani, Philip Huxley, <span class="NLM_string-name hlFld-ContribAuthor">Gavin S. Bennett</span>. </span><span class="cited-content_cbyCitation_article-title">Identification and Optimization of EphA2-Selective Bicycles for the Delivery of Cytotoxic Payloads. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (8)
                                     , 4107-4116. <a href="https://doi.org/10.1021/acs.jmedchem.9b02129" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02129</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b02129%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Band%252BOptimization%252Bof%252BEphA2-Selective%252BBicycles%252Bfor%252Bthe%252BDelivery%252Bof%252BCytotoxic%252BPayloads%26aulast%3DMudd%26aufirst%3DGemma%2BE.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D20122019%26date%3D02042020%26date%3D23032020%26volume%3D63%26issue%3D8%26spage%3D4107%26epage%3D4116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Elmira Ziaei, Azam Saghaeidehkordi, Cassandra Dill, Innokentiy Maslennikov, Shiuan Chen, <span class="NLM_string-name hlFld-ContribAuthor">Kamaljit Kaur</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Triple Negative Breast Cancer Cells with Novel Cytotoxic Peptide–Doxorubicin Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2019,</strong> <em>30 </em>
                                    (12)
                                     , 3098-3106. <a href="https://doi.org/10.1021/acs.bioconjchem.9b00755" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.9b00755</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.9b00755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.9b00755%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DTargeting%252BTriple%252BNegative%252BBreast%252BCancer%252BCells%252Bwith%252BNovel%252BCytotoxic%252BPeptide%2525E2%252580%252593Doxorubicin%252BConjugates%26aulast%3DZiaei%26aufirst%3DElmira%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D06112019%26date%3D11112019%26date%3D26112019%26date%3D12112019%26volume%3D30%26issue%3D12%26spage%3D3098%26epage%3D3106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Luca Gambini, Ahmed F. Salem, Parima Udompholkul, Xiao-Feng Tan, Carlo Baggio, Neh Shah, Alexander Aronson, Jikui Song, <span class="NLM_string-name hlFld-ContribAuthor">Maurizio Pellecchia</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Design of Novel EphA2 Agonistic Agents with Nanomolar Affinity in Vitro and in Cell. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2018,</strong> <em>13 </em>
                                    (9)
                                     , 2633-2644. <a href="https://doi.org/10.1021/acschembio.8b00556" title="DOI URL">https://doi.org/10.1021/acschembio.8b00556</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.8b00556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.8b00556%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DStructure-Based%252BDesign%252Bof%252BNovel%252BEphA2%252BAgonistic%252BAgents%252Bwith%252BNanomolar%252BAffinity%252Bin%252BVitro%252Band%252Bin%252BCell%26aulast%3DGambini%26aufirst%3DLuca%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D14062018%26date%3D15082018%26date%3D29082018%26date%3D15082018%26volume%3D13%26issue%3D9%26spage%3D2633%26epage%3D2644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiaqi  Zhou</span>, <span class="hlFld-ContribAuthor ">Yuanyuan  Li</span>, <span class="hlFld-ContribAuthor ">Wenlong  Huang</span>, <span class="hlFld-ContribAuthor ">Wei  Shi</span>, <span class="hlFld-ContribAuthor ">Hai  Qian</span>. </span><span class="cited-content_cbyCitation_article-title">Source and exploration of the peptides used to construct peptide-drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>224 </em>, 113712. <a href="https://doi.org/10.1016/j.ejmech.2021.113712" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113712</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113712%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSource%252Band%252Bexploration%252Bof%252Bthe%252Bpeptides%252Bused%252Bto%252Bconstruct%252Bpeptide-drug%252Bconjugates%26aulast%3DZhou%26aufirst%3DJiaqi%26date%3D2021%26volume%3D224%26spage%3D113712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Parima  Udompholkul</span>, <span class="hlFld-ContribAuthor ">Carlo  Baggio</span>, <span class="hlFld-ContribAuthor ">Luca  Gambini</span>, <span class="hlFld-ContribAuthor ">Yu  Sun</span>, <span class="hlFld-ContribAuthor ">Ming  Zhao</span>, <span class="hlFld-ContribAuthor ">Robert M.  Hoffman</span>, <span class="hlFld-ContribAuthor ">Maurizio  Pellecchia</span>. </span><span class="cited-content_cbyCitation_article-title">Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (12)
                                     , 3687. <a href="https://doi.org/10.3390/molecules26123687" title="DOI URL">https://doi.org/10.3390/molecules26123687</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26123687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26123687%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DEffective%252BTumor%252BTargeting%252Bby%252BEphA2-Agonist-Biotin-Streptavidin%252BConjugates%26aulast%3DUdompholkul%26aufirst%3DParima%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D12%26spage%3D3687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yiqun  Ma</span>, <span class="hlFld-ContribAuthor ">Liang  Chen</span>, <span class="hlFld-ContribAuthor ">Xilei  Li</span>, <span class="hlFld-ContribAuthor ">Annan  Hu</span>, <span class="hlFld-ContribAuthor ">Huiren  Wang</span>, <span class="hlFld-ContribAuthor ">Hao  Zhou</span>, <span class="hlFld-ContribAuthor ">Bo  Tian</span>, <span class="hlFld-ContribAuthor ">Jian  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Rationally Integrating Peptide-induced Targeting and Multimodal Therapies in a Dual-shell Theranostic Platform for Orthotopic Metastatic Spinal Tumors. </span><span class="cited-content_cbyCitation_journal-name">Biomaterials</span><span> <strong>2021,</strong> <em>12 </em>, 120917. <a href="https://doi.org/10.1016/j.biomaterials.2021.120917" title="DOI URL">https://doi.org/10.1016/j.biomaterials.2021.120917</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biomaterials.2021.120917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biomaterials.2021.120917%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomaterials%26atitle%3DRationally%252BIntegrating%252BPeptide-induced%252BTargeting%252Band%252BMultimodal%252BTherapies%252Bin%252Ba%252BDual-shell%252BTheranostic%252BPlatform%252Bfor%252BOrthotopic%252BMetastatic%252BSpinal%252BTumors%26aulast%3DMa%26aufirst%3DYiqun%26date%3D2021%26volume%3D12%26spage%3D120917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Azam  Saghaeidehkordi</span>, <span class="hlFld-ContribAuthor ">Shiuan  Chen</span>, <span class="hlFld-ContribAuthor ">Sun  Yang</span>, <span class="hlFld-ContribAuthor ">Kamaljit  Kaur</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of a Keratin 1 Targeting Peptide-Doxorubicin Conjugate in a Mouse Model of Triple-Negative Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutics</span><span> <strong>2021,</strong> <em>13 </em>
                                    (5)
                                     , 661. <a href="https://doi.org/10.3390/pharmaceutics13050661" title="DOI URL">https://doi.org/10.3390/pharmaceutics13050661</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/pharmaceutics13050661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fpharmaceutics13050661%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutics%26atitle%3DEvaluation%252Bof%252Ba%252BKeratin%252B1%252BTargeting%252BPeptide-Doxorubicin%252BConjugate%252Bin%252Ba%252BMouse%252BModel%252Bof%252BTriple-Negative%252BBreast%252BCancer%26aulast%3DSaghaeidehkordi%26aufirst%3DAzam%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D5%26spage%3D661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ping  Zhao</span>, <span class="hlFld-ContribAuthor ">Dewei  Jiang</span>, <span class="hlFld-ContribAuthor ">Yunchao  Huang</span>, <span class="hlFld-ContribAuthor ">Ceshi  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">EphA2: A promising therapeutic target in breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Genetics and Genomics</span><span> <strong>2021,</strong> <em>48 </em>
                                    (4)
                                     , 261-267. <a href="https://doi.org/10.1016/j.jgg.2021.02.011" title="DOI URL">https://doi.org/10.1016/j.jgg.2021.02.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jgg.2021.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jgg.2021.02.011%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Genetics%2520and%2520Genomics%26atitle%3DEphA2%25253A%252BA%252Bpromising%252Btherapeutic%252Btarget%252Bin%252Bbreast%252Bcancer%26aulast%3DZhao%26aufirst%3DPing%26date%3D2021%26volume%3D48%26issue%3D4%26spage%3D261%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rui  Zheng</span>, <span class="hlFld-ContribAuthor ">Jia  Yang</span>, <span class="hlFld-ContribAuthor ">Muhetaerjiang  Mamuti</span>, <span class="hlFld-ContribAuthor ">Da‐Yong  Hou</span>, <span class="hlFld-ContribAuthor ">Hong‐Wei  An</span>, <span class="hlFld-ContribAuthor ">Yuliang  Zhao</span>, <span class="hlFld-ContribAuthor ">Hao  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Controllable Self‐Assembly of Peptide‐Cyanine Conjugates In Vivo as Fine‐Tunable Theranostics. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2021,</strong> <em>133 </em>
                                    (14)
                                     , 7888-7898. <a href="https://doi.org/10.1002/ange.202015126" title="DOI URL">https://doi.org/10.1002/ange.202015126</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202015126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202015126%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DControllable%252BSelf%2525E2%252580%252590Assembly%252Bof%252BPeptide%2525E2%252580%252590Cyanine%252BConjugates%252BIn%252BVivo%252Bas%252BFine%2525E2%252580%252590Tunable%252BTheranostics%26aulast%3DZheng%26aufirst%3DRui%26date%3D2021%26date%3D2021%26volume%3D133%26issue%3D14%26spage%3D7888%26epage%3D7898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rui  Zheng</span>, <span class="hlFld-ContribAuthor ">Jia  Yang</span>, <span class="hlFld-ContribAuthor ">Muhetaerjiang  Mamuti</span>, <span class="hlFld-ContribAuthor ">Da‐Yong  Hou</span>, <span class="hlFld-ContribAuthor ">Hong‐Wei  An</span>, <span class="hlFld-ContribAuthor ">Yuliang  Zhao</span>, <span class="hlFld-ContribAuthor ">Hao  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Controllable Self‐Assembly of Peptide‐Cyanine Conjugates In Vivo as Fine‐Tunable Theranostics. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2021,</strong> <em>60 </em>
                                    (14)
                                     , 7809-7819. <a href="https://doi.org/10.1002/anie.202015126" title="DOI URL">https://doi.org/10.1002/anie.202015126</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202015126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202015126%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DControllable%252BSelf%2525E2%252580%252590Assembly%252Bof%252BPeptide%2525E2%252580%252590Cyanine%252BConjugates%252BIn%252BVivo%252Bas%252BFine%2525E2%252580%252590Tunable%252BTheranostics%26aulast%3DZheng%26aufirst%3DRui%26date%3D2021%26date%3D2021%26volume%3D60%26issue%3D14%26spage%3D7809%26epage%3D7819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fang  Qu</span>, <span class="hlFld-ContribAuthor ">Yingshuang  Song</span>, <span class="hlFld-ContribAuthor ">Yaqin  Wu</span>, <span class="hlFld-ContribAuthor ">Yujie  Huang</span>, <span class="hlFld-ContribAuthor ">Qi  Zhong</span>, <span class="hlFld-ContribAuthor ">Yifan  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhen  Fan</span>, <span class="hlFld-ContribAuthor ">Chun  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">The protective role of Ephrin-B2/EphB4 signaling in osteogenic differentiation under inflammatory environment. </span><span class="cited-content_cbyCitation_journal-name">Experimental Cell Research</span><span> <strong>2021,</strong> <em>400 </em>
                                    (2)
                                     , 112505. <a href="https://doi.org/10.1016/j.yexcr.2021.112505" title="DOI URL">https://doi.org/10.1016/j.yexcr.2021.112505</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.yexcr.2021.112505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.yexcr.2021.112505%26sid%3Dliteratum%253Aachs%26jtitle%3DExperimental%2520Cell%2520Research%26atitle%3DThe%252Bprotective%252Brole%252Bof%252BEphrin-B2%25252FEphB4%252Bsignaling%252Bin%252Bosteogenic%252Bdifferentiation%252Bunder%252Binflammatory%252Benvironment%26aulast%3DQu%26aufirst%3DFang%26date%3D2021%26volume%3D400%26issue%3D2%26spage%3D112505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roghayyeh  Baghban</span>, <span class="hlFld-ContribAuthor ">Leila  Roshangar</span>, <span class="hlFld-ContribAuthor ">Rana  Jahanban-Esfahlan</span>, <span class="hlFld-ContribAuthor ">Khaled  Seidi</span>, <span class="hlFld-ContribAuthor ">Abbas  Ebrahimi-Kalan</span>, <span class="hlFld-ContribAuthor ">Mehdi  Jaymand</span>, <span class="hlFld-ContribAuthor ">Saeed  Kolahian</span>, <span class="hlFld-ContribAuthor ">Tahereh  Javaheri</span>, <span class="hlFld-ContribAuthor ">Peyman  Zare</span>. </span><span class="cited-content_cbyCitation_article-title">Tumor microenvironment complexity and therapeutic implications at a glance. </span><span class="cited-content_cbyCitation_journal-name">Cell Communication and Signaling</span><span> <strong>2020,</strong> <em>18 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12964-020-0530-4" title="DOI URL">https://doi.org/10.1186/s12964-020-0530-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12964-020-0530-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12964-020-0530-4%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Communication%2520and%2520Signaling%26atitle%3DTumor%252Bmicroenvironment%252Bcomplexity%252Band%252Btherapeutic%252Bimplications%252Bat%252Ba%252Bglance%26aulast%3DBaghban%26aufirst%3DRoghayyeh%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Max  London</span>, <span class="hlFld-ContribAuthor ">Eugenio  Gallo</span>. </span><span class="cited-content_cbyCitation_article-title">The EphA2 and cancer connection: potential for immune-based interventions. </span><span class="cited-content_cbyCitation_journal-name">Molecular Biology Reports</span><span> <strong>2020,</strong> <em>47 </em>
                                    (10)
                                     , 8037-8048. <a href="https://doi.org/10.1007/s11033-020-05767-y" title="DOI URL">https://doi.org/10.1007/s11033-020-05767-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11033-020-05767-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11033-020-05767-y%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Biology%2520Reports%26atitle%3DThe%252BEphA2%252Band%252Bcancer%252Bconnection%25253A%252Bpotential%252Bfor%252Bimmune-based%252Binterventions%26aulast%3DLondon%26aufirst%3DMax%26date%3D2020%26date%3D2020%26volume%3D47%26issue%3D10%26spage%3D8037%26epage%3D8048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia  Cava</span>, <span class="hlFld-ContribAuthor ">Isabella  Castiglioni</span>. </span><span class="cited-content_cbyCitation_article-title">Integration of Molecular Docking and In Vitro Studies: A Powerful Approach for Drug Discovery in Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Applied Sciences</span><span> <strong>2020,</strong> <em>10 </em>
                                    (19)
                                     , 6981. <a href="https://doi.org/10.3390/app10196981" title="DOI URL">https://doi.org/10.3390/app10196981</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/app10196981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fapp10196981%26sid%3Dliteratum%253Aachs%26jtitle%3DApplied%2520Sciences%26atitle%3DIntegration%252Bof%252BMolecular%252BDocking%252Band%252BIn%252BVitro%252BStudies%25253A%252BA%252BPowerful%252BApproach%252Bfor%252BDrug%252BDiscovery%252Bin%252BBreast%252BCancer%26aulast%3DCava%26aufirst%3DClaudia%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D19%26spage%3D6981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed F.  Salem</span>, <span class="hlFld-ContribAuthor ">Luca  Gambini</span>, <span class="hlFld-ContribAuthor ">Sandrine  Billet</span>, <span class="hlFld-ContribAuthor ">Yu  Sun</span>, <span class="hlFld-ContribAuthor ">Hiromichi  Oshiro</span>, <span class="hlFld-ContribAuthor ">Ming  Zhao</span>, <span class="hlFld-ContribAuthor ">Robert M.  Hoffman</span>, <span class="hlFld-ContribAuthor ">Neil A.  Bhowmick</span>, <span class="hlFld-ContribAuthor ">Maurizio  Pellecchia</span>. </span><span class="cited-content_cbyCitation_article-title">Prostate Cancer Metastases Are Strongly Inhibited by Agonistic Epha2 Ligands in an Orthotopic Mouse Model. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 2854. <a href="https://doi.org/10.3390/cancers12102854" title="DOI URL">https://doi.org/10.3390/cancers12102854</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12102854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12102854%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DProstate%252BCancer%252BMetastases%252BAre%252BStrongly%252BInhibited%252Bby%252BAgonistic%252BEpha2%252BLigands%252Bin%252Ban%252BOrthotopic%252BMouse%252BModel%26aulast%3DSalem%26aufirst%3DAhmed%2BF.%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D2854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kexin  Zheng</span>, <span class="hlFld-ContribAuthor ">Qilong  Li</span>, <span class="hlFld-ContribAuthor ">Dongdong  Lin</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Zong</span>, <span class="hlFld-ContribAuthor ">Xue  Luo</span>, <span class="hlFld-ContribAuthor ">Mei  Yang</span>, <span class="hlFld-ContribAuthor ">Xiqing  Yue</span>, <span class="hlFld-ContribAuthor ">Shiliang  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Peptidomic analysis of pilose antler and its inhibitory effect on triple-negative breast cancer at multiple sites. </span><span class="cited-content_cbyCitation_journal-name">Food & Function</span><span> <strong>2020,</strong> <em>11 </em>
                                    (9)
                                     , 7481-7494. <a href="https://doi.org/10.1039/D0FO01531H" title="DOI URL">https://doi.org/10.1039/D0FO01531H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0FO01531H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0FO01531H%26sid%3Dliteratum%253Aachs%26jtitle%3DFood%2520%2526%2520Function%26atitle%3DPeptidomic%252Banalysis%252Bof%252Bpilose%252Bantler%252Band%252Bits%252Binhibitory%252Beffect%252Bon%252Btriple-negative%252Bbreast%252Bcancer%252Bat%252Bmultiple%252Bsites%26aulast%3DZheng%26aufirst%3DKexin%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D9%26spage%3D7481%26epage%3D7494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sreenivasulu  Kilari</span>, <span class="hlFld-ContribAuthor ">Sai Swetha  Alladi</span>, <span class="hlFld-ContribAuthor ">Harshavardhan  Kenche</span>. </span><span class="cited-content_cbyCitation_article-title">Ephrins. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 59-68. <a href="https://doi.org/10.1002/9780470015902.a0029147" title="DOI URL">https://doi.org/10.1002/9780470015902.a0029147</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9780470015902.a0029147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9780470015902.a0029147%26sid%3Dliteratum%253Aachs%26atitle%3DEphrins%26aulast%3DKilari%26aufirst%3DSreenivasulu%26date%3D2020%26date%3D2020%26spage%3D59%26epage%3D68%26pub%3DWiley%26atitle%3DeLS%26aulast%3DJohn%2BWiley%2B%2526%2BSons%252C%2BLtd%26date%3D2001%26date%3D2001%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sarah  Baudet</span>, <span class="hlFld-ContribAuthor ">Johann  Bécret</span>, <span class="hlFld-ContribAuthor ">Xavier  Nicol</span>. </span><span class="cited-content_cbyCitation_article-title">Approaches to Manipulate Ephrin-A:EphA Forward Signaling Pathway. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2020,</strong> <em>13 </em>
                                    (7)
                                     , 140. <a href="https://doi.org/10.3390/ph13070140" title="DOI URL">https://doi.org/10.3390/ph13070140</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph13070140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph13070140%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DApproaches%252Bto%252BManipulate%252BEphrin-A%25253AEphA%252BForward%252BSignaling%252BPathway%26aulast%3DBaudet%26aufirst%3DSarah%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D7%26spage%3D140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert M.  Hughes</span>, <span class="hlFld-ContribAuthor ">Jitka A.I.  Virag</span>. </span><span class="cited-content_cbyCitation_article-title">Harnessing the Power of Eph/ephrin Biosemiotics for Theranostic Applications. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2020,</strong> <em>13 </em>
                                    (6)
                                     , 112. <a href="https://doi.org/10.3390/ph13060112" title="DOI URL">https://doi.org/10.3390/ph13060112</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph13060112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph13060112%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DHarnessing%252Bthe%252BPower%252Bof%252BEph%25252Fephrin%252BBiosemiotics%252Bfor%252BTheranostic%252BApplications%26aulast%3DHughes%26aufirst%3DRobert%2BM.%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D6%26spage%3D112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed F.  Salem</span>, <span class="hlFld-ContribAuthor ">Luca  Gambini</span>, <span class="hlFld-ContribAuthor ">Parima  Udompholkul</span>, <span class="hlFld-ContribAuthor ">Carlo  Baggio</span>, <span class="hlFld-ContribAuthor ">Maurizio  Pellecchia</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2020,</strong> <em>13 </em>
                                    (5)
                                     , 90. <a href="https://doi.org/10.3390/ph13050090" title="DOI URL">https://doi.org/10.3390/ph13050090</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph13050090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph13050090%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DTherapeutic%252BTargeting%252Bof%252BPancreatic%252BCancer%252Bvia%252BEphA2%252BDimeric%252BAgonistic%252BAgents%26aulast%3DSalem%26aufirst%3DAhmed%2BF.%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D5%26spage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qingguo  Zhao</span>, <span class="hlFld-ContribAuthor ">Bo  Hai</span>, <span class="hlFld-ContribAuthor ">Xiao  Zhang</span>, <span class="hlFld-ContribAuthor ">Jing  Xu</span>, <span class="hlFld-ContribAuthor ">Brian  Koehler</span>, <span class="hlFld-ContribAuthor ">Fei  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Biomimetic nanovesicles made from iPS cell-derived mesenchymal stem cells for targeted therapy of triple-negative breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Nanomedicine: Nanotechnology, Biology and Medicine</span><span> <strong>2020,</strong> <em>24 </em>, 102146. <a href="https://doi.org/10.1016/j.nano.2019.102146" title="DOI URL">https://doi.org/10.1016/j.nano.2019.102146</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.nano.2019.102146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.nano.2019.102146%26sid%3Dliteratum%253Aachs%26jtitle%3DNanomedicine%253A%2520Nanotechnology%252C%2520Biology%2520and%2520Medicine%26atitle%3DBiomimetic%252Bnanovesicles%252Bmade%252Bfrom%252BiPS%252Bcell-derived%252Bmesenchymal%252Bstem%252Bcells%252Bfor%252Btargeted%252Btherapy%252Bof%252Btriple-negative%252Bbreast%252Bcancer%26aulast%3DZhao%26aufirst%3DQingguo%26date%3D2020%26volume%3D24%26spage%3D102146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan  Zhou</span>, <span class="hlFld-ContribAuthor ">Feng  Yu</span>, <span class="hlFld-ContribAuthor ">Bin  Luo</span>, <span class="hlFld-ContribAuthor ">Hua  Luo</span>, <span class="hlFld-ContribAuthor ">Chen  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Cytrarabine (Ara-c) promotes cell apoptosis by inhibiting the phosphorylation of Protein Kinase B (AKT/PKB). </span><span class="cited-content_cbyCitation_journal-name">Process Biochemistry</span><span> <strong>2019,</strong> <em>82 </em>, 144-152. <a href="https://doi.org/10.1016/j.procbio.2019.04.007" title="DOI URL">https://doi.org/10.1016/j.procbio.2019.04.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.procbio.2019.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.procbio.2019.04.007%26sid%3Dliteratum%253Aachs%26jtitle%3DProcess%2520Biochemistry%26atitle%3DCytrarabine%252B%252528Ara-c%252529%252Bpromotes%252Bcell%252Bapoptosis%252Bby%252Binhibiting%252Bthe%252Bphosphorylation%252Bof%252BProtein%252BKinase%252BB%252B%252528AKT%25252FPKB%252529%26aulast%3DZhou%26aufirst%3DYuan%26date%3D2019%26volume%3D82%26spage%3D144%26epage%3D152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maricel  Gomez-Soler</span>, <span class="hlFld-ContribAuthor ">Marina  Petersen Gehring</span>, <span class="hlFld-ContribAuthor ">Bernhard C.  Lechtenberg</span>, <span class="hlFld-ContribAuthor ">Elmer  Zapata-Mercado</span>, <span class="hlFld-ContribAuthor ">Kalina  Hristova</span>, <span class="hlFld-ContribAuthor ">Elena B.  Pasquale</span>. </span><span class="cited-content_cbyCitation_article-title">Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2019,</strong> <em>294 </em>
                                    (22)
                                     , 8791-8805. <a href="https://doi.org/10.1074/jbc.RA119.008213" title="DOI URL">https://doi.org/10.1074/jbc.RA119.008213</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.RA119.008213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.RA119.008213%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DEngineering%252Bnanomolar%252Bpeptide%252Bligands%252Bthat%252Bdifferentially%252Bmodulate%252BEphA2%252Breceptor%252Bsignaling%26aulast%3DGomez-Soler%26aufirst%3DMaricel%26date%3D2019%26volume%3D294%26issue%3D22%26spage%3D8791%26epage%3D8805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">C.  Giorgio</span>, <span class="hlFld-ContribAuthor ">M.  Incerti</span>, <span class="hlFld-ContribAuthor ">D.  Pala</span>, <span class="hlFld-ContribAuthor ">S.  Russo</span>, <span class="hlFld-ContribAuthor ">P.  Chiodelli</span>, <span class="hlFld-ContribAuthor ">M.  Rusnati</span>, <span class="hlFld-ContribAuthor ">A.M.  Cantoni</span>, <span class="hlFld-ContribAuthor ">R.  Di Lecce</span>, <span class="hlFld-ContribAuthor ">E.  Barocelli</span>, <span class="hlFld-ContribAuthor ">S.  Bertoni</span>, <span class="hlFld-ContribAuthor ">P.  Ravassard</span>, <span class="hlFld-ContribAuthor ">F.  Manenti</span>, <span class="hlFld-ContribAuthor ">L.  Piemonti</span>, <span class="hlFld-ContribAuthor ">F.  Ferlenghi</span>, <span class="hlFld-ContribAuthor ">A.  Lodola</span>, <span class="hlFld-ContribAuthor ">M.  Tognolini</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2019,</strong> <em>141 </em>, 319-330. <a href="https://doi.org/10.1016/j.phrs.2019.01.011" title="DOI URL">https://doi.org/10.1016/j.phrs.2019.01.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2019.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2019.01.011%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DInhibition%252Bof%252BEph%25252Fephrin%252Binteraction%252Bwith%252Bthe%252Bsmall%252Bmolecule%252BUniPR500%252Bimproves%252Bglucose%252Btolerance%252Bin%252Bhealthy%252Band%252Binsulin-resistant%252Bmice%26aulast%3DGiorgio%26aufirst%3DC.%26date%3D2019%26volume%3D141%26spage%3D319%26epage%3D330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nayanendu  Saha</span>, <span class="hlFld-ContribAuthor ">Dorothea  Robev</span>, <span class="hlFld-ContribAuthor ">Emilia O.  Mason</span>, <span class="hlFld-ContribAuthor ">Juha P.  Himanen</span>, <span class="hlFld-ContribAuthor ">Dimitar B.  Nikolov</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic potential of targeting the Eph/ephrin signaling complex. </span><span class="cited-content_cbyCitation_journal-name">The International Journal of Biochemistry & Cell Biology</span><span> <strong>2018,</strong> <em>105 </em>, 123-133. <a href="https://doi.org/10.1016/j.biocel.2018.10.006" title="DOI URL">https://doi.org/10.1016/j.biocel.2018.10.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biocel.2018.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biocel.2018.10.006%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520International%2520Journal%2520of%2520Biochemistry%2520%2526%2520Cell%2520Biology%26atitle%3DTherapeutic%252Bpotential%252Bof%252Btargeting%252Bthe%252BEph%25252Fephrin%252Bsignaling%252Bcomplex%26aulast%3DSaha%26aufirst%3DNayanendu%26date%3D2018%26volume%3D105%26spage%3D123%26epage%3D133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryusuke  Tsuchie</span>, <span class="hlFld-ContribAuthor ">Mayu  Shimosato</span>, <span class="hlFld-ContribAuthor ">Keita  Hamasaki</span>. </span><span class="cited-content_cbyCitation_article-title">Hydrophobic Association of a Side Chains Induces Reversible Helix Folding in a Dual Aromatic Ring Tagged Short Peptide. </span><span class="cited-content_cbyCitation_journal-name">Chemistry Letters</span><span> <strong>2018,</strong> <em>47 </em>
                                    (10)
                                     , 1276-1278. <a href="https://doi.org/10.1246/cl.180601" title="DOI URL">https://doi.org/10.1246/cl.180601</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1246/cl.180601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1246%2Fcl.180601%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520Letters%26atitle%3DHydrophobic%252BAssociation%252Bof%252Ba%252BSide%252BChains%252BInduces%252BReversible%252BHelix%252BFolding%252Bin%252Ba%252BDual%252BAromatic%252BRing%252BTagged%252BShort%252BPeptide%26aulast%3DTsuchie%26aufirst%3DRyusuke%26date%3D2018%26volume%3D47%26issue%3D10%26spage%3D1276%26epage%3D1278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ilias  Nikas</span>, <span class="hlFld-ContribAuthor ">Han Suk  Ryu</span>, <span class="hlFld-ContribAuthor ">Stamatios  Theocharis</span>. </span><span class="cited-content_cbyCitation_article-title">Viewing the Eph receptors with a focus on breast cancer heterogeneity. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2018,</strong> <em>434 </em>, 160-171. <a href="https://doi.org/10.1016/j.canlet.2018.07.030" title="DOI URL">https://doi.org/10.1016/j.canlet.2018.07.030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2018.07.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2018.07.030%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DViewing%252Bthe%252BEph%252Breceptors%252Bwith%252Ba%252Bfocus%252Bon%252Bbreast%252Bcancer%252Bheterogeneity%26aulast%3DNikas%26aufirst%3DIlias%26date%3D2018%26volume%3D434%26spage%3D160%26epage%3D171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/medium/jm-2017-01837r_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01837&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/medium/jm-2017-01837r_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures and general scheme for the synthesis of the reported agents. (A) Chemical structures of the YSA peptide, 123B9, and of the derivatized paclitaxel used for the conjugation. (B) General scheme for the synthesis of the (123B9)<sub>2</sub>-motif. Regents and conditions: (1) NH<sub>2</sub>NH<sub>2</sub>, DMF, room temperature (rt), 30 min; (2) 5-hexynoic acid, HTBU, HOBt, DIEPA, DMF, rt, 12 h; (3) TFA, phenol, TIPS, water, rt, 3 h. (C) Chemical structure of (123B9)<sub>2</sub>–L2–PTX. The L2 linker is highlighted by squared parentheses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01837&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/medium/jm-2017-01837r_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Biophysical- and biochemical-activity comparisons of 123B9 and the (123B9)<sub>2</sub>-motif. (A) Isothermal-titration-calorimetry data relative to 123B9 (30 μM) titrated against EphA2-LBD (200 μM), resulting in a dissociation constant of 3.9 μM. (B) Isothermal-titration-calorimetry data relative to the (123B9)<sub>2</sub>-motif against EphA2-LBD, resulting in a dissociation constant of 4.9 μM. (C) Isothermal-titration-calorimetry data relative to the (123B9)<sub>2</sub>-motif against EphA4-LBD, showing no significant binding to this closely related ligand-binding domain. (D) Dose–response DELFIA curves for the displacement of biotinylated 123B9 from EphA2-LBD by compounds 123B9 and the (123B9)<sub>2</sub>-motif (IC<sub>50</sub> values of 4.9 and 4.1 μM, respectively).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01837&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/medium/jm-2017-01837r_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. EphA2 ligand dimers potently stimulate the EphA2 receptor in submicromolar concentrations. EphA2-overexpressing HEK293<i>T</i>/17 cells were starved and then treated with clustered Fc, clustered ephrin-A1 Fc, YSA, 123B9, or the 123B9 dimers for 30 min. The cells were lysed, and then the EphA2 receptor was immunoprecipitated. The samples were blotted with an antiphosphotyrosine antibodies, and then stripped and reblotted with anti-EphA2 antibodies to ensure equal loading. The 123B9 dimers phosphorylated the tyrosine residues in the EphA2 receptors with 2000-fold lower concentrations than YSA or the 123B9 monomer.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01837&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/medium/jm-2017-01837r_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. CTC evaluation using an orthotopic breast-cancer mouse metastatic model. CTC enumeration studies were done using NanoVelcro CTC Chips. (A) CTC counts in MDA-MB-231 breast-cancer cells orthotopically grafted into NOD-SCID mice treated with (123B9)<sub>2</sub>–L2–PTX or Abraxane (ABX). The CTC counts in the (123B9)<sub>2</sub>–L2–PTX group were significantly lower. (B) Captured cells directly stained for pan-cytokeratin (green) and CD45 (red) expression. (C) Pan-cytokeratin-expressing cells histologically evaluated as cancer. The cell clusters captured were elevated in the Abraxane-treated mice (D) compared with those from the (123B9)<sub>2</sub>–L2–PTX-treated mice (E). In panels B–E, the scale bars represent 10 μm.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01837&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/medium/jm-2017-01837r_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Syngeneic breast-cancer metastasis model. 4T1 cells were introduced to BALB/c mice by intracardiac injections and treated with (123B9)<sub>2</sub>–L2–PTX or Abraxane. (A) Gross lung metastasis observed in the control, Abraxane, and (123B9)<sub>2</sub>–L2–PTX groups. (B) Metastasis to the left lung superior lobe quantitated under the microscope (*<i>P</i> < 0.05, ***<i>P</i> < 0.001). (C) Histochemistry on lung sections from the three groups demonstrating the tumors (H&E at 4× magnification) and the vascularization by CD31 immuno-localization (40× magnification).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-5/acs.jmedchem.7b01837/20190222/images/large/jm-2017-01837r_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01837&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i25">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35747" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35747" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 68 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugahara, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teesalu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karmali, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotamraju, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agemy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwald, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoslahti, E.</span></span> <span> </span><span class="NLM_article-title">Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>328</i></span>,  <span class="NLM_fpage">1031</span>– <span class="NLM_lpage">1035</span>, <span class="refDoi"> DOI: 10.1126/science.1183057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1126%2Fscience.1183057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=20378772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtFCnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=328&publication_year=2010&pages=1031-1035&author=K.+N.+Sugaharaauthor=T.+Teesaluauthor=P.+P.+Karmaliauthor=V.+R.+Kotamrajuauthor=L.+Agemyauthor=D.+R.+Greenwaldauthor=E.+Ruoslahti&title=Coadministration+of+a+tumor-penetrating+peptide+enhances+the+efficacy+of+cancer+drugs&doi=10.1126%2Fscience.1183057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs</span></div><div class="casAuthors">Sugahara, Kazuki N.; Teesalu, Tambet; Karmali, Priya Prakash; Kotamraju, Venkata Ramana; Agemy, Lilach; Greenwald, Daniel R.; Ruoslahti, Erkki</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">328</span>
        (<span class="NLM_cas:issue">5981</span>),
    <span class="NLM_cas:pages">1031-1035</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Poor penetration of anticancer drugs into tumors can be an important factor limiting their efficacy.  We studied mouse tumor models to show that a previously characterized tumor-penetrating peptide, iRGD, increased vascular and tissue permeability in a tumor-specific and neuropilin-1-dependent manner, allowing coadministered drugs to penetrate into extravascular tumor tissue.  Importantly, this effect did not require the drugs to be chem. conjugated to the peptide.  Systemic injection with iRGD improved the therapeutic index of drugs of various compns., including a small mol. (doxorubicin), nanoparticles (nab-paclitaxel and doxorubicin liposomes), and a monoclonal antibody (trastuzumab).  Thus, coadministration of iRGD may be a valuable way to enhance the efficacy of anticancer drugs while reducing their side effects, a primary goal of cancer therapy research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnpbZBSXSmfrVg90H21EOLACvtfcHk0lgbVevTiSdTnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtFCnsb4%253D&md5=c8103ff227adc4061b92a62157b7a36f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1126%2Fscience.1183057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1183057%26sid%3Dliteratum%253Aachs%26aulast%3DSugahara%26aufirst%3DK.%2BN.%26aulast%3DTeesalu%26aufirst%3DT.%26aulast%3DKarmali%26aufirst%3DP.%2BP.%26aulast%3DKotamraju%26aufirst%3DV.%2BR.%26aulast%3DAgemy%26aufirst%3DL.%26aulast%3DGreenwald%26aufirst%3DD.%2BR.%26aulast%3DRuoslahti%26aufirst%3DE.%26atitle%3DCoadministration%2520of%2520a%2520tumor-penetrating%2520peptide%2520enhances%2520the%2520efficacy%2520of%2520cancer%2520drugs%26jtitle%3DScience%26date%3D2010%26volume%3D328%26spage%3D1031%26epage%3D1035%26doi%3D10.1126%2Fscience.1183057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teesalu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugahara, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoslahti, E.</span></span> <span> </span><span class="NLM_article-title">Tumor-penetrating peptides</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">216</span>, <span class="refDoi"> DOI: 10.3389/fonc.2013.00216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.3389%2Ffonc.2013.00216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=23986882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A280%3ADC%252BC3sbjtlGrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=216&author=T.+Teesaluauthor=K.+N.+Sugaharaauthor=E.+Ruoslahti&title=Tumor-penetrating+peptides&doi=10.3389%2Ffonc.2013.00216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-penetrating peptides</span></div><div class="casAuthors">Teesalu Tambet; Sugahara Kazuki N; Ruoslahti Erkki</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">216</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Tumor-homing peptides can be used to deliver drugs into tumors.  Phage library screening in live mice has recently identified homing peptides that specifically recognize the endothelium of tumor vessels, extravasate, and penetrate deep into the extravascular tumor tissue.  The prototypic peptide of this class, iRGD (CRGDKGPDC), contains the integrin-binding RGD motif.  RGD mediates tumor-homing through binding to αv integrins, which are selectively expressed on various cells in tumors, including tumor endothelial cells.  The tumor-penetrating properties of iRGD are mediated by a second sequence motif, R/KXXR/K.  This C-end Rule (or CendR) motif is active only when the second basic residue is exposed at the C-terminus of the peptide.  Proteolytic processing of iRGD in tumors activates the cryptic CendR motif, which then binds to neuropilin-1 activating an endocytic bulk transport pathway through tumor tissue.  Phage screening has also yielded tumor-penetrating peptides that function like iRGD in activating the CendR pathway, but bind to a different primary receptor.  Moreover, novel tumor-homing peptides can be constructed from tumor-homing motifs, CendR elements and protease cleavage sites.  Pathologies other than tumors can be targeted with tissue-penetrating peptides, and the primary receptor can also be a vascular "zip code" of a normal tissue.  The CendR technology provides a solution to a major problem in tumor therapy, poor penetration of drugs into tumors.  The tumor-penetrating peptides are capable of taking a payload deep into tumor tissue in mice, and they also penetrate into human tumors ex vivo.  Targeting with these peptides specifically increases the accumulation in tumors of a variety of drugs and contrast agents, such as doxorubicin, antibodies, and nanoparticle-based compounds.  Remarkably the drug to be targeted does not have to be coupled to the peptide; the bulk transport system activated by the peptide sweeps along any compound that is present in the blood.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQW6rUhtQrVfgHqQV89nF-2fW6udTcc2eZwQ9Lvkd8_wLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbjtlGrtg%253D%253D&md5=5bd13d57c5bc6026c30e04de0ab2d087</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2013.00216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2013.00216%26sid%3Dliteratum%253Aachs%26aulast%3DTeesalu%26aufirst%3DT.%26aulast%3DSugahara%26aufirst%3DK.%2BN.%26aulast%3DRuoslahti%26aufirst%3DE.%26atitle%3DTumor-penetrating%2520peptides%26jtitle%3DFront.%2520Oncol.%26date%3D2013%26volume%3D3%26spage%3D216%26doi%3D10.3389%2Ffonc.2013.00216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coffman, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carles-Kinch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donacki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munyon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kifle, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langermann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiener, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span> <span> </span><span class="NLM_article-title">Differential EphA2 epitope display on normal versus malignant cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">7907</span>– <span class="NLM_lpage">7912</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2003&pages=7907-7912&author=K.+T.+Coffmanauthor=M.+Huauthor=K.+Carles-Kinchauthor=D.+Ticeauthor=N.+Donackiauthor=K.+Munyonauthor=G.+Kifleauthor=R.+Woodsauthor=S.+Langermannauthor=P.+A.+Kienerauthor=M.+S.+Kinch&title=Differential+EphA2+epitope+display+on+normal+versus+malignant+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCoffman%26aufirst%3DK.%2BT.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DCarles-Kinch%26aufirst%3DK.%26aulast%3DTice%26aufirst%3DD.%26aulast%3DDonacki%26aufirst%3DN.%26aulast%3DMunyon%26aufirst%3DK.%26aulast%3DKifle%26aufirst%3DG.%26aulast%3DWoods%26aufirst%3DR.%26aulast%3DLangermann%26aufirst%3DS.%26aulast%3DKiener%26aufirst%3DP.%2BA.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26atitle%3DDifferential%2520EphA2%2520epitope%2520display%2520on%2520normal%2520versus%2520malignant%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2003%26volume%3D63%26spage%3D7907%26epage%3D7912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zelinski, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zantek, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irizarry, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span> <span> </span><span class="NLM_article-title">EphA2 overexpression causes tumorigenesis of mammary epithelial cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2301</span>– <span class="NLM_lpage">2306</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=11280802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD3MXit1Ogt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=2301-2306&author=D.+P.+Zelinskiauthor=N.+D.+Zantekauthor=J.+C.+Stewartauthor=A.+R.+Irizarryauthor=M.+S.+Kinch&title=EphA2+overexpression+causes+tumorigenesis+of+mammary+epithelial+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2 overexpression causes tumorigenesis of mammary epithelial cells</span></div><div class="casAuthors">Zelinski, Daniel P.; Zantek, Nicole Dodge; Stewart, Jane C.; Irizarry, Armando R.; Kinch, Michael S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2301-2306</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Elevated levels of protein tyrosine phosphorylation contribute to a malignant phenotype, although the tyrosine kinases that are responsible for this signaling remain largely unknown.  Here we report increased levels of the EphA2 (ECK) protein tyrosine kinase in clin. specimens and cell models of breast cancer.  We also show that EphA2 overexpression is sufficient to confer malignant transformation and tumorigenic potential on nontransformed (MCF-10A) mammary epithelial cells.  The transforming capacity of EphA2 is related to the failure of EphA2 to interact with its cell-attached ligands.  Interestingly, stimulation of EphA2 reverses the malignant growth and invasiveness of EphA2-transformed cells.  Taken together, these results identify EphA2 as a powerful oncoprotein in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo58hxWRfVuHbVg90H21EOLACvtfcHk0liNYGbHa7y8yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXit1Ogt7k%253D&md5=85938000464a9c614e24d0889fbe2dff</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZelinski%26aufirst%3DD.%2BP.%26aulast%3DZantek%26aufirst%3DN.%2BD.%26aulast%3DStewart%26aufirst%3DJ.%2BC.%26aulast%3DIrizarry%26aufirst%3DA.%2BR.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26atitle%3DEphA2%2520overexpression%2520causes%2520tumorigenesis%2520of%2520mammary%2520epithelial%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D2301%26epage%3D2306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ireton, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">149</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.2174/1568009053765780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.2174%2F1568009053765780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=15892616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD2MXksFKksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=149-157&author=R.+C.+Iretonauthor=J.+Chen&title=EphA2+receptor+tyrosine+kinase+as+a+promising+target+for+cancer+therapeutics&doi=10.2174%2F1568009053765780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics</span></div><div class="casAuthors">Ireton, Renee C.; Chen, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">149-157</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Eph receptors are a unique family of receptor tyrosine kinases (RTK) that play crit. roles in embryonic patterning, neuronal targeting, and vascular development during normal embryogenesis.  Eph RTKs and their ligands, the ephrins, are also frequently overexpressed in a variety of cancers and tumor cell lines.  In particular, one family member, EphA2, is overexpressed in breast, prostate, lung, and colon cancers.  Unlike traditional oncogenes that often function only in tumor cells, recent data show that Eph receptors mediate cell-cell interactions both in tumor cells and in the tumor microenvironment, namely the tumor stroma and tumor vasculature.  Thus, EphA2 receptors are attractive targets for drug design, as targeting these mols. could simultaneously inhibit several aspects of tumor progression.  This review focuses on the multiple roles of EphA2 in cancer progression, the mechanisms by which EphA2 inhibition may halt this progression, and the pre-clin. results of EphA2 inhibition in various cancer model systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXkP68V5-EhLVg90H21EOLACvtfcHk0liNYGbHa7y8yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXksFKksbc%253D&md5=4ec492801946594928f5b87a4727134a</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2174%2F1568009053765780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568009053765780%26sid%3Dliteratum%253Aachs%26aulast%3DIreton%26aufirst%3DR.%2BC.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DEphA2%2520receptor%2520tyrosine%2520kinase%2520as%2520a%2520promising%2520target%2520for%2520cancer%2520therapeutics%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2005%26volume%3D5%26spage%3D149%26epage%3D157%26doi%3D10.2174%2F1568009053765780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tandon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemula, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, S. K.</span></span> <span> </span><span class="NLM_article-title">Emerging strategies for EphA2 receptor targeting for cancer therapeutics</span>. <i>Expert Opin. Ther. Targets</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1517/14728222.2011.538682</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1517%2F14728222.2011.538682" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=21142802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGlurbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=31-51&author=M.+Tandonauthor=S.+V.+Vemulaauthor=S.+K.+Mittal&title=Emerging+strategies+for+EphA2+receptor+targeting+for+cancer+therapeutics&doi=10.1517%2F14728222.2011.538682"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging strategies for EphA2 receptor targeting for cancer therapeutics</span></div><div class="casAuthors">Tandon, Manish; Vemula, Sai Vikram; Mittal, Suresh K.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-51</span>CODEN:
                <span class="NLM_cas:coden">EOTTAO</span>;
        ISSN:<span class="NLM_cas:issn">1472-8222</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: High mortality rates with cancers warrant further development of earlier diagnostics and better treatment strategies.  Membrane-bound erythropoietin-producing hepatocellular receptor tyrosine kinase class A2 (EphA2) is overexpressed in breast, prostate, urinary bladder, skin, lung, ovary and brain cancers.  Areas covered in this review: EphA2 overexpression in cancers, its signaling mechanisms and strategies to target its deregulation.  What the reader will gain: High EphA2 expression in cancer cells is correlated with a poor prognosis assocd. with recurrence due to enhanced metastasis.  Interaction of the EphA2 receptor with its ligand (e.g., ephrinA1) triggers events that are deregulated and implicated in carcinogenesis.  EphrinA1-independent oncogenic activity and ephrinA1-dependent tumor suppressor roles for EphA2 are described.  Mol. interactions of EphA2 with signaling proteins are assocd. with the modulation of cytoskeleton dynamics, cell adhesion, proliferation, differentiation and metastasis.  The deregulated signaling by EphA2 and its involvement in oncogenesis provide multiple avenues for the rational design of intervention approaches.  Take home message: EphA2 has been tested as a drug target using multiple approaches such as agonist antibodies, RNA interference, immunotherapy, virus vector-mediated gene transfer, small-mol. inhibitors and nanoparticles.  With over a decade of research, encouraging results with targeting of EphA2 expression in various pre-clin. cancer models necessitate further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkUoM-7uf_sLVg90H21EOLACvtfcHk0lhbvkeUCAZaZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGlurbP&md5=2b082cbbe88132ae4e6b21c56e7defc1</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1517%2F14728222.2011.538682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728222.2011.538682%26sid%3Dliteratum%253Aachs%26aulast%3DTandon%26aufirst%3DM.%26aulast%3DVemula%26aufirst%3DS.%2BV.%26aulast%3DMittal%26aufirst%3DS.%2BK.%26atitle%3DEmerging%2520strategies%2520for%2520EphA2%2520receptor%2520targeting%2520for%2520cancer%2520therapeutics%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Targets%26date%3D2011%26volume%3D15%26spage%3D31%26epage%3D51%26doi%3D10.1517%2F14728222.2011.538682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wykosky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debinski, W.</span></span> <span> </span><span class="NLM_article-title">The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1795</span>– <span class="NLM_lpage">1806</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-08-0244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1158%2F1541-7786.MCR-08-0244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=19074825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsV2iu7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=1795-1806&author=J.+Wykoskyauthor=W.+Debinski&title=The+EphA2+receptor+and+ephrinA1+ligand+in+solid+tumors%3A+function+and+therapeutic+targeting&doi=10.1158%2F1541-7786.MCR-08-0244"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting</span></div><div class="casAuthors">Wykosky, Jill; Debinski, Waldemar</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1795-1806</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The Eph receptor tyrosine kinases and ephrin ligands have been studied extensively for their roles in developmental processes.  In recent years, Eph receptors and ephrins have been found to be integral players in cancer formation and progression.  Among these are EphA2 and ephrinA1, which are involved in the development and maintenance of many different types of solid tumors.  The function of EphA2 and ephrinA1 in tumorigenesis and tumor progression is complex and seems to be dependent on cell type and microenvironment.  These variables affect the expression of the EphA2 and ephrinA1 proteins, the pathways through which they induce signaling, and the functional consequences of that signaling on the behavior of tumor cells and tumor-assocd. cells.  This review will specifically focus on the roles that EphA2 and ephrinA1 play in the different cell types that contribute to the malignancy of solid tumors, with emphasis on the opportunities for therapeutic targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbwIAXRgx44LVg90H21EOLACvtfcHk0lhbvkeUCAZaZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsV2iu7nI&md5=b507c55f0e81cb70cede51f69b3d5870</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-08-0244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-08-0244%26sid%3Dliteratum%253Aachs%26aulast%3DWykosky%26aufirst%3DJ.%26aulast%3DDebinski%26aufirst%3DW.%26atitle%3DThe%2520EphA2%2520receptor%2520and%2520ephrinA1%2520ligand%2520in%2520solid%2520tumors%253A%2520function%2520and%2520therapeutic%2520targeting%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2008%26volume%3D6%26spage%3D1795%26epage%3D1806%26doi%3D10.1158%2F1541-7786.MCR-08-0244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span> <span> </span><span class="NLM_article-title">Eph receptors and ephrins in cancer: bidirectional signalling and beyond</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">165</span>– <span class="NLM_lpage">180</span>, <span class="refDoi"> DOI: 10.1038/nrc2806</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1038%2Fnrc2806" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=20179713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitlaitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=165-180&author=E.+B.+Pasquale&title=Eph+receptors+and+ephrins+in+cancer%3A+bidirectional+signalling+and+beyond&doi=10.1038%2Fnrc2806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Eph receptors and ephrins in cancer: bidirectional signaling and beyond</span></div><div class="casAuthors">Pasquale, Elena B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">165-180</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The Eph receptor tyrosine kinases and their ephrin ligands have intriguing expression patterns in cancer cells and tumor blood vessels, which suggest important roles for their bidirectional signals in many aspects of cancer development and progression.  Eph gene mutations probably also contribute to cancer pathogenesis.  Eph receptors and ephrins have been shown to affect the growth, migration and invasion of cancer cells in culture as well as tumor growth, invasiveness, angiogenesis and metastasis in vivo.  However, Eph signaling activities in cancer seem to be complex, and are characterized by puzzling dichotomies.  Nevertheless, the Eph receptors are promising new therapeutic targets in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryHNhAMFltdbVg90H21EOLACvtfcHk0lhbvkeUCAZaZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitlaitrw%253D&md5=bbbb8188202649354faa3c50d204d0c5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrc2806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2806%26sid%3Dliteratum%253Aachs%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26atitle%3DEph%2520receptors%2520and%2520ephrins%2520in%2520cancer%253A%2520bidirectional%2520signalling%2520and%2520beyond%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D165%26epage%3D180%26doi%3D10.1038%2Fnrc2806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biao-Xue, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xi-Guang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuan-Ying, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zong-Juan, M.</span></span> <span> </span><span class="NLM_article-title">EphA2-dependent molecular targeting therapy for malignant tumors</span>. <i>Curr. Cancer Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1082</span>– <span class="NLM_lpage">1097</span>, <span class="refDoi"> DOI: 10.2174/156800911798073050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.2174%2F156800911798073050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=21933105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A280%3ADC%252BC383gs1ehtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=1082-1097&author=R.+Biao-Xueauthor=C.+Xi-Guangauthor=Y.+Shuan-Yingauthor=L.+Weiauthor=M.+Zong-Juan&title=EphA2-dependent+molecular+targeting+therapy+for+malignant+tumors&doi=10.2174%2F156800911798073050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2-dependent molecular targeting therapy for malignant tumors</span></div><div class="casAuthors">Biao-xue Rong; Xi-guang Cai; Shuan-ying Yang; Wei Li; Zong-juan Ming</div><div class="citationInfo"><span class="NLM_cas:title">Current cancer drug targets</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1082-97</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Clarification of the molecular mechanisms of oncogenesis and drug resistance is a prerequisite for the development of new treatment strategies like molecularly targeted therapies.  Recent studies demonstrate that EphA2 is overexpressed in human cancers and that EphA2 increases tumor invasion and survival.  Thus, an EphA2 receptor antagonist, such as a specific tyrosine kinase inhibitor (in the form of an antibody, small molecule, peptide, or siRNA) or an antibody-drug conjugate that targets the EphA2 receptor could be the basis for a novel targeted antineoplastic therapy.  This review summarizes the role of EphA2 in tumorigenesis and the development of EphA2 receptor antagonists as candidate anti-cancer agents.  We suggests that continued research into the function of EphA2 signaling in the pathobiology of neoplasia could lead to more rationally designed therapeutics targeting EphA2 in solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTMsB4DmqQ9_pp6t8nS6Nc3fW6udTcc2eb3_0hkBAlh_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383gs1ehtA%253D%253D&md5=04ec16254a29e8ee8e910def8cafef70</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F156800911798073050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156800911798073050%26sid%3Dliteratum%253Aachs%26aulast%3DBiao-Xue%26aufirst%3DR.%26aulast%3DXi-Guang%26aufirst%3DC.%26aulast%3DShuan-Ying%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DZong-Juan%26aufirst%3DM.%26atitle%3DEphA2-dependent%2520molecular%2520targeting%2520therapy%2520for%2520malignant%2520tumors%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2011%26volume%3D11%26spage%3D1082%26epage%3D1097%26doi%3D10.2174%2F156800911798073050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beauchamp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debinski, W.</span></span> <span> </span><span class="NLM_article-title">Ephs and ephrins in cancer: ephrin-A1 signalling</span>. <i>Semin. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">115</span>, <span class="refDoi"> DOI: 10.1016/j.semcdb.2011.10.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.semcdb.2011.10.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=109-115&author=A.+Beauchampauthor=W.+Debinski&title=Ephs+and+ephrins+in+cancer%3A+ephrin-A1+signalling&doi=10.1016%2Fj.semcdb.2011.10.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.semcdb.2011.10.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcdb.2011.10.019%26sid%3Dliteratum%253Aachs%26aulast%3DBeauchamp%26aufirst%3DA.%26aulast%3DDebinski%26aufirst%3DW.%26atitle%3DEphs%2520and%2520ephrins%2520in%2520cancer%253A%2520ephrin-A1%2520signalling%26jtitle%3DSemin.%2520Cell%2520Dev.%2520Biol.%26date%3D2012%26volume%3D23%26spage%3D109%26epage%3D115%26doi%3D10.1016%2Fj.semcdb.2011.10.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasqualini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindberg, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span> <span> </span><span class="NLM_article-title">The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6043</span>– <span class="NLM_lpage">6052</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1204004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1038%2Fsj.onc.1204004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=11146556" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsFCrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=6043-6052&author=K.+Ogawaauthor=R.+Pasqualiniauthor=R.+A.+Lindbergauthor=R.+Kainauthor=A.+L.+Freemanauthor=E.+B.+Pasquale&title=The+ephrin-A1+ligand+and+its+receptor%2C+EphA2%2C+are+expressed+during+tumor+neovascularization&doi=10.1038%2Fsj.onc.1204004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization</span></div><div class="casAuthors">Ogawa, Kazushige; Pasqualini, Renata; Lindberg, Richard A.; Kain, Renate; Freeman, Andrew L.; Pasquale, Elena B.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">6043-6052</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Eph receptor tyrosine kinases and their ephrin ligands have been implicated in embryonic vascular development and in in vivo models of angiogenesis.  Eph proteins may also regulate tumor neovascularization, but this role has not been previously investigated.  To screen for Eph proteins expressed in tumor blood vessels, we used tumor xenografts grown in nude mice from MDA-MB-435 human breast cancer cells or KS1767 human Kaposi's sarcoma cells.  By immunohistochem., the ephrin-A1 ligand and one of its receptors, EphA2, were detected throughout tumor vasculature.  Double-labeling with anti-CD34 antibodies demonstrated that both ephrin-A1 and EphA2 were expressed in xenograft endothelial cells and also tumor cells.  Furthermore, EphA2 was tyrosine-phosphorylated in the xenograft tumors, indicating that it was activated, presumably by interacting with ephrin-A1.  Ephrin-A1 and EphA2 were also detected in both the vasculature and tumor cells of surgically removed human cancers.  In an in vitro angiogenesis model, a dominant neg. form of EphA2 inhibited capillary tube-like formation by human umbilical vein endothelial cells (HUVECs), demonstrating a requirement for EphA receptor signaling.  These data suggest that ephrin-A1 and EphA2 play a role in human cancers, at least in part by influencing tumor neovascularization.  Eph proteins may represent promising new targets for antiangiogenic cancer treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCCtY-hNNoh7Vg90H21EOLACvtfcHk0liCmyG4dSw7iQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsFCrsw%253D%253D&md5=26f020aa24c07f8adc321af3d6ac5924</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1204004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1204004%26sid%3Dliteratum%253Aachs%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DPasqualini%26aufirst%3DR.%26aulast%3DLindberg%26aufirst%3DR.%2BA.%26aulast%3DKain%26aufirst%3DR.%26aulast%3DFreeman%26aufirst%3DA.%2BL.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26atitle%3DThe%2520ephrin-A1%2520ligand%2520and%2520its%2520receptor%252C%2520EphA2%252C%2520are%2520expressed%2520during%2520tumor%2520neovascularization%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D6043%26epage%3D6052%26doi%3D10.1038%2Fsj.onc.1204004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker-Daniels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhim, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bostwick, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span> <span> </span><span class="NLM_article-title">Overexpression of the EphA2 tyrosine kinase in prostate cancer</span>. <i>Prostate</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1002%2F%28SICI%291097-0045%2819991201%2941%3A4%3C275%3A%3AAID-PROS8%3E3.0.CO%3B2-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10544301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADyaK1MXotFWktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1999&pages=275-280&author=J.+Walker-Danielsauthor=K.+Coffmanauthor=M.+Azimiauthor=J.+S.+Rhimauthor=D.+G.+Bostwickauthor=P.+Snyderauthor=B.+J.+Kernsauthor=D.+J.+Watersauthor=M.+S.+Kinch&title=Overexpression+of+the+EphA2+tyrosine+kinase+in+prostate+cancer&doi=10.1002%2F%28SICI%291097-0045%2819991201%2941%3A4%3C275%3A%3AAID-PROS8%3E3.0.CO%3B2-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of the EphA2 tyrosine kinase in prostate cancer</span></div><div class="casAuthors">Walker-Daniels, J.; Coffman, K.; Azimi, M.; Rhim, J. S.; Bostwick, D. G.; Snyder, P.; Kerns, B. J.; Waters, D. J.; Kinch, M. S.</div><div class="citationInfo"><span class="NLM_cas:title">Prostate (New York)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">275-280</span>CODEN:
                <span class="NLM_cas:coden">PRSTDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-4137</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">BACKGROUND. Mols. that are highly expressed by human prostate cancers may serve as therapeutically relevant targets or tumor markers.  Tyrosine kinases are frequently over-expressed in metastatic tumor cells and this prompted us to screen for tyrosine kinases that are overexpressed in prostate cancer cells.  METHODS. Expression levels of the EphA2 receptor tyrosine kinase were detd. by Western blot anal. in canine and human prostate cancer cell lines and in immortalized and transformed variants of 267B1 prostatic epithelial cells.  EphA2 levels in benign human prostate and prostate cancers were also detd. in formalin-fixed, paraffin-embedded tissues using immunohistochem. staining.  RESULTS. Metastatic prostate cancer cells overexpressed EphA2 by 10-100 fold as compared with non-invasive prostatic epithelial cells.  EphA2 immunoreactivity in vivo was also significantly greater in human prostate cancers as compared with benign prostate epithelium.  CONCLUSIONS. The EphA2 receptor tyrosine kinase is differentially expressed in human and canine prostate cancer cell lines and overexpressed in human prostate cancers as compared with benign prostate tissues.  Metastasis-derived canine prostate carcinoma cell lines overexpress EphA2 and may provide pre-clin. models to further evaluate the role of EphA2 in prostate carcinogenesis.  Further investigations are needed to det. the utility of EphA2 as a tumor marker and a novel target in human prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbX-v8g0g3xbVg90H21EOLACvtfcHk0lggDK29XDM4RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXotFWktrw%253D&md5=79382dfa07eb5866eb6dc91970fdc49a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-0045%2819991201%2941%3A4%3C275%3A%3AAID-PROS8%3E3.0.CO%3B2-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-0045%252819991201%252941%253A4%253C275%253A%253AAID-PROS8%253E3.0.CO%253B2-T%26sid%3Dliteratum%253Aachs%26aulast%3DWalker-Daniels%26aufirst%3DJ.%26aulast%3DCoffman%26aufirst%3DK.%26aulast%3DAzimi%26aufirst%3DM.%26aulast%3DRhim%26aufirst%3DJ.%2BS.%26aulast%3DBostwick%26aufirst%3DD.%2BG.%26aulast%3DSnyder%26aufirst%3DP.%26aulast%3DKerns%26aufirst%3DB.%2BJ.%26aulast%3DWaters%26aufirst%3DD.%2BJ.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26atitle%3DOverexpression%2520of%2520the%2520EphA2%2520tyrosine%2520kinase%2520in%2520prostate%2520cancer%26jtitle%3DProstate%26date%3D1999%26volume%3D41%26spage%3D275%26epage%3D280%26doi%3D10.1002%2F%28SICI%291097-0045%2819991201%2941%3A4%3C275%3A%3AAID-PROS8%3E3.0.CO%3B2-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flockhart, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldridge, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulbright, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eble, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span> <span> </span><span class="NLM_article-title">High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">2271</span>– <span class="NLM_lpage">2276</span>, <span class="refDoi"> DOI: 10.1016/S0002-9440(10)63584-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2FS0002-9440%2810%2963584-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=14633601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD2cXkslGm" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2003&pages=2271-2276&author=G.+Zengauthor=Z.+Huauthor=M.+S.+Kinchauthor=C.+X.+Panauthor=D.+A.+Flockhartauthor=C.+Kaoauthor=T.+A.+Gardnerauthor=S.+Zhangauthor=L.+Liauthor=L.+A.+Baldridgeauthor=M.+O.+Kochauthor=T.+M.+Ulbrightauthor=J.+N.+Ebleauthor=L.+Cheng&title=High-level+expression+of+EphA2+receptor+tyrosine+kinase+in+prostatic+intraepithelial+neoplasia&doi=10.1016%2FS0002-9440%2810%2963584-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia</span></div><div class="casAuthors">Zeng, Guangyuan; Hu, Zhiqiang; Kinch, Michael S.; Pan, Chong-Xian; Flockhart, David A.; Kao, Chinghai; Gardner, Thomas A.; Zhang, Shaobo; Li, Lang; Baldridge, Lee Ann; Koch, Michael O.; Ulbright, Thomas M.; Eble, John N.; Cheng, Liang</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2271-2276</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">EphA2 is a transmembrane receptor tyrosine kinase that is overexpressed in many carcinomas.  Specific targeting of EphA2 with monoclonal antibodies is sufficient to inhibit the growth, migration and invasiveness of aggressive cancers in animal models.  Using immunohistochem. analyses, the authors measured the expression of EphA2 in prostatic adenocarcinoma, high-grade prostatic intraepithelial neoplasia, and adjacent benign prostate tissue from 93 radical prostatectomy specimens.  These results were related to multiple clin. and pathol. characteristics.  The fraction of cells staining pos. with EphA2 in benign prostatic epithelium (mean, 12%) was significantly lower than that in high-grade prostatic intraepithelial neoplasia (mean, 67%, P < 0.001) and prostatic adenocarcinoma (mean, 85%, P < 0.001).  Moreover, the intensity of EphA2 immunoreactivity in prostatic adenocarcinoma was significantly higher than in benign prostatic tissue (P < 0.001) or high-grade prostatic intraepithelial neoplasia (P < 0.001).  Benign prostatic epithelium showed weak or no immunoreactivity for EphA2 in all cases examd.  Whereas EphA2 immunoreactivity related to neoplastic transformation, it did not correlate with other clin. and pathol. parameters examd.  These data suggest that EphA2 levels increase as prostatic epithelial cells progress toward a more aggressive phenotype.  Progressively higher levels of EphA2 in high-grade prostatic intraepithelial neoplasia and prostatic carcinoma are consistent with recent evidence that EphA2 functions as a powerful oncogene.  Moreover, the presence of high levels of EphA2 in these cells suggests opportunities for prostate cancer prevention and treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJTyngvcUd8bVg90H21EOLACvtfcHk0lggDK29XDM4RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXkslGm&md5=d8a1ab5f0342f77db41c822c2641bfd5</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2963584-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252963584-5%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DG.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DPan%26aufirst%3DC.%2BX.%26aulast%3DFlockhart%26aufirst%3DD.%2BA.%26aulast%3DKao%26aufirst%3DC.%26aulast%3DGardner%26aufirst%3DT.%2BA.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DBaldridge%26aufirst%3DL.%2BA.%26aulast%3DKoch%26aufirst%3DM.%2BO.%26aulast%3DUlbright%26aufirst%3DT.%2BM.%26aulast%3DEble%26aufirst%3DJ.%2BN.%26aulast%3DCheng%26aufirst%3DL.%26atitle%3DHigh-level%2520expression%2520of%2520EphA2%2520receptor%2520tyrosine%2520kinase%2520in%2520prostatic%2520intraepithelial%2520neoplasia%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2003%26volume%3D163%26spage%3D2271%26epage%3D2276%26doi%3D10.1016%2FS0002-9440%2810%2963584-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duxbury, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinner, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashley, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whang, E. E.</span></span> <span> </span><span class="NLM_article-title">Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>320</i></span>,  <span class="NLM_fpage">1096</span>– <span class="NLM_lpage">1102</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2004.06.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.bbrc.2004.06.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=15249202" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1eisr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2004&pages=1096-1102&author=M.+S.+Duxburyauthor=H.+Itoauthor=M.+J.+Zinnerauthor=S.+W.+Ashleyauthor=E.+E.+Whang&title=Ligation+of+EphA2+by+Ephrin+A1-Fc+inhibits+pancreatic+adenocarcinoma+cellular+invasiveness&doi=10.1016%2Fj.bbrc.2004.06.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness</span></div><div class="casAuthors">Duxbury, Mark S.; Ito, Hiromichi; Zinner, Michael J.; Ashley, Stanley W.; Whang, Edward E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1096-1102</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">The Eph tyrosine kinases interact with ligands of the Ephrin family and have diverse cellular functions.  EphA2 has been recognized to be an oncoprotein of importance in a range of cancers.  Here, we examine the effect of EphA2 overexpression and ligation by chimeric Ephrin A1-Fc on the invasive phenotype of pancreatic adenocarcinoma cells.  We show that EphA2 overexpression induces a FAK-dependent increase in MMP-2 expression and invasiveness.  EphA2 ligation induces proteosomal degrdn. of EphA2, attenuates the invasive phenotype, and decreases both FAK phosphorylation and MMP-2 expression.  EphA2 appears to represent a rational therapeutic target and ligation by Ephrin A1-Fc is one strategy to modulate levels of this oncoprotein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwoGIkE2FMFLVg90H21EOLACvtfcHk0lggDK29XDM4RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1eisr0%253D&md5=98cbb73a035773464adfd8b60d979d5b</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2004.06.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2004.06.054%26sid%3Dliteratum%253Aachs%26aulast%3DDuxbury%26aufirst%3DM.%2BS.%26aulast%3DIto%26aufirst%3DH.%26aulast%3DZinner%26aufirst%3DM.%2BJ.%26aulast%3DAshley%26aufirst%3DS.%2BW.%26aulast%3DWhang%26aufirst%3DE.%2BE.%26atitle%3DLigation%2520of%2520EphA2%2520by%2520Ephrin%2520A1-Fc%2520inhibits%2520pancreatic%2520adenocarcinoma%2520cellular%2520invasiveness%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2004%26volume%3D320%26spage%3D1096%26epage%3D1102%26doi%3D10.1016%2Fj.bbrc.2004.06.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duxbury, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zinner, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashley, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whang, E. E.</span></span> <span> </span><span class="NLM_article-title">EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1448</span>– <span class="NLM_lpage">1456</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1207247</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1038%2Fsj.onc.1207247" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=14973554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtlKhtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=1448-1456&author=M.+S.+Duxburyauthor=H.+Itoauthor=M.+J.+Zinnerauthor=S.+W.+Ashleyauthor=E.+E.+Whang&title=EphA2%3A+a+determinant+of+malignant+cellular+behavior+and+a+potential+therapeutic+target+in+pancreatic+adenocarcinoma&doi=10.1038%2Fsj.onc.1207247"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma</span></div><div class="casAuthors">Duxbury, Mark S.; Ito, Hiromichi; Zinner, Michael J.; Ashley, Stanley W.; Whang, Edward E.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1448-1456</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The EphA2 receptor tyrosine kinase is overexpressed in a variety of human cancers.  We sought to characterize the role of EphA2 in pancreatic adenocarcinoma and, using RNA interference (RNAi) mediated by small interfering RNA (siRNA), we detd. the effects of suppressing EphA2 expression in vitro and in vivo.  EphA2 expression in PANC1, MIAPaCa2, BxPC3 and Capan2 cells was assessed by Northern and Western blot.  We artificially overexpressed EphA2 by transient transfection and suppressed EphA2 expression using RNAi.  Cellular invasiveness was quantified by modified Boyden chamber assay.  Anoikis was induced by anchorage-independent polyHEMA culture and caspase 3 activity was quantified fluorometrically.  Focal adhesion kinase (FAK) phosphorylation was assessed by immunopptn.  EphA2 siRNA treatment was assessed in a nude mouse xenograft model.  Pancreatic adenocarcinoma cells differentially express EphA2.  Inherent and induced EphA2 overexpression is assocd. with increased cellular invasiveness and anoikis resistance.  EphA2 siRNA suppresses EphA2 expression, cellular invasiveness, anoikis resistance and FAK phosphorylation in vitro and retards tumor growth and inhibits metastasis in vivo.  EphA2 is both a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVvai6Ri2Z4LVg90H21EOLACvtfcHk0lhs7NloWmJHHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtlKhtbo%253D&md5=0336c1b3bcb340b2a74b21e7464f7a00</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1207247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1207247%26sid%3Dliteratum%253Aachs%26aulast%3DDuxbury%26aufirst%3DM.%2BS.%26aulast%3DIto%26aufirst%3DH.%26aulast%3DZinner%26aufirst%3DM.%2BJ.%26aulast%3DAshley%26aufirst%3DS.%2BW.%26aulast%3DWhang%26aufirst%3DE.%2BE.%26atitle%3DEphA2%253A%2520a%2520determinant%2520of%2520malignant%2520cellular%2520behavior%2520and%2520a%2520potential%2520therapeutic%2520target%2520in%2520pancreatic%2520adenocarcinoma%26jtitle%3DOncogene%26date%3D2004%26volume%3D23%26spage%3D1448%26epage%3D1456%26doi%3D10.1038%2Fsj.onc.1207247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mudali, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakkur, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Embuscado, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobuzio-Donahue, C.
A.</span></span> <span> </span><span class="NLM_article-title">Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status</span>. <i>Clin. Exp. Metastasis</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1007/s10585-006-9045-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1007%2Fs10585-006-9045-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjvFGhtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2007&pages=357-365&author=S.+V.+Mudaliauthor=B.+Fuauthor=S.+S.+Lakkurauthor=M.+Luoauthor=E.+E.+Embuscadoauthor=C.%0AA.+Iacobuzio-Donahue&title=Patterns+of+EphA2+protein+expression+in+primary+and+metastatic+pancreatic+carcinoma+and+correlation+with+genetic+status&doi=10.1007%2Fs10585-006-9045-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status</span></div><div class="casAuthors">Mudali, Shiyama V.; Fu, Baojin; Lakkur, Sindhu S.; Luo, Mingde; Embuscado, Erlinda E.; Iacobuzio-Donahue, Christine A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical & Experimental Metastasis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">357-365</span>CODEN:
                <span class="NLM_cas:coden">CEXMD2</span>;
        ISSN:<span class="NLM_cas:issn">0262-0898</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">EphA2 is a transmembrane receptor tyrosine kinase that functions in the regulation of cell growth, survival, angiogenesis, and migration and EphA2 targeting has been proposed as a novel therapeutic strategy for neoplasms that overexpress this protein.  EphA2 overexpression has been correlated with increased invasive and metastatic ability in pancreatic cancer cell lines.  However, the patterns of EphA2 expression in human pancreatic cancers and assocd. metastases is unknown, as are the genetics of EphA2 in this tumor type.  We collected clinico-pathol. data and paraffin-embedded materials from 98 patients with primary and/or metastatic pancreatic cancer and performed immunohistochem. labeling for EphA2 protein.  EphA2 protein immunolabeling was found in 207 of 219 samples (95%).  The expression was predominantly cytoplasmic, although predominant membranous staining was obsd. in a minority of cases.  When evaluated specifically for labeling intensity, primary and metastatic carcinomas were more strongly pos. compared to benign ducts and PanIN lesions (P < 0.00001 and P < 0.01, resp.) and poorly differentiated carcinomas were more strongly pos. for EphA2 than well and moderately differentiated tumors (P < 0.005).  When primary carcinomas without metastatic disease were specifically compared to carcinomas with assocd. metastatic disease, the advanced carcinomas showed relatively less strong pos. labeling for EphA2 (P < 0.008).  Moreover, decreased EphA2 labeling was more commonly found in liver (P < 0.002), lung (P < 0.004) or peritoneal metastases (P < 0.01) as compared to distant lymph node metastases (P < 0.01).  Genetic sequencing of the tyrosine kinase domain of EPHA2 in 22 samples of xenograft enriched pancreatic cancer did not reveal any inactivating mutations.  However, EPHA2 amplification was found in 1 of 33 pancreatic cancers corresponding to a lymph node metastasis, indicating EPHA2 genomic amplification may underlie EphA2 overexpression in a minority of patients.  Our data confirms that EphA2 is overexpressed in pancreatic cancer, but suggests a relative loss of EphA2 in co-existent pancreatic cancer metastases as well as a role for EPHA2 in organ specific metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsvOa3W9AmhLVg90H21EOLACvtfcHk0lhs7NloWmJHHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjvFGhtr4%253D&md5=586f96358a780e92711c1124d64670e0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs10585-006-9045-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10585-006-9045-7%26sid%3Dliteratum%253Aachs%26aulast%3DMudali%26aufirst%3DS.%2BV.%26aulast%3DFu%26aufirst%3DB.%26aulast%3DLakkur%26aufirst%3DS.%2BS.%26aulast%3DLuo%26aufirst%3DM.%26aulast%3DEmbuscado%26aufirst%3DE.%2BE.%26aulast%3DIacobuzio-Donahue%26aufirst%3DC.%2BA.%26atitle%3DPatterns%2520of%2520EphA2%2520protein%2520expression%2520in%2520primary%2520and%2520metastatic%2520pancreatic%2520carcinoma%2520and%2520correlation%2520with%2520genetic%2520status%26jtitle%3DClin.%2520Exp.%2520Metastasis%26date%3D2007%26volume%3D23%26spage%3D357%26epage%3D365%26doi%3D10.1007%2Fs10585-006-9045-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittal, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bangari, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhariwal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, S. I.</span></span> <span> </span><span class="NLM_article-title">Expression of EphA2 and ephrin A-1 in carcinoma of the urinary bladder</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-1505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1158%2F1078-0432.CCR-05-1505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=16428472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtlGqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=353-360&author=S.+Abrahamauthor=D.+W.+Knappauthor=L.+Chengauthor=P.+W.+Snyderauthor=S.+K.+Mittalauthor=D.+S.+Bangariauthor=M.+Kinchauthor=L.+Wuauthor=J.+Dhariwalauthor=S.+I.+Mohammed&title=Expression+of+EphA2+and+ephrin+A-1+in+carcinoma+of+the+urinary+bladder&doi=10.1158%2F1078-0432.CCR-05-1505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of EphA2 and Ephrin A-1 in Carcinoma of the Urinary Bladder</span></div><div class="casAuthors">Abraham, Shaji; Knapp, Deborah W.; Cheng, Liang; Snyder, Paul W.; Mittal, Suresh K.; Bangari, Dinesh S.; Kinch, Michael; Wu, Lan; Dhariwal, Jay; Mohammed, Sulma I.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">353-360</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The EphA2 receptor tyrosine kinase is believed to play a role in tumor growth and metastasis.  The clin. significance of the expression of EphA2 was obsd. in breast, prostate, colon, skin, cervical, ovarian, and lung cancers.  The purpose of this work was to det. the expression of EphA2 and its ligand, Ephrin A-1, and E-cadherin in carcinoma of the urinary bladder, and det. EphA2 as a new target for therapy in bladder cancer.  Exptl. Design: EphA2 mRNA and protein expression was investigated by reverse transcription-PCR and Western blot, resp., in bladder cancer cell lines.  In addn., the expression of EphA2, Ephrin A-1, and E-cadherin in tissues from patients with different stages of urinary bladder cancer was detd. by immunohistochem.  Furthermore, the ability of Ephrin A-1 to inhibit growth of bladder cancer cells was also investigated using an adenoviral delivery system.  Results: Western blot anal. showed high EphA2 expression in TCCSUP, T24, and UMUC-3 cell lines.  In tissues, the staining intensity of EphA2 was less in normal urothelium but increased greatly in advancing stages of urothelial carcinoma (P < 0.05).  Similarly, the staining intensity of Ephrin A-1 was low in normal tissues and high in cancerous tissues, but it was similar across the various stages of urothelial carcinoma (Ta-T4).  E-cadherin immunoreactivity decreased in urothelial cancer.  Assocn. of EphA2 and Ephrin A-1 expression was found to be significant between Ta stage and T1-T2 (P < 0.04) and Ta and T3-T4 stages (P < 0.0001).  Adenovirus delivery of Ephrin A-1 inhibited proliferation of TCCSUP cells.  Conclusion: EphA2 may serve as a novel target for bladder cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi0Lw0XE9I4rVg90H21EOLACvtfcHk0lhs7NloWmJHHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtlGqug%253D%253D&md5=ab840113d0c83a676cfb9123c4273138</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1505%26sid%3Dliteratum%253Aachs%26aulast%3DAbraham%26aufirst%3DS.%26aulast%3DKnapp%26aufirst%3DD.%2BW.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DSnyder%26aufirst%3DP.%2BW.%26aulast%3DMittal%26aufirst%3DS.%2BK.%26aulast%3DBangari%26aufirst%3DD.%2BS.%26aulast%3DKinch%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DDhariwal%26aufirst%3DJ.%26aulast%3DMohammed%26aufirst%3DS.%2BI.%26atitle%3DExpression%2520of%2520EphA2%2520and%2520ephrin%2520A-1%2520in%2520carcinoma%2520of%2520the%2520urinary%2520bladder%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D353%26epage%3D360%26doi%3D10.1158%2F1078-0432.CCR-05-1505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fokas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bieker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rexin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagenstecher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engenhart-Cabillic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, H. X.</span></span> <span> </span><span class="NLM_article-title">Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.3892/or.19.1.151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.3892%2For.19.1.151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=18097589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A280%3ADC%252BD2sjlvVOnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=151-156&author=L.+F.+Wangauthor=E.+Fokasauthor=M.+Biekerauthor=F.+Roseauthor=P.+Rexinauthor=Y.+Zhuauthor=A.+Pagenstecherauthor=R.+Engenhart-Cabillicauthor=H.+X.+An&title=Increased+expression+of+EphA2+correlates+with+adverse+outcome+in+primary+and+recurrent+glioblastoma+multiforme+patients&doi=10.3892%2For.19.1.151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients</span></div><div class="casAuthors">Wang Lin-Fang; Fokas Emmanouil; Bieker Michael; Rose Frank; Rexin Peter; Zhu Yuan; Pagenstecher Axel; Engenhart-Cabillic Rita; An Han-Xiang</div><div class="citationInfo"><span class="NLM_cas:title">Oncology reports</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">151-6</span>
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    </div><div class="casAbstract">Glioblastoma multiforme (GBM) is the most aggressive form of brain tumor characterized by excessive angiogenesis.  The dismal prognosis of patients with GBM warrants the development of new targeting therapies based on novel molecular markers.  The EphA2 receptor tyrosine kinase plays a pivotal role in tumor angiogenesis and an increased expression in glioma patients has recently been reported.  In this study, we investigated the expression of EphA2 in human normal brain, primary and recurrent GBM and correlated it with clinical pathological parameters and patient's outcome.  In addition, intratumor microvascular density was quantified by immunostaining for the endothelial cell marker, von Willebrand factor.  A different intensity of the membranous and cytoplastic expression of EphA2 was observed in the 40 primary and recurrent samples of GBM analyzed but not in the normal brain.  A high level expression of EphA2 was demonstrated in 24 (60%) of the primary and recurrent GBM analyzed.  The increased expression of the EphA2 protein was significantly associated with the adverse outcome of GBM patients (p<0.01 for overall survival).  The data presented in this study define the expression pattern of EphA2 in both primary and recurrent glioblastoma and suggest an important role of EphA2 in the pathogenesis of GBM.  The EphA2 may be used as a surrogate marker to screen patients for tyrosine kinase inhibitor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrQlWD-_F7-OkdrW1FkXG-fW6udTcc2eZPf6l8zwJmsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjlvVOnug%253D%253D&md5=ffc322f4165474411371be77339ae5c7</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.3892%2For.19.1.151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.19.1.151%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%2BF.%26aulast%3DFokas%26aufirst%3DE.%26aulast%3DBieker%26aufirst%3DM.%26aulast%3DRose%26aufirst%3DF.%26aulast%3DRexin%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DPagenstecher%26aufirst%3DA.%26aulast%3DEngenhart-Cabillic%26aufirst%3DR.%26aulast%3DAn%26aufirst%3DH.%2BX.%26atitle%3DIncreased%2520expression%2520of%2520EphA2%2520correlates%2520with%2520adverse%2520outcome%2520in%2520primary%2520and%2520recurrent%2520glioblastoma%2520multiforme%2520patients%26jtitle%3DOncol.%2520Rep.%26date%3D2008%26volume%3D19%26spage%3D151%26epage%3D156%26doi%3D10.3892%2For.19.1.151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wykosky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibo, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debinski, W.</span></span> <span> </span><span class="NLM_article-title">EphA2 as a novel molecular marker and target in glioblastoma multiforme</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">541</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-05-0056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1158%2F1541-7786.MCR-05-0056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=16254188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFGmsr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2005&pages=541-551&author=J.+Wykoskyauthor=D.+M.+Giboauthor=C.+Stantonauthor=W.+Debinski&title=EphA2+as+a+novel+molecular+marker+and+target+in+glioblastoma+multiforme&doi=10.1158%2F1541-7786.MCR-05-0056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2 as a Novel Molecular Marker and Target in Glioblastoma Multiforme</span></div><div class="casAuthors">Wykosky, Jill; Gibo, Denise M.; Stanton, Constance; Debinski, Waldemar</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">541-551</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We investigated the presence of EphA2, and its ligand, ephrinA1, in glioblastoma multiforme (GBM), a malignant neoplasm of glial cells, and normal brain.  We also initially examd. the functional importance of the interaction between EphA2 and ephrinA1 in glioma cells.  Expression and localization of EphA2 and ephrinA1 in human GBM and normal brain were examd. using Western blotting, immunofluorescence, and immunohistochem.  A functional role for EphA2 was investigated by assessing the activation status of the receptor and the effect of ephrinA1 on the anchorage-independent growth and invasiveness of GBM cells.  We found EphA2 to be elevated in ∼90% of GBM specimens and cell lines but not in normal brain, whereas ephrinA1 was present at consistently low levels in both GBM and normal brain.  EphA2 was activated and phosphorylated by ephrinA1 in GBM cells.  Furthermore, ephrinA1 induced a prominent, dose-dependent inhibitory effect on the anchorage-independent growth and invasiveness of GBM cells highly overexpressing EphA2, which was not seen in cells expressing low levels of the receptor.  Thus, EphA2 is both specifically overexpressed in GBM and expressed differentially with respect to its ligand, ephrinA1, which may reflect on the oncogenic processes of malignant glioma cells.  EphA2 seems to be functionally important in GBM cells and thus may play an important role in GBM pathogenesis.  Hence, EphA2 represents a new marker and novel target for the development of mol. therapeutics against GBM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkjpJH4NTKwrVg90H21EOLACvtfcHk0lie8EVW1dhoSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFGmsr%252FJ&md5=163c288c48ebacc0da6d08f0e09aebb0</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-05-0056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-05-0056%26sid%3Dliteratum%253Aachs%26aulast%3DWykosky%26aufirst%3DJ.%26aulast%3DGibo%26aufirst%3DD.%2BM.%26aulast%3DStanton%26aufirst%3DC.%26aulast%3DDebinski%26aufirst%3DW.%26atitle%3DEphA2%2520as%2520a%2520novel%2520molecular%2520marker%2520and%2520target%2520in%2520glioblastoma%2520multiforme%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2005%26volume%3D3%26spage%3D541%26epage%3D551%26doi%3D10.1158%2F1541-7786.MCR-05-0056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Binda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Visioli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamorte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitter, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huse, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cajola, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanetti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMeco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Filippis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangiola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anile, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bonis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vescovi, A. L.</span></span> <span> </span><span class="NLM_article-title">The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">765</span>– <span class="NLM_lpage">780</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2012.11.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.ccr.2012.11.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=23238013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVWgu7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=765-780&author=E.+Bindaauthor=A.+Visioliauthor=F.+Gianiauthor=G.+Lamorteauthor=M.+Copettiauthor=K.+L.+Pitterauthor=J.+T.+Huseauthor=L.+Cajolaauthor=N.+Zanettiauthor=F.+DiMecoauthor=L.+De+Filippisauthor=A.+Mangiolaauthor=G.+Mairaauthor=C.+Anileauthor=P.+De+Bonisauthor=B.+A.+Reynoldsauthor=E.+B.+Pasqualeauthor=A.+L.+Vescovi&title=The+EphA2+receptor+drives+self-renewal+and+tumorigenicity+in+stem-like+tumor-propagating+cells+from+human+glioblastomas&doi=10.1016%2Fj.ccr.2012.11.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The EphA2 Receptor Drives Self-Renewal and Tumorigenicity in Stem-like Tumor-Propagating Cells from Human Glioblastomas</span></div><div class="casAuthors">Binda, Elena; Visioli, Alberto; Giani, Fabrizio; Lamorte, Giuseppe; Copetti, Massimiliano; Pitter, Ken L.; Huse, Jason T.; Cajola, Laura; Zanetti, Nadia; DiMeco, Francesco; De Filippis, Lidia; Mangiola, Annunziato; Maira, Giulio; Anile, Carmelo; De Bonis, Pasquale; Reynolds, Brent A.; Pasquale, Elena B.; Vescovi, Angelo L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">765-780</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">In human glioblastomas (hGBMs), tumor-propagating cells with stem-like characteristics (TPCs) represent a key therapeutic target.  We found that the EphA2 receptor tyrosine kinase is overexpressed in hGBM TPCs.  Cytofluorimetric sorting into EphA2High and EphA2Low populations demonstrated that EphA2 expression correlates with the size and tumor-propagating ability of the TPC pool in hGBMs.  Both ephrinA1-Fc, which caused EphA2 downregulation in TPCs, and siRNA-mediated knockdown of EPHA2 expression suppressed TPCs self-renewal ex vivo and intracranial tumorigenicity, pointing to EphA2 downregulation as a causal event in the loss of TPCs tumorigenicity.  Infusion of ephrinA1-Fc into intracranial xenografts elicited strong tumor-suppressing effects, suggestive of therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo99dmT2JcdHrVg90H21EOLACvtfcHk0lhleL_C5LJDcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVWgu7fE&md5=913794b634f7b4094861c11e4bd482c7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2012.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2012.11.005%26sid%3Dliteratum%253Aachs%26aulast%3DBinda%26aufirst%3DE.%26aulast%3DVisioli%26aufirst%3DA.%26aulast%3DGiani%26aufirst%3DF.%26aulast%3DLamorte%26aufirst%3DG.%26aulast%3DCopetti%26aufirst%3DM.%26aulast%3DPitter%26aufirst%3DK.%2BL.%26aulast%3DHuse%26aufirst%3DJ.%2BT.%26aulast%3DCajola%26aufirst%3DL.%26aulast%3DZanetti%26aufirst%3DN.%26aulast%3DDiMeco%26aufirst%3DF.%26aulast%3DDe%2BFilippis%26aufirst%3DL.%26aulast%3DMangiola%26aufirst%3DA.%26aulast%3DMaira%26aufirst%3DG.%26aulast%3DAnile%26aufirst%3DC.%26aulast%3DDe%2BBonis%26aufirst%3DP.%26aulast%3DReynolds%26aufirst%3DB.%2BA.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DVescovi%26aufirst%3DA.%2BL.%26atitle%3DThe%2520EphA2%2520receptor%2520drives%2520self-renewal%2520and%2520tumorigenicity%2520in%2520stem-like%2520tumor-propagating%2520cells%2520from%2520human%2520glioblastomas%26jtitle%3DCancer%2520Cell%26date%3D2012%26volume%3D22%26spage%3D765%26epage%3D780%26doi%3D10.1016%2Fj.ccr.2012.11.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thaker, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landen, C. N.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deavers, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamat, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershenson, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A. K.</span></span> <span> </span><span class="NLM_article-title">Analysis of EphA2 expression and mutant p53 in ovarian carcinoma</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1357</span>– <span class="NLM_lpage">1360</span>, <span class="refDoi"> DOI: 10.4161/cbt.5.10.3225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.4161%2Fcbt.5.10.3225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=16969087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsF2lsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1357-1360&author=W.+M.+Merrittauthor=P.+H.+Thakerauthor=C.+N.+Landenauthor=M.+T.+Deaversauthor=M.+S.+Fletcherauthor=Y.+G.+Linauthor=L.+Y.+Hanauthor=A.+A.+Kamatauthor=D.+M.+Gershensonauthor=M.+S.+Kinchauthor=A.+K.+Sood&title=Analysis+of+EphA2+expression+and+mutant+p53+in+ovarian+carcinoma&doi=10.4161%2Fcbt.5.10.3225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of EphA2 expression and mutant p53 in ovarian carcinoma</span></div><div class="casAuthors">Merritt, William M.; Thaker, Premal H.; Landen, Charles N., Jr.; Deavers, Michael T.; Fletcher, Mavis S.; Lin, Yvonne G.; Han, Liz Y.; Kamat, Aparna A.; Schmandt, Rosemarie; Gershenson, David M.; Kinch, Michael S.; Sood, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1357-1360</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">The EphA2 tyrosine kinase receptor is frequently overexpressed in ovarian cancer and this feature is predictive of poor clin. outcome.  Preclin. investigation has also linked EphA2 with p53.  In our present study, we examd. EphA2 and p53 status (both expression and full-length mutation status) in 6 ovarian cell lines and 79 human ovarian cancers to det. potential assocns.  EphA2 was overexpressed in 80% of ovarian cancer cell lines and in 75% of clin. specimens.  In particular, high levels of EphA2 occurred in 91% of tumors with p53 null mutations compared to 68% in tumors with wild-type or missense mutations (p = 0.027).  EphA2 expression did not relate to crit. vs. non-crit. site missense p53 mutations or the location of mutations on specific p53 exons.  We also demonstrated that while EphA2 and p53 can provide independent information regarding clin. status, the combination of EphA2 and p53 status can predict poor clin. outcome.  In particular, the combination of EphA2 overexpression and p53 null status was assocd. with decreased overall patient survival and related to increased incidence of ascites and distant metastasis.  Taken together, these data indicate a complex relationship between EphA2 and p53 that appears to regulate EphA2 expression and clin. outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRjeQ86wSzv7Vg90H21EOLACvtfcHk0lhleL_C5LJDcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsF2lsb0%253D&md5=107a4b727dab8a76a4d6cb39256fc749</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.4161%2Fcbt.5.10.3225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.5.10.3225%26sid%3Dliteratum%253Aachs%26aulast%3DMerritt%26aufirst%3DW.%2BM.%26aulast%3DThaker%26aufirst%3DP.%2BH.%26aulast%3DLanden%26aufirst%3DC.%2BN.%26aulast%3DDeavers%26aufirst%3DM.%2BT.%26aulast%3DFletcher%26aufirst%3DM.%2BS.%26aulast%3DLin%26aufirst%3DY.%2BG.%26aulast%3DHan%26aufirst%3DL.%2BY.%26aulast%3DKamat%26aufirst%3DA.%2BA.%26aulast%3DGershenson%26aufirst%3DD.%2BM.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DSood%26aufirst%3DA.%2BK.%26atitle%3DAnalysis%2520of%2520EphA2%2520expression%2520and%2520mutant%2520p53%2520in%2520ovarian%2520carcinoma%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D1357%26epage%3D1360%26doi%3D10.4161%2Fcbt.5.10.3225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwano, H.</span></span> <span> </span><span class="NLM_article-title">EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">657</span>– <span class="NLM_lpage">663</span>, <span class="refDoi"> DOI: 10.1002/ijc.10860</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1002%2Fijc.10860" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=12494475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmtFKntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2003&pages=657-663&author=T.+Miyazakiauthor=H.+Katoauthor=M.+Fukuchiauthor=M.+Nakajimaauthor=H.+Kuwano&title=EphA2+overexpression+correlates+with+poor+prognosis+in+esophageal+squamous+cell+carcinoma&doi=10.1002%2Fijc.10860"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma</span></div><div class="casAuthors">Miyazaki, Tatsuya; Kato, Hiroyuki; Fukuchi, Minoru; Nakajima, Masanobu; Kuwano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">657-663</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">EphA2 is a member of the Eph family of receptor tyrosine kinases, which interact with cell-bound ligands known as ephrins.  EphA2 expression was investigated by immunohistochem. with an anti-EphA2 monoclonal antibody in 80 patients with esophageal squamous cell carcinoma (ESCC) who had undergone surgery.  EphA2 overexpression was pos. in 40 of the 80 patients (50%).  A significant correlation was obsd. between EphA2 expression and regional lymph node metastasis (p=0.023), no. of lymph node metastases (p=0.011) and poor degree of tumor differentiation (p=0.004).  The survival rates of EphA2-pos. patients were poorer than those of EphA2-neg. patients (p=0.014).  The 5-yr survival rate of patients without EphA2 overexpression was 68%, whereas that of patients with EphA2 overexpression was 29%.  EphA2 expression was also investigated in 7 ESCC cell lines (TE-1, -2, -8, -13, -15, TT and TTn) and 1 immortalized human esophageal keratinocyte cell line (CHEK-1).  Western blotting revealed different levels of EphA2 expression in the 8 cell lines.  EphA2 was expressed at a high level in the ESCC cell lines compared to CHEK-1.  EphA2 phosphorylation was demonstrated in all cell lines.  Northern blot anal. showed that EphA2 mRNA expression in TE-1 was greater than that in the other ESCC cell lines.  The observation of small gaps on Western blot anal. of the ESCC cell lines suggests that there may be a mechanism for EphA2 regulation at the point of translation.  In conclusion, EphA2 overexpression appears to be related to poor degree of tumor differentiation and lymph node metastasis in ESCC.  Consequently, patients with EphA2 overexpression have a poorer prognosis than those without.  EphA2 is a potential target to prevent ESCC cells spreading into the lymphatic drainage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyZLBkO7X3GrVg90H21EOLACvtfcHk0lhleL_C5LJDcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmtFKntg%253D%253D&md5=a3e41d56e291ff333007e36c95f36c5c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1002%2Fijc.10860&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10860%26sid%3Dliteratum%253Aachs%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DKato%26aufirst%3DH.%26aulast%3DFukuchi%26aufirst%3DM.%26aulast%3DNakajima%26aufirst%3DM.%26aulast%3DKuwano%26aufirst%3DH.%26atitle%3DEphA2%2520overexpression%2520correlates%2520with%2520poor%2520prognosis%2520in%2520esophageal%2520squamous%2520cell%2520carcinoma%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2003%26volume%3D103%26spage%3D657%26epage%3D663%26doi%3D10.1002%2Fijc.10860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faoro, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennon, F. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choong, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanteti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husain, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tretiakova, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramnath, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vokes, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgia, R.</span></span> <span> </span><span class="NLM_article-title">EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">18575</span>– <span class="NLM_lpage">18585</span>, <span class="refDoi"> DOI: 10.1074/jbc.M109.075085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1074%2Fjbc.M109.075085" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=18575-18585&author=L.+Faoroauthor=P.+A.+Singletonauthor=G.+M.+Cervantesauthor=F.+E.+Lennonauthor=N.+W.+Choongauthor=R.+Kantetiauthor=B.+D.+Fergusonauthor=A.+N.+Husainauthor=M.+S.+Tretiakovaauthor=N.+Ramnathauthor=E.+E.+Vokesauthor=R.+Salgia&title=EphA2+mutation+in+lung+squamous+cell+carcinoma+promotes+increased+cell+survival%2C+cell+invasion%2C+focal+adhesions%2C+and+mammalian+target+of+rapamycin+activation&doi=10.1074%2Fjbc.M109.075085"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.075085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.075085%26sid%3Dliteratum%253Aachs%26aulast%3DFaoro%26aufirst%3DL.%26aulast%3DSingleton%26aufirst%3DP.%2BA.%26aulast%3DCervantes%26aufirst%3DG.%2BM.%26aulast%3DLennon%26aufirst%3DF.%2BE.%26aulast%3DChoong%26aufirst%3DN.%2BW.%26aulast%3DKanteti%26aufirst%3DR.%26aulast%3DFerguson%26aufirst%3DB.%2BD.%26aulast%3DHusain%26aufirst%3DA.%2BN.%26aulast%3DTretiakova%26aufirst%3DM.%2BS.%26aulast%3DRamnath%26aufirst%3DN.%26aulast%3DVokes%26aufirst%3DE.%2BE.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DEphA2%2520mutation%2520in%2520lung%2520squamous%2520cell%2520carcinoma%2520promotes%2520increased%2520cell%2520survival%252C%2520cell%2520invasion%252C%2520focal%2520adhesions%252C%2520and%2520mammalian%2520target%2520of%2520rapamycin%2520activation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D18575%26epage%3D18585%26doi%3D10.1074%2Fjbc.M109.075085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. H.</span></span> <span> </span><span class="NLM_article-title">Over-expression of EphA2 and ephrinA-1 in human gastric adenocarcinoma and its prognostic value for postoperative patients</span>. <i>Dig. Dis. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2410</span>– <span class="NLM_lpage">2417</span>, <span class="refDoi"> DOI: 10.1007/s10620-008-0649-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1007%2Fs10620-008-0649-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=19101799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KntrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2009&pages=2410-2417&author=W.+J.+Yuanauthor=J.+Geauthor=Z.+K.+Chenauthor=S.+B.+Wuauthor=H.+Shenauthor=P.+Yangauthor=B.+Huauthor=G.+W.+Zhangauthor=Z.+H.+Chen&title=Over-expression+of+EphA2+and+ephrinA-1+in+human+gastric+adenocarcinoma+and+its+prognostic+value+for+postoperative+patients&doi=10.1007%2Fs10620-008-0649-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Over-Expression of EphA2 and EphrinA-1 in Human Gastric Adenocarcinoma and Its Prognostic Value for Postoperative Patients</span></div><div class="casAuthors">Yuan, Wei-Jie; Ge, Jie; Chen, Zhi-Kang; Wu, Shao-Bin; Shen, Hong; Yang, Pu; Hu, Bin; Zhang, Ge-Wen; Chen, Zi-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Digestive Diseases and Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2410-2417</span>CODEN:
                <span class="NLM_cas:coden">DDSCDJ</span>;
        ISSN:<span class="NLM_cas:issn">0163-2116</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">This study aims to investigate the expression and significance of EphA2 and EphrinA-1 in human gastric adenocarcinoma progression and prognosis.  The expression of EphA2 and EphrinA-1 was detected in the cell lines and tissues of gastric adenocarcinoma.  Different expression levels of EphA2 and EphrinA-1 were found in two cell lines.  The expression of EphA2 and EphrinA-1 was significantly higher in gastric adenocarcinoma tissues than in normal tissues.  Statistical anal. showed a significant correlation of EphA2 expression with the depth of tumor invasion, tumor-node-metastasis (TNM) stages, and lymph node metastasis.  EphrinA-1 over-expression was significantly correlated with TNM stages and lymph node metastasis, while EphA2 expression was found to be an independent prognostic factor of postoperative gastric adenocarcinoma.  In conclusion, the increased expression of EphA2 and EphrinA-1 plays an important role in the progression of human gastric adenocarcinoma, in which elevated EphA2 expression is an independent factor that indicates poor prognosis in postoperative gastric adenocarcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT0PcLBKA1b7Vg90H21EOLACvtfcHk0ljAHI8SKgnOfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KntrnI&md5=968038e62b5253ab0aa49b170d56de26</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2Fs10620-008-0649-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10620-008-0649-4%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DW.%2BJ.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%2BK.%26aulast%3DWu%26aufirst%3DS.%2BB.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DG.%2BW.%26aulast%3DChen%26aufirst%3DZ.%2BH.%26atitle%3DOver-expression%2520of%2520EphA2%2520and%2520ephrinA-1%2520in%2520human%2520gastric%2520adenocarcinoma%2520and%2520its%2520prognostic%2520value%2520for%2520postoperative%2520patients%26jtitle%3DDig.%2520Dis.%2520Sci.%26date%3D2009%26volume%3D54%26spage%3D2410%26epage%3D2417%26doi%3D10.1007%2Fs10620-008-0649-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hess, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seftor, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carles-Kinch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seftor, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, M. J.</span></span> <span> </span><span class="NLM_article-title">Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2)</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3250</span>– <span class="NLM_lpage">3255</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=3250-3255&author=A.+R.+Hessauthor=E.+A.+Seftorauthor=L.+M.+Gardnerauthor=K.+Carles-Kinchauthor=G.+B.+Schneiderauthor=R.+E.+Seftorauthor=M.+S.+Kinchauthor=M.+J.+Hendrix&title=Molecular+regulation+of+tumor+cell+vasculogenic+mimicry+by+tyrosine+phosphorylation%3A+role+of+epithelial+cell+kinase+%28Eck%2FEphA2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHess%26aufirst%3DA.%2BR.%26aulast%3DSeftor%26aufirst%3DE.%2BA.%26aulast%3DGardner%26aufirst%3DL.%2BM.%26aulast%3DCarles-Kinch%26aufirst%3DK.%26aulast%3DSchneider%26aufirst%3DG.%2BB.%26aulast%3DSeftor%26aufirst%3DR.%2BE.%26aulast%3DKinch%26aufirst%3DM.%2BS.%26aulast%3DHendrix%26aufirst%3DM.%2BJ.%26atitle%3DMolecular%2520regulation%2520of%2520tumor%2520cell%2520vasculogenic%2520mimicry%2520by%2520tyrosine%2520phosphorylation%253A%2520role%2520of%2520epithelial%2520cell%2520kinase%2520%2528Eck%252FEphA2%2529%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D3250%26epage%3D3255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Margaryan, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strizzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbott, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seftor, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrix, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, A. R.</span></span> <span> </span><span class="NLM_article-title">EphA2 as a promoter of melanoma tumorigenicity</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">288</span>, <span class="refDoi"> DOI: 10.4161/cbt.8.3.7485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.4161%2Fcbt.8.3.7485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=19223760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotV2qt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=279-288&author=N.+V.+Margaryanauthor=L.+Strizziauthor=D.+E.+Abbottauthor=E.+A.+Seftorauthor=M.+S.+Raoauthor=M.+J.+Hendrixauthor=A.+R.+Hess&title=EphA2+as+a+promoter+of+melanoma+tumorigenicity&doi=10.4161%2Fcbt.8.3.7485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">EphA2 as a promoter of melanoma tumorigenicity</span></div><div class="casAuthors">Margaryan, Naira V.; Strizzi, Luigi; Abbott, Daniel E.; Seftor, Elizabeth A.; Rao, M. Sambasiva; Hendrix, Mary J. C.; Hess, Angela R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">279-288</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">The greatest health threat from malignant melanoma is death due to metastatic disease.  Consequently, the identification of markers predictive of metastatic disease is essential for identifying new therapeutic targets.  EphA2, a protein tyrosine kinase receptor commonly expressed in epithelial cells, has been found to be overexpressed and constitutively active in melanoma tumor cells having a metastatic phenotype as characterized by increased invasion, proliferation and vasculogenic mimicry (VM).  Based on this observation, we hypothesized that increased expression of EphA2 by melanoma tumor cells could promote these characteristics of a metastatic phenotype in addn. to promoting tumorigenicity as a whole.  We analyzed a panel of human melanoma tumor cell lines derived from patient tissues classified as primary (either radial growth phase or vertical growth phase) and/or metastatic for the expression of EphA2 and found a correlation between increased EphA2 expression and metastatic potential.  Expts. using the most metastatic of the human melanoma cell lines demonstrated that downregulation of EphA2 results in a significant decrease in invasion, proliferation, clonogenicity and VM in vitro, in addn. to suppressed tumorigenicity in an orthotopic mouse model.  Lastly, utilization of a human phospho-kinase array revealed increased phosphorylation of several different protein kinases involved in mediating various aspects of cellular proliferation.  To the best of our knowledge these results provide the first direct in vivo evidence demonstrating a role for EphA2 in promoting melanoma tumorigenicity and suggest EphA2 as a significant mol. target for the therapeutic intervention of malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp19CzDddCbh7Vg90H21EOLACvtfcHk0lgQpA3W6lf-Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotV2qt70%253D&md5=e186491217adab34563402e43938d2da</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.4161%2Fcbt.8.3.7485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.8.3.7485%26sid%3Dliteratum%253Aachs%26aulast%3DMargaryan%26aufirst%3DN.%2BV.%26aulast%3DStrizzi%26aufirst%3DL.%26aulast%3DAbbott%26aufirst%3DD.%2BE.%26aulast%3DSeftor%26aufirst%3DE.%2BA.%26aulast%3DRao%26aufirst%3DM.%2BS.%26aulast%3DHendrix%26aufirst%3DM.%2BJ.%26aulast%3DHess%26aufirst%3DA.%2BR.%26atitle%3DEphA2%2520as%2520a%2520promoter%2520of%2520melanoma%2520tumorigenicity%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2009%26volume%3D8%26spage%3D279%26epage%3D288%26doi%3D10.4161%2Fcbt.8.3.7485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nara, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tohda, S.</span></span> <span> </span><span class="NLM_article-title">Effect of Eph-ephrin signaling on the growth of human leukemia cells</span>. <i>Anticancer research</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2913</span>– <span class="NLM_lpage">2918</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=2913-2918&author=Y.+Takahashiauthor=M.+Itohauthor=N.+Naraauthor=S.+Tohda&title=Effect+of+Eph-ephrin+signaling+on+the+growth+of+human+leukemia+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DY.%26aulast%3DItoh%26aufirst%3DM.%26aulast%3DNara%26aufirst%3DN.%26aulast%3DTohda%26aufirst%3DS.%26atitle%3DEffect%2520of%2520Eph-ephrin%2520signaling%2520on%2520the%2520growth%2520of%2520human%2520leukemia%2520cells%26jtitle%3DAnticancer%2520research%26date%3D2014%26volume%3D34%26spage%3D2913%26epage%3D2918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trinidad, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapata, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-Colmenar, L. M.</span></span> <span> </span><span class="NLM_article-title">Eph-ephrin bidirectional signaling comes into the context of lymphocyte transendothelial migration</span>. <i>Cell adhesion & migration</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">363</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.4161/cam.4.3.11586</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.4161%2Fcam.4.3.11586" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=363-367&author=E.+M.+Trinidadauthor=A.+G.+Zapataauthor=L.+M.+Alonso-Colmenar&title=Eph-ephrin+bidirectional+signaling+comes+into+the+context+of+lymphocyte+transendothelial+migration&doi=10.4161%2Fcam.4.3.11586"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.4161%2Fcam.4.3.11586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcam.4.3.11586%26sid%3Dliteratum%253Aachs%26aulast%3DTrinidad%26aufirst%3DE.%2BM.%26aulast%3DZapata%26aufirst%3DA.%2BG.%26aulast%3DAlonso-Colmenar%26aufirst%3DL.%2BM.%26atitle%3DEph-ephrin%2520bidirectional%2520signaling%2520comes%2520into%2520the%2520context%2520of%2520lymphocyte%2520transendothelial%2520migration%26jtitle%3DCell%2520adhesion%2520%2526%2520migration%26date%3D2010%26volume%3D4%26spage%3D363%26epage%3D367%26doi%3D10.4161%2Fcam.4.3.11586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alonso-C, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trinidad, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Garcillan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballesteros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellanos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotillo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapata, A. G.</span></span> <span> </span><span class="NLM_article-title">Expression profile of Eph receptors and ephrin ligands in healthy human B lymphocytes and chronic lymphocytic leukemia B-cells</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2008.08.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.leukres.2008.08.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=18819711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVCru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2009&pages=395-406&author=L.+M.+Alonso-Cauthor=E.+M.+Trinidadauthor=B.+de+Garcillanauthor=M.+Ballesterosauthor=M.+Castellanosauthor=I.+Cotilloauthor=J.+J.+Munozauthor=A.+G.+Zapata&title=Expression+profile+of+Eph+receptors+and+ephrin+ligands+in+healthy+human+B+lymphocytes+and+chronic+lymphocytic+leukemia+B-cells&doi=10.1016%2Fj.leukres.2008.08.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Expression profile of Eph receptors and ephrin ligands in healthy human B lymphocytes and chronic lymphocytic leukemia B-cells</span></div><div class="casAuthors">Alonso-C, Luis M.; Trinidad, Eva M.; de Garcillan, Beatriz; Ballesteros, Monica; Castellanos, Milagros; Cotillo, Ignacio; Munoz, Juan J.; Zapata, Agustin G.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">395-406</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Increasing information relates some Eph receptors and their ligands, ephrins (EFN), with the immune system.  Herein, the authors found that normal B-cells from peripheral blood (PB) and lymph nodes (LN) showed a differential expression of certain Eph/EFN members, some of them being modulated upon in vitro stimulation including EFNA1, EFNA4, EphB6 and EphA10.  In contrast, PB CLL B-cells showed a more heterogeneous Eph/EFN profile than their normal PB B-cell counterparts, expressing Eph/EFN members frequently found within the LN and activated B-cells, specially EFNA4, EphB6 and EphA10.  Two of them, EphB6 and EFNA4 were further related with the clin. course of CLL patients.  EphB6 expression correlated with a high content of ZAP-70 mRNA and a poor prognosis.  High serum levels of a sol. EFNA4 isoform pos. correlated with increasing peripheral blood lymphocyte counts and lymphadenopathy.  These findings suggest that Eph/EFN might be relevant in normal B-cell biol. and could represent new potential prognostic markers and therapeutic targets for CLL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6iDfF_JHxlrVg90H21EOLACvtfcHk0lgQpA3W6lf-Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVCru7Y%253D&md5=20a4a9faa8ceffeb5fdfd71f052a5e7b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2008.08.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2008.08.010%26sid%3Dliteratum%253Aachs%26aulast%3DAlonso-C%26aufirst%3DL.%2BM.%26aulast%3DTrinidad%26aufirst%3DE.%2BM.%26aulast%3Dde%2BGarcillan%26aufirst%3DB.%26aulast%3DBallesteros%26aufirst%3DM.%26aulast%3DCastellanos%26aufirst%3DM.%26aulast%3DCotillo%26aufirst%3DI.%26aulast%3DMunoz%26aufirst%3DJ.%2BJ.%26aulast%3DZapata%26aufirst%3DA.%2BG.%26atitle%3DExpression%2520profile%2520of%2520Eph%2520receptors%2520and%2520ephrin%2520ligands%2520in%2520healthy%2520human%2520B%2520lymphocytes%2520and%2520chronic%2520lymphocytic%2520leukemia%2520B-cells%26jtitle%3DLeuk.%2520Res.%26date%3D2009%26volume%3D33%26spage%3D395%26epage%3D406%26doi%3D10.1016%2Fj.leukres.2008.08.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span> <span> </span><span class="NLM_article-title">Copy number variations of EphA3 are associated with multiple types of hematologic malignancies</span>. <i>Clinical lymphoma, myeloma & leukemia</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.3816/CLML.2011.n.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.3816%2FCLML.2011.n.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=50-53&author=M.+Guanauthor=L.+Liuauthor=X.+Zhaoauthor=Q.+Wuauthor=B.+Yuauthor=Y.+Shaoauthor=H.+Yangauthor=X.+Fuauthor=J.+Wanauthor=W.+Zhang&title=Copy+number+variations+of+EphA3+are+associated+with+multiple+types+of+hematologic+malignancies&doi=10.3816%2FCLML.2011.n.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.3816%2FCLML.2011.n.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3816%252FCLML.2011.n.006%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DShao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DFu%26aufirst%3DX.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26atitle%3DCopy%2520number%2520variations%2520of%2520EphA3%2520are%2520associated%2520with%2520multiple%2520types%2520of%2520hematologic%2520malignancies%26jtitle%3DClinical%2520lymphoma%252C%2520myeloma%2520%2526%2520leukemia%26date%3D2011%26volume%3D11%26spage%3D50%26epage%3D53%26doi%3D10.3816%2FCLML.2011.n.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myshkin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tochtrop, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharya, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKerell, A. D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficker, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span> <span> </span><span class="NLM_article-title">A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e42120</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0042120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1371%2Fjournal.pone.0042120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=22916121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ejtbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e42120&author=A.+Pettyauthor=E.+Myshkinauthor=H.+Qinauthor=H.+Guoauthor=H.+Miaoauthor=G.+P.+Tochtropauthor=J.+T.+Hsiehauthor=P.+Pageauthor=L.+Liuauthor=D.+J.+Lindnerauthor=C.+Acharyaauthor=A.+D.+MacKerellauthor=E.+Fickerauthor=J.+Songauthor=B.+Wang&title=A+small+molecule+agonist+of+EphA2+receptor+tyrosine+kinase+inhibits+tumor+cell+migration+in+vitro+and+prostate+cancer+metastasis+in+vivo&doi=10.1371%2Fjournal.pone.0042120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo</span></div><div class="casAuthors">Petty, Aaron; Myshkin, Eugene; Qin, Haina; Guo, Hong; Miao, Hui; Tochtrop, Gregory P.; Hsieh, Jer-Tsong; Page, Phillip; Liu, Lili; Lindner, Daniel J.; Acharya, Chayan; MacKerell, Alexander D., Jr.; Ficker, Eckhard; Song, Jianxing; Wang, Bingcheng</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e42120</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">During tumor progression, EphA2 receptor can gain ligand-independent pro-oncogenic functions due to Akt activation and reduced ephrin-A ligand engagement.  The effects can be reversed by ligand stimulation, which triggers the intrinsic tumor suppressive signaling pathways of EphA2 including inhibition of PI3/Akt and Ras/ERK pathways.  These observations argue for development of small mol. agonists for EphA2 as potential tumor intervention agents.  Through virtual screening and cell-based assays, we report here the identification and characterization of doxazosin as a novel small mol. agonist for EphA2 and EphA4, but not for other Eph receptors tested.  NMR studies revealed extensive contacts of doxazosin with EphA2/A4, recapitulating both hydrophobic and electrostatic interactions recently found in the EphA2/ephrin-A1 complex.  Clin. used as an α1-adrenoreceptor antagonist (Cardura) for treating hypertension and benign prostate hyperplasia, doxazosin activated EphA2 independent of α1-adrenoreceptor.  Similar to ephrin-A1, doxazosin inhibited Akt and ERK kinase activities in an EphA2-dependent manner.  Treatment with doxazosin triggered EphA2 receptor internalization and suppressed haptotactic and chemotactic migration of prostate cancer, breast cancer and glioma cells.  Moreover, in an orthotopic xenograft model, doxazosin reduced distal metastasis of human prostate cancer cells and prolonged survival in recipient mice.  To our knowledge, doxazosin is the first small mol. agonist of a receptor tyrosine kinase that is capable of inhibiting malignant behaviors in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlr0BOi0YQT7Vg90H21EOLACvtfcHk0lj_cFu9vSp98w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ejtbrI&md5=10df3aa4d684e10d4b6135370973466e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0042120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0042120%26sid%3Dliteratum%253Aachs%26aulast%3DPetty%26aufirst%3DA.%26aulast%3DMyshkin%26aufirst%3DE.%26aulast%3DQin%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DMiao%26aufirst%3DH.%26aulast%3DTochtrop%26aufirst%3DG.%2BP.%26aulast%3DHsieh%26aufirst%3DJ.%2BT.%26aulast%3DPage%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLindner%26aufirst%3DD.%2BJ.%26aulast%3DAcharya%26aufirst%3DC.%26aulast%3DMacKerell%26aufirst%3DA.%2BD.%26aulast%3DFicker%26aufirst%3DE.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DB.%26atitle%3DA%2520small%2520molecule%2520agonist%2520of%2520EphA2%2520receptor%2520tyrosine%2520kinase%2520inhibits%2520tumor%2520cell%2520migration%2520in%2520vitro%2520and%2520prostate%2520cancer%2520metastasis%2520in%2520vivo%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De42120%26doi%3D10.1371%2Fjournal.pone.0042120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuwano, H.</span></span> <span> </span><span class="NLM_article-title">Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">605</span>– <span class="NLM_lpage">611</span>, <span class="refDoi"> DOI: 10.3892/or.11.3.605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.3892%2For.11.3.605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=14767510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitVartLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=605-611&author=T.+Saitoauthor=N.+Masudaauthor=T.+Miyazakiauthor=K.+Kanohauthor=H.+Suzukiauthor=T.+Shimuraauthor=T.+Asaoauthor=H.+Kuwano&title=Expression+of+EphA2+and+E-cadherin+in+colorectal+cancer%3A+correlation+with+cancer+metastasis&doi=10.3892%2For.11.3.605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis</span></div><div class="casAuthors">Saito, Tetsuya; Masuda, Norihiro; Miyazaki, Tatsuya; Kanoh, Kenichi; Suzuki, Hideki; Shimura, Tatsuo; Asao, Takayuki; Kuwano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">605-611</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1021-335X</span>.
    
            (<span class="NLM_cas:orgname">Oncology Reports</span>)
        </div><div class="casAbstract">Recently, overexpression of EphA2, a member of the Eph family of receptor tyrosine kinases, was reported in several cancers.  Reduced expression of E-cadherin, an intercellular adhesion mol. of epithelial cells, was reported to be assocd. with aggressive clinicopathol. phenotypes in various cancers.  In epithelial cells, EphA2 and E-cadherin co-localize to sites of cell-cell contact, and it was shown that E-cadherin regulates EphA2.  This study aimed to clarify the relationship between the expression of the EphA2 and E-cadherin proteins and clinicopathol. characteristics, with ref. to the expression levels of both EphA2 and E-cadherin, in patients with colorectal cancer.  The authors performed immunohistochem. staining of EphA2 and E-cadherin with EphA2 and E-cadherin monoclonal antibodies in samples from 194 primary lesions of colorectal cancer.  The expression level of EphA2 had a statistically significant relationship with liver metastasis, lymphatic vessel invasion and clin. stage (p = 0.0477, 0.0316 and 0.0467, resp.).  In addn., the positivity rate of EphA2 was significantly higher in primary lesions with lymph node metastasis than in those without metastasis (p = 0.0014).  However, the expression level of E-cadherin had an inverse relationship with both differentiation level of the tumor and lymphatic vessel invasion (p = 0.0430 and 0.0320, resp.).  Furthermore, a significant relationship between the expression of EphA2 and E-cadherin was obsd.  In conclusion, the authors' study revealed that the overexpression of EphA2 protein in colorectal carcinoma tissue correlates closely with cancer progression and hematogenous and lymphogenous metastasis, suggesting that both EphA2 and E-cadherin may play an important role in tumor metastasis in colorectal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGJ5UMgSywObVg90H21EOLACvtfcHk0lj_cFu9vSp98w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitVartLk%253D&md5=9befcd19834fabcb412ce3e38206ad0d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3892%2For.11.3.605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.11.3.605%26sid%3Dliteratum%253Aachs%26aulast%3DSaito%26aufirst%3DT.%26aulast%3DMasuda%26aufirst%3DN.%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DKanoh%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DH.%26aulast%3DShimura%26aufirst%3DT.%26aulast%3DAsao%26aufirst%3DT.%26aulast%3DKuwano%26aufirst%3DH.%26atitle%3DExpression%2520of%2520EphA2%2520and%2520E-cadherin%2520in%2520colorectal%2520cancer%253A%2520correlation%2520with%2520cancer%2520metastasis%26jtitle%3DOncol.%2520Rep.%26date%3D2004%26volume%3D11%26spage%3D605%26epage%3D611%26doi%3D10.3892%2For.11.3.605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taddei, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelucci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onnis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannoni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raugei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calorini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rucci, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bologna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarugi, P.</span></span> <span> </span><span class="NLM_article-title">Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">1492</span>– <span class="NLM_lpage">1503</span>, <span class="refDoi"> DOI: 10.2353/ajpath.2009.080473</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.2353%2Fajpath.2009.080473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=19264906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVOku7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2009&pages=1492-1503&author=M.+L.+Taddeiauthor=M.+Parriauthor=A.+Angelucciauthor=B.+Onnisauthor=F.+Bianchiniauthor=E.+Giannoniauthor=G.+Raugeiauthor=L.+Caloriniauthor=N.+Rucciauthor=A.+Tetiauthor=M.+Bolognaauthor=P.+Chiarugi&title=Kinase-dependent+and+-independent+roles+of+EphA2+in+the+regulation+of+prostate+cancer+invasion+and+metastasis&doi=10.2353%2Fajpath.2009.080473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis</span></div><div class="casAuthors">Taddei, Maria Letizia; Parri, Matteo; Angelucci, Adriano; Onnis, Barbara; Bianchini, Francesca; Giannoni, Elisa; Raugei, Giovanni; Calorini, Lido; Rucci, Nadia; Teti, Anna; Bologna, Maura; Chiarugi, Paola</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1492-1503</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Ligand-activated Eph tyrosine kinases regulate cellular repulsion, morphol., adhesion, and motility.  EphA2 kinase is frequently up-regulated in several different types of cancers, including prostate, breast, colon, and lung carcinomas, as well as in melanoma.  The existing data do not clarify whether EphA2 receptor phosphorylation or its simple overexpression, which likely leads to Eph kinase-independent responses, plays a role in the progression of malignant prostate cancer.  In this study, we address the role of EphA2 tyrosine phosphorylation in prostate carcinoma cell adhesion, motility, invasion, and formation of metastases.  Tumor cells expressing kinase-deficient EphA2 mutants, as well as an EphA2 variant lacking the cytoplasmic domain, are defective in ephrinA1-mediated cell rounding, retraction fiber formation, de-adhesion from the extracellular matrix, RhoA and Rac1 GTPase regulation, three-dimensional matrix invasion, and in vivo metastasis, suggesting a key role for EphA2 kinase activity.  Nevertheless, EphA2 regulation of cell motility and invasion, as well as the formation of bone and visceral tumor colonies, reveals a component of both EphA2 kinase-dependent and -independent features.  These results uncover a differential requirement for EphA2 kinase activity in the regulation of prostate carcinoma metastasis outcome, suggesting that although the kinase activity of EphA2 is required for the regulation of cell adhesion and cytoskeletal rearrangement, some distinct kinase-dependent and -independent pathways likely cooperate to drive cancer cell migration, invasion, and metastasis outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSqcUiLk3JZrVg90H21EOLACvtfcHk0lh-a077Brf0Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVOku7o%253D&md5=6ea11c43509901cde0a8df2621ec444b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2353%2Fajpath.2009.080473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2353%252Fajpath.2009.080473%26sid%3Dliteratum%253Aachs%26aulast%3DTaddei%26aufirst%3DM.%2BL.%26aulast%3DParri%26aufirst%3DM.%26aulast%3DAngelucci%26aufirst%3DA.%26aulast%3DOnnis%26aufirst%3DB.%26aulast%3DBianchini%26aufirst%3DF.%26aulast%3DGiannoni%26aufirst%3DE.%26aulast%3DRaugei%26aufirst%3DG.%26aulast%3DCalorini%26aufirst%3DL.%26aulast%3DRucci%26aufirst%3DN.%26aulast%3DTeti%26aufirst%3DA.%26aulast%3DBologna%26aufirst%3DM.%26aulast%3DChiarugi%26aufirst%3DP.%26atitle%3DKinase-dependent%2520and%2520-independent%2520roles%2520of%2520EphA2%2520in%2520the%2520regulation%2520of%2520prostate%2520cancer%2520invasion%2520and%2520metastasis%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2009%26volume%3D174%26spage%3D1492%26epage%3D1503%26doi%3D10.2353%2Fajpath.2009.080473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brantley-Sieders, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">7859</span>– <span class="NLM_lpage">7868</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1208937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1038%2Fsj.onc.1208937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=16103880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1GisLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=7859-7868&author=W.+B.+Fangauthor=D.+M.+Brantley-Siedersauthor=M.+A.+Parkerauthor=A.+D.+Reithauthor=J.+Chen&title=A+kinase-dependent+role+for+EphA2+receptor+in+promoting+tumor+growth+and+metastasis&doi=10.1038%2Fsj.onc.1208937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis</span></div><div class="casAuthors">Fang, Wei Bin; Brantley-Sieders, Dana M.; Parker, Monica A.; Reith, Alastair D.; Chen, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">53</span>),
    <span class="NLM_cas:pages">7859-7868</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Receptor tyrosine kinases of the Eph family are upregulated in several different types of cancer.  One family member in particular, the EphA2 receptor, has been linked to breast, prostate, lung and colon cancer, as well as melanoma.  However, mechanisms by which EphA2 contributes to tumor progression are far from clear.  In certain tumor cell lines, EphA2 receptor is underphosphorylated, raising the question of whether ligand-induced receptor phosphorylation and its kinase activity play a role in oncogenesis.  To test directly the role of EphA2 receptor phosphorylation/kinase activity in tumor progression, we generated EphA2 receptor variants that were either lacking the cytoplasmic domain or carrying a point mutation that inhibits its kinase activity.  Expression of these EphA2 mutants in breast cancer cells resulted in decreased tumor vol. and increased tumor apoptosis in primary tumors.  In addn., the nos. of lung metastases were significantly reduced in both exptl. and spontaneous metastasis models.  Reduced tumor vol. and metastasis are not due to defects in tumor angiogenesis, as there is no significant difference in tumor vessel d. between wild-type tumors and tumors expressing EphA2-signaling-defective mutants.  In contrast, tumor cells expressing the EphA2 mutants are defective in RhoA GTPase activation and cell migration.  Taken together, these results suggest that receptor phosphorylation and kinase activity of the EphA2 receptor, at least in part, contribute to tumor malignancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqT7wm3lqIt7Vg90H21EOLACvtfcHk0lh-a077Brf0Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1GisLrL&md5=ca391f6cd90a39642ab2112f6eaa6bd2</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1208937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1208937%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DW.%2BB.%26aulast%3DBrantley-Sieders%26aufirst%3DD.%2BM.%26aulast%3DParker%26aufirst%3DM.%2BA.%26aulast%3DReith%26aufirst%3DA.%2BD.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DA%2520kinase-dependent%2520role%2520for%2520EphA2%2520receptor%2520in%2520promoting%2520tumor%2520growth%2520and%2520metastasis%26jtitle%3DOncogene%26date%3D2005%26volume%3D24%26spage%3D7859%26epage%3D7868%26doi%3D10.1038%2Fsj.onc.1208937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gooya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinneer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazenbaker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swamynathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coats, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiener, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, D. A.</span></span> <span> </span><span class="NLM_article-title">A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">9367</span>– <span class="NLM_lpage">9374</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-1933</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1158%2F0008-5472.CAN-08-1933" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=19010911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9367-9374&author=D.+Jacksonauthor=J.+Gooyaauthor=S.+Maoauthor=K.+Kinneerauthor=L.+Xuauthor=M.+Camaraauthor=C.+Fazenbakerauthor=R.+Flemingauthor=S.+Swamynathanauthor=D.+Meyerauthor=P.+D.+Senterauthor=C.+Gaoauthor=H.+Wuauthor=M.+Kinchauthor=S.+Coatsauthor=P.+A.+Kienerauthor=D.+A.+Tice&title=A+human+antibody-drug+conjugate+targeting+EphA2+inhibits+tumor+growth+in+vivo&doi=10.1158%2F0008-5472.CAN-08-1933"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A Human Antibody-Drug Conjugate Targeting EphA2 Inhibits Tumor Growth In vivo</span></div><div class="casAuthors">Jackson, Dowdy; Gooya, John; Mao, Shenlan; Kinneer, Krista; Xu, Linda; Camara, Margarita; Fazenbaker, Christine; Fleming, Ryan; Swamynathan, Sudha; Meyer, Damon; Senter, Peter D.; Gao, Changshou; Wu, Herren; Kinch, Michael; Coats, Steven; Kiener, Peter A.; Tice, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9367-9374</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The EphA2 receptor tyrosine kinase is selectively expressed on the surface of many different human tumors.  We have previously shown that tumor cells can be targeted by EphA2 monoclonal antibodies and that these antibodies function, in part, by inducing EphA2 internalization and degrdn.  In this report, we describe the isolation and characterization of a fully human monoclonal antibody (1C1) that selectively binds both the human and rodent EphA2 receptor.  After cell binding, the antibody induces rapid tyrosine phosphorylation, internalization, and degrdn. of the EphA2 receptor.  Because monoclonal antibodies that selectively bind tumor cells and internalize provide a vehicle for targeted delivery of cytotoxics, 1C1 was conjugated to the microtubule inhibitor monomethylauristatin phenylalanine using a stable maleimidocaproyl linker.  The anti-EphA2 antibody-drug conjugate [1C1-maleimidocaproyl-MMAF (mcMMAF)] stimulated the activation of caspase-3/caspase-7 and the death of EphA2-expressing cells with IC50 values as low as 3 ng/mL.  Similarly, the conjugate induced degrdn. of the EphA2 receptor and inhibited tumor growth in vivo.  Administration of 1C1-mcMMAF at doses as low as 1 mg/kg once weekly resulted in significant growth inhibition of EphA2-expressing tumors without any observable adverse effects in mouse xenograft and rat syngeneic tumor models.  Our data support the use of an antibody-drug conjugate approach to selectively target and inhibit the growth of EphA2-expressing tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC1fbfPqDzS7Vg90H21EOLACvtfcHk0lh-a077Brf0Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7vK&md5=1e17e48422e5fc318773fd1de578ac16</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1933%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DD.%26aulast%3DGooya%26aufirst%3DJ.%26aulast%3DMao%26aufirst%3DS.%26aulast%3DKinneer%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DCamara%26aufirst%3DM.%26aulast%3DFazenbaker%26aufirst%3DC.%26aulast%3DFleming%26aufirst%3DR.%26aulast%3DSwamynathan%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DD.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DKinch%26aufirst%3DM.%26aulast%3DCoats%26aufirst%3DS.%26aulast%3DKiener%26aufirst%3DP.%2BA.%26aulast%3DTice%26aufirst%3DD.%2BA.%26atitle%3DA%2520human%2520antibody-drug%2520conjugate%2520targeting%2520EphA2%2520inhibits%2520tumor%2520growth%2520in%2520vivo%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D9367%26epage%3D9374%26doi%3D10.1158%2F0008-5472.CAN-08-1933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Annunziata, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohn, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LoRusso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buzoianu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robbie, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechleider, R.</span></span> <span> </span><span class="NLM_article-title">Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1007/s10637-012-9801-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1007%2Fs10637-012-9801-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=22370972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Ogs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=77-84&author=C.+M.+Annunziataauthor=E.+C.+Kohnauthor=P.+LoRussoauthor=N.+D.+Houstonauthor=R.+L.+Colemanauthor=M.+Buzoianuauthor=G.+Robbieauthor=R.+Lechleider&title=Phase+1%2C+open-label+study+of+MEDI-547+in+patients+with+relapsed+or+refractory+solid+tumors&doi=10.1007%2Fs10637-012-9801-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors</span></div><div class="casAuthors">Annunziata, Christina M.; Kohn, Elise C.; LoRusso, Patricia; Houston, Nicole D.; Coleman, Robert L.; Buzoianu, Manuela; Robbie, Gabriel; Lechleider, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-84</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Background: Targeting the cell-surface receptor EphA2, which is highly expressed in some solid tumors, is a novel approach for cancer therapy.  We aimed to evaluate the safety profile, max. tolerated dose (MTD), pharmacokinetics, and antitumor activity of MEDI-547, an antibody drug conjugate composed of the cytotoxic drug auristatin (toxin) linked to a human anti-EphA2 monoclonal antibody (1C1), in patients with solid tumors relapsed/refractory to std. therapy.  Methods: In this phase 1, open-label study with planned dose-escalation and dose-expansion cohorts, patients received a 1-h i.v. infusion of MEDI-547 (0.08 mg/kg) every 3 wk.  Results: Six patients received 0.08 mg/kg; all discontinued treatment.  Dose escalation was not pursued.  The study was stopped before cohort 2 enrollment due to treatment-related bleeding and coagulation events (hemorrhage-related, n = 3; epistaxis, n = 2).  Therefore, lower doses were not explored and an MTD could not be selected.  The most frequently reported treatment-related adverse events (AEs) were increased liver enzymes, decreased Hb, decreased appetite, and epistaxis.  Three patients (50%) experienced treatment-related serious AEs, including conjunctival hemorrhage, pain (led to study drug discontinuation), liver disorder, and hemorrhage.  Best response included progressive disease (n = 5; 83.3%) and stable disease (n = 1; 16.7%).  Minimal or no dissocn. of toxin from 1C1 conjugate occurred in the blood.  Serum MEDI-547 concns. decreased rapidly, ∼70% by 3 days post-dose.  No accumulation of MEDI-547 was obsd. at 0.08 mg/kg upon administration of a second dose 3 wk following dose 1.  Conclusions: The safety profile of MEDI-547 does not support further clin. investigation in patients with advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRCw89EUGfabVg90H21EOLACvtfcHk0li8JkILHZBhrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Ogs78%253D&md5=9af486f7c7287d8c150dade6baaf45b6</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1007%2Fs10637-012-9801-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-012-9801-2%26sid%3Dliteratum%253Aachs%26aulast%3DAnnunziata%26aufirst%3DC.%2BM.%26aulast%3DKohn%26aufirst%3DE.%2BC.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DHouston%26aufirst%3DN.%2BD.%26aulast%3DColeman%26aufirst%3DR.%2BL.%26aulast%3DBuzoianu%26aufirst%3DM.%26aulast%3DRobbie%26aufirst%3DG.%26aulast%3DLechleider%26aufirst%3DR.%26atitle%3DPhase%25201%252C%2520open-label%2520study%2520of%2520MEDI-547%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D77%26epage%3D84%26doi%3D10.1007%2Fs10637-012-9801-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koolpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dail, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span> <span> </span><span class="NLM_article-title">An ephrin mimetic peptide that selectively targets the EphA2 receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">46974</span>– <span class="NLM_lpage">46979</span>, <span class="refDoi"> DOI: 10.1074/jbc.M208495200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1074%2Fjbc.M208495200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=46974-46979&author=M.+Koolpeauthor=M.+Dailauthor=E.+B.+Pasquale&title=An+ephrin+mimetic+peptide+that+selectively+targets+the+EphA2+receptor&doi=10.1074%2Fjbc.M208495200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M208495200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M208495200%26sid%3Dliteratum%253Aachs%26aulast%3DKoolpe%26aufirst%3DM.%26aulast%3DDail%26aufirst%3DM.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26atitle%3DAn%2520ephrin%2520mimetic%2520peptide%2520that%2520selectively%2520targets%2520the%2520EphA2%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D46974%26epage%3D46979%26doi%3D10.1074%2Fjbc.M208495200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggineni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship analysis of peptides targeting the EphA2 receptor</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6687</span>– <span class="NLM_lpage">6695</span>, <span class="refDoi"> DOI: 10.1021/bi1006223</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi1006223" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVSmt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=6687-6695&author=S.+Mitraauthor=S.+Duggineniauthor=M.+Koolpeauthor=X.+Zhuauthor=Z.+Huangauthor=E.+B.+Pasquale&title=Structure-activity+relationship+analysis+of+peptides+targeting+the+EphA2+receptor&doi=10.1021%2Fbi1006223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship Analysis of Peptides Targeting the EphA2 Receptor</span></div><div class="casAuthors">Mitra, Sayantan; Duggineni, Srinivas; Koolpe, Mitchell; Zhu, Xuejun; Huang, Ziwei; Pasquale, Elena B.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">6687-6695</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The EphA2 receptor tyrosine kinase has emerged as a promising new therapeutic target in cancer because of its high level of expression in tumors.  EphA2-specific antibodies have been used to deliver drugs and toxins to tumor cells, leading to inhibition of tumor growth and metastatic dissemination.  The authors previously identified two related peptides, YSA and SWL, that selectively bind to the ligand-binding domain of EphA2 but not other Eph receptors and could therefore be useful as selective targeting agents.  Here the authors characterize the two peptides and a series of derivs.  On the basis of systematic amino acid replacements, only five YSA residues appear to be crit. for high-affinity receptor binding.  Furthermore, a peptide comprising only the first five residues of YSA retains selectivity for EphA2.  Similar to ephrin-A1, the physiol. ligand for EphA2, both YSA and SWL activate EphA2 and inhibit downstream oncogenic signaling pathways in PC3 cancer cells.  The two peptides and derivs. are quite stable in conditioned cell culture medium and show promise for delivering drugs and as imaging agents to EphA2-expressing tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHmJrdhjP9w7Vg90H21EOLACvtfcHk0li8JkILHZBhrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVSmt7o%253D&md5=a542f4e46d5f65a6abb6268dc53fd7d4</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fbi1006223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi1006223%26sid%3Dliteratum%253Aachs%26aulast%3DMitra%26aufirst%3DS.%26aulast%3DDuggineni%26aufirst%3DS.%26aulast%3DKoolpe%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26atitle%3DStructure-activity%2520relationship%2520analysis%2520of%2520peptides%2520targeting%2520the%2520EphA2%2520receptor%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D6687%26epage%3D6695%26doi%3D10.1021%2Fbi1006223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Placzek, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noberini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koolpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2427</span>– <span class="NLM_lpage">2436</span>, <span class="refDoi"> DOI: 10.1021/jm201743s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201743s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFequ7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2427-2436&author=S.+Wangauthor=W.+J.+Placzekauthor=J.+L.+Stebbinsauthor=S.+Mitraauthor=R.+Noberiniauthor=M.+Koolpeauthor=Z.+Zhangauthor=R.+Dahlauthor=E.+B.+Pasqualeauthor=M.+Pellecchia&title=Novel+targeted+system+to+deliver+chemotherapeutic+drugs+to+EphA2-expressing+cancer+cells&doi=10.1021%2Fjm201743s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Targeted System To Deliver Chemotherapeutic Drugs to EphA2-Expressing Cancer Cells</span></div><div class="casAuthors">Wang, Si; Placzek, William J.; Stebbins, John L.; Mitra, Sayantan; Noberini, Roberta; Koolpe, Mitchell; Zhang, Ziming; Dahl, Russell; Pasquale, Elena B.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2427-2436</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The efficacy of anticancer drugs is often limited by their systemic toxicities and adverse side effects.  We report that the EphA2 receptor is overexpressed preferentially in several human cancer cell lines compared to normal tissues and that an EphA2 targeting peptide (YSAYPDSVPMMS) can be effective in delivering anticancer agents to such tumors.  Hence, we report on the synthesis and characterizations of a novel EphA2-targeting agent conjugated with the chemotherapeutic drug paclitaxel.  We found that the peptide-drug conjugate is dramatically more effective than paclitaxel alone at inhibiting tumor growth in a prostate cancer xenograft model, delivering significantly higher levels of drug to the tumor site.  We believe these studies open the way to the development of a new class of therapeutic compds. that exploit the EphA2 receptor for drug delivery to cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1Pu5ES26uUrVg90H21EOLACvtfcHk0lgG-e41qu4Htw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFequ7k%253D&md5=3835d4051c60b26e126da69b9b7510ca</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm201743s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201743s%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DPlaczek%26aufirst%3DW.%2BJ.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DMitra%26aufirst%3DS.%26aulast%3DNoberini%26aufirst%3DR.%26aulast%3DKoolpe%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DNovel%2520targeted%2520system%2520to%2520deliver%2520chemotherapeutic%2520drugs%2520to%2520EphA2-expressing%2520cancer%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2427%26epage%3D2436%26doi%3D10.1021%2Fjm201743s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noberini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billet, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhowmick, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Targeted delivery of paclitaxel to EphA2-expressing cancer cells</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">128</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-2654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1158%2F1078-0432.CCR-12-2654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=23155185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFGitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=128-137&author=S.+Wangauthor=R.+Noberiniauthor=J.+L.+Stebbinsauthor=S.+Dasauthor=Z.+Zhangauthor=B.+Wuauthor=S.+Mitraauthor=S.+Billetauthor=A.+Fernandezauthor=N.+A.+Bhowmickauthor=S.+Kitadaauthor=E.+B.+Pasqualeauthor=P.+B.+Fisherauthor=M.+Pellecchia&title=Targeted+delivery+of+paclitaxel+to+EphA2-expressing+cancer+cells&doi=10.1158%2F1078-0432.CCR-12-2654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Delivery of Paclitaxel to EphA2-Expressing Cancer Cells</span></div><div class="casAuthors">Wang, Si; Noberini, Roberta; Stebbins, John L.; Das, Swadesh; Zhang, Ziming; Wu, Bainan; Mitra, Sayantan; Billet, Sandrine; Fernandez, Ana; Bhowmick, Neil A.; Kitada, Shinichi; Pasquale, Elena B.; Fisher, Paul B.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-137</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: YSA is an EphA2-targeting peptide that effectively delivers anticancer agents to prostate cancer tumors.  Here, we report on how we increased the drug-like properties of this delivery system.  Exptl. Design: By introducing non-natural amino acids, we have designed two new EphA2 targeting peptides: YNH, where norleucine and homoserine replace the two methionine residues of YSA, and dYNH, where a D-tyrosine replaces the L-tyrosine at the first position of the YNH peptide.  We describe the details of the synthesis of YNH and dYNH paclitaxel conjugates (YNH-PTX and dYNH-PTX) and their characterization in cells and in vivo.  Results: dYNH-PTX showed improved stability in mouse serum and significantly reduced tumor size in a prostate cancer xenograft model and also reduced tumor vasculature in a syngeneic orthotopic allograft mouse model of renal cancer compared with vehicle or paclitaxel treatments.  Conclusion: This study reveals that targeting EphA2 with dYNH drug conjugates could represent an effective way to deliver anticancer agents to a variety of tumor types.  Clin Cancer Res; 19(1); 128-37. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM9wK1ey90VLVg90H21EOLACvtfcHk0lgG-e41qu4Htw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFGitQ%253D%253D&md5=9d11d8f57028d5245b0d344652ef311e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2654%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DNoberini%26aufirst%3DR.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DMitra%26aufirst%3DS.%26aulast%3DBillet%26aufirst%3DS.%26aulast%3DFernandez%26aufirst%3DA.%26aulast%3DBhowmick%26aufirst%3DN.%2BA.%26aulast%3DKitada%26aufirst%3DS.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DTargeted%2520delivery%2520of%2520paclitaxel%2520to%2520EphA2-expressing%2520cancer%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D128%26epage%3D137%26doi%3D10.1158%2F1078-0432.CCR-12-2654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barile, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noberini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1403</span>– <span class="NLM_lpage">1412</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201400067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1002%2Fcmdc.201400067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=24677792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVKitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1403-1412&author=E.+Barileauthor=S.+Wangauthor=S.+K.+Dasauthor=R.+Noberiniauthor=R.+Dahlauthor=J.+L.+Stebbinsauthor=E.+B.+Pasqualeauthor=P.+B.+Fisherauthor=M.+Pellecchia&title=Design%2C+synthesis+and+bioevaluation+of+an+EphA2+receptor-based+targeted+delivery+system&doi=10.1002%2Fcmdc.201400067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis and Bioevaluation of an EphA2 Receptor-Based Targeted Delivery System</span></div><div class="casAuthors">Barile, Elisa; Wang, Si; Das, Swadesh K.; Noberini, Roberta; Dahl, Russell; Stebbins, John L.; Pasquale, Elena B.; Fisher, Paul B.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1403-1412</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Because of its overexpression in a range of solid tumors, the EphA2 receptor is a validated target for cancer therapeutics.  The authors recently described a new targeted delivery system based on specific EphA2-targeting peptides conjugated with the chemotherapeutic agent paclitaxel.  Here, the chem. determinants responsible for the stability and degrdn. of these agents in plasma were investigated.  Introducing modifications in both the peptide and the linker between the peptide and paclitaxel resulted in drug conjugates that are both long-lived in rat plasma and that markedly decrease tumor size in a prostate cancer xenograft model compared with paclitaxel alone treatment.  These studies identify crit. rate-limiting degrdn. sites on the peptide-drug conjugates, enabling the design of agents with increased stability and efficacy.  These results provide support for the central hypothesis that peptide-drug conjugates targeting EphA2 represent an innovative and potentially effective strategy to selectively deliver cytotoxic drugs to cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0PtVZMIpXmrVg90H21EOLACvtfcHk0lgZOy9yFcO_eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVKitrk%253D&md5=4b83eea1d0ea2ee884f003e7565eb65f</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201400067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201400067%26sid%3Dliteratum%253Aachs%26aulast%3DBarile%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DDas%26aufirst%3DS.%2BK.%26aulast%3DNoberini%26aufirst%3DR.%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DDesign%252C%2520synthesis%2520and%2520bioevaluation%2520of%2520an%2520EphA2%2520receptor-based%2520targeted%2520delivery%2520system%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D1403%26epage%3D1412%26doi%3D10.1002%2Fcmdc.201400067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barile, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zharkikh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purves, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshima, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Design and characterization of novel EphA2 agonists for targeted delivery of chemotherapy to cancer Cells</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">887</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2015.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.chembiol.2015.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=26165155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCqtbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=876-887&author=B.+Wuauthor=S.+Wangauthor=S.+K.+Deauthor=E.+Barileauthor=B.+A.+Quinnauthor=I.+Zharkikhauthor=A.+Purvesauthor=J.+L.+Stebbinsauthor=R.+G.+Oshimaauthor=P.+B.+Fisherauthor=M.+Pellecchia&title=Design+and+characterization+of+novel+EphA2+agonists+for+targeted+delivery+of+chemotherapy+to+cancer+Cells&doi=10.1016%2Fj.chembiol.2015.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells</span></div><div class="casAuthors">Wu, Bainan; Wang, Si; De, Surya K.; Barile, Elisa; Quinn, Bridget A.; Zharkikh, Irina; Purves, Angela; Stebbins, John L.; Oshima, Robert G.; Fisher, Paul B.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">876-887</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The development of novel, targeted delivery agents for anti-cancer therapies requires the design and optimization of potent and selective tumor-targeting agents that are stable and amenable to conjugation with chemotherapeutic drugs.  While short peptides represent potentially an excellent platform for these purposes, they often get degraded and are eliminated too rapidly in vivo.  In this study, we used a combination of NMR-guided structure-activity relationships along with biochem. and cellular studies to derive a novel tumor-homing agent, named 123B9, targeting the EphA2 tyrosine kinase receptor ligand-binding domain.  Conjugating 123B9 to the chemotherapeutic drug paclitaxel (PTX) via a stable linker results in an agent that is significantly more effective than the unconjugated drug in both a pancreatic cancer xenograft model and a melanoma lung colonization and metastases model.  Hence, 123B9 could represent a promising strategy for the development of novel targeted therapies for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5FFEE4-jdhLVg90H21EOLACvtfcHk0lgZOy9yFcO_eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCqtbbM&md5=5bd8b17e5b9bac6ce74e54cd1049d4b9</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2015.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2015.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DDe%26aufirst%3DS.%2BK.%26aulast%3DBarile%26aufirst%3DE.%26aulast%3DQuinn%26aufirst%3DB.%2BA.%26aulast%3DZharkikh%26aufirst%3DI.%26aulast%3DPurves%26aufirst%3DA.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DOshima%26aufirst%3DR.%2BG.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DDesign%2520and%2520characterization%2520of%2520novel%2520EphA2%2520agonists%2520for%2520targeted%2520delivery%2520of%2520chemotherapy%2520to%2520cancer%2520Cells%26jtitle%3DChem.%2520Biol.%26date%3D2015%26volume%3D22%26spage%3D876%26epage%3D887%26doi%3D10.1016%2Fj.chembiol.2015.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barile, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emdad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morvaridi, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandol, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">17103</span>– <span class="NLM_lpage">17110</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.7931</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.18632%2Foncotarget.7931" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=26959746" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A280%3ADC%252BC28jotlGitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=17103-17110&author=B.+A.+Quinnauthor=S.+Wangauthor=E.+Barileauthor=S.+K.+Dasauthor=L.+Emdadauthor=D.+Sarkarauthor=S.+K.+Deauthor=S.+K.+Morvaridiauthor=J.+L.+Stebbinsauthor=S.+J.+Pandolauthor=P.+B.+Fisherauthor=M.+Pellecchia&title=Therapy+of+pancreatic+cancer+via+an+EphA2+receptor-targeted+delivery+of+gemcitabine&doi=10.18632%2Foncotarget.7931"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine</span></div><div class="casAuthors">Quinn Bridget A; Das Swadesh K; Emdad Luni; Sarkar Devanand; Fisher Paul B; Wang Si; Barile Elisa; De Surya K; Stebbins John L; Fisher Paul B; Pellecchia Maurizio; Barile Elisa; De Surya K; Pellecchia Maurizio; Morvaridi Susan Kharagh; Pandol Stephen J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">17103-10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">First line treatment for pancreatic cancer consists of surgical resection, if possible, and a subsequent course of chemotherapy using the nucleoside analogue gemcitabine.  In some patients, an active transport mechanism allows gemcitabine to enter efficiently into the tumor cells, resulting in a significant clinical benefit.  However, in most patients, low expression of gemcitabine transporters limits the efficacy of the drug to marginal levels, and patients need frequent administration of the drug at high doses, significantly increasing systemic drug toxicity.  In this article we focus on a novel targeted delivery approach for gemcitabine consisting of conjugating the drug with an EphA2 targeting agent.  We show that the EphA2 receptor is highly expressed in pancreatic cancers, and accordingly, the drug-conjugate is more effective than gemcitabine alone in targeting pancreatic tumors.  Our preliminary observations suggest that this approach may provide a general benefit to pancreatic cancer patients and offers a comprehensive strategy for enhancing delivery of diverse therapeutic agents to a wide range of cancers overexpressing EphA2, thereby potentially reducing toxicity while enhancing therapeutic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkle74R4yp-ekdrW1FkXG-fW6udTcc2eaPBeJRp3RwG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jotlGitA%253D%253D&md5=0b5e311729fc3517d90882844ab3d3f2</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.7931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.7931%26sid%3Dliteratum%253Aachs%26aulast%3DQuinn%26aufirst%3DB.%2BA.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DBarile%26aufirst%3DE.%26aulast%3DDas%26aufirst%3DS.%2BK.%26aulast%3DEmdad%26aufirst%3DL.%26aulast%3DSarkar%26aufirst%3DD.%26aulast%3DDe%26aufirst%3DS.%2BK.%26aulast%3DMorvaridi%26aufirst%3DS.%2BK.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DPandol%26aufirst%3DS.%2BJ.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DTherapy%2520of%2520pancreatic%2520cancer%2520via%2520an%2520EphA2%2520receptor-targeted%2520delivery%2520of%2520gemcitabine%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D17103%26epage%3D17110%26doi%3D10.18632%2Foncotarget.7931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jan, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ro, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisarska, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, H. R.</span></span> <span> </span><span class="NLM_article-title">Imprinted nanovelcro microchips for isolation and characterization of circulating fetal trophoblasts: toward non-invasive prenatal diagnostics</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">8167</span>– <span class="NLM_lpage">8177</span>, <span class="refDoi"> DOI: 10.1021/acsnano.7b03073</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.7b03073" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=8167-8177&author=S.+Houauthor=J.+F.+Chenauthor=M.+Songauthor=Y.+Zhuauthor=Y.+J.+Janauthor=S.+H.+Chenauthor=T.+H.+Wengauthor=D.+A.+Lingauthor=S.+F.+Chenauthor=T.+Roauthor=A.+J.+Liangauthor=T.+Leeauthor=H.+Jinauthor=M.+Liauthor=L.+Liuauthor=Y.+S.+Hsiaoauthor=P.+Chenauthor=H.+H.+Yuauthor=M.+S.+Tsaiauthor=M.+D.+Pisarskaauthor=A.+Chenauthor=L.+C.+Chenauthor=H.+R.+Tseng&title=Imprinted+nanovelcro+microchips+for+isolation+and+characterization+of+circulating+fetal+trophoblasts%3A+toward+non-invasive+prenatal+diagnostics&doi=10.1021%2Facsnano.7b03073"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facsnano.7b03073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.7b03073%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%2BF.%26aulast%3DSong%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DJan%26aufirst%3DY.%2BJ.%26aulast%3DChen%26aufirst%3DS.%2BH.%26aulast%3DWeng%26aufirst%3DT.%2BH.%26aulast%3DLing%26aufirst%3DD.%2BA.%26aulast%3DChen%26aufirst%3DS.%2BF.%26aulast%3DRo%26aufirst%3DT.%26aulast%3DLiang%26aufirst%3DA.%2BJ.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DHsiao%26aufirst%3DY.%2BS.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DYu%26aufirst%3DH.%2BH.%26aulast%3DTsai%26aufirst%3DM.%2BS.%26aulast%3DPisarska%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DL.%2BC.%26aulast%3DTseng%26aufirst%3DH.%2BR.%26atitle%3DImprinted%2520nanovelcro%2520microchips%2520for%2520isolation%2520and%2520characterization%2520of%2520circulating%2520fetal%2520trophoblasts%253A%2520toward%2520non-invasive%2520prenatal%2520diagnostics%26jtitle%3DACS%2520Nano%26date%3D2017%26volume%3D11%26spage%3D8167%26epage%3D8177%26doi%3D10.1021%2Facsnano.7b03073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agopian, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posadas, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, H. R.</span></span> <span> </span><span class="NLM_article-title">Clinical applications of nanovelcro rare-cell assays for detection and characterization of circulating tumor cells</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1425</span>– <span class="NLM_lpage">1439</span>, <span class="refDoi"> DOI: 10.7150/thno.15359</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.7150%2Fthno.15359" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=27375790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC2sXns1Cisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=1425-1439&author=J.+F.+Chenauthor=Y.+Zhuauthor=Y.+T.+Luauthor=E.+Hodaraauthor=S.+Houauthor=V.+G.+Agopianauthor=J.+S.+Tomlinsonauthor=E.+M.+Posadasauthor=H.+R.+Tseng&title=Clinical+applications+of+nanovelcro+rare-cell+assays+for+detection+and+characterization+of+circulating+tumor+cells&doi=10.7150%2Fthno.15359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical applications of nanovelcro rare cell assays for detection and characterization of circulating tumor cells</span></div><div class="casAuthors">Chen, Jie-Fu; Zhu, Yazhen; Lu, Yi-Tsung; Hodara, Elisabeth; Hou, Shuang; Agopian, Vatche G.; Tomlinson, James S.; Posadas, Edwin M.; Tseng, Hsian-Rong</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1425-1439</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Liq. biopsy of tumor through isolation of circulating tumor cells (CTCs) allows non-invasive, repetitive, and systemic sampling of disease.  Although detecting and enumerating CTCs is of prognostic significance in metastatic cancer, it is conceivable that performing mol. and functional characterization on CTCs will reveal unprecedented insight into the pathogenic mechanisms driving lethal disease.  Nanomaterial-embedded cancer diagnostic platforms, i.e., NanoVelcro CTC Assays represent a unique rare-cell sorting method that enables detection isolation, and characterization of CTCs in peripheral blood, providing an opportunity to noninvasively monitor disease progression in individual cancer patients.  Over the past decade, a series of NanoVelcro CTC Assays has been demonstrated for exploring the full potential of CTCs as a clin. biomarker, including CTC enumeration, phenotyping, genotyping and expression profiling.  In this review article, the authors will briefly introduce the development of three generations of NanoVelcro CTC Assays, and highlight the clin. applications of each generation for various types of solid cancers, including prostate cancer, pancreatic cancer, lung cancer, and melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq14bqqVWPzDLVg90H21EOLACvtfcHk0ljAaBLU9Ne5IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXns1Cisr4%253D&md5=2476c77edf0dda57465fb899039a4b28</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.7150%2Fthno.15359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.15359%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%2BF.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%2BT.%26aulast%3DHodara%26aufirst%3DE.%26aulast%3DHou%26aufirst%3DS.%26aulast%3DAgopian%26aufirst%3DV.%2BG.%26aulast%3DTomlinson%26aufirst%3DJ.%2BS.%26aulast%3DPosadas%26aufirst%3DE.%2BM.%26aulast%3DTseng%26aufirst%3DH.%2BR.%26atitle%3DClinical%2520applications%2520of%2520nanovelcro%2520rare-cell%2520assays%2520for%2520detection%2520and%2520characterization%2520of%2520circulating%2520tumor%2520cells%26jtitle%3DTheranostics%26date%3D2016%26volume%3D6%26spage%3D1425%26epage%3D1439%26doi%3D10.7150%2Fthno.15359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarioglu, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aceto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kojic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donaldson, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeinali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamza, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engstrom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaresan, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittner, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaswamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shioda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ting, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maheswaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toner, M.</span></span> <span> </span><span class="NLM_article-title">A microfluidic device for label-free, physical capture of circulating tumor cell clusters</span>. <i>Nat. Methods</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">685</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1038/nmeth.3404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1038%2Fnmeth.3404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=25984697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFWqtbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=685-691&author=A.+F.+Sariogluauthor=N.+Acetoauthor=N.+Kojicauthor=M.+C.+Donaldsonauthor=M.+Zeinaliauthor=B.+Hamzaauthor=A.+Engstromauthor=H.+Zhuauthor=T.+K.+Sundaresanauthor=D.+T.+Miyamotoauthor=X.+Luoauthor=A.+Bardiaauthor=B.+S.+Wittnerauthor=S.+Ramaswamyauthor=T.+Shiodaauthor=D.+T.+Tingauthor=S.+L.+Stottauthor=R.+Kapurauthor=S.+Maheswaranauthor=D.+A.+Haberauthor=M.+Toner&title=A+microfluidic+device+for+label-free%2C+physical+capture+of+circulating+tumor+cell+clusters&doi=10.1038%2Fnmeth.3404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A microfluidic device for label-free, physical capture of circulating tumor cell clusters</span></div><div class="casAuthors">Sarioglu, A. Fatih; Aceto, Nicola; Kojic, Nikola; Donaldson, Maria C.; Zeinali, Mahnaz; Hamza, Bashar; Engstrom, Amanda; Zhu, Huili; Sundaresan, Tilak K.; Miyamoto, David T.; Luo, Xi; Bardia, Aditya; Wittner, Ben S.; Ramaswamy, Sridhar; Shioda, Toshi; Ting, David T.; Stott, Shannon L.; Kapur, Ravi; Maheswaran, Shyamala; Haber, Daniel A.; Toner, Mehmet</div><div class="citationInfo"><span class="NLM_cas:title">Nature Methods</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">685-691</span>CODEN:
                <span class="NLM_cas:coden">NMAEA3</span>;
        ISSN:<span class="NLM_cas:issn">1548-7091</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer cells metastasize through the bloodstream either as single migratory circulating tumor cells (CTCs) or as multicellular groupings (CTC clusters).  Existing technologies for CTC enrichment are designed to isolate single CTCs, and although CTC clusters are detectable in some cases, their true prevalence and significance remain to be detd.  Here we developed a microchip technol. (the Cluster-Chip) to capture CTC clusters independently of tumor-specific markers from unprocessed blood.  CTC clusters are isolated through specialized bifurcating traps under low-shear stress conditions that preserve their integrity, and even two-cell clusters are captured efficiently.  Using the Cluster-Chip, we identified CTC clusters in 30-40% of patients with metastatic breast or prostate cancer or with melanoma.  RNA sequencing of CTC clusters confirmed their tumor origin and identified tissue-derived macrophages within the clusters.  Efficient capture of CTC clusters will enable the detailed characterization of their biol. properties and role in metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZETw8HzHH_bVg90H21EOLACvtfcHk0ljAaBLU9Ne5IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFWqtbbE&md5=6ce523882376f88875f506e33cb04b22</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnmeth.3404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmeth.3404%26sid%3Dliteratum%253Aachs%26aulast%3DSarioglu%26aufirst%3DA.%2BF.%26aulast%3DAceto%26aufirst%3DN.%26aulast%3DKojic%26aufirst%3DN.%26aulast%3DDonaldson%26aufirst%3DM.%2BC.%26aulast%3DZeinali%26aufirst%3DM.%26aulast%3DHamza%26aufirst%3DB.%26aulast%3DEngstrom%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DSundaresan%26aufirst%3DT.%2BK.%26aulast%3DMiyamoto%26aufirst%3DD.%2BT.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DBardia%26aufirst%3DA.%26aulast%3DWittner%26aufirst%3DB.%2BS.%26aulast%3DRamaswamy%26aufirst%3DS.%26aulast%3DShioda%26aufirst%3DT.%26aulast%3DTing%26aufirst%3DD.%2BT.%26aulast%3DStott%26aufirst%3DS.%2BL.%26aulast%3DKapur%26aufirst%3DR.%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DToner%26aufirst%3DM.%26atitle%3DA%2520microfluidic%2520device%2520for%2520label-free%252C%2520physical%2520capture%2520of%2520circulating%2520tumor%2520cell%2520clusters%26jtitle%3DNat.%2520Methods%26date%3D2015%26volume%3D12%26spage%3D685%26epage%3D691%26doi%3D10.1038%2Fnmeth.3404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Au, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storey, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javaid, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarioglu, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madden, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Keefe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maheswaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langenau, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toner, M.</span></span> <span> </span><span class="NLM_article-title">Clusters of circulating tumor cells traverse capillary-sized vessels</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">4947</span>– <span class="NLM_lpage">4952</span>, <span class="refDoi"> DOI: 10.1073/pnas.1524448113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1073%2Fpnas.1524448113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=27091969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmt1Shurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=4947-4952&author=S.+H.+Auauthor=B.+D.+Storeyauthor=J.+C.+Mooreauthor=Q.+Tangauthor=Y.+L.+Chenauthor=S.+Javaidauthor=A.+F.+Sariogluauthor=R.+Sullivanauthor=M.+W.+Maddenauthor=R.+O%E2%80%99Keefeauthor=D.+A.+Haberauthor=S.+Maheswaranauthor=D.+M.+Langenauauthor=S.+L.+Stottauthor=M.+Toner&title=Clusters+of+circulating+tumor+cells+traverse+capillary-sized+vessels&doi=10.1073%2Fpnas.1524448113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Clusters of circulating tumor cells traverse capillary-sized vessels</span></div><div class="casAuthors">Au, Sam H.; Storey, Brian D.; Moore, John C.; Tang, Qin; Chen, Yeng-Long; Javaid, Sarah; Sarioglu, A. Fatih; Sullivan, Ryan; Madden, Marissa W.; O'Keefe, Ryan; Haber, Daniel A.; Maheswaran, Shyamala; Langenau, David M.; Stott, Shannon L.; Toner, Mehmet</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4947-4952</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Multicellular aggregates of circulating tumor cells (CTC clusters) are potent initiators of distant organ metastasis.  However, it is currently assumed that CTC clusters are too large to pass through narrow vessels to reach these organs.  Here, we present evidence that challenges this assumption through the use of microfluidic devices designed to mimic human capillary constrictions and CTC clusters obtained from patient and cancer cell origins.  Over 90% of clusters contg. up to 20 cells successfully traversed 5- to 10-μm constrictions even in whole blood.  Clusters rapidly and reversibly reorganized into single-file chain-like geometries that substantially reduced their hydrodynamic resistances.  Xenotransplantation of human CTC clusters into zebrafish showed similar reorganization and transit through capillary-sized vessels in vivo.  Preliminary expts. demonstrated that clusters could be disrupted during transit using drugs that affected cellular interaction energies.  These findings suggest that CTC clusters may contribute a greater role to tumor dissemination than previously believed and may point to strategies for combating CTC cluster-initiated metastasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXe_FYTSq_U7Vg90H21EOLACvtfcHk0ljsd7dsInaH0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmt1Shurs%253D&md5=574c93c923954fcd660b8e6474864a68</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1524448113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1524448113%26sid%3Dliteratum%253Aachs%26aulast%3DAu%26aufirst%3DS.%2BH.%26aulast%3DStorey%26aufirst%3DB.%2BD.%26aulast%3DMoore%26aufirst%3DJ.%2BC.%26aulast%3DTang%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DY.%2BL.%26aulast%3DJavaid%26aufirst%3DS.%26aulast%3DSarioglu%26aufirst%3DA.%2BF.%26aulast%3DSullivan%26aufirst%3DR.%26aulast%3DMadden%26aufirst%3DM.%2BW.%26aulast%3DO%25E2%2580%2599Keefe%26aufirst%3DR.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DLangenau%26aufirst%3DD.%2BM.%26aulast%3DStott%26aufirst%3DS.%2BL.%26aulast%3DToner%26aufirst%3DM.%26atitle%3DClusters%2520of%2520circulating%2520tumor%2520cells%2520traverse%2520capillary-sized%2520vessels%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3D4947%26epage%3D4952%26doi%3D10.1073%2Fpnas.1524448113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giorgio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Incerti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corrado, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiodelli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callegari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferlenghi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballabeni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barocelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognolini, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2017.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.bcp.2017.11.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2018&pages=21-29&author=C.+Giorgioauthor=M.+Incertiauthor=M.+Corradoauthor=M.+Rusnatiauthor=P.+Chiodelliauthor=S.+Russoauthor=D.+Callegariauthor=F.+Ferlenghiauthor=V.+Ballabeniauthor=E.+Barocelliauthor=A.+Lodolaauthor=M.+Tognolini&title=Pharmacological+evaluation+of+new+bioavailable+small+molecules+targeting+Eph%2Fephrin+interaction&doi=10.1016%2Fj.bcp.2017.11.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2017.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2017.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DGiorgio%26aufirst%3DC.%26aulast%3DIncerti%26aufirst%3DM.%26aulast%3DCorrado%26aufirst%3DM.%26aulast%3DRusnati%26aufirst%3DM.%26aulast%3DChiodelli%26aufirst%3DP.%26aulast%3DRusso%26aufirst%3DS.%26aulast%3DCallegari%26aufirst%3DD.%26aulast%3DFerlenghi%26aufirst%3DF.%26aulast%3DBallabeni%26aufirst%3DV.%26aulast%3DBarocelli%26aufirst%3DE.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DTognolini%26aufirst%3DM.%26atitle%3DPharmacological%2520evaluation%2520of%2520new%2520bioavailable%2520small%2520molecules%2520targeting%2520Eph%252Fephrin%2520interaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2018%26volume%3D147%26spage%3D21%26epage%3D29%26doi%3D10.1016%2Fj.bcp.2017.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Petty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idippily, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobba, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geldenhuys, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of small molecule agonists of EphA2 receptor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">1261</span>– <span class="NLM_lpage">1276</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.10.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.ejmech.2017.10.026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=1261-1276&author=A.+Pettyauthor=N.+Idippilyauthor=V.+Bobbaauthor=W.+J.+Geldenhuysauthor=B.+Zhongauthor=B.+Suauthor=B.+Wang&title=Design+and+synthesis+of+small+molecule+agonists+of+EphA2+receptor&doi=10.1016%2Fj.ejmech.2017.10.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DPetty%26aufirst%3DA.%26aulast%3DIdippily%26aufirst%3DN.%26aulast%3DBobba%26aufirst%3DV.%26aulast%3DGeldenhuys%26aufirst%3DW.%2BJ.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DSu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DB.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520small%2520molecule%2520agonists%2520of%2520EphA2%2520receptor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D1261%26epage%3D1276%26doi%3D10.1016%2Fj.ejmech.2017.10.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hassan-Mohamed, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Incerti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanotti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barocelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognolini, M.</span></span> <span> </span><span class="NLM_article-title">UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">5195</span>– <span class="NLM_lpage">5208</span>, <span class="refDoi"> DOI: 10.1111/bph.12669</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1111%2Fbph.12669" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=24597515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVamt7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2014&pages=5195-5208&author=I.+Hassan-Mohamedauthor=C.+Giorgioauthor=M.+Incertiauthor=S.+Russoauthor=D.+Palaauthor=E.+B.+Pasqualeauthor=I.+Zanottiauthor=P.+Viciniauthor=E.+Barocelliauthor=S.+Rivaraauthor=M.+Morauthor=A.+Lodolaauthor=M.+Tognolini&title=UniPR129+is+a+competitive+small+molecule+Eph-ephrin+antagonist+blocking+in+vitro+angiogenesis+at+low+micromolar+concentrations&doi=10.1111%2Fbph.12669"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations</span></div><div class="casAuthors">Hassan-Mohamed, I.; Giorgio, C.; Incerti, M.; Russo, S.; Pala, D.; Pasquale, E. B.; Zanotti, I.; Vicini, P.; Barocelli, E.; Rivara, S.; Mor, M.; Lodola, A.; Tognolini, M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5195-5208</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : The Eph receptor tyrosine kinases and their ephrin ligands are key players in tumorigenesis and many reports have correlated changes in their expression with a poor clin. prognosis in many solid tumors.  Agents targeting the Eph-ephrin system might emerge as new tools useful for the inhibition of different components of cancer progression.  Even if different classes of small mols. targeting Eph-ephrin interactions have been reported, their use is hampered by poor chem. stability and low potency.  Stable and potent ligands are crucial to achieve robust pharmacol. performance.  Exptl. Approach : UniPR129 (the L-homo-Trp conjugate of lithocholic acid) was designed by means of computational methods, synthesized and tested for its ability to inhibit the interaction between the EphA2 receptor and the ephrin-A1 ligand in an elisa binding study.  The ability of UniPR129 to disrupt EphA2-ephrin-A1 interaction was functionally evaluated in a prostate adenocarcinoma cell line and its anti-angiogenic effect was tested in vitro using cultures of HUVECs.  Key Results : UniPR129 disrupted EphA2-ephrin-A1 interaction with Ki = 370 nM in an elisa binding assay and with low micromolar potency in cellular functional assays, including inhibition of EphA2 activation, inhibition of PC3 cell rounding and disruption of in vitro angiogenesis, without cytotoxic effects.  Conclusions and Implications : The discovery of UniPR129 represents not only a major advance in potency compared with the existing Eph-ephrin antagonists but also an improvement in terms of cytotoxicity, making this mol. a useful pharmacol. tool and a promising lead compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjj_0wPmI-9rVg90H21EOLACvtfcHk0lj3ByGlfxQ3rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVamt7bF&md5=941a213e381fa47f61573fc654661956</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Fbph.12669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12669%26sid%3Dliteratum%253Aachs%26aulast%3DHassan-Mohamed%26aufirst%3DI.%26aulast%3DGiorgio%26aufirst%3DC.%26aulast%3DIncerti%26aufirst%3DM.%26aulast%3DRusso%26aufirst%3DS.%26aulast%3DPala%26aufirst%3DD.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DZanotti%26aufirst%3DI.%26aulast%3DVicini%26aufirst%3DP.%26aulast%3DBarocelli%26aufirst%3DE.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DTognolini%26aufirst%3DM.%26atitle%3DUniPR129%2520is%2520a%2520competitive%2520small%2520molecule%2520Eph-ephrin%2520antagonist%2520blocking%2520in%2520vitro%2520angiogenesis%2520at%2520low%2520micromolar%2520concentrations%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D171%26spage%3D5195%26epage%3D5208%26doi%3D10.1111%2Fbph.12669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tognolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Incerti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan-Mohamed, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodola, A.</span></span> <span> </span><span class="NLM_article-title">Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201300305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1002%2Fcmdc.201300305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=24115725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2nsL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=67-72&author=M.+Tognoliniauthor=M.+Incertiauthor=D.+Palaauthor=S.+Russoauthor=R.+Castelliauthor=I.+Hassan-Mohamedauthor=C.+Giorgioauthor=A.+Lodola&title=Target+hopping+as+a+useful+tool+for+the+identification+of+novel+EphA2+protein-protein+antagonists&doi=10.1002%2Fcmdc.201300305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein-Protein Antagonists</span></div><div class="casAuthors">Tognolini, Massimiliano; Incerti, Matteo; Pala, Daniele; Russo, Simonetta; Castelli, Riccardo; Hassan-Mohamed, Iftiin; Giorgio, Carmine; Lodola, Alessio</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-72</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The target hopping approach was used to identify novel EphA2 protein-protein interaction inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTnb61cln51bVg90H21EOLACvtfcHk0lj3ByGlfxQ3rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2nsL7L&md5=ff9f51ec9a4c0a04dfb860a64c5949fe</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300305%26sid%3Dliteratum%253Aachs%26aulast%3DTognolini%26aufirst%3DM.%26aulast%3DIncerti%26aufirst%3DM.%26aulast%3DPala%26aufirst%3DD.%26aulast%3DRusso%26aufirst%3DS.%26aulast%3DCastelli%26aufirst%3DR.%26aulast%3DHassan-Mohamed%26aufirst%3DI.%26aulast%3DGiorgio%26aufirst%3DC.%26aulast%3DLodola%26aufirst%3DA.%26atitle%3DTarget%2520hopping%2520as%2520a%2520useful%2520tool%2520for%2520the%2520identification%2520of%2520novel%2520EphA2%2520protein-protein%2520antagonists%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D67%26epage%3D72%26doi%3D10.1002%2Fcmdc.201300305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulinich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salem, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barile, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethell, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Potent and selective EphA4 agonists for the treatment of ALS</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.chembiol.2017.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=28196613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisF2isLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=293-305&author=B.+Wuauthor=S.+K.+Deauthor=A.+Kulinichauthor=A.+F.+Salemauthor=J.+Koeppenauthor=R.+Wangauthor=E.+Barileauthor=S.+Wangauthor=D.+Zhangauthor=I.+Ethellauthor=M.+Pellecchia&title=Potent+and+selective+EphA4+agonists+for+the+treatment+of+ALS&doi=10.1016%2Fj.chembiol.2017.01.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and Selective EphA4 Agonists for the Treatment of ALS</span></div><div class="casAuthors">Wu, Bainan; De, Surya K.; Kulinich, Anna; Salem, Ahmed F.; Koeppen, Jordan; Wang, Rengang; Barile, Elisa; Wang, Si; Zhang, Dongxiang; Ethell, Iryna; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">293-305</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Amyotrophic lateral sclerosis (ALS) is a progressive degenerative disease that affects motor neurons.  Recent studies identified the receptor tyrosine kinase EphA4 as a disease-modifying gene that is crit. for the progression of motor neuron degeneration.  We report on the design and characterization of a family of EphA4 targeting agents that bind to its ligand binding domain with nanomolar affinity.  The mols. exhibit excellent selectivity and display efficacy in a SOD1 mutant mouse model of ALS.  Interestingly, the mols. appear to act as agonists for the receptor in certain surrogate cellular assays.  While the exact mechanisms responsible for the therapeutic effect of the new agonists remain to be elucidated, we believe that the described agent represents both an invaluable pharmacol. tool to further decipher the role of the EphA4 in ALS and potentially other human diseases, and a significant stepping stone for the development of novel treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpuO9wvkH8jLVg90H21EOLACvtfcHk0lj3ByGlfxQ3rA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisF2isLw%253D&md5=4701fc563841cf233e9e8c8ac7c256f7</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DB.%26aulast%3DDe%26aufirst%3DS.%2BK.%26aulast%3DKulinich%26aufirst%3DA.%26aulast%3DSalem%26aufirst%3DA.%2BF.%26aulast%3DKoeppen%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DBarile%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DEthell%26aufirst%3DI.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DPotent%2520and%2520selective%2520EphA4%2520agonists%2520for%2520the%2520treatment%2520of%2520ALS%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2017%26volume%3D24%26spage%3D293%26epage%3D305%26doi%3D10.1016%2Fj.chembiol.2017.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barile, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purves, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">High-Throughput Screening by nuclear magnetic resonance (HTS by NMR) for the identification of PPIs antagonists</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2032</span>– <span class="NLM_lpage">2042</span>, <span class="refDoi"> DOI: 10.2174/1568026615666150519102459</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.2174%2F1568026615666150519102459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=25986689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFKrsbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=2032-2042&author=B.+Wuauthor=E.+Barileauthor=S.+K.+Deauthor=J.+Weiauthor=A.+Purvesauthor=M.+Pellecchia&title=High-Throughput+Screening+by+nuclear+magnetic+resonance+%28HTS+by+NMR%29+for+the+identification+of+PPIs+antagonists&doi=10.2174%2F1568026615666150519102459"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">High-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs Antagonists</span></div><div class="casAuthors">Wu, Bainan; Barile, Elisa; De, Surya K.; Wei, Jun; Purves, Angela; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2032-2042</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In recent years the ever so complex field of drug discovery has embraced novel design strategies based on biophys. fragment screening (fragment-based drug design; FBDD) using NMR spectroscopy (NMR) and/or structure-guided approaches, most often using X-ray crystallog. and computer modeling.  Experience from recent years unveiled that these methods are more effective and less prone to artifacts compared to biochem. high-throughput screening (HTS) of large collection of compds. in designing protein inhibitors.  Hence these strategies are increasingly becoming the most utilized in the modern pharmaceutical industry.  Nonetheless, there is still an impending need to develop innovative and effective strategies to tackle other more challenging targets such as those involving protein-protein interactions (PPIs).  While HTS strategies notoriously fail to identify viable hits against such targets, few successful examples of PPIs antagonists derived by FBDD strategies exist.  Recently, we reported on a new strategy that combines some of the basic principles of fragment-based screening with combinatorial chem. and NMR-based screening.  The approach, termed HTS by NMR, combines the advantages of combinatorial chem. and NMR-based screening to rapidly and unambiguously identify bona fide inhibitors of PPIs.  This review will reiterate the crit. aspects of the approach with examples of possible applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkGSp-cBTsYbVg90H21EOLACvtfcHk0lgBHWOPid6nwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFKrsbnN&md5=85549ba32660d4907ffc8b30e36956ee</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.2174%2F1568026615666150519102459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026615666150519102459%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DB.%26aulast%3DBarile%26aufirst%3DE.%26aulast%3DDe%26aufirst%3DS.%2BK.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DPurves%26aufirst%3DA.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DHigh-Throughput%2520Screening%2520by%2520nuclear%2520magnetic%2520resonance%2520%2528HTS%2520by%2520NMR%2529%2520for%2520the%2520identification%2520of%2520PPIs%2520antagonists%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2015%26volume%3D15%26spage%3D2032%26epage%3D2042%26doi%3D10.2174%2F1568026615666150519102459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noberini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barile, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giulianotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinilla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghten, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">HTS by NMR of combinatorial libraries: a fragment-based approach to ligand discovery</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">33</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2012.10.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.chembiol.2012.10.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=23352136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1ems7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=19-33&author=B.+Wuauthor=Z.+Zhangauthor=R.+Noberiniauthor=E.+Barileauthor=M.+Giulianottiauthor=C.+Pinillaauthor=R.+A.+Houghtenauthor=E.+B.+Pasqualeauthor=M.+Pellecchia&title=HTS+by+NMR+of+combinatorial+libraries%3A+a+fragment-based+approach+to+ligand+discovery&doi=10.1016%2Fj.chembiol.2012.10.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">HTS by NMR of Combinatorial Libraries: A Fragment-Based Approach to Ligand Discovery</span></div><div class="casAuthors">Wu, Bainan; Zhang, Ziming; Noberini, Roberta; Barile, Elisa; Giulianotti, Marc; Pinilla, Clemencia; Houghten, Richard A.; Pasquale, Elena B.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-33</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Fragment-based ligand design (FBLD) approaches have become more widely used in drug discovery projects from both academia and industry, and are even often preferred to traditional high-throughput screening (HTS) of large collection of compds. (>105).  A key advantage of FBLD approaches is that these often rely on robust biophys. methods such as NMR spectroscopy for detection of ligand binding, hence are less prone to artifacts that too often plague the results from HTS campaigns.  In this article, we introduce a screening strategy that takes advantage of both the robustness of protein NMR spectroscopy as the detection method, and the basic principles of combinatorial chem. to enable the screening of large libraries of fragments (>105 compds.) preassembled on a common backbone.  We used the method to identify compds. that target protein-protein interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqurl4asdOJGrVg90H21EOLACvtfcHk0lgBHWOPid6nwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1ems7s%253D&md5=0e6be57be59243913c34178cf10a2329</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.10.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.10.015%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DNoberini%26aufirst%3DR.%26aulast%3DBarile%26aufirst%3DE.%26aulast%3DGiulianotti%26aufirst%3DM.%26aulast%3DPinilla%26aufirst%3DC.%26aulast%3DHoughten%26aufirst%3DR.%2BA.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DHTS%2520by%2520NMR%2520of%2520combinatorial%2520libraries%253A%2520a%2520fragment-based%2520approach%2520to%2520ligand%2520discovery%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D19%26epage%3D33%26doi%3D10.1016%2Fj.chembiol.2012.10.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Incerti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan-Mohamed, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noberini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vicini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piersanti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barocelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodola, A.</span></span> <span> </span><span class="NLM_article-title">Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2936</span>– <span class="NLM_lpage">2947</span>, <span class="refDoi"> DOI: 10.1021/jm301890k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301890k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2936-2947&author=M.+Incertiauthor=M.+Tognoliniauthor=S.+Russoauthor=D.+Palaauthor=C.+Giorgioauthor=I.+Hassan-Mohamedauthor=R.+Noberiniauthor=E.+B.+Pasqualeauthor=P.+Viciniauthor=S.+Piersantiauthor=S.+Rivaraauthor=E.+Barocelliauthor=M.+Morauthor=A.+Lodola&title=Amino+acid+conjugates+of+lithocholic+acid+as+antagonists+of+the+EphA2+receptor&doi=10.1021%2Fjm301890k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm301890k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301890k%26sid%3Dliteratum%253Aachs%26aulast%3DIncerti%26aufirst%3DM.%26aulast%3DTognolini%26aufirst%3DM.%26aulast%3DRusso%26aufirst%3DS.%26aulast%3DPala%26aufirst%3DD.%26aulast%3DGiorgio%26aufirst%3DC.%26aulast%3DHassan-Mohamed%26aufirst%3DI.%26aulast%3DNoberini%26aufirst%3DR.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DVicini%26aufirst%3DP.%26aulast%3DPiersanti%26aufirst%3DS.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DBarocelli%26aufirst%3DE.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DLodola%26aufirst%3DA.%26atitle%3DAmino%2520acid%2520conjugates%2520of%2520lithocholic%2520acid%2520as%2520antagonists%2520of%2520the%2520EphA2%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2936%26epage%3D2947%26doi%3D10.1021%2Fjm301890k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tognolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacondio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Incerti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callegari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giorgio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan-Mohamed, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanotti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugatti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnati, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Festuccia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barocelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodola, A.</span></span> <span> </span><span class="NLM_article-title">Delta(5)-cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">312</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.08.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.ejmech.2015.08.048" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2015&pages=312-324&author=R.+Castelliauthor=M.+Tognoliniauthor=F.+Vacondioauthor=M.+Incertiauthor=D.+Palaauthor=D.+Callegariauthor=S.+Bertoniauthor=C.+Giorgioauthor=I.+Hassan-Mohamedauthor=I.+Zanottiauthor=A.+Bugattiauthor=M.+Rusnatiauthor=C.+Festucciaauthor=S.+Rivaraauthor=E.+Barocelliauthor=M.+Morauthor=A.+Lodola&title=Delta%285%29-cholenoyl-amino+acids+as+selective+and+orally+available+antagonists+of+the+Eph-ephrin+system&doi=10.1016%2Fj.ejmech.2015.08.048"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.08.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.08.048%26sid%3Dliteratum%253Aachs%26aulast%3DCastelli%26aufirst%3DR.%26aulast%3DTognolini%26aufirst%3DM.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DIncerti%26aufirst%3DM.%26aulast%3DPala%26aufirst%3DD.%26aulast%3DCallegari%26aufirst%3DD.%26aulast%3DBertoni%26aufirst%3DS.%26aulast%3DGiorgio%26aufirst%3DC.%26aulast%3DHassan-Mohamed%26aufirst%3DI.%26aulast%3DZanotti%26aufirst%3DI.%26aulast%3DBugatti%26aufirst%3DA.%26aulast%3DRusnati%26aufirst%3DM.%26aulast%3DFestuccia%26aufirst%3DC.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DBarocelli%26aufirst%3DE.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DLodola%26aufirst%3DA.%26atitle%3DDelta%25285%2529-cholenoyl-amino%2520acids%2520as%2520selective%2520and%2520orally%2520available%2520antagonists%2520of%2520the%2520Eph-ephrin%2520system%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D103%26spage%3D312%26epage%3D324%26doi%3D10.1016%2Fj.ejmech.2015.08.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barile, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zharkikh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purves, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oshima, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pellecchia, M.</span></span> <span> </span><span class="NLM_article-title">Design and characterization of novel EphA2 agonists for targeted delivery of chemotherapy to cancer cells</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">887</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2015.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.chembiol.2015.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=26165155" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCqtbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=876-887&author=B.+Wuauthor=S.+Wangauthor=S.+K.+Deauthor=E.+Barileauthor=B.+A.+Quinnauthor=I.+Zharkikhauthor=A.+Purvesauthor=J.+L.+Stebbinsauthor=R.+G.+Oshimaauthor=P.+B.+Fisherauthor=M.+Pellecchia&title=Design+and+characterization+of+novel+EphA2+agonists+for+targeted+delivery+of+chemotherapy+to+cancer+cells&doi=10.1016%2Fj.chembiol.2015.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells</span></div><div class="casAuthors">Wu, Bainan; Wang, Si; De, Surya K.; Barile, Elisa; Quinn, Bridget A.; Zharkikh, Irina; Purves, Angela; Stebbins, John L.; Oshima, Robert G.; Fisher, Paul B.; Pellecchia, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">876-887</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The development of novel, targeted delivery agents for anti-cancer therapies requires the design and optimization of potent and selective tumor-targeting agents that are stable and amenable to conjugation with chemotherapeutic drugs.  While short peptides represent potentially an excellent platform for these purposes, they often get degraded and are eliminated too rapidly in vivo.  In this study, we used a combination of NMR-guided structure-activity relationships along with biochem. and cellular studies to derive a novel tumor-homing agent, named 123B9, targeting the EphA2 tyrosine kinase receptor ligand-binding domain.  Conjugating 123B9 to the chemotherapeutic drug paclitaxel (PTX) via a stable linker results in an agent that is significantly more effective than the unconjugated drug in both a pancreatic cancer xenograft model and a melanoma lung colonization and metastases model.  Hence, 123B9 could represent a promising strategy for the development of novel targeted therapies for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5FFEE4-jdhLVg90H21EOLACvtfcHk0li-ytZ4aj2cHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCqtbbM&md5=5bd8b17e5b9bac6ce74e54cd1049d4b9</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2015.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2015.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DDe%26aufirst%3DS.%2BK.%26aulast%3DBarile%26aufirst%3DE.%26aulast%3DQuinn%26aufirst%3DB.%2BA.%26aulast%3DZharkikh%26aufirst%3DI.%26aulast%3DPurves%26aufirst%3DA.%26aulast%3DStebbins%26aufirst%3DJ.%2BL.%26aulast%3DOshima%26aufirst%3DR.%2BG.%26aulast%3DFisher%26aufirst%3DP.%2BB.%26aulast%3DPellecchia%26aufirst%3DM.%26atitle%3DDesign%2520and%2520characterization%2520of%2520novel%2520EphA2%2520agonists%2520for%2520targeted%2520delivery%2520of%2520chemotherapy%2520to%2520cancer%2520cells%26jtitle%3DChem.%2520Biol.%26date%3D2015%26volume%3D22%26spage%3D876%26epage%3D887%26doi%3D10.1016%2Fj.chembiol.2015.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duggineni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamberto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquale, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of potent bivalent peptide agonists targeting the EphA2 receptor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">344</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1021/ml3004523</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml3004523" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitFajur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=344-348&author=S.+Duggineniauthor=S.+Mitraauthor=I.+Lambertoauthor=X.+Hanauthor=Y.+Xuauthor=J.+Anauthor=E.+B.+Pasqualeauthor=Z.+Huang&title=Design+and+synthesis+of+potent+bivalent+peptide+agonists+targeting+the+EphA2+receptor&doi=10.1021%2Fml3004523"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Potent Bivalent Peptide Agonists Targeting the EphA2 Receptor</span></div><div class="casAuthors">Duggineni, Srinivas; Mitra, Sayantan; Lamberto, Ilaria; Han, Xiaofeng; Xu, Yan; An, Jing; Pasquale, Elena B.; Huang, Ziwei</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">344-348</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Designing potent and selective peptides and small mols. that target Eph receptor tyrosine kinases remains a challenge, and new strategies are needed for developing novel and potent ligands for these receptors.  In this study, we performed a structure-activity relationship study of a previously identified 12 amino acid-long peptide, SWL, by alanine scanning to identify residues important for receptor binding.  To further enhance and optimize the receptor binding affinity of the SWL peptide, we applied the concept of bivalent ligand design to synthesize several SWL-derived dimeric peptides as novel ligands capable of binding simultaneously to two EphA2 receptor mols.  The dimeric peptides possess higher receptor binding affinity than the original monomeric SWL peptide, consistent with bivalent binding.  The most potent dimeric peptide, a SWL dimer with a six-carbon linker, has about 13-fold increased potency as compared to SWL.  Furthermore, similar to SWL, the dimeric peptide is an agonist and can promote EphA2 tyrosine phosphorylation (activation) in cultured cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5CfG69V9xzLVg90H21EOLACvtfcHk0li-ytZ4aj2cHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitFajur4%253D&md5=cfde81669466bc1ce0733c0816baf7c9</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fml3004523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml3004523%26sid%3Dliteratum%253Aachs%26aulast%3DDuggineni%26aufirst%3DS.%26aulast%3DMitra%26aufirst%3DS.%26aulast%3DLamberto%26aufirst%3DI.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DAn%26aufirst%3DJ.%26aulast%3DPasquale%26aufirst%3DE.%2BB.%26aulast%3DHuang%26aufirst%3DZ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520potent%2520bivalent%2520peptide%2520agonists%2520targeting%2520the%2520EphA2%2520receptor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D344%26epage%3D348%26doi%3D10.1021%2Fml3004523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldrich, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maisonpierre, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lhotak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldfarb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yancopoulos, G. D.</span></span> <span> </span><span class="NLM_article-title">Ligands for eph-related receptor tyrosine kinases that require membrane attachment or clustering for activity</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>266</i></span>,  <span class="NLM_fpage">816</span>– <span class="NLM_lpage">819</span>, <span class="refDoi"> DOI: 10.1126/science.7973638</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1126%2Fscience.7973638" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=7973638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADyaK2MXitVGgt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=266&publication_year=1994&pages=816-819&author=S.+Davisauthor=N.+W.+Galeauthor=T.+H.+Aldrichauthor=P.+C.+Maisonpierreauthor=V.+Lhotakauthor=T.+Pawsonauthor=M.+Goldfarbauthor=G.+D.+Yancopoulos&title=Ligands+for+eph-related+receptor+tyrosine+kinases+that+require+membrane+attachment+or+clustering+for+activity&doi=10.1126%2Fscience.7973638"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity</span></div><div class="casAuthors">Davis, Samuel; Gale, Nicholas W.; Aldrich, Thomas H.; Maisonpierre, Peter C.; Lhotak, Vladimir; Pawson, Tony; Goldfarb, Mitchell; Yancopoulos, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">266</span>
        (<span class="NLM_cas:issue">5186</span>),
    <span class="NLM_cas:pages">816-19</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The EPH-related transmembrane tyrosine kinases constitute the largest known family of receptor-like tyrosine kinases, with many members displaying specific patterns of expression in the developing and adult nervous system.  A three cell surface-bound ligands (B61, EHK1-L, and ELK-L) exhibiting distinct, but overlapping, specificities for these EPH-related kinases as well as tissue distribution were identified, cloned and sequenced.  These ligands were unable to act as conventional sol. factors.  However, they did function when presented in membrane-bound form, suggesting that they require direct cell-to-cell contact to activate their receptors.  Membrane attachment may serve to facilitate ligand dimerization or aggregation, because antibody-mediated clustering activated previously inactive sol. forms of these ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXYS_jRbSuUrVg90H21EOLACvtfcHk0li-ytZ4aj2cHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXitVGgt7s%253D&md5=702b337e26b15fd7b411d54b78d014b3</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1126%2Fscience.7973638&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.7973638%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DS.%26aulast%3DGale%26aufirst%3DN.%2BW.%26aulast%3DAldrich%26aufirst%3DT.%2BH.%26aulast%3DMaisonpierre%26aufirst%3DP.%2BC.%26aulast%3DLhotak%26aufirst%3DV.%26aulast%3DPawson%26aufirst%3DT.%26aulast%3DGoldfarb%26aufirst%3DM.%26aulast%3DYancopoulos%26aufirst%3DG.%2BD.%26atitle%3DLigands%2520for%2520eph-related%2520receptor%2520tyrosine%2520kinases%2520that%2520require%2520membrane%2520attachment%2520or%2520clustering%2520for%2520activity%26jtitle%3DScience%26date%3D1994%26volume%3D266%26spage%3D816%26epage%3D819%26doi%3D10.1126%2Fscience.7973638" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bakrania, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Variya, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S. S.</span></span> <span> </span><span class="NLM_article-title">Novel targets for paclitaxel nano formulations: hopes and hypes in triple negative breast cancer</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">591</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.07.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.phrs.2016.07.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=27461138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ygsrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=577-591&author=A.+K.+Bakraniaauthor=B.+C.+Variyaauthor=S.+S.+Patel&title=Novel+targets+for+paclitaxel+nano+formulations%3A+hopes+and+hypes+in+triple+negative+breast+cancer&doi=10.1016%2Fj.phrs.2016.07.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer</span></div><div class="casAuthors">Bakrania, Anita K.; Variya, Bhavesh C.; Patel, Snehal S.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">577-591</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Triple neg. breast cancer is defined as one of the utmost prevailing breast cancers worldwide, possessing an inadequate prognosis and treatment option limited to chemotherapy and radiotherapy, creating a challenge for researchers as far as developing a specific targeted therapy is concerned.  The past research era has shown several promising outcomes for TNBC such as nano-formulations of the chemotherapeutic agents already used for the management of the malignant tumor.  Taking a glance at paclitaxel nano formulations, it has been proven beneficial in several researches in the past decade; nevertheless its soly. is often a challenge to scientists in achieving success.  We have henceforth discussed the basic heterogeneity of triple neg. breast cancer along with the current management options as well as a brief outlook on pros and cons of paclitaxel, known as the most widely used chemotherapeutic agent for the treatment of the disease.  We further analyzed the need of nanotechnol. pertaining to the problems encountered with the current paclitaxel formulations available discussing the strategic progress in various nano-formulations till date taking into account the basic research strategies required in terms of soly., permeability, physicochem. properties, active and passive targeting.  A thorough review in recent advances in active targeting for TNBC was carried out whereby the various ligands which are at present finding its way into TNBC research such as hyaluronic acid, folic acid, transferrin, etc. were discussed.  These ligands have specific receptor affinity to TNBC tumor cells hence can be beneficial for novel drug targeting approaches.  Conversely, there are currently several novel strategies in the research pipeline whose targeting ligands have not yet been studied.  Therefore, we reviewed upon the numerous novel receptor targets along with the resp. nano-formulation aspects which have not yet been fully researched upon and could be exemplified as outstanding target strategies for TNBC which is currently an urgent requirement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSvLub0Fq-LbVg90H21EOLACvtfcHk0ljNbcNa-qHiyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ygsrjL&md5=e24e7ce07227134ef35403d034d13988</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.07.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.07.023%26sid%3Dliteratum%253Aachs%26aulast%3DBakrania%26aufirst%3DA.%2BK.%26aulast%3DVariya%26aufirst%3DB.%2BC.%26aulast%3DPatel%26aufirst%3DS.%2BS.%26atitle%3DNovel%2520targets%2520for%2520paclitaxel%2520nano%2520formulations%253A%2520hopes%2520and%2520hypes%2520in%2520triple%2520negative%2520breast%2520cancer%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D577%26epage%3D591%26doi%3D10.1016%2Fj.phrs.2016.07.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nehate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saneja, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khare, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubey, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P. N.</span></span> <span> </span><span class="NLM_article-title">Paclitaxel formulations: challenges and novel delivery options</span>. <i>Curr. Drug Delivery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">666</span>– <span class="NLM_lpage">686</span>, <span class="refDoi"> DOI: 10.2174/1567201811666140609154949</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.2174%2F1567201811666140609154949" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=24909147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFygu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=666-686&author=C.+Nehateauthor=S.+Jainauthor=A.+Sanejaauthor=V.+Khareauthor=N.+Alamauthor=R.+D.+Dubeyauthor=P.+N.+Gupta&title=Paclitaxel+formulations%3A+challenges+and+novel+delivery+options&doi=10.2174%2F1567201811666140609154949"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel Formulations: Challenges and Novel Delivery Options</span></div><div class="casAuthors">Nehate, Chetan; Jain, Sharad; Saneja, Ankit; Khare, Vaibhav; Alam, Noor; Dubey, Ravindra Dhar; Gupta, Prem N.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Delivery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">666-686</span>CODEN:
                <span class="NLM_cas:coden">CDDUBJ</span>;
        ISSN:<span class="NLM_cas:issn">1567-2018</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Paclitaxel (PTX), a taxane plant product, is one of the most effective broad-spectrum anti-cancer agents and approved for the treatment of a variety of cancers including ovarian, breast, lung, head and neck as well as Kaposi's sarcoma.  Poor aq. soly. and serious side effects assocd. with com. prepn. of PTX (Taxol) triggered the development of alternative PTX formulations.  Over past three decades, plethora of research work has been published towards the development of cremophor free and efficient formulations.  Various nanocarrier systems including nanoparticles, liposomes, micelles, bioconjugates and dendrimers have been employed in order to improve PTX soly. and eliminate undesired side effects.  These nanocarriers offer the advantage of high degree of encapsulation and cellular uptake, escape from elimination by P-glycoprotein (P-gp) mediated efflux, and can be explored for targeted drug delivery.  The potential of these nanocarriers is reflected by the fact that various nanocarriers of PTX are in different stages of clin. trials and a few have already been commercialized including Abraxane, Lipusu and Genexol PM.  This review focuses on the various challenges assocd. with PTX formulation development, limitations of existing formulations and novel approaches for the development of alternative formulations for PTX and also highlights the development of novel formulations in clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotvOzqjm_TbrVg90H21EOLACvtfcHk0ljNbcNa-qHiyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFygu7fP&md5=ee429ec0dd5626ac8789a8bc80c0b856</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.2174%2F1567201811666140609154949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1567201811666140609154949%26sid%3Dliteratum%253Aachs%26aulast%3DNehate%26aufirst%3DC.%26aulast%3DJain%26aufirst%3DS.%26aulast%3DSaneja%26aufirst%3DA.%26aulast%3DKhare%26aufirst%3DV.%26aulast%3DAlam%26aufirst%3DN.%26aulast%3DDubey%26aufirst%3DR.%2BD.%26aulast%3DGupta%26aufirst%3DP.%2BN.%26atitle%3DPaclitaxel%2520formulations%253A%2520challenges%2520and%2520novel%2520delivery%2520options%26jtitle%3DCurr.%2520Drug%2520Delivery%26date%3D2014%26volume%3D11%26spage%3D666%26epage%3D686%26doi%3D10.2174%2F1567201811666140609154949" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singla, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, D.</span></span> <span> </span><span class="NLM_article-title">Paclitaxel and its formulations</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>235</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1016/S0378-5173(01)00986-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2FS0378-5173%2801%2900986-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=11879753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsV2qsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=235&publication_year=2002&pages=179-192&author=A.+K.+Singlaauthor=A.+Gargauthor=D.+Aggarwal&title=Paclitaxel+and+its+formulations&doi=10.1016%2FS0378-5173%2801%2900986-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel and its formulations</span></div><div class="casAuthors">Singla, Anil K.; Garg, Alka; Aggarwal, Deepika</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">235</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">179-192</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review with refs.  Paclitaxel (Taxol) is a promising antitumor agent with poor water soly.  It is effective for various cancers esp. ovarian and breast cancer.  I.v. administration of a current formulation in a non-aq. vehicle contg. Cremophor EL may cause allergic reactions and pptn. on aq. diln.  Moreover, the extensive clin. use of this drug is somewhat delayed due to the lack of appropriate delivery vehicles.  Due to this there is a need for the development of alternate formulation of paclitaxel having good aq. soly. and at the same time free of any side effects.  Various approaches employed so far include cosolvents, emulsions, micelles, liposomes, microspheres nanoparticles, cyclodextrins, pastes, and implants etc. which are discussed in this study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRkpWcoDTMmbVg90H21EOLACvtfcHk0ljNbcNa-qHiyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsV2qsro%253D&md5=bfa6d3f8055b197735c2be13bbe19eca</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2FS0378-5173%2801%2900986-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-5173%252801%252900986-3%26sid%3Dliteratum%253Aachs%26aulast%3DSingla%26aufirst%3DA.%2BK.%26aulast%3DGarg%26aufirst%3DA.%26aulast%3DAggarwal%26aufirst%3DD.%26atitle%3DPaclitaxel%2520and%2520its%2520formulations%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2002%26volume%3D235%26spage%3D179%26epage%3D192%26doi%3D10.1016%2FS0378-5173%2801%2900986-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brachmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerwin, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carleton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinghoffer, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmisano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chopra, R.</span></span> <span> </span><span class="NLM_article-title">Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">699</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1007/s00280-015-2833-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1007%2Fs00280-015-2833-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=26231955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFagur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2015&pages=699-712&author=N.+Chenauthor=C.+Brachmannauthor=X.+Liuauthor=D.+W.+Pierceauthor=J.+Deyauthor=W.+S.+Kerwinauthor=Y.+Liauthor=S.+Zhouauthor=S.+Houauthor=M.+Carletonauthor=R.+A.+Klinghofferauthor=M.+Palmisanoauthor=R.+Chopra&title=Albumin-bound+nanoparticle+%28nab%29+paclitaxel+exhibits+enhanced+paclitaxel+tissue+distribution+and+tumor+penetration&doi=10.1007%2Fs00280-015-2833-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration</span></div><div class="casAuthors">Chen, Nianhang; Brachmann, Carrie; Liu, Xiping; Pierce, Daniel W.; Dey, Joyoti; Kerwin, William S.; Li, Yan; Zhou, Simon; Hou, Shihe; Carleton, Michael; Klinghoffer, Richard A.; Palmisano, Maria; Chopra, Rajesh</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">699-712</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: nab-paclitaxel demonstrates improved clin. efficacy compared with conventional Cremophor EL (CrEL)-paclitaxel in multiple tumor types.  This study explored the distinctions in drug distribution between nab-paclitaxel and CrEL-paclitaxel and the underlying mechanisms.  Methods: Uptake and transcytosis of paclitaxel were analyzed by vascular permeability assay across human endothelial cell monolayers.  The tissue penetration of paclitaxel within tumors was evaluated by local injections into tumor xenografts and quant. image anal.  The distribution profile of paclitaxel in solid-tumor patients was assessed using pharmacokinetic modeling and simulation.  Results: Live imaging demonstrated that albumin and paclitaxel were present in punctae in endothelial cells and could be obsd. in very close proximity, suggesting cotransport.  Uptake and transport of albumin, nab-paclitaxel and paclitaxel were inhibited by clin. relevant CrEL concns.  Further, nab-paclitaxel causes greater mitotic arrest in wider area within xenografted tumors than CrEL- or DMSO-paclitaxel following local microinjection, demonstrating enhanced paclitaxel penetration and uptake by albumin within tumors.  Modeling of paclitaxel distribution in patients with solid tumors indicated that nab-paclitaxel is more dependent upon transporter-mediated pathways for drug distribution into tissues than CrEL-paclitaxel.  The percent dose delivered to tissue via transporter-mediated pathways is predicted to be const. with nab-paclitaxel but decrease with increasing CrEL-paclitaxel dose.  Conclusions: Compared with CrEL-paclitaxel, nab-paclitaxel demonstrated more efficient transport across endothelial cells, greater penetration and cytotoxic induction in xenograft tumors, and enhanced extravascular distribution in patients that are attributed to carrier-mediated transport.  These observations are consistent with the distinct clin. efficacy and toxicity profile of nab-paclitaxel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquUPORPsNHN7Vg90H21EOLACvtfcHk0lhJUEvKAB3YEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFagur%252FJ&md5=f4cd73246f00961f3c931528d0f85fdf</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1007%2Fs00280-015-2833-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-015-2833-5%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DN.%26aulast%3DBrachmann%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DPierce%26aufirst%3DD.%2BW.%26aulast%3DDey%26aufirst%3DJ.%26aulast%3DKerwin%26aufirst%3DW.%2BS.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DHou%26aufirst%3DS.%26aulast%3DCarleton%26aufirst%3DM.%26aulast%3DKlinghoffer%26aufirst%3DR.%2BA.%26aulast%3DPalmisano%26aufirst%3DM.%26aulast%3DChopra%26aufirst%3DR.%26atitle%3DAlbumin-bound%2520nanoparticle%2520%2528nab%2529%2520paclitaxel%2520exhibits%2520enhanced%2520paclitaxel%2520tissue%2520distribution%2520and%2520tumor%2520penetration%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2015%26volume%3D76%26spage%3D699%26epage%3D712%26doi%3D10.1007%2Fs00280-015-2833-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chougule, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span> <span> </span><span class="NLM_article-title">EphA2 targeting pegylated nanocarrier drug delivery system for treatment of lung cancer</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">2796</span>– <span class="NLM_lpage">2809</span>, <span class="refDoi"> DOI: 10.1007/s11095-014-1377-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1007%2Fs11095-014-1377-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2014&pages=2796-2809&author=A.+R.+Patelauthor=M.+Chouguleauthor=M.+Singh&title=EphA2+targeting+pegylated+nanocarrier+drug+delivery+system+for+treatment+of+lung+cancer&doi=10.1007%2Fs11095-014-1377-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1007%2Fs11095-014-1377-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-014-1377-4%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DA.%2BR.%26aulast%3DChougule%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DM.%26atitle%3DEphA2%2520targeting%2520pegylated%2520nanocarrier%2520drug%2520delivery%2520system%2520for%2520treatment%2520of%2520lung%2520cancer%26jtitle%3DPharm.%2520Res.%26date%3D2014%26volume%3D31%26spage%3D2796%26epage%3D2809%26doi%3D10.1007%2Fs11095-014-1377-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, J.</span></span> <span> </span><span class="NLM_article-title">Cell-penetrating peptide-siRNA conjugate loaded YSA-modified nanobubbles for ultrasound triggered siRNA delivery</span>. <i>Colloids Surf., B</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">650</span>, <span class="refDoi"> DOI: 10.1016/j.colsurfb.2015.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.colsurfb.2015.10.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2015&pages=641-650&author=X.+Xieauthor=Y.+Yangauthor=W.+Linauthor=H.+Liuauthor=H.+Liuauthor=Y.+Yangauthor=Y.+Chenauthor=X.+Fuauthor=J.+Deng&title=Cell-penetrating+peptide-siRNA+conjugate+loaded+YSA-modified+nanobubbles+for+ultrasound+triggered+siRNA+delivery&doi=10.1016%2Fj.colsurfb.2015.10.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.colsurfb.2015.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.colsurfb.2015.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DX.%26aulast%3DDeng%26aufirst%3DJ.%26atitle%3DCell-penetrating%2520peptide-siRNA%2520conjugate%2520loaded%2520YSA-modified%2520nanobubbles%2520for%2520ultrasound%2520triggered%2520siRNA%2520delivery%26jtitle%3DColloids%2520Surf.%252C%2520B%26date%3D2015%26volume%3D136%26spage%3D641%26epage%3D650%26doi%3D10.1016%2Fj.colsurfb.2015.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebrahimnejad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tice, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Quantitative radioimmuno PET imaging of EphA2 in tumor-bearing mice</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2024</span>– <span class="NLM_lpage">2036</span>, <span class="refDoi"> DOI: 10.1007/s00259-007-0503-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1007%2Fs00259-007-0503-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=17673999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlyiurzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2007&pages=2024-2036&author=W.+Caiauthor=A.+Ebrahimnejadauthor=K.+Chenauthor=Q.+Caoauthor=Z.+B.+Liauthor=D.+A.+Ticeauthor=X.+Chen&title=Quantitative+radioimmuno+PET+imaging+of+EphA2+in+tumor-bearing+mice&doi=10.1007%2Fs00259-007-0503-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice</span></div><div class="casAuthors">Cai, Weibo; Ebrahimnejad, Alireza; Chen, Kai; Cao, Qizhen; Li, Zi-Bo; Tice, David A.; Chen, Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2024-2036</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: EphA2 receptor tyrosine kinase is significantly overexpressed in a wide variety of cancer types.  High EphA2 expression has been correlated with increased metastatic potential and poor patient survival.  Although many recent reports have focused on blocking the EphA2 signaling pathway in cancer, the in vivo imaging of EphA2 has not yet been investigated.  Methods: We labeled 1C1, a humanized monoclonal antibody against both human and murine EphA2, with 64Cu through the chelating agent 1,4,7,10-tetraazacyclododecane N,N',N'',N'''-tetraacetic acid (DOTA) and carried out positron emission tomog. (PET) imaging of eight tumor models with different EphA2 expression levels.  Western blotting of tumor tissue lysate was performed to correlate the EphA2 expression level with 64Cu-DOTA-1C1 uptake in the tumors.  Immunofluorescence staining and biodistribution studies were also carried out to validate the in vivo results.  Results: The radiolabeling yield was 88.9 ± 9.5% (n = 7) and the specific activity of 64Cu-DOTA-1C1 was 1.32 ± 0.14 GBq/mg of 1C1 mAb.  The antibody retained antigen-binding affinity/specificity after DOTA conjugation as measured by FACS anal.  The uptake of 64Cu-DOTA-1C1 in CT-26 tumors was as high as 25.1 ± 2.5 %ID/g (n = 3) at 18 h post injection.  64Cu-DOTA-IgG, an isotype-matched control, exhibited minimal non-specific uptake in all eight tumor models.  In vivo EphA2 specificity of 64Cu-DOTA-1C1 was confirmed by successful blocking of CT-26 tumor uptake by unlabeled 1C1.  Most importantly, the tumor uptake value obtained from PET imaging had excellent linear correlation with the relative tumor tissue EphA2 expression level measured by Western blot, where r 2 equals 0.90 and 0.92 at 18 h and 42 h post injection, resp.  Conclusion: The tumor uptake of 64Cu-DOTA-1C1 measured by microPET imaging reflects tumor EphA2 expression level in vivo.  This is, to our knowledge, the first report of quant. radioimmunoPET imaging of EphA2 in living subjects.  Future clin. investigation of 64Cu-DOTA-1C1 is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzMZbuvqQ4m7Vg90H21EOLACvtfcHk0lhJUEvKAB3YEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlyiurzO&md5=6353b6d0f2d30a2fb7e5126f34862c39</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1007%2Fs00259-007-0503-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-007-0503-5%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DW.%26aulast%3DEbrahimnejad%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DZ.%2BB.%26aulast%3DTice%26aufirst%3DD.%2BA.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DQuantitative%2520radioimmuno%2520PET%2520imaging%2520of%2520EphA2%2520in%2520tumor-bearing%2520mice%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2007%26volume%3D34%26spage%3D2024%26epage%3D2036%26doi%3D10.1007%2Fs00259-007-0503-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, R.</span></span> <span> </span><span class="NLM_article-title">(99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">450</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.1016/j.nucmedbio.2014.03.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.1016%2Fj.nucmedbio.2014.03.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=24768147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=1%3ACAS%3A528%3ADC%252BC2cXntFCqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=450-456&author=Y.+Liuauthor=X.+Lanauthor=T.+Wuauthor=J.+Langauthor=X.+Jinauthor=X.+Sunauthor=Q.+Wenauthor=R.+An&title=%2899m%29Tc-labeled+SWL+specific+peptide+for+targeting+EphA2+receptor&doi=10.1016%2Fj.nucmedbio.2014.03.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">99mTc-labeled SWL specific peptide for targeting EphA2 receptor</span></div><div class="casAuthors">Liu, Yu; Lan, Xiaoli; Wu, Tao; Lang, Juntao; Jin, Xueyan; Sun, Xun; Wen, Qiong; An, Rui</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">450-456</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">EphA2, one member of the Eph receptor family, is widely expressed in multiple aggressive cancers.  SWL, a small peptide identified by phage display, has high binding affinity to EphA2, suggesting that it could be exploited for targeted mol. imaging.  Therefore, a novel peptide-based probe, 99mTc-HYNIC-SWL, was developed and its potential to specifically target EphA2-pos. tumors was investigated.The SWL peptide was labeled with hydrazinonicotinic acid (HYNIC), followed by 99mTc labeling.  Immunofluorescence staining was carried out to detect the expression of EphA2 in A549 lung cancer cells and OCM-1 melanoma cells.  Satn. binding expts. were performed by incubating A549 cells with increasing concns. of radiolabeled peptide in vitro.  To test the probe in vivo, nude mice bearing either A549 or OCM-1 derived tumors were established, injected with 99mTc-HYNIC-SWL, and subjected to SPECT imaging.  Mice injected with excess unlabeled SWL were used as a specific control.  Ex vivo γ-counting of dissected tissues from the mice was also performed to evaluate biodistribution.  Immunofluorescence staining showed that A549 cells intensively expressed EphA2, while OCM-1 cells had little expression.  99mTc-HYNIC-SWL displayed high binding affinity with A549 cells (KD = 2.6 ± 0.7 nM).  From the SPECT images and the results of the biodistribution study, significantly higher uptake of the tracer was seen in A549 tumors (1.44 ± 0.12 %ID/g) than in OCM-1 tumors (0.43 ± 0.20 %ID/g) at 1 h after injection.  Pre-injection with excess unlabeled peptide in A549-bearing nude mice, significantly reduced tumor uptake of the radiolabeled probe (0.58 ± 0.20 %ID/g) was seen.  These data suggest that 99mTc-HYNIC-SWL specifically targets EphA2 in tumors.The expression of EphA2 can be noninvasively investigated using 99mTc-HYNIC-SWL by SPECT imaging.  The in vitro and in vivo characteristics of 99mTc-HYNIC-SWL make it a promising probe for EphA2-pos. tumor imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5VuLqYK3h2rVg90H21EOLACvtfcHk0lilQfV53ous4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXntFCqtr8%253D&md5=40192836654e1ac71adf6556c040b3fd</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2014.03.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2014.03.020%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLan%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DLang%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DWen%26aufirst%3DQ.%26aulast%3DAn%26aufirst%3DR.%26atitle%3D%252899m%2529Tc-labeled%2520SWL%2520specific%2520peptide%2520for%2520targeting%2520EphA2%2520receptor%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2014%26volume%3D41%26spage%3D450%26epage%3D456%26doi%3D10.1016%2Fj.nucmedbio.2014.03.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichterman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OuYang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posadas, E. M.</span></span> <span> </span><span class="NLM_article-title">A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">44781</span>– <span class="NLM_lpage">44793</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.6330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;key=10.18632%2Foncotarget.6330" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=44781-44793&author=R.+Jiangauthor=Y.+T.+Luauthor=H.+Hoauthor=B.+Liauthor=J.+F.+Chenauthor=M.+Linauthor=F.+Liauthor=K.+Wuauthor=H.+Wuauthor=J.+Lichtermanauthor=H.+Wanauthor=C.+L.+Luauthor=W.+OuYangauthor=M.+Niauthor=L.+Wangauthor=G.+Liauthor=T.+Leeauthor=X.+Zhangauthor=J.+Yangauthor=M.+Rettigauthor=L.+W.+Chungauthor=H.+Yangauthor=K.+C.+Liauthor=Y.+Houauthor=H.+R.+Tsengauthor=S.+Houauthor=X.+Xuauthor=J.+Wangauthor=E.+M.+Posadas&title=A+comparison+of+isolated+circulating+tumor+cells+and+tissue+biopsies+using+whole-genome+sequencing+in+prostate+cancer&doi=10.18632%2Foncotarget.6330"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.6330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.6330%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DR.%26aulast%3DLu%26aufirst%3DY.%2BT.%26aulast%3DHo%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DJ.%2BF.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DLichterman%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DC.%2BL.%26aulast%3DOuYang%26aufirst%3DW.%26aulast%3DNi%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DRettig%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DL.%2BW.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DK.%2BC.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DTseng%26aufirst%3DH.%2BR.%26aulast%3DHou%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPosadas%26aufirst%3DE.%2BM.%26atitle%3DA%2520comparison%2520of%2520isolated%2520circulating%2520tumor%2520cells%2520and%2520tissue%2520biopsies%2520using%2520whole-genome%2520sequencing%2520in%2520prostate%2520cancer%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D44781%26epage%3D44793%26doi%3D10.18632%2Foncotarget.6330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i21"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01837">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_67748"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01837">10.1021/acs.jmedchem.7b01837</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Biological data cited in <a id="rightTab-" class=" internalNav" href="#fig2">Figures <a id="rightTab-" class=" internalNav" href="#fig2">2</a></a> and <a id="rightTab-" class=" internalNav" href="#fig3">3</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01837/suppl_file/jm7b01837_si_001.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01837/suppl_file/jm7b01837_si_001.csv">jm7b01837_si_001.csv (0.9 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01837&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-5%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01837%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01837" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a2fb08f452362","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
